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Abstract 
Transition metal-catalyzed cyclization reactions involving allenes were demonstrated as 
l methods for the synthesis of novel heterocyclic compounds. Multiple scaffolds were 
ssed from pivotal allenic amino-ester intermediates by varying the reaction conditions. 
ium(I)-catalyzed allenic Alder-ene reaction of allenynes afforded cross-conjugated trienes 
gh yields. Double bond selectivity in the allenic cyclocarbonylation reaction of allenynes 
accomplished by utilizing either rhodium(I)-catalyzed or molybdenum-mediated conditions, 
gaining access to 4-alkylidene or α-alkylidene cyclopentenones, respectively. In addition, a 
led study of the molybdenum-mediated reaction uncovered an unexpected diastereocontrol 
ent based on the amino acid side chain. Furthermore, replacement of the alkyne with an 
e led to discovery of a novel rhodium(I)-catalyzed cycloisomerization of ene-allenes 
ding tetrahydroazepines.  
The novel molecular scaffolds obtained in this manner were studied in complexity 
rating reactions that were employed in the synthesis of libraries of compounds for biological 
ation. For example, stereoselective sequential Diels-Alder reactions of the cross-conjugated 
es allowed rapid access to polycyclic molecular skeletons. Additionally, a Stetter/Paal-Knorr 
ion sequence was developed to gain access to novel tricyclic pyrroles.  
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1.0  Introduction 
1.1 The Role of Diversity-Oriented Synthesis in Modern Biomedical Research 
Modern drug discovery efforts are based upon a deep understanding of the cellular 
pathways responsible for a particular disease. The extreme complexity of the cellular circuitry 
has made the goal of understanding all of its aspects a formidable challenge. Significant progress 
in this area has been made by using modern biochemical tools such as mutagenesis, which is 
commonly used to irreversibly modify proteins in order to understand their cellular function. 
However, there are many aspects of the cell’s biochemistry that remain a mystery. These include 
important signaling pathways based on dynamic protein-protein interactions that are particularly 
difficult to study.1 Therefore, there is a tremendous need for innovative strategies to discover 
new cellular pathways and probe the function of various protein targets. 
Small organic molecules are useful research probes for studying cellular pathways. Small 
molecules are capable of interacting with macromolecules such as proteins generally in a 
reversible manner, thereby modulating their function.2 Observing the effects that result from 
such interactions in designed assays can often lead to an understanding of the role a particular 
target plays in the cell. Additionally, if the protein is a known therapeutically relevant target, lead 
compounds for drug discovery can be identified. The great number of relevant protein targets 
and their immense structural diversity dictates that the small molecules screened against these 
 1 
targets must also be structurally and functionally diverse.3, 4  
Nature is one of the greatest sources of diverse small molecules with a broad bioactivity 
profile. However, a major limitation of screening natural products is their limited availability.5 
Therefore, synthetic small molecules constitute a major portion of the modern screening palette. 
Advances in the field of synthetic organic chemistry have led to development of many 
methodologies for efficient assembly of small molecules. The field of combinatorial synthesis 
has evolved in the past two decades as a consequence of the demand for diverse small molecules 
for biomedical research.6 The synthetic strategy that is most commonly utilized in the 
combinatorial approach involves appending different building blocks around a common 
structural core. This approach has been greatly facilitated by development of practical 
technologies that allow the streamlined parallel synthesis of large numbers of compounds 
(thousands) in a short period of time. Although this approach will undoubtedly continue to lead 
to identification of additional biological agents, researchers have questioned whether the level of 
structural diversity that is achieved is sufficient to complement the wide variety of modern 
biomedical targets.7 The appendage diversity that is achieved by varying substituents around a 
common core is thought to limit the compounds to a narrow “chemical space”. Very often, and 
particularly in the pharmaceutical company setting, the molecules accessed in this manner are 
designed to fall within defined physico-chemical parameters that increase their chances of 
becoming drug candidates.8 For example, the well known Lipinski rules for drug-like molecules 
consider properties aimed at increasing bio-availability (molecular weight, solubility, number of 
hydrogen-bond donors and acceptors, etc).9   
The need for novel, chemically diverse small molecules has been made clear in the 
National Institutes of Health (NIH) roadmap for medical research (http://nihroadmap.nih.gov/). 
 2 
According to these guidelines, the goal of biomedical research in the future is to identify a 
comprehensive set of small molecules that are capable of selectively modifying the function of 
the majority of biological targets in the human cell. Since the number of relevant biological 
targets continues to grow as a result of intense research, this important goal can only be achieved 
by effectively integrating the development of new synthetic technologies to generate novel 
chemically diverse entities, with assays against a broad range of biological targets. New 
synthetic technologies encompass methods for more efficient synthesis of small molecules, their 
purification, isolation and characterization. In recent years, organic chemists have become 
increasingly aware of these issues and have begun addressing them by innovative combinatorial 
strategies and diversity-oriented synthesis (DOS).10 Diversity-oriented synthesis aims to develop 
new and adapt existing synthetic methodologies for generating structurally diverse molecules 
specifically for biological screening. Because synthetic chemists generate novel compounds 
continuously, the term diversity-oriented synthesis is carefully assigned only to the designed and 
deliberate synthesis of collections of small molecules populating novel chemical space. Contrary 
to the classical combinatorial approach, modern DOS efforts put their main emphasis on the 
diversity of the molecular scaffolds that are accessed and not on the numbers of compounds.11 
Therefore, the synthesis of libraries of compounds is generally limited between tens to hundreds 
of compounds, and not thousands (or more) as in the classical combinatorial approach.12 
Moreover, the compounds are accessed in milligram quantities, which allows a thorough 
assessment of their biological activity in a wide variety of biological assays.13  
Characterizing the diversity of molecular libraries is another important aspect of DOS.14 
This is commonly done by using computational methods to predict various physico-chemical 
properties (i.e., molecular descriptors) which are then compared to those of existing libraries.9 
 3 
These can include more common parameters such as number of rotatable bonds, H-bond donor 
and acceptor groups, solvent-accessible surface area, clogP (distribution coefficient for 
octanol/water), but also pharmacologically related ones such as predicted affinity for serum-
protein binding, intestinal permeability, metabolizable groups in the molecule, etc. 
Computational prediction of parameters like these allows the practicing DOS chemist to design 
libraries that posess a broad diversity profile. 
In designing such “discovery libraries” of novel compounds, at least three forms of 
structural diversity have been considered and include appendage, stereochemical and skeletal 
diversity (Scheme 1.1). An ideal DOS strategy incorporates all three forms. 
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Scheme 1.1 Three forms of diversity in small molecule library synthesis. 
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(1) Appendage diversity is the most common form of diversity and involves decorating a 
common structural scaffold with different substituents or functional groups. When appendages 
are introduced via a coupling reaction subsequent to formation of the core scaffold, this 
represents back-end diversification. In contrast, front-end diversification results when bulding 
blocks possessing the appendage diversity elements are brought together in the key scaffold 
formation step (appendage diversity, Scheme 1.1). 
(2) Stereochemical diversity can be achieved by utilizing asymmetric synthetic methods 
to access both enantiomers of a compound from an achiral precursor. In addition, substrate-based 
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stereocontrol elements can be used to access different diastereomers from a common precursor. 
This form of diversity is important because it is well known that stereoisomeric compounds 
(enantiomers, diastereomers or atropisomers) can have different biological activity by virtue of 
displaying functional groups differently in three-dimensional space (stereochemical diversity, 
Scheme 1.1).15
(3) Skeletal diversity is arguably the most important but relatively difficult to achieve in 
an efficient manner. There are at least two conceptually distinct ways it can be accomplished: 
- The first one involves designing structurally similar substrates that under common reaction 
conditions undergo diverging transformations affording skeletally distinct products. The 
chemical information that leads to different products is therefore encoded in the substrates 
(substrate-based control, Scheme 1.1). This is the most commonly utilized synthetic approach to 
skeletal diversity.16 For example, Schreiber demonstrated that substituted furans 1-3 containing 
one, two or no alcohols in the side chain can undergo different transformations when treated to 
oxidative acidic conditions (NBS and PPTS).10c The reaction proceeds via an oxidative opening 
of the furan to a cis-endione intermediate 4, which then is subject to nucleophilic attack by the 
hydroxyl groups to give skeletally distinct products 5-7 (Scheme 1.2). 
Scheme 1.2 Substrate-controlled skeletal diversity.  
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Another example from the Schreiber group involves a 1,3-dipolar cycloaddition between an 
indole dipolarophile and an in situ generated cyclic oxonium ylide to give skeletally different 
products by varying the placement of the reactive functional groups around a common pyridone 
core 8 (Scheme 1.3).17  
Scheme 1.3 Synthesis of skeletally distinct products by substrate-design. 
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Despite the fact that a high degree of skeletal diversity can be accessed via the substrate-based 
approach, the efficiency of the overall process is compromised since all of the precursors need to 
be synthesized independently. 
- Therefore, a more efficient approach to skeletal diversity involves subjecting a common 
synthetic precursor to different reaction conditions to give skeletally unique products (reagent-
based control, Scheme 1.1). Although there are some applications of this concept, it remains the 
most difficult to achieve, particularly in the context of cyclic skeleton synthesis.18 For example, 
Schaus and Porco have shown that aryl-ether C-glycoside derivative 15 unveils phenol 16 via a 
[3,3]-sigmatropic rearrangement under microwave irradiation, or furanyl alcohol 17 via a Au-
 7 
promoted rearrangement  (Scheme 1.4).19
Scheme 1.4 Reagent-controlled skeletal diversity. 
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Another example of the “common precursor” approach is illustrated in Scheme 1.5. Spring et al. 
have exploited the versatility of a fluorous-tagged20 diazoacetate 18 to gain access to a broad 
range of skeletally distinct scaffolds by utilizing different reaction conditions.21 Since the pivotal 
intermediate 18 is relatively unfunctionalized, the diversity in the product results from the nature 
of the second reagent used in the reaction.  
Scheme 1.5 Skeletal diversity via reactions of a fluorous-tagged diazoacetate. 
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1.1.1 Transition Metal-Catalyzed Reactions in Diversity-Oriented Synthesis 
Accessing all three forms of diversity requires DOS strategies with branching reaction 
pathways available to common synthetic precursors. In this manner, structurally distinct 
scaffolds can be obtained from a relatively smaller pool of reactants, thereby increasing the 
overall efficiency of the process. Therefore, there is a strong incentive to develop new chemical 
transformations and design strategies towards this goal. The development of many useful 
transition metal-catalyzed reactions in the last decades has opened the door for their application 
to DOS.22 Transition-metal catalyzed reactions are generally environmentally benign and 
economic synthetic processes, proceeding with high levels of selectivity (chemo-, regio-, and/or 
stereoselectivity) and minimize the use of raw materials and generation of byproducts. Among 
these, Pd-catalyzed coupling reactions (Heck,23 Stille,24 Sonogashira,25 Suzuki,26 etc.) and allylic 
substitution reactions27 are regarded as some of the most important with highest impact on the 
field of modern organic synthesis. Not surprisingly, these reactions have seen the most 
application in combinatorial and diversity-oriented synthesis. The majority of classical 
combinatorial strategies in the past have been largely limited to utilizing transition metal-
catalyzed coupling reactions only introducing appendage diversity (for examples see Pd-
catalyzed Suzuki,28 Heck29 and Stille30 coupling reactions). In addition, intramolecular versions 
of these and related reactions have seen recent use to create skeletal diversity in the synthesis of 
small and medium size rings.31 Related transformations such as the coupling of aryl boronic 
acids and amides recently developed by Buchwald32 are also becoming increasingly popular in 
the generation of cyclic-skeletons.33 Another very important transformation that has found wide 
use in combinatorial and diversity-oriented synthesis is the Ru-catalyzed ring-closing 
methathesis developed by Grubbs.34 Some recent examples of diverse cyclic scaffolds generated 
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by using the above-mentioned classes of reactions are illustrated in Scheme 1.6. 
Scheme 1.6 Recent examples of diverse cyclic skeletons accessed via transition metal-catalyzed 
cyclization reactions. 
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Transition metal catalyzed reactions that transform relatively simple acyclic starting 
materials to cyclic (or polycyclic) products via a carbocyclization process are another important 
class of reactions that has received attention in the past decade.35 Carbocyclization, in general, 
refers to a cyclization process that involves carbon-carbon bond formation via a carbometalation, 
whereas a C*-M (Carbon-Metal) species delivers the carbon and metal component across an 
unsaturated bond (C=C) thereby affording a C*-C-C-M species.36 In particular, carbocyclization 
reactions of precursors containing unsaturated functional groups (e.g., alkenes, alkynes) have 
been very useful in the syntheses of carbocyclic and heterocyclic molecules.35-37 Examples of 
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such reactions include transition metal catalyzed ene-type cycloisomerizations,37, , 38 39 [4+2] and 
[5+2] cycloadditions40 and [2+2+1] cyclocarbonylation41 reactions of enynes (Scheme 1.7). 
Aside from increasing molecular complexity, an important aspect of these reactions is that metal 
catalysis often allows for bond formation that would be difficult or impossible under 
conventional methods, to readily occur under mild conditions. A typical example is the 
intramolecular [4+2] cycloaddition of electronically unactivated dieneynes proceeding under 
Rh(I) catalysis (27 to 30, Scheme 1.7).42  
Scheme 1.7 Some carbocyclization reactions of 1,6-enynes. 
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The vast potential for increasing molecular complexity and achieving skeletal diversity 
via metal catalyzed carbocyclization reactions (e.g., cycloadditon, cycloisomerization, 
cyclocarbonylation, etc.) remains an untapped resource for DOS. One of the few examples of 
utilizing a Pauson-Khand cyclocarbonylation reaction in the synthesis of a library of amino-acid 
derived bicyclic skeletons 35 was reported by Bolton in 1997 (Scheme 1.8).43 More recently, a 
cyclocarbonylation reaction was also employed to prepare a library of fused tricyclic systems 37 
shown in Scheme 1.8.44  
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Scheme 1.8 Examples of using a cyclocarbonylation reaction in diverse skeleton synthesis. 
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Although olefins and acetylenes are most commonly utilized in carbocyclization reactions, use of 
allenes as π-components is becoming increasingly prevalent. For a relatively long time since 
their first synthesis,45 allenes were considered no more than a chemical curiosity and remained 
underutilized.46 Intense research in the past decades, however, has resulted in many useful 
synthetic methods involving allenes.47, 48, 49  The two cumulated double bonds of the allene 
display high reactivity towards a range of transition metals, and have been exploited in a variety 
of ways. Using allenes as olefin components in transition metal-catalyzed reactions often has the 
advantage of increased reactivity. This is largely due to the strain associated with  having two 
cumulated double bonds which is estimated at 10 kcal/mol.50 Despite this fact, transition metal-
catalyzed carbocyclizations of allenes (e.g., cycloaddition and cycloisomerization reactions) 
remain largely unexplored and underutilized in synthesis, presumably because there are no 
known control elements for effecting double bond selectivity other than substrate modification.51, 
52 Recent studies by Brummond and coworkers have resulted in some of the first examples of 
reagent-based control of olefin selectivity in the allenic cyclocarbonylation (Pauson-Khand 
reaction) and cycloisomerization reactions.53 Reagent-based control of double bond-selectivity in 
transition metal-catalyzed carbocyclization reactions of allenes is ideally suited for application to 
DOS since skeletally different products can be obtained. For example, selective engagement of 
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the proximal olefin of allenyne 38 in a cyclocarbonylation reaction leads to an α-alkylidene 
cyclopentenone 39 (Scheme 1.9). Alternatively, the same transformation of the distal double 
bond leads to a 4-alkylidene cyclopentenone 40. Furthermore, a cycloisomerization reaction 
involving the distal double bond of the allene can lead to a cross-conjugated triene 41. 
Scheme 1.9 Skeletal diversity using carbocyclization reactions of allenynes. 
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Each reaction results in increase of molecular complexity since relatively simple acyclic 
precursors are transformed to mono- or bicyclic skeletons. Furthermore, a novel reactive moiety 
is generated (enone, cross-conjugated triene) that can be further exploited in diversity generating 
transformations. Therefore, implementing a diversity-oriented synthetic strategy based on 
transition metal-catalyzed cyclocarbonylation and cycloisomerization reactions of allenes is of 
great interest. Herein, the efforts toward this goal are described. In this study, two important 
goals have been combined: (1) development of new synthetic methodologies for efficient 
assembly of complex small molecules; and (2) synthesis of collections of these compounds 
specifically for use as biological probes. At the initiation of the project, we envisioned 
employing the three reaction pathways available to a single allenyne (Scheme 1.9). It was 
reasoned that other reaction pathways may be available to an appropriately designed precursor. 
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The allenyne substrate was designed to contain an amino-ester tether (Chapter 2). The scope and 
limitation of the cycloisomerization reaction leading to cross-conjugated trienes was studied with 
this substrate class, and the results are presented in Chapter 3. In addition, the discovery of a 
novel cycloisomerization reaction of ene-allenes is discussed in Chapter 3. The synthesis of 4- 
and α-alkylidene cyclopentenones via cyclocarbonylation reaction is discussed in Chapter 4. 
Diversification of each of the three scaffolds was examined to increase molecular complexity 
and establish protocols for library synthesis (these results are discussed within the corresponding 
chapters). 
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2.0  Design and Synthesis of the Pivotal Intermediates 
2.1 Design of the Pivotal Intermediates 
In designing a pivotal allene intermediate for the planned DOS strategy, three aspects 
were considered: (1) incorporating higher number of N and O heteroatoms was important since 
compounds containing them are more likely to have a desirable pharmacological profile and 
exhibit interesting biological effects via specific interactions with proteins; (2) potential for 
diversification of the molecular scaffolds by employing both front-end and back-end appendage 
diversity strategies; and (3) ease of preparation and availability of the starting precursors. 
Incorporating nitrogen and oxygen containing functional groups in the pivotal allenes is also 
important because they would allow for rapid attachment of pre-functionalized alkynes and 
alkenes used in the carbocyclization reactions, thereby incorporating front-end diversity into the 
scaffolds. Additionally, the reactivity of nitrogen and oxygen containing functional groups can 
be exploited in back-end functionalization of the scaffolds subsequent to their formation.   
With this in mind, several known methods for preparation of functionalized allenes were 
considered.48a Claisen rearrangement of propargyl ethers and esters is a versatile method for 
preparation of allenes.54 In 1985, Fujusawa reported the Claisen rearrangement of α-hydroxy-
propargyl ester 42 via ester-enolate 43 leading to α-hydroxy-β-allenic acid 44 (Scheme 2.1).55 
However, the scope of this transformation was limited to the rearrangement of α-unsubstituted 
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esters (glycolates) thereby limiting the diversity that can be introduced at this position. 
Moreover, it was reasoned that converting these carboxylic acids to esters will increase the 
likelihood of a base-promoted isomerization of the allene to a 2,4-dienoic ester.    
Scheme 2.1 Ester-enolate Claisen rearrangement of propargyl glycolates. 
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The corresponding Claisen rearrangement of propargylic α-amino-esters was more attractive. 
Work by Castelhano and Krantz demonstrated that mild dehydrative conditions (Et3N, CCl4, 
PPh3) effect the rearrangement of benzoyl protected amino ester 45 to 4-allenyl-5-oxazolone 46, 
which is transformed to methyl ester 47 when treated with MeOH (Scheme 2.2).56 Furthermore, 
Kazmaier reported an ester-enolate Claisen rearrangement of variety of propargyl amino-esters 
48 using LDA/ZnCl2 affording allenic amino acids 50 with diastereoselectivity greater than 
93%.57
Scheme 2.2 Methods for preparation of allenic amino acids. 
BzHN
R1
O
O
R2
N
O
Ph
O
R1
NHBzMeO2C
R1
• R
2
H
•
R2
H
PHN
O
O
R2
R3
PN
O
O
R2
R3
Zn
R1 R1
NHPHO2C
R1
•
R2
H
R3LDA, ZnCl2, THF
45 46 47
48 49 50
P = Boc, Cbz, Tos
PPh3, CCl4, Et3N
MeCN
MeOH, HCl
[3,3] sigmatropic
rearrangement
 
 16 
The allenic amino acid derivatives obtained via these two methods appeared ideal for adapting to 
the DOS strategy (both methods are discussed in detail in Section 2.2). Notably, the propargyl 
esters are easily obtained in one step by coupling of the corresponding N-protected amino acid 
and a propargyl alcohol, allowing for multiple points of diversity to be introduced. Therefore, the 
allenic amino esters obtained in this manner were elected as pivotal intermediates for 
development of a DOS strategy based on transition metal catalyzed cycloisomerization and 
cyclocarbonylation reactions of allenes. 
2.2 Synthesis of the Pivotal Intermediates 
2.2.1 Synthesis of Allenic Amino Esters  
2.2.1.1 Claisen Rearrangement via an Oxazole 
The Claisen rearrangement of allyl and propargyl esters of α-amino-acids is a versatile 
method for preparing unsaturated amino acid derivatives. This field was pioneered by Steglich in 
the late 1970’s by demonstrating that N-benzoyl protected amino esters 51, under dehydrative 
conditions (P2O5/CHCl3 or COCl2/pyridine), afford 4,4-disubstituted oxazolone derivatives 53 
(Scheme 2.3).58 The reaction involves an in situ formation and [3,3] sigmatropic rearrangement 
of  allyloxy-oxazole 52. 
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Scheme 2.3 Claisen rearrangement via an oxazole. 
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Interest in preparing allenic amino acid derivatives was spurred by their potential to act as 
specific inhibitors of vitamin B6-linked decarboxylases.59 Krantz and Castelhano reported that a 
combination of PPh3, CCl4 and Et3N provides a milder and robust protocol for effecting the same 
transformation of propargyl esters (45 to 47, Scheme 2.2).56 It was established, however, that the 
benzamide protecting group is essential for reaction to proceed, which is attributed to a 
stabilizing effect of the phenyl group on the oxazole intermediate. The use of other protecting 
groups including trifluoroacetamide, Boc and Cbz groups was unsuccessful.  
Using this protocol, the phenylalanine-derived allene 58a was prepared as outlined in 
Scheme 2.4. Esterification of N-benzoyl phenylalanine 54a with 3-butyne-2-ol by using DCC 
and DMAP gave ester 56a in 78% yield. The reaction proceeds via the intermediacy of 
oxazolone 55a which is then subject to nucleophilic attack by the alcohol. Treatment of ester 56a 
with CCl4, PPh3 and Et3N in acetonitrile affords the 4-allenyl-2-oxazolin-5-one 57a, which is 
treated with MeOH/HCl to give allene 58a in 74% yield as a 1.7 : 1 mixture of diastereomers (as 
previously reported by Krantz).56  
Scheme 2.4 Synthesis of phenylalanine-derived allene 58a. 
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This protocol proved particularly useful for preparation of monosubstituted allenes, which are 
summarized in Table 2.1. These substrates were prepared in order to study the scope and 
limitations of the Mo-mediated and Rh-catalyzed cyclocarbonylation reaction. Phenylalanine, 
alanine and leucine derived allenes (58b, 58c and 58d, respectively) were prepared in yields 
ranging from 40 to 95% for the Claisen rearrangement step. The broad variations in yield do not 
reflect differences in reactivity, but rather, difficulties associated with purification of the 
resulting allenes from triphenylphosphineoxide (Ph3PO), which is a byproduct in the reaction. 
Initial experiments were performed utilizing a procedure where an aqueous workup of the 
reaction mixture after the methanolysis step was followed directly by flash chromatography to 
separate the product from Ph3PO. However, more polar allenes such as the alanine derived 58c 
proved difficult to separate completely and thus lower yields were obtained (40%). 
Table 2.1 Synthesis of monosubstituted allenes 58b-58h. 
1. PPh3, CCl4, Et3N, MeCN, rt
2. MeOH, HCl, rt.
BzHN
R1
O
O
NHBzMeO2C
R1
•
BzHN
R1
O
OH
OH
Entry               R1                   Ester/Yield%     Allene/Yield%   Entry               R1                  Ester/Yield%     Allene/Yield%
Me
OMe
F
S
NBoc
1                                              56b/98                58b/95
2                                              56c/68                58c/40
3                                              56d/90                58d/62
4                                              56e/85                58e/70
5                                          56f/42                 58f/65
6                                          56g/52                58g/83
7                                          56h/66                58h/64a
54 56 58
DCC, DMAP
CH2Cl2
a Claisen rearrangement step was performed at 50 oC; MeOH, Et3N was used instead of MeOH, HCl to prevent Boc-removal.  
 In later experiments, it proved advantageous to circumvent the aqueous work-up, and precipitate 
the solid Ph3PO by addition of hexanes to a solution of the crude reaction mixture in diethyl 
ether. This was followed by chromatography of the filtrate after removal of the solvents under 
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vacuum. In this manner, yields between 60-80% were generally obtained. Using this protocol, 
unnatural aromatic amino acids were utilized to prepare p-methoxyphenyl (58e), p-fluorophenyl 
(58f), 2-thienyl (58g) and an N-Boc-indolyl (58h) derivatized allenes in yields ranging from 64 
to 83%. The rearrangement of the N-Boc-indolyl derivative 56h required heating to 50 °C to 
proceed which is attributed to the bulkiness of this group. 
A serine derived allene 58i was also synthesized following the route outlined in Scheme 
2.5. Esterification of acid 59 with 3-butyn-2-ol in 73% yield was followed by removal of the Boc 
protecting group in 60  with TFA and coupling of the primary amine with benzoyl chloride to 
afford amido-ester 61 in 60% yield for the two steps. Claisen rearrangement of 61 afforded 
allene 58i in 87% yield as a ~2 : 1 mixture of diastereomers (determined by integration of the 
allenic methyl group resonances in the 1H NMR spectrum).  
Scheme 2.5 Synthesis of serine derived allene 58i. 
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2.2.1.2 Ester-enolate Claisen Rearrangement 
The ester-enolate version of the Claisen rearrangement was first introduced by Ireland60 in 1976 
and has since become a widely used method for acyclic stereocontrol.61 Extension of the scope of 
the reaction to α-hydroxy and α-amino ester derivatives was reported by Bartlett and coworkers 
in 1982.62 Subsequently, Kazmaier reported an ester-enolate Claisen rearrangement of α-amino 
acid propargylic esters to form α-allenyl amino acids with diastereoselectivity ranging between 
93-98%.57 Control of the enolate geometry was accomplished by using an equimolar amount of 
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ZnCl2, which results in a Zn-chelate 49 with fixed Z-geometry (Scheme 2.6). Rearrangement of 
this intermediate via a chair-like transition state 49A, where the R2 substituent is in a 
pseudoeqatorial position, leads to the major allene diastereomer syn-50. On the contrary, 
rearrangement via transition state 49B where the R2 substituent is in a pseudoaxial position, 
affords the minor diastereomer anti-50. The syn/anti notation for the allene products was 
introduced by Hoppe in analogy of the aldol product terminology.63  
Scheme 2.6 Diastereocontrol in the ester-enolate Claisen rearrangement. 
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Notably, the reaction conditions were compatible with either carbamate (Boc, Cbz) or 
sulfonamide (tosyl) protecting groups. All examples in this initial report by Kazmaier involved 
terminally substituted alkynes in the propargylic esters (R3 = alkyl, Table 2.2). Consequently, all 
of the prepared allenes contained an alkyl group at the proximal allenic position (i.e., 
trisubstituted allenes).  
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Table 2.2 Claisen rearrangement examples reported by Kazmaier. 
PHN
R1
O
O
R2
R3
50
NHPHO2C
R1
•
R2
H
R3
48
LDA, ZnCl2
THF, -78 oC to rt
Entry        P           R1        R2         R3           Yield (%)         diastereoselectivity (%)a
1             Boc         H         H          t-Bu               58                      
2             Boc         H         Me       t-Bu                54                            93
3             Cbz         H         Et           Bu               78                             95
4             Cbz         Me     i-Pr           Pr                66                          > 95
5             Boc         Bn      i-Pr           Pr                59                          > 95
6             Tos       i-Bu      i-Pr           Pr                57                          > 95
adiastereoselectivity was determined by 1H NMR  
Therefore, initial efforts were focused on reproducing Kazmaier’s protocol by preparing 
trisubstituted allenes. Propargylic esters 64a and 64b were obtained by coupling of the 
corresponding acid 62 and alcohol 63 using DCC and DMAP in 88% and 77% yield, 
respectively (Scheme 2.7). Claisen rearrangement of 64a using the reported conditions (LDA, 
ZnCl2, THF, -78 °C to rt) proceeded to give the intermediate allenic acid, which was converted 
to the methyl ester 65a by treatment with MeI and KHCO3 in 22% overall yield. Since following 
both reactions by TLC did not reveal significant formation of any byproducts, the low yield was 
attributed to loss of the intermediate carboxylic acid during silica gel chromatography due to 
increased polarity. To circumvent this problem, in all subsequent reactions, the crude reaction 
mixture after Claisen rearrangement was immediately treated with MeI and KHCO3 without 
intermediate purification.a Applying this strategy to the preparation of 65b resulted in 73% yield 
after one final purification step. 
                                                 
a Since sufficient amounts of 65a were prepared using the unoptimized protocol this reaction was not repeated. 
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Scheme 2.7 Synthesis of trisubstituted allenes 65a and 65b using Kazmaier’s protocol.  
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•
R2
H
R3
PHN
O
OH
R1
OH
C6H14
PHN
O
O
R2
R3
R1
63a
64a - 88%
64b - 77%
DCC, DMAP
CH2Cl2, rt
1. LDA, ZnCl2, THF, -78 oC to rt
2. KHCO3, MeI, DMF, rt.
62a P = Boc, R1 = Bn
62b P = Cbz, R1 = Me
OH
C4H10
63b
63a or 63b
65a - 22%: P = Boc, R1 = Bn,
R2 = n-Hex, R3 = Me
65b - 73%: P = Cbz, R1 = Me,
R2 = i-Pr, R3 = n-Bu
 
Preparing 1,3-disubstituted allenes using this protocol was also pursued. To this end, propargylic 
ester 64c was prepared in 97% yield from N-Cbz-alanine 62c and 3-butyn-2-ol (Scheme 2.8). 
Applying the two-step reaction sequence to this substrate resulted in the corresponding allenic-
amino ester 65c in 70% yield  as a  mixture of diastereomers in 1 : 1 ratio as determined by 1H 
NMR. This result was disappointing since the high diastereoselectivity is considered the major 
advantage of utilizing Kazmaier’s protocol. Since all examples of Claisen rearrangement 
proceeding with high diastereoselectivity reported by Kazmaier contain a terminally substituted 
alkyne, the lack of diastereoselectivity in the case of 64c is attributed to the absence of this 
substituent. Nevertheless, the origin of this effect is not clear. 
Scheme 2.8 Synthesis and Claisen rearrangement of 64c. 
NHCbzMeO2C
•
H
CbzHN
O
OH
OH
CbzHN
O
O
62c 64c 65c
DCC, DMAP
CH2Cl2, rt, 97%
1. LDA, ZnCl2, THF, -78 oC to rt
2. KHCO3, MeI, DMF, rt
70%
 
To circumvent this problem, disubstituted allenes were prepared diastereoselectively by utilizing 
a TMS group to temporarily protect the alkyne terminus (Scheme 2.9). Following the original 
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protocol, a solution of 64d in THF (kept at rt) was added to a solution of LDA at -78 °C followed 
by addition of ZnCl2 (0.5 M in THF; kept at rt). The resulting Zn-enolate was then warmed to rt 
affording the intermediate carboxylic acid, which was converted to the methyl ester after 
aqueous work-up. Removal of the allenyl-TMS group was accomplished by treatment of 67d 
with TBAF in presence of a phosphate buffer (pH = 7.0) to give the disubstituted allene 65d in 
49% yield for the three steps.64 This yield was reproducibly obtained when the three steps are 
performed without purification of the carboxylic acid and allenyl-TMS intermediate. 
Scheme 2.9 Synthesis of disubstituted allenes 65d-f. 
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Allene 65d was obtained as nearly a single diastereomer (diastereomer ratio of ~95 : 5 was 
determined by 1H NMR). The relative stereochemistry of the major diastereomer was assigned as 
syn, in accordance with Kazmaier’s results.57 This route was then applied to the synthesis of one 
additional allene (65e) containing an isopropyl group at the terminal position, which was 
obtained in 48% yield. At later stages of the project, during the preparation of Boc-protected 
allenic amino-ester 65f, additional optimization of the Claisen rearrangement protocol was 
performed. It was reasoned that formation of unidentified byproducts in this step can be 
minimized by keeping the temperature of the reaction solution stable at -78 °C during the 
addition of the propargyl ester 64f to LDA. Indeed, it was found that by cooling the THF 
solution of 64f to -78 °C and adding it to a solution of LDA simultaneously with ZnCl2 (0.5 M in 
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THF), the yield was increased from ~45% to 60% for the three step sequence (the protocols for 
the remaining two steps were kept identical). Presumably, simultaneous addition of ZnCl2 and 
the substrate to LDA is advantageous by immediately leading to the stabilized Zn-enolate, which 
minimizes side reactions resulting from exposure of the propargyl ester to excess LDA. 
Thus far, all of the allenic amino-esters that were prepared utilize an α-substituted amino 
acid as a precursor and contain a quaternary α-stereocenter. Since the ultimate goal of the project 
is to prepare small molecule biological probes, being able to prepare analogues lacking an α-
substituent was considered important in eventually establishing structure-activity relationships. 
In Kazmaier’s original report, glycine propargyl esters were utilized sucessfuly to obtain the 
corresponding allenic amino-acids (Table 2.2, entries 1-3). However, it was reasoned that 
converting these acids to the methyl ester would result in increased acidity at the α-position, 
thereby increasing the propensity for isomerization of the allene to a more stable 1,3-diene. With 
this in mind, the Claisen rearrangement of glycine-ester 69 was attempted (Scheme 2.10). The 
rearrangement proceeded to afford the allenic carboxylic acid, which was converted to the 
methyl ester 70 without event in 44% yield. In an initial experiment to remove the allenyl-TMS 
group, a solution of 70 in THF was directly treated with TBAF. The only isolable product from 
this reaction was the diene 72 in quantitative yield as a mixture of isomers in a 1 : 1 ratio which 
was determined by integration of the olefin resonances in the 1H NMR (the two isomers were 
separated by flash chromatography). It was reasoned that the mild basicity of TBAF is cause for 
this isomerization, so our next attempt involved adding a phosphate buffer with pH = 7.3 to 
TBAF prior to treating 70. This protocol prevented the observed isomerization and allowed the 
isolation of 71 in 79% yield. To determine whether the formation of the diene is indeed 
promoted by base, a small sample of 71 in THF was treated with equimolar amount of Cs2CO3 
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and resulted in isomerization to 72 within 10 min (Cs2CO3 was chosen since it could be used as a 
base for N-alkylation of 71).  
Scheme 2.10 Synthesis of glycine-derived allenic amino-ester. 
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H
H
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double bond isomers  
2.2.2 N-Alkylation of Allenic Amino Esters 
The next goal was to develop a general procedure for N-alkylation of the allenic amino-
esters that would introduce the alkyne component of the precursors for transition metal-catalyzed 
carbocyclization reactions. It was quickly found that treatment of the amides or carbamates with 
NaH in DMF at rt for 2-5 min, followed by addition of the corresponding propargylic bromide 
results in clean N-alkylation. Using this protocol on the Bz-protected substrate 58a and 1-bromo-
2-butyne gave allenyne 73a in 83% yield (Table 2.3). Varying the substitution pattern of the 
alkyne was important in order to study the scope of the carbocyclization reactions. Therefore, 
terminally unsubstituted alkyne was incorporated via N-alkylation with propargyl bromide 
affording 73b in 73% yield, whereas alkylation with 3-phenyl-1-bromopropyne gave a phenyl 
substituted allenyne 73d in 89% yield. Attempts to prepare precursor 73c with a TMS group on 
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the terminus of the alkyne led to desilylation which was attributed to to presence of NaOH in the 
bulk NaH. This problem was circumvented by utilizing KH (in mineral oil) as a base and THF as 
a solvent, which gave 73c in 75% yield. The same protocols were applied to synthesize the Cbz-
protected substrates 73f-i derived from alanine in yields ranging from 68-86%. These two sets of 
allenynes were envisioned to serve as main model systems for studying the transition metal-
catalyzed reactions and subsequent diversification of the scaffolds. In order to examine the effect 
of allene substitution on the carbocyclization reactions, allenynes 73j, 73k and 73l were 
synthesized in 73-86% yields. Allenynes possessing a terminal allene 74a-i were synthesized in 
order to study the diastereoselectivity in the Mo-mediated cyclocarbonylation reaction described 
in Section 4.4. Yields for preparing these compounds varied from 66-94%. Allenynes 74b, 74d 
and 74e were also prepared in larger quantities (5-10 g) for library synthesis using a modified 
protocol where a solution of the allenyne was slowly added to a slurry of NaH at 0 °C in order to 
avoid overheating from the exothermic reaction. Finally, we were also interested in preparing 
substrates containing an alkene instead of an alkyne (ene-allenes) in order to study the effect of 
this group on the cycloisomerization reaction affording cross-conjugated trienes. The yields for 
alkylation with allyl or crotyl bromide generally were lower, ranging from 42-71% (75a-e). 
Nevertheless, this protocol proved generally robust and performed uniformly across a broad 
range of substrates, which is ideal for performing these reactions in parallel for eventual library 
synthesis. 
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Table 2.3 Synthesis of allenynes and ene-allenes via N-alkylation. 
•
R2
R3
R4
PHN
R1MeO2C NaH, DMF, rt
Br
R5
•
R2
R3
R4
PN
R1MeO2C
R5
• H
CbzN
MeMeO2C
R5
73f : R5 = Me, 84%
73g : R5 = H, 77%
73h : R5 = TMS, 86%a
73i : R5 = Ph, 68%
• H
BzN
BnMeO2C
R5
73a : R5 = Me, 83%
73b : R5 = H, 73%
73c : R5 = TMS, 75%a
73d : R5 = Ph, 89%
• H
CbzN
MeMeO2C
73j : 86%
•
H
H
BzN
BnMeO2C
R5
74a: R5 = Me, 84%
74b : R5 = H, 66%
•
H
H
BzN
MeMeO2C
R5
74c : R5 = Me, 93%
74d : R5 = H, 94%
• H
BzN
MeO2C
73e : 94%
TBSO
•
C6H13
H
BocN
BnMeO2C
• H
CbzN
MeMeO2C
n-Bu
73k : 78%
73l : 73%
•
H
H
BzN
MeO2C
H
•
H
H
BzN
MeO2C
H
74e : 77%
•
H
H
BzN
MeO2C
H
•
H
H
BzN
MeO2C
H
MeO
F
S
74f : 84%
74g : 85% 74h : 89%
•
H
H
BzN
MeO2C
H
NBoc
74i : 78%
a Conditions: KH, THF
• H
BzN
BnMeO2C
75b : 71%
• H
CbzN
MeO2C
75c : 66%
• H
BzN
BnMeO2C
75a : 56%
• H
CbzN
MeO2C
• H
BzN
MeO2C
75d : 61% 75e : 42%
TBSO
73a-l, 74a-i, 75a-e
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N-Alkylation of the glycine-derived allene 71 was also attempted. Under the standard conditions 
(NaH, 1-bromo-2-butyne, DMF) the reaction afforded a mixture of products containing the 
previously characterized diene 72 and its N-alkylated derivative 76 (Scheme 2.11). This result 
was obtained despite quenching the reaction with pH = 7.0 buffer in an effort to prevent 
exposing the crude reaction mixture to aqueous base.  
Scheme 2.11 Attempted alkylation of 71. 
NHBocMeO2C
H
•
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H
H
H
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H
H
H
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• H
BocN
HMeO2C
not observed
 
Attempting to N-alkylate 71 using milder basic conditions (Cs2CO3, TBAI and 1-bromo-2-
butyne) led only to the diene isomer 72, which is not surprising since it was shown that Cs2CO3 
alone promotes this facile isomerization. Since treatment of 71 with base appeared to cause 
isomerization to 72, further experiments towards preparing a glycine-derived allenyne were 
suspended.  
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3.0  Synthesis and Use of Cross-Conjugated Trienes 
3.1 Transition Metal-Catalyzed Ene-type Cycloisomerization Reactions 
The ene reaction is recognized as a thermal pericyclic reaction of an olefin containing an 
allylic hydrogen (ene) and a multiple bond (X=Y, enophile), resulting in formation of a new C-C 
and Y-H bond as shown in Scheme 3.1.65 The reaction was first discovered by Alder in 1943, 
and is often referred to as the Alder-ene reaction.66 Since then, intramolecular variants have been 
studied extensively. Depending on the placement of the ene component in the starting material, 
there are three types of intramolecular ene reactions: type I – connected via the olefin terminal; 
type II – connected via the central carbon; and type III – connected via the allylic terminal.67
Scheme 3.1 Classification of ene reactions. 
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∆
∆
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H
∆
H H
Type II
Type I
H
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Y
X
Y
H
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1
2
3
1
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3
X=Y : C=C, C=O, C=S, O=O, N=O etc.
three types of intramolecular ene-reaction
 
Thermal ene reactions of unactivated substrates generally require very high temperatures 
between 300-500 °C to proceed, which has limited their direct application in synthesis. To 
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circumvent this issue, variants such as the metallo-ene reaction have been developed. In this 
case, the transfer of hydrogen is replaced by a metal (lithium, magnesium, zinc) and requires 
milder conditions.68 More recently, transition metals have been used to effect ene-type reactions. 
In this regard, 1,n-enynes have served as a standard substrate class for development of new 
methodologies.37-39 Because an alkyne is used as an enophile component, the product of the 
rearrangement is generally a 1,4- or 1,3-diene (81 or 82) (Scheme 3.2).  Transition metal 
catalyzed ene-reactions do not occur via the classical pericyclic mechanism, and they are often 
referred to as formal ene reactions or ene-type cycloisomerizations. A recent review by 
Malacria39 has categorized the three mechanisms by which enyne cycloisomerization can occur: 
path a involves simultaneous complexation of the metal to the olefin and the alkyne, leading to 
oxidative addition and formation of a metallocycle 78. This intermediate then undergoes a β-
hydride elimination from one allylic position giving the product; path b occurs via a π-allyl 
complex 79 formed by insertion of the metal into the allylic position; and path c involves a 
carbo- or hydrometalation of the alkyne leading to vinyl-metal species 80, which then undergoes 
carbometallation of the olefin. 
Scheme 3.2 Transition metal-catalyzed ene-type cycloisomerization of enynes. 
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A number of metals have been used to effect enyne cycloisomerization via these three pathways, 
including Pd, Ru, Fe, Ni, Rh, and Ir.39 The metallocycle pathway is particularly intriguing since 
these intermediates have proven high synthetic utility otherwise. For example, metallocyclic 
intermediates formed from enynes have been utilized in processes such as cyclocarbonylation, 
[2+2], [4+2], [2+2+2] and [5+2] cycloadditions etc.40-42  
Some of the first examples of enyne cycloisomerization were reported by Trost employing Pd(II) 
catalyst.69 For example, enyne 83 rearranges to 1,4-diene 84 when treated with 5 mol % 
(PPh3)2Pd(OAc)2 (Scheme 3.3).69a When steric bulk is introduced at the terminal allylic position 
by a cyclohexyl substituent (85), 1,3-diene 86 is obtained. The former transformation has been 
extensively applied by Trost to the total synthesis of several natural products.70
Scheme 3.3 Pd(II)-catalyzed cycloisomerization of enynes. 
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E
E
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85 86  
More recently, Zhang has successfully performed Rh(I)-catalyzed enyne cycloisomerizations 
exclusively affording 1,4-dienes. A cationic Rh(I) complex containing a 1,4-diphosphine ligand 
(either dppb or 2,2’-bisdiphenylphosphine-1,1’-dicyclopentane - BICPO71) was shown to 
catalyze the cycloisomerization of a variety of enynes 87 leading to 5-membered carbo- and 
heterocycles 88 (Scheme 3.4).72 This method is limited to cis-alkenes, while trans-alkenes 
proved unreactive. Nevertheless, Rh(I) catalysts have proven highly advantageous, since most 
reactions can be performed at rt and the phosphine ligands can be readily tuned to develop an 
enantioselective version of the reaction. This idea was put into practice by Zhang by utilizing 
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BINAP as a chiral ligand to obtain various 5-membered carbo- and heterocycles with high 
enantiopurity (>99% ee) (89 to 90, Scheme 3.4).73
Scheme 3.4 Rh(I)-catalyzed cycloisomerization of enynes. 
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3.1.1 Allenic Cycloisomerization Reaction. 
The first example of allenyne cycloisomerization was provided by Malacria in 1996 by 
transforming 91 to cross-conjugated triene 93 using stoichiometic amount of CpCo(CO)2 in 
refluxing xylene (Scheme 3.5).74 A mechanism involving a π-allyl Co-hydride species 92 was 
invoked to explain this result. Presumably, reaction with the distal double bond of the allene was 
directed by the sterically demanding t-butyl group on the proximal carbon. 
Scheme 3.5 Allenic cycloisomerization reported by Malacria. 
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 Additionally, Sato reported the formation of 5-membered cross-conjugated trienes 97 from 
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allenynol derivatives 95 proceeding via a metallocyclic intermediate 96, by using stoichiometric 
(η2-propene)Ti(i-PrO)2 (Scheme 3.6).75 Livinghouse and Oh have also observed cross-conjugated 
trienes during transition-metal catalyzed reactions of allenynes.76
Scheme 3.6 Allenic cycloisomerization reported by Sato. 
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In 2002, Brummond reported the first systematic study of the Rh(I)-catalyzed allenic 
Alder-ene reaction.77 It was shown that [Rh(CO)2Cl]2 serves as a very general catalyst for 
converting allenynes into cross-conjugated trienes. For example, the cycloisomerization of 98 
using 2 mol % catalyst, at 90 °C gives triene 99 in 72% yield (Scheme 3.7). The appending 
olefin is obtained as a kinetic mixture of E : Z isomers (5 : 1), while the exocyclic olefin is 
obtained as a single isomer with E-geometry. 
Scheme 3.7 Rh(I)-catalyzed allenic Alder-ene reaction. 
•
CH2C7H15
H
TMS
2 mol % [Rh(CO)2Cl]2
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TMS
98 99 E : Z = 5 : 1
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H2
H1 4.5 % nOe
 
A mechanism based on a deuterium labeling study has been proposed to account for these 
observations (Scheme 3.8). The first step is complexation of the Rh(I) to the alkyne and the distal 
double bond of the allene, eventually leading to a metallocyclic Rh(III) intermediate 102 via 
oxidative addition. The next step involves elimination of a β-deuteride (hydride) leading to a 
Rh(III)-deuteride species 103, which undergoes a facile reductive elimination setting the 
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stereochemistry of the exocyclic olefin in the triene 104 and regenerating the active catalyst.  
Scheme 3.8 Mechanism of the Rh(I)-catalyzed allenic Alder-ene reaction. 
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According to the proposed mechanism, the stereochemistry of the appending olefin in the 
resulting triene is set during the β-hydride elimination step. Brummond and coworkers have 
shown that the selectivity for the E-isomer in the reaction of 98 (Scheme 3.7) can be drastically 
increased (>100 : 1) by utilizing an in situ generated cationic Ir(I) catalyst ([Ir(COD)Cl]2, 
AgBF4). This protocol, however, was limited to substrates containing a silicon group on the 
terminus of the alkyne. 
The scope of the [Rh(CO)2Cl]2-catalyzed reaction has been demonstrated on carbon, 
nitrogen and oxygen tethered allenynes. With most substrates, the reaction proceeds at rt 
affording a variety of trienes in good yields (Scheme 3.9). 
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Scheme 3.9 Examples of Rh(I)-catalyzed allenic Alder-ene reaction. 
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Finally, it should be noted that following the initial report by Brummond, Shibata78 and Mukai79 
have also reported Rh(I)-catalyzed cycloisomerization of allenynes leading to cross-conjugated 
trienes.80  
In summary, the Rh(I)-catalyzed cycloisomerization of allenynes allows rapid access to cyclic 
cross-conjugated trienes. Additional studies in the Brummond group have been aimed at 
extending the scope and utility of this transformation. The presence of three stereodefined olefins 
in the cross-conjugated trienes makes them valuable synthetic intermediates, and offers unique 
opportunities for exploiting these compounds in target- and diversity-oriented synthesis. 
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3.2 Rhodium(I)-Catalyzed Allenic Cycloisomerization Reaction of Amino-Ester 
Tethered Allenynes 
Synthetic investigations started with the Rh(I)-catalyzed allenic Alder-ene reaction. 
When allenyne 73a was submitted to the optimized reaction conditions (5 mol % [Rh(CO)2Cl]2, 
toluene),77 cycloisomerization proceeded at rt in less than 10 min to give the expected cross-
conjugated triene 111a in 80% yield (Scheme 3.10).81 The structure of triene 111a was assigned 
based on the characteristic olefin resonances in the 1H NMR spectrum (Scheme 3.11). Triene 
111a was obtained as a single isomer of the exocyclic olefin, which is assigned Z-geometry in 
accordance with previous examples and mechanistic studies by Brummond and coworkers (vide 
supra, Schemes 3.7 to 3.9).77  
Scheme 3.10 Allenic Alder-ene reaction of 73a. 
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Scheme 3.11 1H NMR of 111a (olefin region, CDCl3, rt, 300 MHz). 
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The scope of this transformation was next examined by varying different substituents on the 
allenyne. First, only allenynes substituted with a methyl group on the terminal allenic position 
were tested to avoid formation of E/Z isomers of the appending olefin. In all cases, the reaction 
proceeded in 10 min to afford the cross-conjugated trienes 111b-111i (Table 3.1). The reaction 
conditions were compatible with either a Bz- (entries 1-4) or Cbz- (entries 5-8) protected amine. 
Allenynes 73b and 73g with a terminal alkyne reacted to give 111b and 111g in 74% and 84% 
yield, respectively (entries 1 and 6). Substitution of the alkyne terminus with either a TMS 
(entries 2 and 7) or phenyl group (entries 3 and 8) resulted in the corresponding trienes in yields 
ranging between 81-95%. Finally, variations at the amino acid side chain R1 with a methyl 
(entries 5-8), benzyl (entries 1-3) and silyloxymethylene (entry 4) group were also incorporated 
without event.  
Table 3.1 Allenic Alder-ene reaction affording cross-conjugated trienes. 
• H
N
R1MeO2C
R2
5 mol % [Rh(CO)2Cl]2
toluene, rt, 10 min
N
P
MeO2C
R1
R2
111b-i
P
entry      allenyne      P             R1            R2        triene       yield%     entry      allenyne      P         R1         R2        triene       yield%
 
   1          73b           Bz           Bn            H          111b           74           5           73f           Cbz      Me       Me        111f              81
 
   2          73c           Bz           Bn          TMS       111c           92           6           73g           Cbz      Me        H         111g             84
   
   3          73d           Bz           Bn            Ph        111d           81           7           73h          Cbz      Me      TMS       111h             87
 
   4          73e           Bz     -CH2OTBS    Me        111e           89           8           73i           Cbz      Me        Ph         111i              95
73b-i
 
It is noteworthy to mention that Bz-protected allenynes (73a-73e, entries 1-4 and Scheme 3.1) 
were subjected to the reaction conditions as mixtures of diastereomers (~1.7 : 1, see Chapter 2) 
while the Cbz-protected allenynes (entries 5-8) were nearly single isomers (all compounds are 
racemic; see Chapter 2 for preparation of allenic amino-esters). Nevertheless, all reactions 
resulted in the corresponding cross-conjugated triene as a single isomer indicating that the 
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exocyclic olefin geometry is not related to the relative stereochemistry of the allenyne, and is a 
result of the last reductive elimination step in the mechanism of the reaction.b  
It should be noted that the rate with which the reaction of these amino-ester tethered 
substrates proceeded was noticeably higher compared to previous examples reported by 
Brummond and coworkers, some of which required up to 6 h for completion.77 That the 
increased reactivity of the amino-ester substrates is likely a result of a Thorpe-Ingold effect 
imposed by the quaternary center adjacent to the allene.82 In addition, the carbomethoxy group 
may play a directing role by reversibly coordinating to the metal center.83
Next, variations of the substituents on the allene moiety were tested (Scheme 3.12). Allenyne 
73j, substituted with an isopropyl group at the terminal allenic position reacted to afford triene 
111j with trisubstituted appending olefin in 95% yield. In this case, there is only one hydrogen 
atom that can undergo β-hydride elimination. This does not affect the rate or the yield of the 
reaction, since 111j was produced in 95% yield after 10 min.  
Scheme 3.12 Preparation of polysubstituted trienes 111j-111l. 
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b For the proposed mechanism of the reaction, see Scheme 3.8. 
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Additionally, trisubstituted allenes 73k and 73l underwent the Alder-ene reaction affording 111k 
and 111l in 78% and 80% yield, respectively. In the case of 111l, only the E isomer of the 
appending olefin was observed, characterized by J = 16.0 Hz for the vinyl hydrogens in the 1H 
NMR spectrum. This is in contrast to earlier examples from the Brummond group, where Rh(I)-
catalyzed reaction of alkyl allenes resulted in mixture of appending olefin isomers in E/Z ratio in 
the range of 3-6 : 1.77 The geometry of the appending olefin is determined during the β-hydride 
elimination step of the reaction mechanism, which requires a coplanar arrangement of the Rh-C 
bond and the C-H bond that is being broken. Therefore, β-hydride elimination in the formation 
of 111l can occur via rotamer A or B as shown in Scheme 3.13. Rotamer B, which would lead to 
the Z-olefin isomer, results in an unfavorable steric interaction between the appending alkyl 
group and the methyl substituent in the ring and is strongly disfavored. Therefore, β-hydride 
elimination via rotamer A leads to the exclusive E-isomer 111l. 
Scheme 3.13 Mechanistic rationale for the exclusive E geometry of 111l. 
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3.2.1 Preparation of Enol-ether Trienes via an Allenic Cycloisomerization Reaction 
The success of the Rh(I)-catalyzed allenic cycloisomerization reaction of amino-ester 
tethered substrates prompted further examination of the scope of this transformation. In these and 
previous examples from the Brummond group, variations of the substitution pattern of the allene 
have been limited to introducing different alkyl groups. Consequently, the resulting trienes 
possess three cross-conjugated olefins with similar electronic properties, and are expected to 
react unselectively with various electrophilic reagents (e.g., epoxidation and dihydroxylation 
agents). Being able to perform selective reactions on the three olefins is important in applying 
these compounds to complex molecule synthesis. Therefore, we were interested in preparing 
trienes in which the olefins are electronically differentiated. Although a number of different 
strategies can be undertaken towards this goal, we became particularly interested in preparing 
trienes possessing an electron rich enol-ether as the appending olefin. Preparing this class of 
trienes was envisioned by cycloisomerization reaction of allenynes possessing a protected 
alcohol group at the allylic position of the allene (Scheme 3.14). According to the proposed 
mechanism of the reaction, β-hydride elimination in metallocycle 113 would have to occur from 
a carbon possessing an oxygen substituent. The feasibility of this process has been demonstrated 
by Trost84 in the Ru(II)-catalyzed and Zhang85 in the Rh(I)-catalyzed cycloisomerization of 1,5-
enynes to prepare five-membered rings possessing an appending enol ether. 
Scheme 3.14 Proposed cycloisomerization to form enol-ether trienes. 
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The requisite allenynes of general structure 112 were prepared as outlined in Scheme 3.15. The 
mono-benzyl protected diol 116a was synthesized in >95% yield by addition of ethynyl-
magnesium bromide to commercially available aldehyde 115a. The corresponding mono-TBS 
protected diol 116b was prepared by diprotection of 1,4-butanediol with TBSCl, followed by 
ozonolysis and alkynylation of the resulting aldehyde. With alcohol 116b in hand, the 
DCC/DMAP mediated coupling with Bz-phenylalanine was attempted under the standard 
conditions (rt, in CH2Cl2). However, this reaction led only to formation of the oxazolone 
intermediate 55a. It was reasoned that the sterically hindered nature of the secondary alcohol 
prevents the facile opening of 55a under the reaction conditions. To solve this problem, 55a was 
formed by separately treating benzoyl-phenylalanine with DCC and DMAP. Upon isolation, the 
oxazolone was treated to neat alcohol 116a or 116b in presence of catalytic amount of Et3N. 
Under these conditions formation of esters 120a and 120b was observed, albeit in relatively low 
isolated yields (54% for the benzyl-protected and 32% for the TBS-protected alcohol). The lower 
yield for the TBS-protected case is attributed to increased steric influence by the silyl group. 
Next, the Claisen rearrangement of these propargyl esters 120a and 120b was attempted under 
dehydrative conditions reported by Krantz. Reaction of the benzyl-protected 120a proceeded at 
40 °C to give the desired allene 121a in >95% yield after treatment with MeOH. In contrast, the 
reaction of the TBS-protected 120b required heating to 60 °C and afforded the product 121b in 
lower yield (76%). Notably, formation of methyl ester was accomplished by using MeOH/Et3N 
instead of the standard MeOH/HCl in order to avoid potential cleavage of the TBS-ether under 
strong acidic conditions. As expected, allenes 121a and 121b were obtained as mixtures of 
diastereomers in ~2 : 1 ratio determined by 1H NMR. 
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Scheme 3.15 Synthesis of cycloisomerization precursors 122a-c. 
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Finally, the desired cycloisomerization precursors 122a and 122b were prepared by alkylation 
with 1-bromo-2-butyne in presence of NaH. Removal of the TBS protecting group in 122b was 
accomplished using TBAF, to obtain allenic alcohol 122c in 62% yield (2 steps from 121b). 
Precursors 122a-c were next tested in the Rh(I)-catalyzed cycloisomerization reaction. 
Treatment of 122a to 5 mol% [Rh(CO)2Cl]2 led to the formation of the expected triene 123a 
which was isolated in 64% yield after 1 h (Scheme 3.16). Triene 123a was obtained as a mixture 
of E and Z isomers of the vinyl-ether in 8 : 1 ratio (determined by integration of the olefinic 
resonances in the 1H NMR spectrum; the E isomer is characterized by a coupling constant of J = 
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12.5 Hz for the vinyl hydrogens, compared to J = 7.9 Hz for the Z-isomer). The rate of this 
cycloisomerization was somewhat slower than the previous examples of alkyl-substituted allenes 
(from Table 3.1), and took approximately 1 h for completion (following the reaction by 1H NMR 
showed 1 : 1 ratio of product and starting material after 15 min). The TBS-protected allenyne 
122b reacted similarly, affording silyl enol ether 123b in 60% yield and increased selectivity for 
the E-olefin (>10 : 1 ratio determined by integration of the olefin resonances in the 1H NMR 
spectrum). 
Scheme 3.16 Cycloisomerization of 122a and 122b. 
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Finally, the cycloisomerization of the free alcohol 122c was tested (Scheme 3.17). Upon addition 
of 5 mol% [Rh(CO)2Cl]2, the starting material was consumed in 1.5 h at rt, to give a mixture of 
two aldehydes in 2 : 1 ratio based on integration of the aldehyde proton resonances in the 1H 
NMR spectrum (the two aldehydes were obtained in unoptimized 50% yield). Unfortunately, 
these aldehydes could not be separated by flash chromatography. The major isomer was assigned 
structure 124, based on the presence of a triplet for the aldehyde proton Ha (J = 2.4 Hz), and a 
singlet for the olefinic proton Hb within the ring. The minor isomer displayed a doublet for the 
aldehyde proton Ha suggesting structure 125.  Presumably, the initial product of the reaction is 
trienol 123c, which tautomerizes in 1,2- or 1,4-fashion to give the two aldehydes. Alternatively, 
aldehyde 125 could arise from 124 by isomerization of the endocyclic olefin into conjugation 
with the aldehyde. 
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Scheme 3.17 Cycloisomerization of allenic alcohol 122c. 
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 In summary, the scope and limitations of the Rh(I)-catalyzed allenic Alder-ene reaction 
of amino-ester tethered allenynes were explored. The reaction displays a broad scope and 
functional group compatibility proving it ideal for DOS. Although the triene products obtained in 
this manner may serve as useful biological probes, the potential reactivity of the triene moiety in 
biological systems was concerning. Instead, it was reasoned that this reactivity can be exploited 
towards the efficient assembly of more complex molecular scaffolds. These efforts are described 
next. 
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3.3 Diversification of Cross-Conjugated Trienes via Diels-Alder Reaction 
3.3.1 Intermolecular Diels-Alder Approach – First Generation Triene 
Sequential Diels-Alder reactions of the amino ester trienes can quickly lead to complex 
molecular scaffolds, particularly if two different dienophiles are utilized in tandem fashion. 
Sequential Diels-Alder reactions of acyclic cross-conjugated trienes 125 affording functionalized 
decalins 127 were initially studied by Tsuge,86 who utilized bis-silylenolether 128, and by Fallis, 
who employed monosubstituted triene 129 (Scheme 3.18).87 However, sequential reactions of 
these acyclic trienes have proven difficult to control, typically affording mixtures of 
regioisomers. Moreover, preparation of the acyclic trienes is not trivial, in part due to their 
instability and tendency to polymerize.88, 89 Therefore, these compounds have seen only limited 
synthetic application, despite their potential.90  
Scheme 3.18 Tandem Diels-Alder reactions of acyclic cross-conjugated trienes. 
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Acyclic cross-conjugated tetraene ([4]dendralene-130) has also been recently examined for 
participation in tandem Diels-Alder reactions by Willis and coworkers (Scheme 3.19).91 For 
example, the reaction of 130 with excess N-methylmaleimide affords a mixture of mono-, di and 
tri-cycloaddition products. Nevertheless, this example underlines the fact that rapid increase in 
molecular complexity can be obtained via tandem cycloaddition reactions of cross-conjugated 
polyenes. 
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Scheme 3.19 Tandem cycloadditions of [4]-dendralene reported by Willis. 
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It was reasoned that the cyclic trienes obtained via an allenic Alder-ene reaction (Table 3.1) 
could offer a solution to the regioselectivity issues in these tandem cycloaddition reactions by 
locking one diene in an unreactive s-trans conformation. We were interested in exploring the 
feasibility of both cycloaddition pathways illustrated in Scheme 3.20. Pathway A involves 
sequential intermolecular cycloaddition reactions of triene 111 using two different dienophiles 
(111→138→139). Alternatively, pathway B, involves an intra-/intermolecular cycloaddition 
sequence (111→140→141→142).  
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Scheme 3.20 Diels-Alder reactions of triene 111. 
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Exploring these pathways offers an opportunity to study the reactivity of cyclic cross-conjugated 
trienes as novel chemical entities. Furthermore, it was reasoned that these rigid and 
conformationally defined polycycles would serve as useful biological probes. In medicinal 
chemistry, conformationally defined polycyclic small molecules often exhibit higher potency and 
specificity of binding to biological targets compared to their acyclic analogues, since they do not 
have to undergo conformational changes in order to adapt to a binding site.92
The more direct pathway A was initially more appealing, so investigations began with the 
reaction of triene 111f with N-phenylmaleimide (Scheme 3.21). Unfortunately, the initial Diels-
Alder cycloadduct 143 was not observed, but it immediately underwent a second Diels-Alder 
reaction to afford 144 as a 5 : 2 : 1 mixture of diastereomers in 83% yield. The ratio of 
diastereomers was determined by normal phase HPLC, which allowed their complete 
separation.c
 
 
                                                 
c The ratio was determined by integration of the peaks in the HPLC trace (refractive index detector was used). 
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Scheme 3.21 Intermolecular Diels-Alder reaction of 111f. 
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The relative stereochemistry of the major diastereomer from this mixture was assigned by X-ray 
crystallography, and results from endo selectivity in the first cycloaddition occuring from the 
same face of the methyl group, while the second dienophile adds from the less hindered convex 
face of the newly formed diene in endo mode (Appendix A). Attempts to obtain the cycloadduct 
143, by reaction of 111f with equimolar amount of dienophile resulted in formation of 144 and 
recovered triene. This result is attributed to the higher reactivity of the second diene of 143 
because it is locked in an s-cis conformation. Other dienophiles (maleic anhydride and 4-phenyl-
[1,2,4]-triazole-3,5-dione) also reacted with 111f to give mixtures of diastereomeric products 
similar to 144. Although the cycloaddition reaction of 111f illustrated in Scheme 3.21 affords a 
complex molecular scaffold in a rapid manner, obtaining the product as a mixture of 
diastereomers discouraged applying this reaction to library synthesis. Biological testing of 
mixtures of multiple compounds may complicate the interpretation of the results. Although 
separation of the diastereomers by HPLC was feasible it may prove costly and time consuming 
when preparing a larger scale library. Therefore, controlling the chemo- and diastereoselectivity 
of the Diels-Alder reaction of the triene was important, and a new strategy for tandem 
intermolecular cycloaddition was considered.  
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3.3.2 Intermolecular Diels-Alder Approach-Second Generation Triene 
It was reasoned that tying back the appending ester in a ring would increase the reactivity 
of the diene in the first Diels-Alder reaction by reducing the steric bulk. Moreover, this 
constraint leads to a sterically biased triene, in which one face is blocked by the R1 group. 
Finally, introducing an electron withdrawing carbonyl group at the C6 position would slow the 
second Diels-Alder reaction. The novel imidazo-pyridinone triene 147 addresses all of these 
issues (Scheme 3.22).  
Scheme 3.22 Novel fused bicyclic Diels-Alder precursor 147. 
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Putting the synthesis of 147 into practice required examination of the Rh(I)-catalyzed 
cycloisomerization of amide-tethered allenyne 145 to form δ-lactam triene 146. Traditionally, 
lactams are synthesized via carbon-nitrogen bond formation. For example, lactams are formed 
via dehydration of amino-acids,93 by cyclization of an amide onto an alkene,94 alkyne95 or an 
allene,96 and intramolecular vinylation of amides.97 Alternatively, lactams can be synthesized 
from ketones by Schmidt or Beckmann rearrangement.98 There are very few examples of lactam 
syntheses via transition metal catalyzed carbon-carbon bond formation, and most involve a ring-
closing metathesis.99 Synthesis of lactams via cycloisomerization reaction appears particularly 
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attractive, since additional functionality is generated in the course of the reaction (a cross-
conjugated triene in this case). Surprisingly, there are only few examples of lactam formation via 
cycloisomerization reactions, and are strictly limited to preparing γ-lactams. For example, in 
1999, Lu reported a Pd(0)-catalyzed tandem cyclization/amination of dienyne 148 leading to α-
alkylidene-γ-lactam 149 (Scheme 3.23).100 More recently, Zhang reported an enantioselective 
Rh(I)-catalyzed cycloisomerization of amide-tethered enyne 150, affording γ-lactam 151 with 
>99% ee.101 Notably, both reports used a benzyl protected amide, and Zhang reported that 
reaction did not proceed with the unprotected amide. 
Scheme 3.23 Transition metal-catalyzed formation of γ-lactams. 
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To test the feasibility of a Rh(I)-catalyzed formation of δ-lactam trienes, amide-tethered 
allenynes 145a-145d were synthesized by Boc-deprotection of amine 65f to 152 followed by 
coupling with alkynoic acids 153a-d (Scheme 3.24). The use of a DCC/DMAP coupling protocol 
(conditions A) proved useful in preparing amides 145b and 145d in sufficient amounts for 
testing the subsequent cycloisomerization reaction (~100 mg). Nevertheless, this protocol results 
in formation of additional byproducts including dicyclohexylurea which made the purification 
difficult, and the yields irreproducible. To circumvent this issue, an alternative protocol was 
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applied for the preparation of 145a and 145c.d Treatment of the alkynoic acid with 
isobutylchloroformate and N-methylmorpholine afforded a mixed anhydride, which was treated 
in situ with amine 152 to give the corresponding amide. This proved a robust protocol, which 
reproducibly gave 70-85% yield of the desired amides. 
Scheme 3.24 Preparation of amide-tethered allenynes. 
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With these allenynes in hand, the cycloisomerization reaction was tested (Table 3.2). When 145a 
was subjected to the optimized conditions for triene formation (5 mol% [Rh(CO)2Cl]2, toluene, 
0.3M), reaction did not occur at rt (entry 1). Instead, triene formation was effected by heating 
145a to 90 °C. With this information in mind, the catalyst loading was varied between 2.5 and 10 
mol% (entries 2-4) to establish its effect on the efficiency and yield of the reaction at 90 °C. All 
reactions were performed in toluene at 0.03M concentration.e  With, 2.5 mol% the reaction was 
relatively sluggish and consumption of the starting material was incomplete after 90 min, 
affording triene 146a in only 18% yield (along with ~50% recovered starting material). 
Increasing the catalyst loading to 5 mol% resulted in shorter reaction time of 50 min and 
                                                 
d This protocol was first applied to the synthesis of related amides by Dr. Donald A. Probst. 
e Work performed by Dr. Donald A. Probst determined that running the reaction at higher concentration (0.1-0.5M) 
leads to formation of an unidentified polymeric side product and lowers the yield of triene. 
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increased yield of the triene (47%). Further increase in catalyst loading to 10 mol% resulted in 
complete consumption of the starting material in less than 30 min, and 92% yield of the triene 
146a (this reaction was performed on ~1g of 145a, demonstrating the scalability of the reaction). 
Next, the cycloisomerization of propynamide 145b was tested with 10 mol% of catalyst. 
Consumption of the starting material occurred after 2h and resulted in 146b isolated in only 45% 
yield (entry 5). Trimethylsilyl (145c) and phenyl (145d) substituted propynamides also 
underwent the rearrangement to afford the corresponding trienes 146c and 146d in 77% and 66% 
yield, respectively (entries 6 and 7). Notably, the reaction of the TMS-substituted alkyne 
required only 15 min. 
Table 3.2 Synthesis of δ-lactam trienes. 
• H
HN
Bn
MeO2C
R
 [Rh(CO)2Cl]2
toluene (0.03M), 90 oC
HN
MeO2C
Bn
R
146a-d
O O
entry      allenyne              R          catalyst (mol%)      time        triene          yield%   
  
   1            145a                Me                 5                                   146a             0a
   2            145a                Me                2.5              90 min        146a             18b
   3            145a                Me                 5                45 min        146a             47b
   4            145a                Me                10               30 min        146a             92
   5            145b                H                  10              120 min        146b            45
        
   6            145c                TMS             10               15 min         146c            77         
   
   7            145d                Ph                10                30 min        146d            66
a conditions: 5 mol% [Rh(CO)2Cl]2, toluene, rt; 
b Incomplete reaction;starting material was recovered.
145a-d
 
The higher temperature required to effect the cycloisomerization of these unprotected amides is 
attributed to a prefered trans-conformation of the secondary amide, placing the reactive termini 
away from each other (Scheme 3.25).102  
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Scheme 3.25 Amide bond rotamers of 145a. 
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To confirm this, allenyne 145e with benzamide protection on the amide nitrogen was synthesized 
in 69% yield by treatment of 145a with BzCl at 70 °C (Scheme 3.26). Indeed, reaction of this 
precursor using 10 mol% of [Rh(CO)2Cl]2 occurred in less than 1h at rt, affording cross-
conjugated triene 146e in 75% yield. 
Scheme 3.26 Preparation and cycloisomerization of 145e. 
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With a synthetic route to lactam triene 146a, a facially differentiated precursor for the 
Diels-Alder reaction was next prepared. Saponification of the methyl ester occurred within 5 min 
upon treatment of 146a with LiOH. After aqueous work-up, the acid was obtained in sufficient 
purity (by 1H NMR) and was immediately coupled with glycine-methyl ester using EDCI, HOBt 
and DMAP to give diamide 154a (Scheme 3.27). In order to complete the synthesis of hydantoin 
147a, amide 154a was reacted with phosgene (COCl2). Interestingly, the exclusive product of the 
reaction was the unexpected imino-oxazolidinone 155a in 55% yield for three steps (this 
structural assignment was made later based on an X-ray crystal structure of the Diels-Alder 
product 156a, vide infra). Nevertheless, imino-oxazolidinone 155a should provide the same 
steric and electronic control elements as hydantoin 147a. An additional substrate functionalized 
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as an isobutyl-amide 155b was prepared using the same protocol in 41% yield over three steps. 
To our knowledge, oxazolidinones with this substitution pattern have not been reported.103  
Scheme 3.27 Synthesis of novel imino-oxazolidinone trienes 155a and 155b. 
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It was rationalized that the imino-oxazolidinone 155a resulting from O-acylation of the 
appending amide is a kinetic product of the reaction, and a consequence of the preferred 
conformation of the amide side chain in 154a.  To confirm this, computational modeling of 154a 
was performed using Cache. The energy minimized model placed the appending amide oxygen 
O2 and lactam nitrogen N1 of 154a in the same direction, confirming the observed reactivity 
(Figure 3.1).f Finally, it should be noted that the newly obtained imino-oxazolidinone ring in 
155a and 155b proved relatively sensitive to silica gel, since prolonged chromatographing led to 
opening to the parent diamides 154a and 154b, respectively. 
 
 
 
 
 
 
                                                 
f Energy minimization was performed with Cache Worksystem Pro. version 6.1.10. First, global minimum search 
was performed using MM3 parameters, followed by optimization of the side chain conformation with AM1 
parameters. Then, energy minimization of the sample was performed using AM1 parameters. 
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Figure 3.1 Stereoviews of the energy minimized models of 154a and 155a. 
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The newly obtained bicyclic triene 155a was also modeled in order to visualize its three-
dimensional structure. As illustrated in Figure 3.1 the fused bicyclic structure is relatively planar 
due to the presence of multiple sp2-hybridized atoms and the bottom face is blocked by the 
benzyl substituent. Therefore, cycloaddition reaction with the diene is expected to occur 
selectively with the top face (the facial assignment is relative since all compounds are racemic). 
To test this hypothesis, triene 155a was reacted with N-phenylmaleimide (1.3 equiv.). Reaction 
occurred in less then 1 h at 90 °C to afford the cycloadduct 156a in 73% yield as a single 
diastereomer (Scheme 3.28). The relative stereochemistry of 156a was assigned by X-ray 
crystallography, confirming that the cycloaddition occurred with endo selectivity and the diene 
approached from the opposite face of the benzyl group (Appendix B). Excess dienophile (2 
equiv) still gave exclusive formation of 156a, indicating a reduction in the rate of the second 
cycloaddition. Similarly, cycloaddition of 155b with N-methylmaleimide resulted in formation of 
156b in 95% yield as a single diastereomer. Additional experimentation by Dr. Yan (Brummond 
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group) demonstrated that this cycloaddition is limited mainly to using maleimides.104 Other 
dienophiles (diethylfumarate, p-benzoquinone and dimethylacetylene dicarboxylate) generally 
gave yields of the cycloadduct lower than 50%. 
Scheme 3.28 Diels-Alder reaction of imino-oxazolidinones 155a and 155b. 
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The X-ray crystal structure of 156a reveals several interesting features. As a result of the endo-
cycloaddition occurring from the concave face of 155a, the product adopts a folded shape with 
the N-phenylpyrrolidinone moiety projecting directly above the new diene system (Figure 3.2). 
Moreover, the two double bonds of the 1,3-diene are twisted out of planarity by a 39.9° angle. In 
addition, the α,β-unsaturated amide is also twisted in the opposite direction by 42.4°.  
Figure 3.2 Stereoview of the X-ray crystal structure of 156a with diene and amide torsional 
angles. 
torsional angle
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torsional angle
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These steric and electronic features of the new diene significantly impart its reactivity towards 
electron poor dienophiles. For example, the second cycloaddition of the new diene could not be 
effected using electron deficient dienophiles, except with diethylfumarate (demonstrated by Dr. 
Bingli Yan). Therefore ethyl vinyl ether was examined as a small, electron rich dienophile to 
better match the character of the diene. Heating 156a in a mixture of toluene/ethylvinylether at 
90 °C afforded 70% yield of pyran 157a. This was somewhat unexpected since only a few 
inverse electron demand hetero-Diels-Alder reactions of α,β-unsaturated amides have been 
reported, and generally result in formation of an aromatic compound (e.g., indole, thiazole, 
pyrazole).105 Since lanthanide Lewis acids including Eu(fod)3 have been used to catalyze hetero-
Diels-Alder reactions, we tested this reagent to accelerate the cycloaddition of 156a and ethyl 
vinyl ether. With 10 mol% of Eu(fod)3, the reaction proceeded at rt, giving 157a in 95% yield as 
a single diastereomer (Scheme 3.29).106 Exposure of 157a to aqueous HCl afforded aldehyde 
158a, resulting from hydrolysis of the acetal moiety and isomerization of the double bond into 
conjugation with the amide. 
Scheme 3.29 Hetero Diels-Alder reaction of 156a with ethyl vinyl ether. 
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Next, hydrolysis of the oxazolidinone moiety in 156a to the parent diamide was explored 
as means to introduce structural diversity in the products and increase the number of hydrogen-
bond donors. It was anticipated that this transformation would increase the water solubility of 
these compounds, and improve their pharmacological profile.8 When 156a was heated to 70 °C 
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in 1M HCl/dioxane (1 : 1) for 1h, the hydrolysis product was not observed and the starting 
material was recovered in ~80% yield. The stability of the imino-oxazolidinone in this 
compound to acidic conditions is in sharp contrast to the bicyclic-triene 155a which is readily 
hydrolyzed in presence of aqueous acid.g Next, an attempt was made to cleave the imino-
oxazolidinone under Lewis acid conditions, by using a combination of BF3OEt2 and Me2S 
(conditions that have been utilized previously to cleave a Cbz protecting group).107 
Unfortunately, these conditions did not effect the desired transformation either (starting material 
was recovered in 86% yield). On the contrary, treatment of 156a with LiOH in THF/H2O caused 
complete decomposition.108  
Since both acidic and basic conditions failed to cleave the imino-oxazolidinone moiety in 
156a, its susceptibility to primary amines as nucleophilic reagents was next examined. To this 
end, a solution of 156a in CDCl3 was treated with benzylamine and the reaction was followed by 
1H NMR.  
Scheme 3.30 Reaction of 156a with benzylamine. 
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Although cleavage of the oxazolidinone moiety occured as established by the appearance of new 
amide and urea N-H resonances in the downfield region (8-9 ppm), a gradual disappearance of 
both olefinic peaks of the diene was observed. Based on these observations, it was speculated 
                                                 
g Personal communication by Dr. Bingli Yan 
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that the final product of the reaction is 160a resulting from cleavage of the imino-oxazolidinone 
and 1,4-addition of benzyl amine to the α,β-unsaturated amide, followed by isomerization of the 
remaining olefin into conjugation within the δ-lactam ring (Scheme 3.30, via intermediacy of 
159a). 
Since this 1,4-addition side process was not desired, reduction of the diene in 156a and 156b was 
attempted using Pd/C and H2 (1 atm). Interestingly, complete reduction of either substrate was 
not observed after 4h at rt, but the α,β-unsaturated amides 161a and 161b were isolated in 80% 
and 95% yield respectively (Scheme 3.31). This result is again attributed to the steric hindrance 
around the diene. Presumably, reduction of the more accessible exocyclic double bond leads to 
intermediate 162 followed by isomerization of the remaining olefin into conjugation with the 
amide. Next, solutions of 161a and 161b in CDCl3 were treated with a primary amine 
(isobutylamine and allylamine, respectively) which cleanly effected opening of the imino-
oxazolidinone to ureas 163a and 163b.h  
Scheme 3.31 Reduction and functionalization of 156a and 156b. 
N
O
N
O
Bn
O
R1
H
N
O
OR2
N
O
N
O
Bn
O
R1
H
N
O
OR2
Pd/C, H2
THF, rt
156a, R1 = CO2Me, R2 = Ph
156b R1 = i-Pr, R2 = Me
R3-NH2
N
O
NH
O
BnR1
H
N
O
OR2
O
NH
R3
161a, 80%
161b, 95%
163a, R1 = CO2Me, R2 = Ph, 
          R3 = i-Bu, 75%
163b, R1 = i-Pr, R2 = Me, 
          R3 = Allyl, 92%
N
O
N
O
Bn
O
R1
H
N
O
OR2
H
162
 
The structure of 163a was assigned by 1H NMR (in CDCl3) based on the presence of two 
downfield resonances at 9.02 ppm (t, J = 5.8 Hz, 1H) assigned to the urea N-H proton and 8.46 
                                                 
h In addition to isobutylamine and allylamine shown in Scheme 3.31, benzylamine and 2-methoxyethylamine were 
also used to afford ring opening in >80% yield. 
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ppm (dd, J = 7.1, 4.6 Hz, 1H) assigned to the appending amide proton.i The presence of sharp 
signals for these protons instead of the normally-observed broad resonances, suggested an 
ordered secondary structure of the urea and amide side chains. It was speculated that this 
ordering is a result of intramolecular hydrogen bonding within the molecule. The chemical shifts 
of the amide and urea protons support this notion, since it is known that participation of N-H 
protons in hydrogen bonding normally results in a downfield shift.109 To examine this 
computationally, 163a was modeled using Cache.j  The minimized model of 163a resulted in 
arrangement of the side chains as shown in Figure 3.3, with two potential hydrogen bonds: (a) 
between the urea N-H and lactam carbonyl oxygen (distance 2.287 Å); and (b) between the 
appending amide N-H and the adjacent pyrrolidine-dione carbonyl oxygen (distance  2.140 Å). 
As a result of this secondary bonding, the two side chains are presumably held rigidly which 
accounts for the sharp N-H resonances in the NMR spectrum. It was reasoned that this feature 
may be useful in designing biological probes that project functional groups in specific three-
dimensional space. For example, many potent protease inhibitors are small peptide-like 
molecules that posess a defined secondary structure, resulting in strong interaction with the 
enzyme.110 We anticipate that the rigid amido-ureas may also prove as useful biological probes 
to study protein function. 
 
 
                                                 
i To determine whether these two resonances arise from the amide and urea N-H protons, a solution of the product in 
CDCl3 was shaken in an NMR tube  in presence of excess D2O and the primary amine used in the ring-opening 
reaction. The exchange was followed by 1H NMR spectroscopy which showed disappearance of the two resonances 
within ~30 min. Reversed exchange from deuterium to hydrogen was also accomplished using the same protocol 
with H2O. 
j Energy minimization was performed with Cache Worksystem Pro. version 6.1.10. First, global minimum search 
was performed using MM3 parameters, followed by optimization of the side chain conformation with AM1 
parameters. Then, energy minimization of the sample was performed using AM1 parameters. 
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 Figure 3.3 Energy-minimized model of 163a with potential hydrogen bonds labeled in green. 
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Consequently, the focus shifted to designing a library of these polycyclic scaffolds using the 
synthetic routes that were developed. As outlined in Scheme 3.32, this synthetic pathway offers 
at least five points of diversity to be introduced gradually as the complexity of the scaffold 
increases. The imino-oxazolidinone moiety was envisioned as a crucial part of the triene 
precursor 166 because in enables a highly stereo- and chemoselective Diels-Alder reaction with a 
number of maleimides. Furthermore, this moiety is used as a key diversity element, because the 
transformation of 167 to 168 results in the conversion of a molecule rich in hydrogen-bond 
acceptors to one that contains two hydrogen-bond donor groups. This transformation is expected 
to bring about significant differences in the physico-chemical properties and potentially the 
biological activity of the compounds. Since both classes of compounds were envisioned as 
library members, a broad range of diversity was therefore accessed via a relatively simple set of 
transformations. The library synthesis was put into practice by the staff at the University of 
Pittsburgh Center for Chemical Methodologies and Library Development (UPCMLD, 
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http://ccc.chem.pitt.edu/). Using four points of diversity (allenic amino-ester, amine for 
oxazolidinone formation, N-alkyl maleimide and amine for the oxazolidinone opening reaction), 
the center synthesized 200 library members in quantities of 5-100 mg each.111 These compounds 
have been made broadly available to biological collaborators for testing. 
Scheme 3.32 Synthesis of a library of polycyclic scaffolds from cross-conjugated trienes. 
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In summary, a novel Rh(I)-catalyzed cycloisomerization of allenynes was achieved, 
affording δ-lactam trienes. These compounds proved useful in the synthesis of structurally 
unique poly-heterocyclic scaffolds via a stereocontrolled Diels-Alder reaction. The sequence of 
reactions is amenable to library synthesis which has been recently completed by the staff at the 
UPCMLD. 
3.3.3 Intra-/Intermolecular Diels-Alder Approach for the Synthesis of Complex Polycyclic 
Scaffolds 
An alternative approach to elaborating the amino-ester tethered cross-conjugated trienes 
into complex polycyclic scaffolds involves performing a sequence of intramolecular and 
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intermolecular cycloaddition reactions as outlined previously in Scheme 3.20 (path B). Although 
this approach requires some functionalization of the existing triene in order to tether a requisite 
dienophile, it also offers possibility for greater stereocontrol since the initial cycloaddition will 
be performed intramolecularly. For, example, Brummond and You have demonstrated that 
triene-yne systems 170, undergo a Rh(I) catalyzed formal [4+2] cycloaddition stereoselectively 
affording tricyclic trienes 171 (Scheme 3.33).112 Moreover, a one-pot protocol for tandem 
cycloisomerization/cycloaddition of the parent allenynes 169 was achieved and the resulting 
diene of 171 was used in subsequent intermolecular cycloaddition reactions. 
Scheme 3.33 Rh(I)-catalyzed [4+2] cycloaddition of cross-conjugated trienes. 
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 Applying this same strategy to the amino-acid derived substrates was enticing. To this end 
trieneyne 174 was prepared according to the sequence outlined in Scheme 3.34. Reduction of the 
methyl ester in 58a was accomplished in 67% yield by addition of DIBALH (3 equiv.) at -78 °C 
and warming to 0 °C.   
Scheme 3.34 Synthesis of trieneyne 174. 
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Next, amido-alcohol 172 was N,O-dialkylated in one pot using NaH and 1-bromo-2-butyne to 
afford allene-diyne 173 in 66% yield (both yields are unoptimized). Subjecting 173 to 5 mol% of 
[Rh(CO)2Cl]2 at rt resulted in cycloisomerization to the desired trieneyne 174 in 80% yield. 
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Notably, exclusive cycloisomerization of the N-tethered allenyne system was observed despite 
the presence of an O-tethered allenyne that could also undergo the reaction to give an oxepine. 
This is not surprising since the rate of cycloisomerization to form a larger ring size is expected to 
be slower. Subjecting 174 to the conditions previously reported by Brummond and You for 
effecting the desired cycloaddition ([Rh(dppe)Cl]2, AgSbF6, 1,2-dichloroethane) led to no 
reaction at rt, and eventual decomposition of the starting material upon refluxing for 12h 
(Scheme 3.35).113 Therefore, two other Rh(I)-catalysts were utilized. In 1999, Chung, reported 
[Rh(naphthalene)(COD)]BF4 as an efficient catalytic system for both inter- and intramolecular 
cycloaddition of dieneynes at rt.114 Unfortunately, these conditions did not result in the desired 
cycloaddition product either (starting material was recovered in 71%). Finally, we resorted to 
testing a catalytic system first reported by Livinghouse in 1990.115  In this report, it was 
demonstrated that [Rh(COE)2Cl]2, in the presence of the fluorinated phosphite ligand 
P[OCH(CF3)2]3 catalyzes the intramolecular cycloaddition reaction of diene-ynes (COE = 
cyclooctene). It was reasoned that the electron withdrawing properties of this ligand will increase 
the affinity of the metal toward coordination of the trienyne. However, the desired cycloaddition 
product was not observed in this case either (starting material was recovered in 78%). 
Scheme 3.35 Attempted Rh(I)-catalyzed cycloadditions of 174. 
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conditions:
A. 10 mol % [Rh(dppe)Cl]2, AgSbF6, DCE; decomposition over 12h at reflux.
B. 10 mol % [Rh(naphtalene)COD]BF4, CH2Cl2,  50 oC; recovered starting material in 71%.
C. 10 mol % [Rh(COE)2Cl]2, P[OCH(CF3)2]3, THF, reflux;   recovered starting material in 78%.  
Since these three catalytic conditions failed to provide cycloadduct 175, further study on 
effecting the cycloaddition of 174 was suspended. In addition, we tested the cycloaddition 
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reaction of butynyl-ester 176 (see experimental section for full details on the preparation of this 
precursor). To our knowledge there are no reports of ester-tethered dieneyne participating in a 
transition metal-catalyzed cycloaddition reaction, although ester-tethered enynes have been 
shown to participate in a cycloisomerization reaction.116 Interestingly, prolonged heating of 
butynyl-ester 176 in presence of in situ generated catalytic Rh(I) ([Rh(dppe)Cl]2, AgSbF6, 1,2-
dichloroethane) resulted in formation of γ-lactone 178 in 78% yield (Scheme 3.36). The structure 
of 178 was assigned based on the presence of a new olefinic resonance attributed to Hb in the 
downfield region (at 7.14 ppm) displaying allylic coupling with the methyl group protons (q, J = 
1.6 Hz). In addition to this, the presence of an amide was deduced based on a resonance in the 1H 
NMR as a broad singlet (at 6.39 ppm) and a broad amide stretching band for the N-H bond in the 
IR (at 3344 cm-1). Compound 178 was rationalized to arise from Rh(I)-catalyzed 
depropargylation of 176, followed by cyclization of the resulting carboxylic acid of 177 onto C4, 
concomitant with allylic disposition of the C2 benzamide. This represents an overall 5-endo-trig 
process known to be disfavored by Baldwin’s guidelines.117
Scheme 3.36 Unexpected formation of γ-butenolide 178. 
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Since γ-lactones (butenolides) are important both as synthetic targets and intermediates, the 
formation of 178 merited some further study.118 To support the hypothesis that acid 177 is an 
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intermediate in the reaction we sought a method to independently prepare this compound and 
subject it to the same reaction conditions. Acid 177 was synthesized starting with propargylic 
ester 179 as outlined in Scheme 3.37.k Claisen rearrangement under dehydrative conditions gave 
allenyl oxazolone 180 which was isolated and hydrolyzed to allenic-acid 181 using 1M HCl. 
Then, 181 was carefully N-alkylated with 1-bromo-2-butyne to give allenyne-acid 182. Rh(I)-
catalyzed cycloisomerization of this precursor was acheved using 10 mol % of catalyst, and 
heating to 35 °C for 2h. The reaction time for the cycloisomerization of the free acid was 
considerably longer compared to the methyl ester (2h vs 10 min, see 111a, Scheme 3.1) and 
resulted in relatively low yield of the triene 177 (60%).  
Scheme 3.37 Synthesis of carboxylic acid 177. 
N
OH
Bz
O
177
• H
BzN
HOOC
10 mol % 
[Rh(CO)2Cl]2
toluene, 35 oC
 2h, 60%
• H
BzHN
HOOC
Br
NaH, DMF
85%
N
O
Ph
O
•
H
179
1M HCl
70 oC
>95%
180 181
1 equiv.
BzHN
O
O
PPh3
CCl4
Et3N
MeCN
182
When 177 was subjected to the the catalytic Rh(I) conditions  ([Rh(dppe)Cl]2, AgSbF6, 1,2-
dichloroethane) the reaction resulted in 73% yield of 178 (Scheme 3.38). Thus, the free acid 177 
is a probable intermediate in the cyclization of propargyl ester 176. Heating 177 in presence of 
20 mol% AgSbF6 alone gave no reaction, indicating that the cyclization is not catalyzed by the 
silver salt additive.119 Furthermore, heating 177 in 1,2-dichloroethane also gave recovered 
starting material. These experiments demonstrate that presence of the Rh catalyst is necessary for 
transforming acid 177 to 178, however the exact mechanism is not clear. The overall 
                                                 
k Initially we attempted to prepare acid 177 by saponification of the corresponding methyl ester with LiOH in 
THF/H2O (conditions  utilized previously to cleave the methyl ester of lactam-triene 145a, Scheme 3.27). However, 
these conditions did not cause saponification and the starting material was recovered. The resistance of this ester to 
saponification under basic conditions is presumably due to electronic and/or steric effects imposed by the 
neighboring benzoyl protecting group. 
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transformation can be regarded as Rh(I)-catalyzed substitution of an allylic amide. The related 
reaction of activated allylic amines finds precedent in recent work by Lautens.120
Scheme 3.38 Rh(I)-catalyzed rearrangement of acid 177. 
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We finally turned our attention to examining a thermal intramolecular Diels-Alder 
reaction as a method for increasing molecular complexity in a diastereoselective manner. For this 
purpose, tetraene 184 (Scheme 3.39) was synthesized by reduction of the methyl ester of 111f 
using DIBALH, followed by condensation of the resulting alcohol with acryloyl chloride (the 
low overall yield of 33% for this transformation is unoptimized). 
Scheme 3.39 Synthesis of thermal Diels-Alder precursor 184. 
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 The reactive portion of this cycloaddition precursor, a hexadienyl-acrylate, belongs to a 
class of substrates whose application in synthesis remains underutilized. Recently, a 
comprehensive study examined the effects contributing to the observed stereochemistry for 
thermal and Lewis acid catalyzed reactions of relatively unfunctionalized hexadienyl-
acrylates.121 In general, difficulties associated with Diels-Alder reactions of ester-tethered 
substrates are attributed to existence of the ester moiety in a transoid conformation to minimize 
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repulsive dipole interactions (Scheme 3.40). Rotation into the required cisoid conformation 
results in increase of the net dipole moment and steric repulsion between the two alkyl groups.122  
Scheme 3.40 Ester bond rotamers of 184. 
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Promoting the desired cycloaddition by heating 184 in toluene at 110 °C resulted in 
decomposition over a 24 h period (entry 1, Table 3.3). Attempts to catalyze this reaction with 
Et2AlCl or BF3·OEt2 gave either no reaction or decomposition, depending on the temperature 
(entries 2, 3 and 4, Table 3.3).123 It is noteworthy mentioning that Taguchi recently reported that 
both In(OTf)3 and TfN[Al(Me)Cl]2 serve as efficient Lewis acid catalysts for the Diels-Alder 
reaction of hexadienyl-acrylates.124
Table 3.3 Diels-Alder reaction of tetraene 184. 
N
Cbz
O
O
N
Cbz
O
O
conditions H
H
Entry             Conditions                           Result / Yield%
1              toluene, 110 oC                        decomposition
2              Et2AlCl, toluene, -78 oC           no reaction
3              Et2AlCl, toluene, 80 oC            decomposition
4              BF3OEt2, toluene, 80 oC          decomposition
5              acetonitrile, 90 oC                     no reaction
6              DMSO, 80 oC, 8h                     43%
7              DMSO / H2O, 80 oC, 6h           50%
184 185
 
Earlier studies have unveiled a dramatic solvent effect on the ester tethered Diels-Alder 
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reaction.125 Therefore, more polar solvents were examined, and the reaction was found to 
proceed in DMSO, at 80°C, giving 43% yield of the desired tricyclic lactone 185 as a single 
diastereomer. The relative stereochemistry, resulting from endo cycloaddition, was assigned 
based on the X-ray crystal structure of a later intermediate 186b (Table 3.4, vide infra). The 
cycloaddition could be marginally accelerated by using a mixed solvent system consisting of 
DMSO / H2O (2 : 1). Highest yield (50%) of the tricyclic lactone 185 was obtained when the 
reaction was performed at lower concentrations (0.01M), suggesting that side reactions may be 
responsible for the low yield. 
With 185 in hand, we examined its participation in subsequent intermolecular Diels-
Alder reactions (Table 3.4). Reaction with 4-phenyl-[1,2,4]-triazole-3,5-dione was complete in 5 
min to afford 186a as a single diastereomer (entry 1). N-Phenylmaleimide reacted at rt within 6 h 
to give 186b in 95% yield and diastereoselectivity greater than 10 : 1 (entry 2). The relative 
stereochemistry of 186b was established by X-ray crystallography indicating endo approach of 
the dienophile from the convex face of the fused tricycle (Appendix C). Maleic anhydride 
reacted similarly to give 186c (entry 3). The relatively high reactivity of the diene towards these 
activated dienophiles, suggests that less active dienophiles may also undergo the reaction (e.g. 
acrolein, methyl vinyl ether, cyclopentenone, etc.); however further studies in that direction were 
not pursued. 
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Table 3.4 Diels-Alder reactions of 185. 
N
Cbz
N
X
X
Cbz
toluene
dienophile
Entry / Product    Dienophile        Temperature / Time       Yield              dra
O
O
O
rt / 3 h              78%       > 10 : 1
N
N
NPh
O
O
 rt / 5 min          95%           1 : 0
O
O
O
O
NPh
O
O
rt / 6 h             95%       > 10 : 1
186a-c
1 / 186ab
2 / 186bc
3 / 186cc
H
H
H
H
185
Notes: a diastereomer ratio; b 1 equiv. of dienophile was used; c 1.5 equiv. of 
dienophile was used;
N
Cbz
O
O
H
H
N
O
O
PhH
186b
X-ray of 186b
 
 It should be noted that compounds 186a-c possess a steroidal-like heterocyclic skeleton, and 
may therefore serve as useful biological probes. The rapid manner and selectivity by which these 
scaffolds are assembled using this strategy make it attractive for generation of libraries of 
compounds. Unfortunately, the low yields obtained during the synthesis of the key tricyclic 
intermediate 185 from triene 111f (~15% overall) are a limiting factor in preparing a larger scale 
library.   
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3.4 Rhodium(I)-Catalyzed Cycloisomerization of Ene-Allenes 
The Rh(I)-catalyzed allenic Alder-ene reactions of amino ester tethered allenynes 
discussed earlier in this chapter (Section 3.2), generally proceed in 10 min to give the 
corresponding cross-conjugated trienes in high yield (Table 3.1). The success of this 
transformation prompted us to examine the effect of replacing the alkyne moiety with an alkene. 
It is well known that in the related Rh(I)-catalyzed cyclocarbonylation reaction of 1,n-enynes, 
replacing the alkyne component with an alkene completely diminishes the reactivity.126 This can 
be attributed to lower propensity of the diene to undergo the first oxidative addition step forming 
a five-membered metallocycle, which is a presumed intermediate in the reaction. In the case of 
ene-allenes, however, the increased reactivity of the allene may compensate for this issue. At the 
time this study was initiated, there were only few examples utilizing ene-allenes in 
cycloisomerization reactions. For example, Trost first reported the cycloisomerization of 1,6-
ene-allenes 187 to five-membered dienes 188 by using bimetallic Ni-Cr catalyst (Scheme 
3.41).127  
Scheme 3.41 Cycloisomerization of ene-allenes. 
X
•
R
R
X = Me, -CO2Et, NTs, O etc.
conditions
X R
R
conditions: A. 10 mol% (p-diphenylphosphinopolystyrene)NiCl2 and 30 mol% CrCl2.
                  B. 5 mol% RuClH(CO)(PPh3)3.
                  C. 5 mol% [RhCl(cod)]2, 10 mol% P(OPh)3.
187 188
 
Subsequently, the same transformation was reported by Kang using RuClH(CO)(PPh3)3 as a 
catalyst,128 and Itoh, using [RhCl(COD)]2 as catalyst with a triphenylphosphite ligand.129
To examine the effect of replacing the alkyne with an alkene on the Rh(I)-catalyzed 
 72 
allenic Alder-ene reaction, ene-allene 75a was subjected to 10 mol% [Rh(CO)2Cl]2 in DCE; 
reaction did not occur at rt. However, upon heating to 90 °C, the starting material was consumed 
and tetrahydroazepine 189 was isolated as the sole product in 43% yield. It was determined that 
the low isolated yield was due to decomposition of the product during purification. Minimal 
exposure of the crude reaction mixture to silica gel resulted in 95% yield of 189 (Scheme 3.42). 
The presence of an enamide olefin in 189 is characterized with two resonances in the 1H NMR 
spectrum (in CDCl3) at 5.03 ppm (dd, J = 8.1, 2.5 Hz) and 4.53 ppm (dd, J = 8.1, 4.1 Hz) 
(Scheme 3.43). In addition, the exocyclic olefin displays a signal at 5.52 ppm (q, J = 6.8 Hz). 
Scheme 3.42 Formation of tetrahydroazepine 189. 
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•
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Scheme 3.43 Selected data from the 1H NMR spectrum of 189 in CDCl3. 
189
N
Bn
MeO2C
Bz
Ha Hb
Hc
Ha 5.03 (dd, J = 8.1, 2.5 Hz)
Hb 4.53 (dd, J = 8.1, 4.1 Hz)
Hc 5.52 (q, J = 6.8 Hz)
 
Furthermore, 189 was isolated from the reaction as mainly one stereoisomerl with respect to the 
C2 and C5 relative stereochemistry, and E-geometry of the exocyclic olefin, which is predicted 
based on a mechanistic hypothesis (see Scheme 3.45).m The relative stereochemistry of the C2 
and C5 stereocenters was not determined.  
                                                 
l The 1H NMR spectrum of the reaction mixture after passing through a short silica gel column displayed additional 
peaks,  which may be attributed to small amounts of a second isomer  (estimated ~10%).  
m Additional examples of azepines prepared by Dr. Hongfeng Chen were also obtained as the E isomer of the 
exocyclic olefin: Brummond, K. M.; Chen, H.; Mitasev, B. Org. Lett. 2004, 6, 2161. 
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The transformation of ene-allene 75a to tetrahydroazepine 189 represents a formal 
intramolecular ene-reaction of type III (Scheme 3.44).130 This type is characterized by terminal 
placement of the double bond in the “ene” unit, thereby leading to formation of the largest ring 
possible (191 to 192). 
Scheme 3.44 Type III intramolecular ene reaction. 
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There are only a few examples of type III ene reactions and these generally require very high 
temperatures to occur. For example, the thermal rearrangement of ortho-allylbutenyl benzene 
193 occurs at 350 °C to give a mixture of fused benzocyclononadienes 194 and 195 in 
quantitative yield.131 Similarly, thioaldehyde 196 undergoes an intramolecular ene reaction under 
flash vacuum pyrolysis (FVP) at 500 °C affording a thialactone 197, in a rare example of 7-
membered ring formation.132 The high temperature required for this reaction to occur can be 
attributed to the strained nature of the transition state 198 required for an ene reaction. Therefore, 
the formation of tetrahydroazepine 189 via a Rh(I)-catalyzed cycloisomerization reaction of 75a 
at 90 °C is an intriguing result.  Moreover, azepines are an important synthetic target due to their 
presence in a variety of natural products (cephalotaxanes, Stemona and Securinega alkaloids, 
Figure 3.4).133, 134  
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Figure 3.4 Examples of natural products containing an azepine ring. 
N
O
O
H
H
Et
H H
H
stenine
(Stemona alkaloid)
Me
N
O
O
H
securinine
(Securinega alkaloid)
N
O
O
HO
OMe
H
cephalotaxine
(cephalotaxane alkaloid)  
At least two mechanistic pathways can be proposed for the cycloisomerization reaction of 
ene-allene 75a to azepine 189 (Scheme 3.45). Path A involves oxidative insertion of Rh(I) 
between the alkene and the proximal double bond of the allene, in an endo mode, affording a 
Rh(III) bridging metallocycle 200. Extraction of Ha via a β-hydride elimination would lead to 
Rh(III)-hydride species 201, which then undergoes a reductive elimination to afford the observed 
product 189.  
Scheme 3.45 Proposed mechanisms of the Rh(I)-catalyzed cycloisomerization of ene-allene 75a. 
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Bridging rhodacycles related to 200 have been proposed as intermediates in the rearrangement of 
strained cycloalkanes by Halpern135 and Gassman (Scheme 3.46).136 For example, treatment of 
bicyclo[2.2.0]hexane 204a with catalytic amount of [Rh2(nbd)2Cl2] leads to exclusive formation 
of cyclohexene (207a). This observation is readily accommodated by a mechanism involving 
oxidative insertion of Rh(I) into the strained C-C bond, to form a bridging metallocycle 205 
which undergoes a β-hydride elimination and reductive elimination to give cyclohexene. The 
same reaction of tetradeuteriated bicyclo[2.2.0]hexane 204b results in 3,4,5,6-
tetradeuteriocyclohexene 207b in support of this mechanism. Moreover, when 204a is treated 
with 25 mol% [Rh(CO)2Cl]2, it affords an isolable acyl-rhodacycle 208 in 88% yield. 
Interestingly, treatment of this compound with PPh3 initiates a sequence of β-hydride elimination 
and reductive elimination steps to give aldehyde 210. These results clearly indicate that bridging 
rhodacycle 200 is a viable intermediate in the cycloisomerization of ene-allenes as outlined in 
Path A (Scheme 3.45). 
Scheme 3.46 Bridged Rh(III)-metallocycles via oxidative addition of Rh(I) into strained bonds. 
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The alternative mechanistic path B involves an oxidative addition of Rh(I) into the allyl 
C-H bond of intermediate 199 leading to a π-allyl rhodium hydride species 202 (Scheme 3.45). 
Insertions of this type are common for many transition metals (e.g., Rh, Ru, Ir) and often result 
in isomerization of the allylic amide to an enamide.137 Next, endo-carbocyclization of this 
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species onto the proximal double bond of the allene assembles the azepine core 203 resulting in a 
Rh(III)-hydride species which undergoes a reductive elimination to give the product 189. 
Recently, a cyclization of a (π-allyl)-Pd-OAc species onto the internal double bond of the allene 
in all-carbon tethered ene-allenes leading to 5-membered ring formation has been reported.138 In 
addition, Trost reported a cycloisomerization of 1,6-enynes catalyzed by CpRu(CH3CN)2PF6, 
which was rationalized by a similar C-H insertion-carbocyclization mechanism.139  
Exclusive formation of the exocyclic olefin in azepine 189 with E geometry can be 
rationalized by coordination of the crotyl moiety away from the terminal allenyl methyl group to 
avoid unfavorable steric interactions, as shown in intermediate 199 (Scheme 3.45). To test 
whether the methyl group on the alkene moiety influences the resulting stereochemistry of the 
exocyclic olefin, ene-allene 75b was subjected to the Rh(I)-catalyzed reaction conditions. The 
reaction resulted in the formation of azepine 211 as a mixture of exocyclic olefin isomers in 2.5 : 
1 ratio (Scheme 3.47), clearly indicating a decrease in selectivity.  
Scheme 3.47 Rh(I)-catalyzed ene reaction of 75b. 
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The two isomers were separated by normal phase HPLC and the major product 211a was 
assigned Z-geometry based on nOe data (it should be noted that the E/Z notation is changed from 
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azepine 189 due to absence of the 5-methyl group). In particular, when the exocyclic olefin 
resonance (Hb) of 211a was irradiated, enhancements of 1% and 2.9% were observed for the bis-
allylic methylene resonances Ha and Ha’. In contrast, no enhancement of the same resonances 
was observed when the methyl group signal Hc was irradiated. The minor diastereomer 211b was 
assigned E-geometry of the exocyclic olefin by irradiating the methyl group resonance, which 
resulted in 1.8% enhancement for the bis-allylic methylene resonances Ha and Ha’. The formation 
of both Z and E isomers in this case is attributed to the less sterically demanding allyl substituent 
which allows reaction to occur from either face of the allene. Reaction via 75b-A is marginally 
preferred over 75b-B (Scheme 3.48) resulting in a ratio of 2.5 : 1 for the exocyclic olefin 
geometry. 
Scheme 3.48 Rationale for the observed olefin geometry in the cycloisomerization of 75b. 
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Three additional amino-ester tethered ene-allenes were subjected to [Rh(CO)2Cl]2 and resulted in 
azepine formation (Scheme 3.49). The Cbz-protected azepines 212 and 213 were obtained as 
single isomers in relatively low yield (63% and 51%, respectively). Finally, ene-allene 75e 
containing a TBS-ether in the side chain gave 72% yield of azepine 214 as a 4 : 1 mixture of 
isomers, which were not separated. 
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Scheme 3.49 Rh(I)-catalyzed ene reaction of 75c-e. 
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These, and additional examples from the Brummond group, demonstrate the broad scope and 
good functional group compatibility of the Rh(I) catalyzed reaction. It was demonstrated that 
highest rates of conversion and yields up to 95% can be obtained by using a bulky group on the 
terminus of the allene (e.g., t-butyl). Additionally, replacing the nitrogen tether with oxygen, 
leads to formation of oxepines in moderate yields (Scheme 3.50). A valuable feature of these 
cycloisomerizations is the generation of two stereodefined olefins, one of which is an enamide 
(or vinylether) and can potentially be exploited in further transformations aimed at target- or 
diversity-oriented synthesis.140  
Scheme 3.50 Formation of oxepine 216 via cycloisomerization of ene-allene 215.n
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In summary, a novel Rh(I)-catalyzed cycloisomerization of ene-allenes leading to 
functionalized azepines was discovered. The application of these unique compounds to DOS is 
subject of current investigation. Finally, it should be noted that in 2004, Itoh reported a similar 
cycloisomerization reaction of a carbon tethered ene-allene affording a 4-alkylidenecycloheptene 
under Rh(I) catalysis.141
                                                 
n Reactions performed by Dr. Hongfeng Chen (Brummond group) 
 79 
4.0  Synthesis and Use of Amino-Acid Derived Cyclopentenones  
4.1 Transition Metal Catalyzed Cyclocarbonylation – Pauson-Khand Reaction 
The cocyclization of an alkyne, alkene and carbon monoxide to form a cyclopentenone 
(217) constitutes a formal [2+2+1] cycloaddition and was first described by Pauson and Khand 
in 1973 (Scheme 4.1).142 Since then, the Pauson-Khand reaction has become one of the most 
convenient methods for synthesis of cyclopentenones, which are synthetically important class of 
molecules.143 The initial reaction conditions utilized a stoichiometric amount of 
dicobaltoctacarbonyl (Co2(CO)8) to effect the intermolecular reaction of an alkyne and an alkene.  
Scheme 4.1 Intermolecular Co2(CO)8-mediated Pauson-Khand reaction. 
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A widely accepted mechanism for this Co-mediated cyclocarbonylation reaction was proposed 
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by Magnus144 and it involves the intermediacy of the cobalt complex 218, formed by 
complexation of Co2(CO)8 to the alkyne, which was later firmly established by Krafft (Scheme 
1.1).145 These conditions, however, were limited to promoting the reaction of strained olefins 
(e.g., norbornadiene), typically with low efficiency. Furthermore, use of unsymmetrical olefins 
generally led to formation of regioisomers. Despite these initial disadvantages, the potential 
application of this transformation to complex molecule synthesis was apparent, and wealth of 
research in the past three decades has resulted in improved methods for effecting related Co-
mediated cyclocarbonylation reactions. In the intramolecular version of the reaction, first 
reported by Schore in 1981, enyne 223 was converted to a fused bicyclic cyclopentenone 224 
(Scheme 4.2).146 Tethering of the alkyne and alkene gives the advantage of exclusive 
regioselectivity and increased reactivity.  
Scheme 4.2 Intramolecular Pauson-Khand reaction of a tethered enyne. 
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Extensive efforts in the past have been aimed at improving the efficiency of the Co-mediated 
reaction by using various additives.147 Silica gel is believed to accelerate the reaction by acting as 
a polar surface to facilitate CO ligand exchange. Primary amines (e.g., cyclohexylamine) are 
more effective additives and are believed to act by stabilizing certain coordinatively unsaturated 
intermediates in the reaction pathway. Thioethers and phosphines have similar effect on 
accelerating the reaction. Amine oxides are another class of effective additives, which generally 
act by oxidizing a coordinated CO ligand to CO2 thereby creating a vacant site on the metal. 
Although the use of stoichiometric amount of Co2(CO)8 to promote the Pauson-Khand reaction is 
still widely used today, there has been a significant progress in developing a catalytic reaction 
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with this metal under CO atmosphere.148 In addition, a number of other transition metals have 
been demonstrated as useful mediators or catalysts for the Pauson-Khand reaction, including Mo, 
Ru, Rh, and Ti.41a, 149 Currently, the name Pauson-Khand reaction is used to refer only to the 
initial Co-mediated transformation developed by Pauson and Khand, whereas all other related 
transformations are known as cyclocarbonylation reactions. The common mechanistic features of 
nearly all cyclocarbonylations are presented in Scheme 4.3. The reaction is initiated by 
coordination of the metal to the enyne, followed by the formation of a metallocycle 227 which 
occurs via oxidative addition of the metal into the olefin and alkyne. Then, migration of one of 
the metal-carbon bonds occurs into a CO ligand leading to an acyl-metallocycle 228, which 
undergoes a reductive elimination to give the product 229. 
Scheme 4.3 Common mechanistic features of transition metal-catalyzed cyclocarbonylation 
reactions. 
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4.1.1 Mo(CO)6-Mediated Cyclocarbonylation Reaction. 
Mo(CO)6 was reported to mediate the cyclocarbonylation reaction of 1,3-enynes by Jeong in 
1993.150  The reagent is used in a stoichiometric amount in conjunction with a promoter, which 
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usually is DMSO. Heating to 100 ºC is generally required for reaction to proceed (Scheme 4.4). 
The role of DMSO is believed to involve oxidation of one or more CO ligands to CO2, which 
then leaves, opening a vacant site on the metal for coordination of the enyne. In this initial report, 
it was shown that 1,3-enynes with diester, ether or nitrogen in the tether can participate in the 
Mo(CO)6-promoted cyclization to afford the corresponding [5,5]-fused bicyclic systems (230 to 
231, Scheme 4.4). Notably, attempts to prepare [6,5]-fused systems by extending the enyne 
tether by one carbon were unsuccessful.  
Scheme 4.4 Mo(CO)6-mediated cyclocarbonylation reaction. 
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There has been only one report on a catalytic version of the Mo-mediated cyclocarbonylation 
reported to date, but it is limited to highly reactive substrates.151 Recently, Carretero found that 
Mo(CO)3(DMF)3 serves as a milder and more efficient promoter for the intramolecular 
cyclization of enynes.152 This air-sensitive complex can be synthesized from Mo(CO)6 itself and 
allows the reaction of enynes to occur at rt with improved yields and without the necessity of 
promoters (Scheme 4.5). 
Scheme 4.5 Improved protocol for the Mo-mediated cyclocarbonylation reaction.  
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4.1.2 Late Transition Metal-Catalyzed Cyclocarbonylation Reaction. 
Late transition metals such as Rh and Ru have been widely utilized in a variety of 
catalytic transformations of 1,n-enynes including [4+2] and [5+2] cycloadditions, and ene-type 
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cycloisomerization reactions.40-42 Such reactions are presumed to proceed via intermediacy of 
metallocyclopentenes formed by oxidative addition of the metal into the enyne. It has been 
demonstrated that under an atmosphere of CO, these metallocyclopentene intermediates can be 
intercepted and subsequently lead to insertion of CO in one of the metal-carbon bonds, thereby 
constituting a catalytic cyclocarbonylation reaction. The first examples of late transition metal-
catalyzed cyclocarbonylations appeared in the literature in the late 1990’s. Initially, Murai153 and 
Mitsudo154 demonstrated the use of Ru3(CO)12 under CO pressure of 10-15 atm to perform the 
cycloaddition of diester-tethered substrate 232 upon heating to 140-150 °C (Scheme 4.6). 
Scheme 4.6 Ru-catalyzed cyclocarbonylation reaction. 
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Subsequently, in 1998, Narasaka155 and Jeong156 independently reported the first examples of a 
Rh(I)-catalyzed cyclocarbonylation reactions. Narasaka detailed the use of the dimeric square-
planar complex [Rh(CO)2Cl]2 to catalyze the reaction of a range of substrates with catalyst 
loading as low as 1 mol %. For example, the reaction of 234 proceeds at either 90 °C with 5 mol 
% of catalyst or 130 °C with 1 mol %, to give cyclopentenone 235 in high yield (Scheme 4.7). 
Scheme 4.7 [Rh(CO)2Cl]2-catalyzed cyclocarbonylation reported by Narasaka. 
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Most importantly, with this catalyst the reaction can be carried out under 1 atm of CO by simply 
using a balloon, which is in sharp contrast to many previous catalytic Pauson-Khand reactions 
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that require high pressures of CO.148 This was further exemplified by Jeong, who utilized a 
number of Rh(I) complexes with phosphine ligands.156 It was demonstrated that RhCl(PPh3)3 
(Wilkinson’s catalyst), trans-RhCl(CO)(PPh3)2 and RhCl(CO)(dppe) catalyze the 
cyclocarbonylation of 1,3-enynes at 110 °C when activated with an additive such as AgOH or 
AgOTf, while the dimeric trans-[RhCl(CO)(dppp)]2 does not require any additive (Scheme 4.8).  
Scheme 4.8 Rh(I)-catalyzed cyclocarbonylation reaction reported by Jeong. 
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These initial discoveries have led to the first practical examples of a Rh(I)-catalyzed asymmetric 
cyclocarbonylation reaction by using chiral phosphine ligands.157, 158
4.1.3 Allenic Cyclocarbonylation Reaction. 
Use of an allene as the olefin component in the cyclocarbonylation reaction is particularly 
intriguing, since two different products can be formed depending on which double bond reacts 
(Scheme 4.9). In an intramolecular process, reaction of the proximal double bond leads to an α-
alkylidene cyclopentenone (path A), whereas reaction with the distal double bond forms a 4-
alkylidene cyclopentenone (path B). 
Scheme 4.9 Allenic cyclocarbonylation reaction.  
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In 1995, Brummond and coworkers reported the first examples of an allenic cyclocarbonylation 
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reaction.159 It was shown that Jeong’s Mo(CO)6 conditions applied to allenyne 242 containing a 
terminally unsubstituted allene selectively afford the α-alkylidene cyclopentenone 243 arising 
from reaction with the proximal double bond of the allene (Scheme 4.10). 
Scheme 4.10 Mo(CO)6-mediated cyclocarbonylation reaction of 242. 
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Subsequent detailed studies by Brummond established that the double bond selectivity is 
substrate dependent (Scheme 4.11).160 In addition to terminally unsubstituted allenes (242), 
substrates possessing one or two substituents on the terminal allenic position were found to react 
selectively with the proximal double bond to give α-alkylidene cyclopentenones. In the case of 
terminally monosubstituted allenes, the products are obtained as mixtures of E and Z isomers of 
the exocyclic olefin. For example, reaction of allenyne 244 gives 245 as a 2 : 1 mixture of 
diastereomers. The terminally disubstituted allene in 246 also reacts to give α-alkylidene 
cyclopentenone 247 as a single product in 59% yield. In contrast, placing an additional 
substituent on the proximal carbon of the allene as in 248, leads exclusively to formation of 4-
alkylidene cyclopentenone 249. These trends were proven general by subjecting variety of 
additional substrates to the reaction conditions.160b-c  
Scheme 4.11 Mo-mediated allenic cyclocarbonylation reactions. 
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In contrast to the Mo(CO)6-mediated cyclocarbonylation reaction, which exhibits excellent 
double bond selectivity, the standard Pauson-Khand promoter Co2(CO)8 proved largely 
unselective by giving mixtures of constitutional group isomers. Subsequently, Cazes reported 
low selectivity in more examples of Co-mediated allenic Pauson-Khand reaction.161
The substrate-controlled selectivity observed in the Mo-mediated reaction by Brummond 
has been exploited towards the synthesis of the potent antitumor agent 
hydroxymethylacylfulvene (HMAF) (250). Due to the presence of a methyl group at the 
proximal allenic position, the cyclocarbonylation reaction of allenyne 251 proceeds to give 
exclusively the 4-alkylidene cyclopentenone 252 desired for the synthesis of HMAF (Scheme 
4.12).162  
Scheme 4.12 Application of the allenic cyclocarbonylation reaction to the synthesis of HMAF. 
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The alternative pathway, selective for the proximal double bond of the allene, was employed in 
the synthesis of 5-deoxy-∆12,14-prostaglandin J2 (253) by utilizing a cleavable silicon tether in the 
allenyne 254 which gave 38 % yield of α-alkylidene cyclopentenones 255a and 255b (Scheme 
4.13).163
Scheme 4.13 Application of the allenic cyclocarbonylation reaction to the synthesis of 5-deoxy-
∆12,14-PGJ2 (253). 
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Since 1,3-disubstituted allenes inherently exhibit axial chirality, there is a potential for 
transfer of this chiral information to the stereocenter at the ring fusion in the α-alkylidene 
cyclopentenones during the cyclocarbonylation reaction. Brummond and coworkers 
demonstrated that this is indeed the case, by submitting enantioenriched dimethylphenylsilyl-
substituted allenyne 256 to the Mo-mediated conditions, which afforded the E-isomer of 257 
with 8 : 1 selectivity and complete retention of enantiopurity (95% ee) (Scheme 4.14).164 The 
lower enantiopurity (63% ee) of the Z-isomer was attributed to isomerization during the 
purification steps. The transfer of chirality is rationalized by selective coordination of the metal 
to the less hindered face of the allene, minimizing the interaction between the alkyne and the 
bulky silyl group as shown in 258A, which leads to the major E-isomer.  
Scheme 4.14 Transfer of chirality in the allenic cyclocarbonylation reaction. 
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Brummond and coworkers screened other metal catalysts in order to achieve catalyst-
based double bond selectivity and extend the overall utility of the allenic cyclocarbonylation 
reaction. It was found that the Rh(I) conditions first reported by Narasaka  (5 mol % 
[Rh(CO)2Cl]2) effect the reaction exclusively with the distal double bond of the allene.165 For 
example, reaction of the silicon tethered allenyne 259 gave 76% yield of the 4-alkylidene 
cyclopentenone 260 when heated to 90 °C under 1 atm (balloon pressure) of CO (Scheme 4.15). 
The remarkable regiochemical preference for reaction to occur with this selectivity was shown 
by preparing a number of other cyclopentenones, some of which are shown in Scheme 4.15.  
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Scheme 4.15 Rh(I)-catalyzed allenic cyclocarbonylation reaction.  
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Importantly, even terminally disubstituted allenes reacted exclusively with the distal double bond 
(264). The selectivity and reactivity for the distal double bond in the Rh(I)-catalyzed reaction 
was retained in substrates containing an additional carbon in the tether, thereby allowing the 
construction of seven membered rings (Scheme 4.16). Notably, formation of seven-membered 
rings has not been possible via the Pauson-Khand reaction of enynes, and therefore the ability to 
form the larger-size ring is attributed to the allenic moiety. The first example of seven membered 
ring formation in a Co-mediated allenic Pauson-Khand reaction was reported by Cazes; however, 
selectivity was accomplished with a sterically biased allene.161 Additionally, Narasaka166 and 
Mukai167 have reported examples of a Rh(I)-catalyzed allenic cyclocarbonylation reaction 
affording seven membered rings (in Mukai’s case, the proximal allenic position is substituted 
with a phenylsulfonyl group). 
Scheme 4.16 Formation of bicyclo[5.3.0]decadienes via an allenic cyclocarbonylation reaction. 
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The bicyclo[5.3.0]decadiene system obtained in this manner is found in a variety of terpenoid 
natural products with a broad range of biological activities.168 Brummond and coworkers have 
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used this reaction to craft an approach towards to naturally occurring antibiotic guanacastepene 
A (267).169, 170 To this end, reaction of allenyne 268 with 10 mol% [Rh(CO)2Cl]2 at 80 °C 
affords the [6,7,5]-fused tricyclic enone 269 in 65% yield (Scheme 4.17). 
Scheme 4.17 Allenic cyclocarbonylation reaction toward the synthesis of guanacastepene A. 
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In summary, the allenic cyclocarbonylation reaction has proven as a useful method for 
the synthesis of α- and 4-alkylidene cyclopentenones. The regioselectivity can be controlled by 
the choice of metal used to effect the reaction, thereby allowing for conversion of a single 
precursor to two structurally distinct products.  
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4.2 Rhodium(I)-Catalyzed Cyclocarbonylation of Amino-Ester Tethered Allenynes for 
Preparation of 4-Alkylidene Cyclopentenones  
 
Our next goal was to demonstrate that the amino ester-tethered allenynes could be used in 
the preparation of 4-alkylidene cyclopentenones via a selective cyclocarbonylation reaction with 
the distal double bond of the allene. In 2002, Brummond and coworkers reported that 
[Rh(CO)2Cl]2 effectively catalyzes the cyclocarbonylation reaction of variety of allenynes, 
selectively affording 4-alkylidene cyclopentenones.165 In all reported cases, product formation 
was effected under 1 atm of CO and heating to 90 °C in toluene. In sharp contrast, when allenyne 
73f was subjected to 5 mol% [Rh(CO)2Cl]2 in toluene under 1 atm of CO, reaction proceeded at 
rt to give only the cross-conjugated triene 111f in 77% yield and none of the expected 
cyclopentenone 270f (Scheme 4.18).  
Scheme 4.18 Attempted cyclocarbonylation reaction of 73f. 
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This result was somewhat anticipated since it was already established that cycloisomerization of 
the amino-ester tethered allenynes proceeds at an exceedingly fast rate (less than 10 min in 
presence of 5 mol % [Rh(CO)2Cl]2). Performing the reaction under CO atmosphere only 
noticeably slowed the rate of the cycloisomerization (1h vs. 10 min).  
It was rationalized that both triene 111f and cyclopentenone 270f are formed from a 
common Rh(III)-metallocyclopentene intermediate 271 as shown in Scheme 4.19. The 
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cycloisomerization pathway involves β-hydride elimination from the adjacent methyl group to 
give Rh(III)-H species 272, followed by reductive elimination. Alternatively, migratory insertion 
of CO in the vinyl-Rh(III) bond leads to acyl-metallocyclohexene 273, which is transformed to 
cyclopentenone 270f via a reductive elimination. 
Scheme 4.19 Mechanism for the cycloisomerization and cyclocarbonylation reaction of 73f. 
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A: CO insertion; B: reductive elimination; C: β-hydride elimination; D: reductive elimination.  
The reaction of 73f in presence of [Rh(CO)2Cl]2 clearly indicated that the cycloisomerization 
pathway leading to 111f is greatly favored with this catalyst. To circumvent this issue, other 
catalytic conditions were examined.  
In 2000, Shibata reported the use of Ir(I) catalysts for the intramolecular 
cyclocarbonylation reaction of enynes.171 Borrowing from this report, [Ir(CO)3Cl] was used in an 
attempt to effect selective formation of 270f. Heating allenyne 73f to 90 °C under 1 atm of CO, 
resulted in a mixture of all three possible products in 73% yield (entry 1, Table 4.1). 
Interestingly, the α-alkylidene cyclopentenone 274f (48%) resulting from reaction with the 
proximal double bond of the allene was formed preferentially over 270f (15%), along with a 
small amount of undesired triene 111f (10%). This result was encouraging despite the complete 
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lack of double bond selectivity, since cyclocarbonylation was the predominating reaction 
pathway. In an effort to inhibit the formation of the triene either sterically or electronically, PPh3 
was added to the iridium catalyst. Formation of the triene 111f was avoided by using an in situ 
prepared catalyst by addition of 20 mol % of PPh3 to 10 mol % [Ir(cod)Cl]2  (Ir : P ratio = 1 : 1). 
However, these conditions also gave a mixture of cyclocarbonylation products in 60 % yield 
with the α-alkylidene cyclopentenone 274f preferred (entry 2, Table 4.1). Both results indicate 
that Ir-based catalysts may have a unique preference to promote the reaction with the proximal 
double bond of the allene. This was confirmed in a report by Shibata in 2003 by converting 
terminally disubstituted allenynes to α-alkylidene cyclopentenones using IrCl(CO)(PPh3)2.172  
Table 4.1 Cyclocarbonylation conditions for allenyne 73f. 
• H
CbzN
MeO2C
N
Cbz
MeO2C
73f
N
Cbz
MeO2C
O NCbz O
MeO2C
conditions
270f 274f 111f
entry                             conditionsa                                                                 yield                 ratio 270f : 274f : 111f
1             [Ir(CO)3Cl], CO, toluene, 90 °C                                                      73%                             2 : 6.5 : 1.5
2             [Ir(COD)Cl]2, PPh3, CO, toluene,  90 °C                                        60%                             1.5 : 8.5 : 0
3             Rh(PPh3)3Cl, CO, toluene, 90°C,                                             no reaction 
4             Rh(CO)Cl(PPh3)2, CO, toluene, 90°C                                      no reaction
5             Rh(CO)Cl(PPh3)2, AgOTf,b CO, toluene, 50°C                            66%                           7.5 : 2.5 : trace
a 10 mol % of catalyst and 1 atm of CO was used in all cases; b 10 mol %  
Next, the effect of ligands on the Rh(I) catalyst was examined because it was reasoned that the 
undesired β-hydride elimination pathway from metallocylopentene 271 could also be suppressed 
in presence of phosphine ligands. It is well known that a vacant site on the Rh(III)-center is 
required for β-hydride elimination to occur.173, 174 Therefore, coordinatively saturated Rh(III)-
metallocycle is deemed more likely to undergo CO insertion than β-hydride elimination. With 
this in mind, Rh(PPh3)3Cl (Wilkinson’s catalyst)175 and trans-Rh(CO)Cl(PPh3)2 were tested.176 
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As shown in Table 4.1 (entries 3 and 4), reaction with 73f did not occur upon heating to 90 °C. 
The unreactive nature of these two catalysts is attributed to very low π-acidity due to presence of 
phosphine ligands. These observations are in accord with those by Jeong, who first reported that 
activation of both catalysts by Ag-additives is necessary in the cyclocarbonylation reaction of 
enynes.156 Addition of Ag(I) salts with non-coordinating anions (e.g., CF3SO3-, BF4-, SbF6-, PF6-) 
to a metal-halide complex replaces the strongly coordinating halide with a weakly coordinating 
counterion thereby creating a vacant binding site on the metal and increasing its π-acidity. When 
trans-Rh(CO)Cl(PPh3)2 was treated with equimolar amount  of AgOTf, reaction of 73f occurred 
at 50 °C to give a mixture of cyclocarbonylation products 270f and 274f in 66% yield, with the 
desired 4-alkylidene cyclopentenone preferred by ca. 3 : 1 (entry 5, Table 4.1).  
A similar result was obtained when N-benzoyl protected allenyne 73a was submitted to 
the same reaction conditions (entry 1, Table 4.2). Changing the solvent from toluene to DCE, 
resulted in formation of the cyclocarbonylation product 270a (55%) and triene 111a in 10% yield 
(entry 2, Table 4.2). Based on this result DCE was retained as a solvent, and variation of the Ag-
salt additive was examined. The type of the counterion is known to have an effect on the 
outcome of transition metal catalyzed reactions, but strict survey to our knowledge has not been 
performed in the context of Rh(I)-catalyzed cyclocarbonylation reactions.177 Interestingly, when 
using AgBF4, the only isolated product was the desired 4-alkylidene cyclopentenone 270a in 
76% yield (entry 3, Table 4.2). However, this reaction required 36 h at rt for completion, which 
may seriously limit its broader application.  
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Table 4.2 Cyclocarbonylation reaction conditions for allenyne 73a. 
• H
BzN
BnMeO2C
N
Bz
MeO2C
Bn
73a
N
Bz
MeO2C
Bn
O NBz O
Bn
MeO2C
conditions
270a 274a 111a
entry                                     conditionsa                                                           yield               ratio 270a : 274a : 111a
1                   Rh(CO)Cl(PPh3)2, AgOTf, CO, toluene, 50 oC                           52%                            4 : 1 : trace
2                   Rh(CO)Cl(PPh3)2, AgOTf, CO, DCE, rt                                       65%                            8.5 : 0 : 1.5
 
3                   Rh(CO)Cl(PPh3)2, AgBF4, CO, DCE, rt, 36h                               76%                           10 : 0 : 0
 
4                  [Rh(CO)2Cl]2, PPh3, AgBF4, CO, DCE, rt, 1h                           76%                           10 : 0 : 0b
a 10 mol % of catalyst and 1 atm of CO was used in all cases; b 10 mol %  [Rh(CO)2Cl]2, 30 mol % PPh3, 22 mol % AgBF4.  
Based on observations that RhCl(PPh3)3 activated by AgBF4 on average gave longer reaction 
times it was reasoned that reducing the amount of PPh3 would have an effect on increasing the 
rate of the reaction. Therefore, an experiment was designed where the catalytic species was 
prepared in situ from 10 mol % of [Rh(CO)2Cl]2, 30 mol % PPh3 and 22 mol % of AgBF4 (P : Rh 
ratio = 1.5 : 1).o When allenyne was added under 1 atm CO, reaction occurred at rt in 1h to give 
4-alkylidene cyclopentenone 270a in 76% yield (entry 4, Table 4.2).  To our knowledge, this is 
the first example of a Rh(I)-catalyzed cyclocarbonylation reaction occurring at rt (the initial 
examples by Jeong and Narasaka required heating over 100 °C).178
These conditions were then tested on a set of substrates to examine the scope. Variation 
of the alkyne terminus with a TMS group (entries 2 and 6, Table 4.3) resulted in formation of α-
silyl-cyclopentenones 270c and 270h in high yield. This result is in contrast to Narasaka’s who 
reported obtaining desilylated products in the reaction of trimethylsilyl-alkynes at higher 
                                                 
o PPh3 : Rh ratio of 1.5 : 1 proved necessary since increasing the amount of PPh3 (P : Rh = 2 : 1) led to slower 
reaction (as in entry 3), whereas lowering the amount of PPh3 (P : Rh = 1 : 1) led to formation of triene 111a. 
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temperatures. The reaction conditions were also tolerant of a phenyl-substituted alkyne (entries 3 
and 7) giving α-phenyl-cyclopentenones 270d and 270i in ca. 75% yield. The reaction of serine 
derived allenyne 73e proceeded to give cyclopentenone 270e in 81% yield. In nearly all cases, 
filtration of the reaction mixture over a short column of silica gel and eluting with 
EtOAc/hexanes provides the product with satisfactory purity for characterization (the rhodium 
catalyst shows high affinity for silica gel and does not elute with these solvents). 
Table 4.3 Preparation of 4-alkylidene cyclopentenones via a Rh(I)-catalyzed allenic 
cyclocarbonylation reaction. 
•
R2
H
PN
R1MeO2C
R3
73b-j
N
P
MeO2C
R1
R3
O
R2
270b-j
10 mol % [Rh(CO)2Cl]2
30 mol% PPh3, 22 mol % AgBF4
DCE, rt - 40 oC, 1h
entry/allenyne      P          R1          R2          R3     product     yield%     entry/allenyne    P         R1         R2          R3        product          yield%
 
   1/73b               Bz         Bn          Me        H        270b         32             5/73f            Cbz      Me         Me         Me            270f              75
   2/73c               Bz         Bn          Me      TMS     270c          98            6/ 73h          Cbz       Me        Me        TMS           270h             78
   
   3/73d               Bz         Bn          Me       Ph       270d          74            7/73i            Cbz       Me        Me          Ph            270i              75
 
   4/73e               Bz   -CH2OTBS   Me      Me       270e           81           8/73j            Cbz       Me        i-Pr          Me            270j              74
Note: the products in entries 2, 3 and 4 were obtained as mixtures of diastereomers in ~1.7 : 1 ratio.  
To test whether the newly developed catalytic reaction conditions are compatible with terminal 
alkynes, allenyne 73b was subjected to the reaction conditions. The reaction resulted in a 
complex mixture of unidentified products with the desired 4-alkylidene cyclopentenone 270b 
isolated in only 32% yield (entry 1). This observation is attributed to competing reaction 
pathways resulting from oxidative insertion of the Rh(I)-catalyst into the acetylenic C-H bond, 
which is well precedented.179 Finally, reaction of 73j with an isopropyl group on the allene 
terminus afforded 74% yield of the cyclopentenone 270j demonstrating that increase in steric 
bulk at this position does not affect the selectivity (entry 8). 
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Notably, the allenic cyclocarbonylation reactions summarized in Tables 4.2 and 4.3 
occurred with transfer of stereochemical information from the starting allenynes. For example, 
allenyne 73a which was subjected to the reaction conditions as a mixture of diastereomers in 1.7 
: 1 ratio, reacted to give the corresponding  ratio of diastereomeric cyclopentenones 270a which 
were separated by normal phase HPLC. Alternatively, the N-Cbz protected allenyne 73f (entry 5, 
Table 4.3) was used as a nearly single diastereomer, and reacted to give cyclopentenone 270f as 
a single diastereomer (diastereomer ratio of ~95 : 5 is obtained in the Claisen rearrangement, see 
Chapter 2).  
Scheme 4.20 Transfer of stereochemical information in the reaction of 73f. 
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The transfer of stereochemical information is a result of the axial chirality of the allene 
which allows reaction to occur from only one diastereotopic face. As illustrated in Scheme 4.20, 
despite the free rotation around the C1-C2 bond, oxidative addition of Rh(I) to form a [6,5]-fused 
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metallocycle can occur only from rotamer 73f-A (Scheme 4.20). The relative stereochemistry at 
the C4 is then retained in the course of the reaction giving a single diastereomer 270f with the 
relative stereochemistry predicted as shown.p Previously, chirality transfer in the Mo-mediated 
allenic cyclocarbonylation reaction affording α-alkylidene cyclopentenones has been 
observed.180  
Because the new Rh(I) catalytic conditions were optimized exclusively utilizing amino-
ester tethered allenynes, in was intriguing in whether their scope extends to other, less 
functionalized substrates. To test this, tosyl-amide tethered allenyne was subjected to the in situ 
prepared catalyst. It was found that the reaction of this substrate required heating to 50 °C, and 
gave a 70% yield of the 4-alkylidene cyclopentenone 276 selectively (Scheme 4.21). This result 
demonstrates that the selectivity observed in the cyclocarbonylation reaction of amino-ester 
tethered substrates is not influenced by the quaternary center, and the conditions may be 
applicable to a broader set of substrates. 
Scheme 4.21 Cyclocarbonylation reaction of N-tosyl tethered allenyne 275. 
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Finally, it should be noted that allenynes with terminally unsubstituted allenes are readily 
transformed to 4-alkylidene cyclopentenones by using the standard catalytic conditions (5 mol % 
[Rh(CO)2Cl]2, CO) because triene formation is not an option. For example, allenyne 74c gives 
cyclopentenone 277 in 72% yield (Scheme 4.22). 
 
                                                 
p The stereochemistry of the starting allenyne is obtained in the Claisen rearrangement and is assigned in accordance 
with the original results reported by Kazmaier (see Chapter 2; Kazmaier, U.; Görbitz, C. H. Synthesis 1996, 1489). 
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Scheme 4.22 Cyclocarbonylation reaction of a terminally unsubstituted allene. 
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4.3 Diversification of 4-Alkylidene Cyclopentenones 
In 2000, Brummond and Lu reported the total synthesis of hydroxymethylacylfulvene 
(HMAF, 250), a potent anticancer agent.162 HMAF has generated considerable interest because it 
displays anticancer activity against a number of different malignancies including breast, lung and 
colon carcinoma.181 The mechanism that contributes to HMAF’s proapoptotic and 
antiproliferative activity against cancer cells is believed to involve irreversible damage caused by 
covalent binding to proteins and/or nucleic acids in the cell. HMAF is structurally characterized 
by the presence of a unique pentafulvene moiety, rarely seen in biologically active compounds or 
natural products.182 In the synthesis of HMAF reported by Brummond, formation of fulvene 278 
was effected by 1,2-addition of MeLi to cyclopentenone 252 followed by acid-promoted 
elimination (Scheme 4.23). We became interested in applying this protocol to the amino-ester 
derived 4-alkylidene cyclopentenones to access novel fused pentafulvenes and examine their 
biological activity. 
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Scheme 4.23 Structure of HMAF and key fulvene synthesis step. 
OH
HO
O
O
HO
OTBS
HO
OTBS
1. CH3Li
2. HCl (0.1 M)
96%
250
hydroxymethylacylfulvene (HMAF)252 278
 
Therefore, cyclopentenone 270a was treated with MeLi/CeCl3 (1.5 equiv.) to afford tertiary 
alcohol 279a (Scheme 4.24).q Immediate treatment of the crude reaction mixture with aq. HCl 
and warming to rt led to formation of a bright yellow solution, from which fulvene 280a was 
isolated in 74% yield (pentafulvenes are generally characterized by yellow color, Lat. fulvus = 
yellow).183  
Scheme 4.24 Synthesis of novel pentafulvenes. 
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The structure of 280a was assigned based on the presence of one olefin peak in the 1H NMR 
spectrum at 6.29 ppm for Ha and three methyl groups (Scheme 4.24). Similarly, the N-Cbz 
protected cyclopentenone 270f afforded fulvene 280f in 50% yield. Unfortunately, the newly 
synthesized fulvenes proved unstable and readily decomposed when kept on the bench-top either 
                                                 
q The presumed tertiary alcohol 279 was treated in situ with aq. HCl and was not characterized. 
 100 
neat or in solution. This decomposition was qualitatively assessed by collecting the 1H NMR 
spectrum of 280a at different times. A solution of 280a in CDCl3 stored at rt for 5 days resulted 
in appearance of additional broadened resonances in the upfield region (1.0 – 2.0 ppm). The 
decomposition was accelerated when 280a was stored neat. In contrast, storing 280a in 
deoxygenated frozen benzener at -10 °C proved advantageous in extending its shelf life up to 
three months.  Unfortunately, these observations rendered the newly synthesized fulvenes 
unsuitable for biological evaluation because the results may be compromised by the presence of 
impurities. The pathway of decomposition has not been determined, however it is well known 
that simple alkyl-pentafulvenes readily polymerize in presence of traces of acid (Scheme 
4.25).184 Additionally, polymerization of pentafulvenes has been triggered by reaction with 
molecular oxygen.185  
Scheme 4.25 Acid catalyzed polymerization of pentafulvenes. 
R1 R2 R1 R2
H
H+
R1 R2 R
1 R2
R1
R2
+
R1 R2
n
284
H+
281 282 283
R1 R2
 
The electron density of the fulvene moiety in 270a and 270f is likely responsible for the 
observed decomposition. Based on the structure of HMAF (252, Scheme 4.23), it was 
hypothesized that an acyl group may impart greater stability to these compounds by reducing the 
electron density of the fulvene. To examine this effect we sought to prepare fulvene 286 (Scheme 
4.26). To this end, the cyclocarbonylation reaction of amide tethered allenyne 145e was briefly 
examined.  
 
                                                 
r Benzene was deoxygenated prior to freezing by bubbling nitrogen via a needle. 
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Scheme 4.26 Design of novel acyl-fulvenes. 
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Subjecting 145e to 10 mol% of [Rh(CO)2Cl]2 under CO atmosphere led to formation of the 
cross-conjugated triene 146e, which was isolated in 70 % yield (Scheme 4.27). To circumvent 
the formation of triene, the newly developed cationic Rh(I)-conditions were applied next. 
Treatment of 145e to the in situ prepared catalyst (10 mol% [Rh(CO)2Cl]2, 30 mol% PPh3 and 22 
mol% AgBF4) at 50 °C resulted in complete consumption of the starting material in 3h and 
generation of a mixture of unidentified products in 44% yield by mass recovery. The major 
compound isolated from this mixture in 22% yield displayed a molecular ion peak in the mass 
spectrum same as the starting material (m/z = 401), indicating that it is likely a product of an 
isomerization reaction. Unfortunately, the desired cyclocarbonylation product 285 was not 
observed. 
Scheme 4.27 Attempted cyclocarbonylation reactions of 145e. 
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Due to these discouraging results, further study on generating a library of amino-acid derived 
fulvenes was discontinued. In addition to stabilizing the fulvene moiety by installing an acyl 
substituent, another potential strategy for future investigation involves exploiting the reactivity of 
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the newly synthesized fulvenes (e.g. 280a) in other complexity generating reactions. For 
example, alkyl-fulvenes have been demonstrated as useful cycloaddition partners in a variety of 
reactions including [4+2],186 [6+3],187 [2+2]188 and [3+2] cycloadditions (Scheme 4.28).189 The 
vast majority of the reported examples involve symmetrical fulvenes, substituted only at the 
exocyclic olefin. The method of fulvene preparation that we have demonstrated allows the 
synthesis of polysubstituted ring-fused fulvenes whose cycloaddition reactions have not been 
examined. 
Scheme 4.28 Selected cycloaddition reactions of fulvenes 
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In summary, a new Rh(I)-catalytic system for the allenic cyclocarbonylation reaction was 
developed affording amino-ester tethered 4-alkylidene cyclopentenones in high yields and 
selectivity. These protocols have been applied to the preparation of a library of sixteen 
compounds using fluorous mixture synthesis by Dr. Sukhdev Manku in the Curran group.190, 191  
Diversification of the 4-alkylidene cyclopentenones by converting them to fulvenes did not result 
in useful biological probes because these compounds proved relatively unstable.  
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4.4 Mo(CO)6-Mediated Cyclocarbonylation Reaction for Preparation of α-Alkylidene 
Cyclopentenones 
Brummond and coworkers had previously shown that the Mo(CO)6 mediated 
cyclocarbonylation reaction of 1,3-disubstituted allenes generally proceeds to give α-alkylidene 
cyclopentenones as mixtures of E and Z isomers (see Scheme 4.11).160 A similar trend was 
anticipated with the amino-ester derived substrates. Indeed, subjection of allenyne 73a 
containing a methyl group on the terminus of the allene to the standard reaction conditions (1.25 
equiv. Mo(CO)6, 10 equiv. DMSO, toluene, 90 °C) resulted in a complex mixture of 
cyclocarbonylation products without one particular major product according to 1H NMR analysis 
of the crude reaction mixture (presumably diastereomers and E/Z isomers of 274a and 
diastereomers of the minor product 270a). 
Scheme 4.29 Mo-mediated cyclocarbonylation reactions of 73a and 73b. 
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Since the starting Bz-protected allenyne 73a was submitted to the reaction as a mixture of 
diastereomers in 1.7 : 1 ratio, it was reasoned that each diastereomer reacts to give the product 
274a as a mixture of diastereomers with respect to the relative stereochemistry of the two sp3 
 104 
stereocenters and mixture of E/Z isomers of the alkylidene olefin, further complicating the 
characterization. Therefore the Cbz-protected allenyne 73f as single diastereomer was tested next 
(Scheme 4.29). The cyclocarbonylation reaction of 73f with Mo(CO)6 provided α-alkylidene 
cyclopentenone 274f with ~20 : 1 selectivity over the 4-alkylidene cyclopentenone 270f 
(determined by 1H NMR and HPLC/UV). Cyclopentenone 274f was present as a mixture of 
mainly two isomers in ~7 : 1 ratio which were separated by normal phase HPLC. The major 
isomer was assigned Z-geometry of the alkylidene olefin based on the 1H NMR signal appearing 
at 5.98 (q, J = 7.3 Hz, 1H) while the minor diastereomer was assigned E-geometry since the 
olefin signal appeared further downfield at 6.65 (q, J = 7.2 Hz, 1H). Nevertheless, obtaining the 
products as mixture of isomers was disappointing particularly since separation of the products 
was possible only by HPLC.  
To eliminate the formation of E and Z isomers and focus on determining the 
diastereoselectivity of the reaction, our subsequent investigations were focused on the reaction of 
monosubstituted allenes. When phenylalanine derived allenynes 74a (R = Me) and 74b (R=H) 
were submitted to the standard cyclocarbonylation conditions (1.25 equiv. Mo(CO)6, 10 equiv. 
DMSO, toluene, 90 °C), the reaction proceeded to give mixtures of products (Scheme 4.30). The 
major diastereomer 287a (57%) could be easily separated by column chromatography from 288a 
and 289a. Likewise, 287b (55%) was also chromatographed away from 288b and 289b. 
Unfortunately, 288a and 289a could not be separated; likewise, 288b and 289b also coeluted. 
The composition of the reaction mixture was determined by integration of the olefinic 
resonances in the 1H NMR spectrum of the crude reaction mixture (Scheme 4.30).s Allenyne 74a 
gave the α-alkylidene cyclopentenones 287a and 288a in 6.4 : 1 ratio, whereas 74b gave 287b 
                                                 
s These ratios are averages and showed reasonable variation in different experiments (±10%). The ratios in all 
subsequent reactions were determined by integration of the olefinic resonances in the 1H NMR spectrum. 
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and 288b in 3 : 1 ratio. Notably, both reactions resulted in ~15% of the 4-alkylidene 
cyclopenenone (289a, 289b) resulting from reaction with the distal double bond of the allene.  
Scheme 4.30 Cyclocarbonylation reaction of phenylalanine derived allenynes. 
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The relative stereochemistry of the major diastereomer 287b was unambiguously assigned by X-
ray crystallography, where the benzyl group and Ha are syn (Scheme 4.31) (for X-ray data see 
Appendix D). The same relative stereochemistry was assigned to 287a, based on an X-ray 
structure of a later intermediate (296, in Scheme 4.41, vide infra). 
Scheme 4.31 X-ray crystal structure of 287b. 
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MeO2C
HaBn
287b
X-ray of 287b  
The cyclocarbonylation reaction of allenynes 74c, 74d and 74e, possessing aliphatic side chains 
was examined next (Scheme 4.32).  The alanine-derived allenynes (R1 = Me) 74c and 74d 
afforded α-alkylidene cyclopentenones with dramatically increased selectivity (14 : 1), and high 
diastereoselectivity (~10 : 1). The leucine derived allenyne 74e also reacted selectively with the 
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proximal double bond to give α-alkylidene cyclopentenones in 5.4 : 1 ratio. 
Scheme 4.32 Cyclocarbonylation reaction of allenynes 74c, 74d  and 74e. 
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The relative stereochemistry of the major products 287c-287e was initially predicted to be the 
same as in the phenylalanine case 287b. However, chromatography of the product mixture from 
the reaction of 74e gave a new compound characterized as dienone 290e possessing a double 
bond across the ring fusion (Scheme 4.33).t Because there was no evidence of compound 290e 
being present in the 1H NMR of the crude reaction mixture prior to chromatography, it was 
assumed that 290e was result of an isomerization reaction promoted by silica gel. This was later 
confirmed in a separate experiment by adsorbing the crude reaction mixture onto silica gel for 1 
h, followed by elution and collecting the 1H NMR spectrum which showed the presence of this 
new compound. 
 
 
 
 
                                                 
t The structure of 290e was assigned based on 1H NMR, 13C NMR, DEPT135 and mass spectral data. 
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Scheme 4.33 Isomerization of enones 287d, 287e and 288b. 
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Closer studies revealed that 290e resulted exclusively from isomerization of the major 
diastereomer 287e, while the minor diastereomer was considerably more stable to silica gel. To 
examine whether this isomerization was acid- or base-promoted, the crude reaction mixture was 
treated separately to minor excess of AcOH and Et3N (~10 equiv).  While the Et3N-treated 
sample displayed rapid isomerization within 1h (as followed by 1H NMR), the AcOH-treated 
sample was stable indefinitely. We took advantage of this observation by using 1% acetic acid in 
the eluting solvent during column chromatography on silica gel, which allowed for isolation of 
all three enones from the reaction (287e, 288e and 289e). Then, the enones were separately 
readsorbed onto silica gel and their spectrum was collected after 1 h. Diastereomer 287e 
completely isomerized to 290e within 1 h (Scheme 4.33), while diastereomer 288e did not 
isomerize. Moreover, exposure of 287e and 288e to Et3N led to rapid isomerization of 287e, and 
slower isomerization of 288e. Similarly, the alanine-derived cyclopentenone 287d isomerizes to 
290d upon treatment with silica gel or Et3N. It was also shown that the minor diastereomer 288b 
in the phenylalanine case isomerizes to 290b. The new enones 290d, 290e and 290b proved to be 
highly unstable and decomposed upon storage.192  
Since the major diasteromer 287b, from the reaction of the phenylalanine derived 
allenyne 74b did not isomerize in a manner like 287e, we suspected that these two major 
products may have opposite stereochemistry. The NOESY spectrum of both diastereomers 287e 
and 288e revealed this to be true (Scheme 4.34). The major diastereomer 287e is the one where 
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the methyl ester and Ha are syn.  
Scheme 4.34 Assignment of the relative stereochemistry of 287e and 288e based on NOESY 
correlation spectrum. 
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Similar observations collected from the reaction of the alanine-derived allenyne 74d led us to 
postulate that in all cases where the R1 is aliphatic, the product with the methyl ester and Ha in 
syn orientation is obtained as the major diastereomer.u The facile isomerization of diastereomers 
287d, 287e and 288b may be a result of the methyl ester carbonyl serving as an internal Lewis 
base in labilizing the C-Ha bond as shown in Scheme 4.35. 
Scheme 4.35 Ester assistance in the isomerization of 287e to 290e. 
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 It is noteworthy to mention that the α-alkylidene cyclopentenones 287a, 288a and 287c, 288c 
(Schemes 4.30 and 4.32, respectively) did not isomerize under the silica gel conditions. In these 
cases, the olefin is already tetrasubstituted and may account for this observation. 
To rationalize the isomerization of only one cyclopentenone diastereomer, ab initio 
energy calculations were performed comparing the energies of the phenylalanine-derived 
                                                 
u Another substrate derived from norvaline (R1 = n-Bu) was shown to give the same diastereoselectivity as alanine 
and leucine (personal communication from Dr. Stefan Fischer, Curran group). 
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cyclopentenones 287b, 288b and the isomer 290b. The calculations indicated that the 
transformation of 288b to 290b is favorable by ca. 1.9 kcal/mol, whereas 287b and 290b are 
nearly isoenergetic (Scheme 4.36).193 Therefore, these calculations support the observed results. 
Scheme 4.36 Ab initio energy calculations of α-methylene cyclopentenones 287b, 288b and 
290b. 
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 To determine whether the diastereoselectivity in the cyclocarbonylation reaction of allenynes 
with aromatic side chains could be increased, we tested four other substrates containing a p-
OMe-phenyl (74f), p-F-phenyl (74g), 2-thienyl (74h) and 3-N-Boc-indolyl (74i) moiety. These 
were chosen to provide an electron donating, electron withdrawing and two heterocyclic groups 
respectively. Interestingly, the cyclocarbonylation reaction of all four substrates proceeded with 
nearly the same diastereoselectivity (2-3 : 1) as the phenylalanine case giving the product with 
the aromatic group and Ha in syn orientation as the major diastereomers (Scheme 4.37).  
Scheme 4.37 Cyclocarbonylation reaction of allenynes 74f-i. 
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From these results, it was concluded that opposite diastereomers are favored in the 
cyclocarbonylation reaction of allenynes with aliphatic vs. aromatic side chains.  It is speculated 
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that the major diastereomer in the aliphatic case (e.g. 74e leading to 287e) results from a 
transition state shown in Scheme 4.38 where the alkyl group is placed in a pseudoequatorial 
position. In addition, there may be an interaction between the carbonyl oxygen of the methyl 
ester and the oxophilic molybdenum center contributing to this transition state being favored. 
The origin of reversed diastereoselectivity in the presence of an aromatic residue in the side 
chain is subject to speculation. One potential explanation is based on coordination of the 
aromatic ring in the side chain with the molybdenum center as shown on 74b (Scheme 4.38). It is 
well known that Mo(CO)6 readily reacts with various arenes to form [Mo(η6-arene)(CO)3] 
“piano-stool” complexes.194 Since the Mo(CO)6-mediated cyclocarbonylation reaction takes 
place in toluene, formation of the octahedral complex [Mo(η6-toluene)(CO)3] (291) has been 
proposed as the initial step of the reaction.195 A recent study has demonstrated that the arene 
ligands in these molybdenum complexes can be readily exchanged even at rt.196 Thus, it is 
conceivable that temporary chelation of the phenyl ring in allenyne 74b with the molybdenum 
center as shown in Scheme 4.38 may be responsible for the stereochemistry observed in the 
major diastereomer 287b.  
Scheme 4.38 Arene complexation rationale for the diastereoselectivity in the cyclocarbonylation 
reaction. 
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4.5 Diversification of α-Alkylidene Cyclopentenones 
4.5.1 Studies Towards the Synthesis of Tricyclic Pyrroles 
Although the amino-ester derived α-alkylidene cyclopentenones could potentially serve 
as useful tools to study biological systems, we were somewhat concerned with the reactivity of 
the exocyclic enone moiety towards nucleophilic reagents, which may lead to non-specific 
alkylation of biomolecules.  It was reasoned that the reactivity of the enone could instead be 
utilized in various Michael-type additions to increase the molecular complexity of the newly 
obtained cyclopentenones.197 More specifically, umpolung198 addition of an aldehyde to the 
enone via a Stetter reaction would yield a 1,4-diketone B resulting in increase of molecular 
complexity (Scheme 4.39).199, 200 Moreover, this 1,4-dicarbonyl moiety is synthetically versatile 
and could, in principle, be utilized in a Paal-Knorr reaction to afford furan C under acidic 
conditions or pyrrole D in presence of an amine.201, 202 Additionally, aldol condensation was 
envisioned under basic conditions, affording enone E  (Scheme 4.39).203  
Scheme 4.39 Diversification potential of α-alkylidene cyclopentenones. 
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We were motivated to first examine the formation of pyrroles D for three reasons: (1) 
multicomponent processes involving a Stetter/Paal-Knorr reaction sequence have been utilized 
previously for the synthesis of functionalized pyrroles;204 (2) an additional diversification site 
could be easily introduced by the preparation of pyrrole by using a variety of amines (R3-NH2); 
and (3) a plethora of biologically interesting compounds from natural and synthetic origin 
possess pyrroles as part of their substructure thus it is presumed that these compounds will be 
useful as potential biological probes.205  
To this end, the conversion of 287a and 287b to 1,4-diketones was explored using a 
Stetter reaction protocol reported by Tius.206 Diversifications were performed only with 
phenylalanine derived α-methylene cyclopentenones 287a and 287b since the major 
diastereomers 287d and 287e (from the alanine and leucine derived substrates, respectively) 
isomerize under basic conditions needed for the Stetter reaction.v Treatment of 287a to 
butyraldehyde, Et3N and thiazolium salt 292 in 1,4-dioxane for 6h at 70 °C resulted in the Stetter 
product 293 in 73% yield as a 4 : 1 mixture of diastereomers.  
Scheme 4.40 Stetter reaction of 287a and 287b with butyraldehyde. 
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The major diastereomer 293a selectively precipitates from an EtOAc/hexanes solution of the 
                                                 
v Treatment of 287d and 287e to the Stetter reaction conditions resulted mainly in decomposition and very low 
yields of 1,4-diketone. 
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crude mixture after workup and can be easily isolated in this manner. The relative 
stereochemistry of 293a was subsequently assigned by X-ray crystallography of the reduced 
product (296, Scheme 4.41). Cyclopentenone 287b was also submitted to the same reaction 
conditions to give a 66% yield of product 294 with identical diastereoselectivity.  
A single attempt to convert 293a to pyrrole 295 using a Paal-Knorr protocol was unsuccessful.  It 
was reasoned that the strained nature of the product 295 was problematic and that reduction of 
the double bond in 293a would alleviate some of this strain. Reduction of cyclopentenones 293a 
and 294a to give single diastereomer of cyclopentanones 296 and 297, respectively, was effected 
using Pd/C, H2 (Scheme 4.41).207 The structure and relative stereochemistry of 296 was assigned 
by X-ray crystallography, confirming that reduction occurred from the convex face to give the 
cis-fused bicycle (Appendix E). 
Scheme 4.41 Attempted pyrrole synthesis and reduction of 205a and 206a. 
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When 297 was treated with benzylamine and AcOH in methanol in the presence of molecular 
sieves at 70 °C, it afforded tricyclic N-benzyl pyrrole 298a in 90% yield (Scheme 4.42).  
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Scheme 4.42 Synthesis of pyrrole 298a. 
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Other amines were tested in this pyrrole forming reaction to determine its scope and the results 
are shown in Table 4.4. The reaction with an amino acid derivative was first attempted, since 
incorporation of a second amino acid would be an interesting diversification feature.  The soluble 
glycine-methyl ester hydrochloride participated in the reaction and gave pyrrole 298b in 70% 
yield (entry 1, Table 4.4) but the more sterically hindered valine methyl ester, failed to 
participate under the same reaction conditions (entry 2). Next the aromatic amine, anisidine was 
used (entry 3) and the reaction proceeded to give 298c in 85% yield. Similarly, ethanolamine 
gave 298d in 76% yield (entry 4). Finally, 2-amino pyridine gave none of the desired product 
(entry 5).  
Table 4.4 Preparation of tricyclic pyrroles from 297. 
N OBz
MeO2C
Bn
O
NBz
MeO2C
Bn
N
R
R-NH2, AcOH, MeOH
Entry            Amine                   Temp.         Time(h)     Product   Yield (%)
H2N
OH
H2N
OMe
H2N
CO2Me
60 °C            2              298c         85a
 70 °C            1              298d        76b
70 °C            4              298b         70a
NH2N 70 °C            4                       no reactiona
H2N
CO2Me
70 °C            4                       no reactiona
iPr
1 
2 
3 
4
5
297 298b-d
H
H H
H
a R-NH2 (5 equiv.), AcOH (5 equiv.); b R-NH2 (10 equiv.), AcOH (8 equiv.).  
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Based upon this small sampling of amines, aliphatic amines of type H2N-CH2-R appear to be the 
best substrates for the pyrrole formation since substitution next to the amine results in complete 
recovery of the starting material likely due to sterics. Of the two aromatic amines tested, 2-
amino-pyridine was relatively unreactive which can be attributed to the presence of second basic 
nitrogen in the molecule proximal to the reactive primary amine. Formation of a  pyrrole from a 
single diastereomer of the methyl substituted diketone 296 using furfuryl amine proceeded to 
give the product 299 in 75% yield as a mixture of two diastereomers in 2 : 1 ratio (Scheme 4.43). 
The diastereomers are likely a result of epimerization of the stereocenter bearing the methyl 
group. The epimerization of this stereocenter in the pyrrole formation was unfortunate and 
deemed uncontrollable under the acidic reaction conditions. 
Scheme 4.43 Formation of pyrrole 296 as a diastereomeric mixture. 
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Unfortunately, the new alkyl pyrroles 298a-d exhibited a considerable tendency to 
decompose when stored neat or open to the atmosphere, rendering them less than desirable for 
biological assays. This decomposition was initially only qualitatively assessed and later 
confirmed by an NMR study performed by Dr. Stefan Fischer (Scheme 4.47, vide infra). Thus, 
stabilizing the pyrrole moiety by introducing an electron withdrawing substituent was explored. 
An acyl substituent attached to the 2 position of the pyrrole seemed like a plausible solution 
since this group could be introduced via the Stetter reaction using 1,4-addition of 
glyoxylamides.208 Two glyoxylamides from dimethyl amine (302) and pyrrolidine (303) were 
prepared by oxidative cleavage of the corresponding tartaric acid amides 300 and 301 with 
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periodic acid (H5IO6).209 These highly electrophilic aldehydes both participated in the Stetter 
reaction with 287b when 30 mol % of the thiazolium salt catalyst 292 was used, affording the 
products 304 and 305, respectively in 10 min as single diastereomers (Scheme 4.44).  
Scheme 4.44 Addition of glyoxylamides to 287b and subsequent reduction. 
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It is noteworthy that subsequent to Stetter’s original report in 1987, there are no additional 
examples in the literature that utilize this 1,4-addition of glyoxylamides. It appears that this 
reaction is a viable entry into the α-keto-amide moiety that is both synthetically useful,210 and 
present in biologically active molecules.211 Next, the double bond of enones 304 and 305 was 
reduced giving 306 and 307 in 81% and 74% yield, respectively. A slightly modified protocol for 
pyrrole formation was developed using 3 equivalents of the amine, excess acetic acid and ethanol 
as solvent. Heating of 307 at 50 °C for 2-3 hours generally gave complete conversion to pyrroles 
308a-n, which were isolated following an acidic workup and short column chromatography 
purification (Table 4.5). This reaction allows direct access to the pyrrole-2-carboxamide moiety 
which has not been previously synthesized via a Paal-Knorr synthesis.212  
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Table 4.5 Preparation of a 14-member library of acyl-pyrroles from 307. 
BzN O
Bn
MeO2C
H O
O
N
H
H2N R, AcOH, EtOH
50 °C, 2-3 hours
BzN
Bn
MeO2C
H
H
N
O
N
R
H2N
OHH2N
H2N
H2N
OMe
OMe
OMe
OH
H2N O
H2N
OH
H2N N
O
H2N N
O
H2N
O
H2N
H2N
H2N CO2Me
H2N
NH3
307 308a-n
amine                           product    yield (%) amine                           product    yield (%)
308a            80%
308b            88%
308c            72%
308d            85%
308e            63%
308f            39%
308g            81%
308h            70%
308i              93%
308j              89%
308k             69%
308l              79%
308m            95%
308n             64%
 
Two pyrroles were also prepared from diketone 306 using the same conditions (Scheme 4.45).  
Scheme 4.45 Preparation of pyrroles from diketone 306. 
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The most suitable aliphatic amines for the Paal-Knorr reaction do not have branching at the 
position alpha to the amine since cyclohexylamine failed to give any product (Scheme 4.46). 
When 2,2,2-trifluoroethylamine was used the reaction rate was significantly retarded, and the 
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reaction failed to go to completion, which is attributed to the electron withdrawing effect of the 
trfluoromethyl group. Increased heating drives the reaction further but results in impurities 
(Scheme 4.46). 
Scheme 4.46 Unsuccessful examples of pyrrole formation. 
H2N H2N CF3
slow and incomplete reaction
BzN O
Bn
MeO2C
H O
O
N
BzN N
R
O
N
Bn
MeO2C
H
R-NH2, AcOH, EtOH 
50 °C, 3h
307 309
H H
no reaction  
To determine whether the newly formed acyl pyrroles 308a-p are more stable than the alkyl-
pyrroles as initially hypothesized, we performed an NMR experiment where an alkyl and acyl-
pyrrole of benzyl amine were placed in an NMR tube with a standard (p-phthalic acid ethyl ester) 
in d6-DMSO.w The sample was kept at rt in a sealed NMR tube. Monitoring of the 1H NMR of 
the sample over a period of 60 days, revealed that the alkyl-pyrrole 298a had been reduced to 
half of its initial amount, whereas the acyl-pyrrole 308a remained virtually unchanged (Scheme 
4.47). 
 
 
 
 
 
 
                                                 
w NMR study was performed by Dr. Stefan Fischer (Prof. Curran group). 
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Scheme 4.47 Comparison of the stability between alkyl-pyrrole 298a and acyl-pyrrole 308a. 
BzN
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MeO2C
H
H
N
O
N
BzN
Bn
MeO2C
H
H
N
CO2Et
CO2Et
acyl pyrrole (308a) alkyl pyrrole (298a)
standard
initial ratio             4.9                                                             1.9
ratio after                4.8                                                            3.8
60 daysa
aThe ratios shown are standard / compound. The sample was kept in an NMR tube in d6 DMSO at rt under N2 atmosphere.  
Since compounds 308a-p represent a new class of angularly fused tricyclic pyrroles with high 
molecular complexity, we became interested in synthesizing a discovery library for biological 
evaluation. To obtain a better understanding of the three-dimensional structure of the pyrroles, 
energy minimization was performed on the simplest pyrrole member 308n (Figure 4.1).x
Figure 4.1 Two different stereoviews (top and bottom) of the energy-minimized model of 308n. 
 
 
                                                 
x Energy minimization was performed with Cache Worksystem Pro. version 6.1.10. First, global minimum search 
was performed using MM3 parameters, followed by energy minimization using AM1 paramaters. 
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4.5.2 Synthesis of a Library of Tricyclic Pyrroles 
The methodology involving a cyclocarbonylation/Stetter/Paal-Knorr reaction sequence 
that allows the synthesis of tricyclic pyrrole-2-carboxamides 308a-p has been applied to library 
synthesis within the University of Pittsburgh Center for Chemical Methodologies and Library 
Development (UPCMLD).213 The library design is based on three points of diversity: (1) amino 
acid side chain R1; (2) glyoxylamide used in the Stetter reaction (R2); and (3) amine used in the 
pyrrole formation (R3) (Scheme 4.48). While studying the Mo(CO)6-mediated 
cyclocarbonylation reaction of allenynes, it was demonstrated that only amino-esters containing 
an aromatic group in the side chain afford a stable diastereomer in the reaction that can be taken 
the subsequent steps. Therefore the amino-ester building blocks were a limited source of front-
end diversity and were chosen to contain a benzyl, p-fluorobenzyl and p-methoxybenzyl group 
(310{1-3}). Similarly, the library was designed using only two glyoxylamide building blocks 
(N,N-dimethyl 311{1} and pyrolidinyl 311{2}). Since the pyrrole formation is used as a last step 
in the synthesis, the choice of the amine was used as a greatest source of appendage diversity. A 
subset of 41 amines 313{1-41} was selected from a larger set of 300 primary amines, based on 
calculating properties such as molecular weight, clogP(octanol/water) of the product, cost and 
diversity (a range of aliphatic, heteroatom-containing aliphatic, aromatic and heteroaromatic 
amines were included).  
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Scheme 4.48 Synthesis of a library of tricyclic pyrroles. 
NH3 x HOAc
H2NMe
H2N
H2N
F
H2N
OMe
H2N
OHHO
H2N
OMe
O
H2N
S
OH
H2N
NH
OH
H2N
N NH
H2N
N
NH
O
H2N
N O
H2N
H2N
H2N
H2N
H2N
H2N
H2N
H2N
H2N
H2N
MeO OMe
MeO OH
F
O
O
OCF3
MeF
F
F F
F
ClF3C
SO2Me
H2N
OH
OH
H2N
OH
OMe
H2N
OMe
Br
H2N
N
H2N
N
H2N
N
OH
Me
HO
CH3
H2N
O
H2N
S
H2N
N
N
H2N
O
N
H2N
NH
N
Me
Br
Me
Me
Ph
Me
N
N
H2N
H2N
H2N
N
NO2
Me
H
N
H2N
H
N
OMe
H2N
H
N
OH
H2N
H
N
F
H2N HN
N
CF3
Cl
BzN O
R1
MeO2C
H
O
N
R2
R2
O
Et3N, 1,4-dioxane,
30 mol% 292
70 °C, 20 min,
75-93%
310{1-3}
H2 (1 atm), Pd/C, MeOH, 18h
88-99%
BzN O
R1
MeO2C
H O
O
N
R2
R2
H1.
2.
BzN N
R3
O
N
R2
R2R1
MeO2C
H
313{1-41} R3-NH2
AcOH, EtOH 
µW, 150W, 60-100 °C
15-30 min
0-80%
314{1-3,1-2,1-41}
H
312{1-3,1-2}
R1 :
F OMe
310{1} 310{3}310{2}
R3 :
O
N
O
O
N
O
R2 :
311{1} 311{2}
313{1}
313{2}
313{3}
313{4}
313{5}
313{6}
313{7}
313{8}
313{9}
313{10}
313{11}
313{12}
313{14}
313{20}
313{15}
313{21}
313{16}
313{22}
313{17}
313{23}
313{18}
313{19}
313{24}
313{26}
313{25}
313{28}
313{29}
313{30}
313{31}
313{32}
313{33}
313{34}
313{35}
313{36}
313{37}
313{38}
313{39}
313{40}
313{41}
H2N
OH
313{13}
313{27}
311{1-2}
 
Using the previously discussed cyclocarbonylation protocol, α-alkylidene cyclopentenones 
310{1-3} were obtained in 40-50% yield for the diastereomer shown (all reactions subsequent to 
this step were performed by the staff at the UPCMLD). Next, performing six Stetter reactions in 
parallel using a Radley’s carousel station, followed by reduction of the double bond afforded 
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diketones 312{1-3,1-2} in yields ranging between 75-93% and 88-99% yields for each step, 
respectively. Using an optimized microwave reaction protocol for the pyrrole formation (150 W, 
80 °C, 15 min),214 the six diketones were reacted with the 41 amines outlined in Scheme 4.48. Of 
the possible 246 reactions, 210 were performed affording 172 pyrroles 314{1-3,1-2,1-41} in 
average yield of 53% after purification. The average amount of each library member obtained 
was 14.7 mg, in average purity of 94% (determined by LC/MS analysis with UV detection at  
210, 220, 240 nm). 
Computational prediction of pharmacologically relevant physico-chemical properties of 
small molecule libraries is important in characterizing their potential to to serve as biological 
tools or drug candidates. Physico-chemical properties for the tricyclic pyrrole library have been 
calculated using QikProp 2.1215 and are outlined in Table 4.6.y The majority of molecular 
descriptors listed (molecular weight, molecular volume, clogP, number of hydrogen bond donors 
and acceptors, number of primary metabolites, etc.) fall within the range of values for most 
known drugs (first column). The distribution of predicted physico-chemical properties can also 
be used to to characterize the diversity of the library members. As can be seen from Figure 4.2, 
the pyrroles display broad distribution of molecular weights (472-763 g/mol), clogP values (3.3-
8.9) and number of hydrogen bond acceptors (7-13). Less distribution is seen in the number of 
hydrogen bond donors (0-2). The number of rotatable bonds ranges from 5-12, whereas FISA 
(hydrophilic component of the solvent accessible surface area) ranges between 15.4-153.1 Å2. 
 
 
 
                                                 
y Calculations were performed by Dr. Stefan Werner. 
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 Table 4.6 Computational analysis of molecular descriptors for the pyrroles 314{1-3,1-2,1-41} 
using QikProp 2.1 (table reproduced with permission from Dr. Stefan Werner). 
 
Parameter 
Range for 
95% of all 
Drugs 
Average ± Standard 
Deviation for 179 
Pyrroles 
Number of 
Compounds 
out of 
Range 
molecular weight (g/mol) 130 to 725 620±57 5 
molecular volume (Å3)a 500 to 2000 1800±100 3 
FISA (Å2)b 7 to 330 64±33 0 
number of rotatable bondsc 0 to 15 8.3±1.5 0 
number of hydrogen bond donorsd 0 to 6 0.5±0.7 0 
number of hydrogen bond acceptorse 2 to 20 9.6±1.3 0 
logP (octanol/water) -2 to 6 6.6±1.3 119 
logKhsa (serum protein binding) -1.5 to 1.2 1.2±0.5 94 
number of primary metabolites 1 to 8 5.0±1.3 6 
 
a total solvent accessible volume, using a probe with a 1.4 Å radius. b hydrophilic component of the solvent 
accessible surface area (SASA), using a probe with a 1.4 Å radius (SASA on N, O and attached H). c non-trivial (not 
CX3), non-hindered (not alkene, amide, small ring). d estimated number of hydrogen bonds that would be donated by 
the solute from water molecules in an aqueous solution. e estimated number of hydrogen bonds that would be 
accepted by the solute from water molecules in an aqueous solution. 
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 Figure 4.2 Distribution for physico-chemical parameters: molecular weight (A), log of the 
octanol/water partition coefficient (logP) (B), number of hydrogen donor bonds (HBD) (C), sum 
of nitrogen and oxygen atoms (D) and for the number of rotatable bonds (E) and the hydrophilic 
component of the solvent accessible surface area (FISA) (F); calculated for the 178 pyrroles 
314{1-3,1-2,1-41} using QikProp 2.1 (reproduced with permission from Dr. Stefan Werner) 
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4.5.3 Biological Evaluation of Tricyclic Pyrroles 
The library of tricyclic pyrroles has been made available to a broad range of collaborators via the 
biological outreach program at the UPCMLD (Figure 4.3). 
Figure 4.3 List of assays performed on the tricyclic pyrroles 314{1-3,1-2,1-41}. 
Testing facility                                             Assay type
JMI Labs                                                       antibacterial assays 
Southern Research Institute                          antiviral assays:
                                                                       influenza 
                                                                       tacaribe
                                                                       west nile
                                                                       ponta toro
                                                                       denga
                                                                       yellow fever
                                                                       herpes-HSV, VZV, HSV-1
                                                                       tuberculosis
                                                                       hepatitis C and B
PDSP 
(Phychoactive Drug Screening Program)     40-50 assays
Testing facility                                             Assay type
NIH-Chemical Genomics Center                  various assays:
                                                                       Prx2
                                                                       sOGT
                                                                       P450-cyp1a2
                                                                       GR-EFC
National Cancer Institute                              60 cell-line cytotoxicity assays
                                                                      HIV protease inhibition
ChemBank 
(Broad Institute-Harvard University)           various assays:
                                                                      
                                                                      CREB reporter assay
                                                                      NOX superoxide generation
                                                                      yeast growth modification assay
 
In addition, members of this library have been identified as inhibitors of cytoplasmic dynein by 
Prof. Day’s lab (University of Pittsburgh) and as inhibitors of human mitogen-activated protein 
kinase phosphatase-1 (MKP-1) by Prof. Lazo’s lab (University of Pittsburgh). 
Cytoplasmic dynein is an ATPase motor protein involved in multiple cellular 
processes.216 For example, dynein provides force for nuclear envelope breakdown, formation in 
the mitotic spindle and chromosomal segregation.216d In addition, dynein is responsible for 
intracellular transport of organelles, protein complexes etc. Small molecules that interfere with 
dynein activity can be used to study its important functions in the cell. Unfortunately, there are 
only a few known inhibitors of dynein, characterized with low activity and/or lack of 
specificity.217 Therefore, the discovery of structurally novel inhibitors of dynein is an important 
area of research. Using a cell-based phenotypic assay, Day and coworkers have identified 
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tricyclic pyrrole 314{3,2,26} (Figure 4.4) as an inhibitor of cytoplasmic dynein activity.218 
Concentration-dependent experiments have shown that 314{3,2,26} uncompetitively inhibits 
dynein’s ATPase activity with IC50 value of 2.0 µM.z These very encouraging results have 
prompted further studies into the mechanism of action of 314{3,2,26}. 
Figure 4.4 Structures of bioactive tricyclic pyrroles. 
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Mitogen-activated protein kinases (MAPK) are important cellular proteins that act as 
effectors of various growth factors, stress detectors and drug sensors in the cell.219 Their function 
is regulated by a number of mitogen-activated protein kinase phosphatases (MKPs). MKP-1 is a 
dual specificity phosphatase, meaning it is capable of dephosphorylating both phosphotyrosine 
and phosphothreonine residues on a same protein substrate. Furthermore, MKP-1 expression is 
elevated in prostate, breast, gastric and renal cancers.220 Therefore, MKP-1 is an important target 
for inhibition by small molecules in order to further understand its function and potentially 
generate lead structures for cancer chemotherapy. However, MKP-1 has evaded inhibition by 
small molecules and the few known inhibitors are not potent and/or not selective.221 Lazo and 
coworkers have screened 172 members of the tricyclic pyrrole library in an effort to identify 
novel inhibitors of MKP-1.222 The study resulted in identification of 22 compounds with IC50 
                                                 
z Biological tests were performed by Mr. Guangyu Zhu under the supervision of Professor Billy W. Day. 
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values lower than 30 µM.aa Most notable were library members 314{2,1,27} and 314{2,1,19} 
(Figure 5.4) with IC50 values of 8.0 µM and 8.3 µM, respectively. Both pyrroles showed high 
selectivity for MKP-1 over other phosphatases, including the dual-specificity phosphatase MKP-
3. Importantly, the pyrroles 314{2,1,27} and 314{2,1,19} were identified as the most potent 
inhibitors of MKP-1 from a broader screen of over 65,000 compounds from the NIH repository 
(http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=374). These promising results have 
prompted further studies into the mechanism of action of 314{2,1,27} and 314{2,1,19} and 
development of more potent analogues. 
 
 
 
 
 
 
 
 
 
 
                                                 
aa Biological tests were performed by Mr. John J. Skoko under the supervision of Professor John S. Lazo. 
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4.6 Synthesis of α-Alkylidene Cyclopentenones via a Rhodium(I)-Catalyzed Allenic 
Cyclocarbonylation Reaction 
During our investigations of the Mo(CO)6-mediated cyclocarbonylation reaction of 
amino-ester tethered allenynes, a number of issues were encountered: (1) the reaction was not 
entirely selective for the proximal double bond of the allene, affording up to 20% of the 
undesired 4-alkylidene cyclopentenone particularly in the reaction of sterically encumbered 
amino acids; (2) the desired α-alkylidene cyclopentenones were obtained as mixtures of 
diastereomers with unpredictable diastereoselectivity depending on the nature of the amino-acid 
side chain (Schemes 4.30 and 4.32); and (3) because Mo(CO)6 is used in stoichiometric amount, 
purification issues were encountered upon scale-up during library synthesis. In addition, 
generating large amounts of unidentified molybdenum waste posed an environmental concern. 
However, the amino-acid derived α-alkylidene cyclopentenones obtained via this protocol 
proved extremely useful in the synthesis of a library of tricyclic pyrroles and can potentially be 
used in other DOS applications. For these reasons, we have recently begun investigating the 
possibility to conduct a catalytic cyclocarbonylation reaction selective for the proximal double 
bond of the allene.  
In 2003, Shibata reported that IrCl(CO)(PPh3)2 (Vaska’s complex) selectively catalyzes 
the formation of α-alkylidene cyclopentenone 316 from trisubstituted allenyne 315.223 It was 
demonstrated that the course of the reaction with the proximal double bond of the allene is 
sterically influenced by the substitution pattern of the allene, since disubstituted substrate 317 
gave a mixture of cyclocarbonylation products with 318c dominating.  
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Scheme 4.49 Ir(I)-catalyzed cyclocarbonylation reaction by Shibata. 
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In the course of the study on developing conditions for preparation of 4-alkylidene 
cyclopentenones, a similar trend was observed when using Ir(I)-catalysts (Table 4.1, in Section 
4.2). Subsequently, it was shown that an in situ prepared catalyst by sequential addition of PPh3 
and AgBF4 to [Rh(CO)2Cl]2 exhibits remarkable reactivity in promoting the reaction with the 
distal double bond of the allene (Scheme 4.50, for details see Section 4.2). 
Scheme 4.50 Rh(I) catalyzed formation of 4-alkylidene cyclopentenones.  
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We became interested whether the double bond selectivity of this Rh(I)-catalyzed allenic 
cyclocarbonylation reaction can be reversed by using diphosphine ligands. It is generally 
accepted that diphosphine ligands can have a profound effect on various transition metal-
catalyzed reactions. Most often this effect is on the rate and observed yield of the reaction, 
however there are some instances where ligands have affected the formation of structurally 
different products. Recent reviews by van Leeuwen and coworkers have summarized and related 
such effects to the natural bite angle of diphosphines.224 One compelling example is the ligand 
effect on the Pd-catalyzed hydroxycarbonylation reaction of styrene, where formation of a 
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branched and linear carboxylic acid is possible. Van Leeuwen and coworkers found that use of 
PPh3 leads to predominant formation of the branched product. As shown in Table 4.7, switching 
to bidentate phosphine ligands leads to gradual reversal of the selectivity, and with dppb (1,4-
bis(diphenylphosphino)butane) the linear product is favored. In addition to the product ratios, the 
efficiency of the reaction was also dependent on the nature of the diphosphine ligand (see 
conversion column in Table 4.7). The authors associated these effects to the increasing bite angle 
of the diphosphine ligand. 
Table 4.7 Effect of the phosphine ligand on the Pd-catalyzed hydroxycarbonylation of styrene 
reported by van Leeuwen. 
4 mol % [PdCl2(PhCN)2]
phosphine,a CO, 100-150 oC
oxalic acid, dimethoxyethane
20-24h
COOH
COOH
320 - branched 320 - linear319
phosphine                       bite angle (deg)        % conversion            branched : linear ratio
PPh3                                                                       96                                   84 : 16 
dppe                                         78                            5                                   47 : 53
dppp                                         86                           28                                  23 : 77
BINAP                                      93                           42                                  30 : 70
dppb                                         98                           95                                  17 : 83
a P : Pd ratio = 4 : 1  
To examine whether double-bond selectivity in the Rh(I)-catalyzed allenic cyclocarbonylation 
reaction can be influenced with diphosphine ligands, terminally unsubstituted allenes 74 
(Scheme 4.50) were chosen to minimize steric bias, and avoid formation of E and Z isomers in 
the reaction. Preliminary results of this investigation are presented here. 
A preliminary screen of common bidentate phosphine ligands (dppm, dppe, BINAP and 
dppb) was first preformed. It was found that the reactive species prepared by addition of dppb to 
10 mol % [Rh(CO)2Cl]2 followed by AgBF4 (in 2 : 1 : 2 molar ratio) effected the transformation 
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of 321 to 322 in 37 % yield when the reaction was performed under Ar atmosphere (Scheme 
4.51).bb In this experiment 322 was formed with high diastereoselectivity (>10 : 1) and high 
regioselectivity, since only trace amounts of the 4-alkylidene cyclopentenone were observed. 
Similarly, the methyl-substituted allenyne 74c, resulted in selective formation of α-alkylidene 
cyclopentenones in 43% yield (7 : 1 diastereomeric ratio). Since both reactions were performed 
under Ar atmosphere, the yield around 40% suggested that the reaction is stoichiometric in Rh(I), 
and the carbon monoxide incorporated in the products results from the starting catalyst (10 mol 
% [Rh(CO)2Cl]2 contains 40 mol % CO).  
Scheme 4.51 Rh(I)-mediated formation of α-alkylidene cyclopentenones. 
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Although these results were encouraging, attempts to perform the reaction catalytically under CO 
atmosphere (1 atm, balloon pressure) gave only recovered starting material and no 
cyclocarbonylation products if CO atmosphere is introduced to the system prior to addition of the 
allenyne.  Furthermore, reproducibility issues were encountered, mainly due to the multiple 
components required for preparation of the active Rh-species.cc It was also found that the 
                                                 
bb Use of dppm and dppe in the same experiment gave predominantly the 4-alkylidene cyclopentenone, while 
BINAP unselectively gave mixtures of products in a very sluggish reaction. 
cc In particular, the amount of dppb relative to [Rh(CO)2Cl]2 proved critical for obtaining high regio- and 
diastereoselectivity. Decreasing the amount of dppb below 20 mol% led to unselective reaction with both double 
bonds. 
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reactivity of the species prepared in situ depends on the commercial source of [Rh(CO)2Cl]2. 
Based on the stoichiometry of all components in the initial experiment, it was hypothesized that 
the active Rh(I)-species formed in situ has a general formula [Rh(CO)2dppb]BF4 (325). To 
resolve the reproducibility issues, a more convenient route to prepare and identify this complex 
was sought (to our knowledge, this compound has not been characterized before). To this end, 
commercially available [Rh(cod)2]BF4 (323) was treated with dppb (1 equiv) in DCE presumably 
affording the known yellow complex [Rh(cod)(dppb)]BF4 (324) via ligand exchange (cod = 1,5-
cyclooctadiene).225 Replacement of the remaining cyclooctadiene ligand with CO was 
accomplished by treatment with CO (1 atm) at 80 °C. In this manner, a bright yellow powder is 
obtained in 92% yield upon cooling to rt and addition of Et2O (yield is based on the assumed 
formula [Rh(CO)2dppb]BF4]).226 This compound displays a single resonance in the 31P NMR 
spectrum (doublet, δ = 21.4 ppm, J(Rh-P) = 119.7 Hz) and a strong CO stretching band in the IR 
spectrum (ν = 2024 cm-1) suggesting a square planar geometry as shown in Scheme 4.52 (the 31P 
NMR data for three related complexes 324,225 326227 and 327225 is also listed for comparison). 
This is indeed the most common geometry observed for d8 Rh(I) complexes.228 Efforts to 
crystalize 325 and obtain an X-ray structure were unsuccesful.dd
 
 
 
 
 
 
                                                 
dd Attempts to grow crystals of this complex using a common technique by layering Et2O onto a solution of the 
compound in CH2Cl2 have thus far proved fruitless. For an example, see reference 225. 
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Scheme 4.52 Synthesis and 31P NMR data for [Rh(CO)2dppb]BF4 and related complexes. 
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With 325 in hand, it was tested in promoting the cyclocarbonylation reaction of 74c. As 
expected, reaction did not occur under full atmosphere of CO. Similar phenomenon of CO 
impeding the rate of the Rh(I)- or Ir(I)-catalyzed cyclocarbonylation reaction has been observed 
by Narasaka and Shibata, and is attributed to competitive binding of CO and the substrate to the 
catalyst.223, 229 Therefore, using partial pressure of CO to catalyze the reaction was attempted. It 
was soon discovered that the reaction can be driven to completion under partial pressure of CO 
(0.2 atm), and heating to 80 °C.ee In this manner, using 5 mol % of catalyst resulted in 87% yield 
of the α-alkylidene cyclopentenone (Scheme 4.53). It was found that either the pre-isolated 
catalyst or a freshly prepared solution can be used without noticeable difference in reactivity and 
yield. The product was obtained as a mixture of diastereomers 288c : 287c = 2.2 : 1 ratio which 
were separated by semi-preparative HPLC (normal-phase, 35% EtOAc/hexanes). This is 
                                                 
ee The partial pressure of CO is approximate, and it was created by injecting a measured volume of CO from a 
syringe into a sealed reaction vessel containing a solution of substrate and catalyst. Reactions were most commonly 
performed on ~20 mg scale in a 15 mL test tube (3 mL of CO was injected). 
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considerably lower than the ratio of 7 : 1 obtained in the initial experiment (Scheme 4.51) and is 
attributed to the higher temperature required for the catalytic reaction (80 °C vs. rt). The major 
diastereomer 288c, is the one where the methyl substituent and the hydrogen at the ring fusion 
are syn (interestingly, the major diastereomer is different than the one observed in the Mo-
mediated cyclocarbonylation reaction of 74c, Scheme 4.32). 
Scheme 4.53 Rh(I)-catalyzed cyclocarbonylation reaction of 74c. 
•
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H H
5 mol % [Rh(CO)2dppb]BF4
DCE, CO (0.2 atm), 80 oC, 2h
87%
74c 288c 287c
288c : 287c = 2.2 : 1  
A number of other solvents (benzene, toluene, DCE, THF and TFE) were tested for the reaction 
in an effort to increase the diastereoselectivity; however, the initially used DCE gave the best 
combination of reactivity and selectivity. Interestingly, TFE resulted in a shorter reaction time of 
30 min, but no diastereoselectivity (the α-alkylidene cyclopentenone was obtained as a 1 : 1 
mixture of diastereomers). A similar rate increase phenomenon when using TFE for a Rh(I)-
catalyzed cyclocarbonylation reaction was first reported by Wender and is attributed to the 
acidity of this solvent which results in activation of CO towards insertion via hydrogen 
bonding.230
Next, the scope of this Rh(I)-catalyzed cyclocarbonylation reaction to form α-alkylidene 
cyclopentenones was examined (Table 4.8).ff Allenyne 74a, containing a methyl-substituted 
                                                 
ff All reactions in Table 4.8. (except 74c, shown for comparison) were performed only to determine the ratio of 
products. The reported yields are those of crude mixtures obtained after filtration of the reaction solution over a 
short plug of silica gel eluting with EtOAc/hexanes. Separation of the product mixtures was not performed. The 
major diastereomers A in the reaction of 74a and 74b have been characterized previously in the Mo-mediated 
cyclocarbonylation reaction (Scheme 4.30). The minor diastereomer B in the reaction of 74d has been characterized 
previously in the Mo-mediated cyclocarbonylation reaction (Scheme 4.32). Likewise, both diastereomers A and B in 
the reaction of 74e have been characterized from the Mo-mediated cyclocarbonylation reaction (Scheme 4.32). 
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alkyne gave a mixture of A and B in 89% yield in 9 : 1 ratio, which is the highest obtained to 
date with this catalyst. When phenylalanine derived allenyne 74b with terminally unsubstituted 
alkyne was subjected to the same conditions, it afforded the products with low 
diastereoselectivity (1.7 : 1). Allenyne 74d, with a terminal alkyne, gave a mixture of A and B in 
2.8 : 1 ratio in 92 % yield, while leucine-derived allenyne 74e afforded α-alkylidene 
cyclopentenones A and B in 2.4 : 1 ratio. In these two cases, formation of additional unidentified 
products was observed in the crude 1H NMR spectrum. Nevertheless, the compatibility of this 
catalyst with terminal alkynes is in contrast to our catalytic conditions for preparation of 4-
alkylidene cyclopentenones ([Rh(CO)2Cl]2, PPh3, AgBF4) that were not compatible with terminal 
alkynes (see Table 4.3, Section 4.2).   
Table 4.8 Rh(I)-catalyzed cyclocarbonylation reaction forming α-alkylidene cyclopentenones. 
•
H
H
BzN
R1
MeO2C
R2
5 mol % [Rh(CO)2dppb]BF4
DCE, CO (0.2 atm), 80 oC
BzN
R2
O
MeO2C
R1
BzN
R2
O
MeO2C
R1H H
Entry/allenyne                 R1              R2               Yield %a                Ratio of A : Bb
1/74a                            Bn            Me                   89%                             9 : 1
2/74b                            Bn            H                     93%                          1.7 : 1 
3/74c                            Me           Me                    87%                           2.2 : 1 
4/74d                            Me            H                     92%                           2.8 : 1
5/74e                           i-Bu            H                     82%                           2.4 : 1
aYields are of crude mixture of products; Trace amounts of the [6,5] 
cyclopentenone were observed in all cases. b ratios were determined by 
integration of the olefinic resonances in the 1H NMR spectrum of the crude 
reaction mixture after filtration over a short plug of silica gel.
A B
 
Notably, the reversal of diastereoselectivity between aliphatic and aromatic side chains that is 
unique for the Mo(CO)6 mediated cyclocarbonylation reaction  is not observed in this case, since 
either alanine, leucine and phenylalanine derived allenynes all gave the same major 
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diastereomer. 
Next, allenyne 328 was subjected to the reaction conditions to test whether the double 
bond selectivity can be retained in the presence of a methyl group at the proximal allenic 
position. Unfortunately, the sluggish reaction resulted in 48% yield of the 4-alkylidene 
cyclopentenone 329, while the desired 330 was not observed (Scheme 4.54).  
Scheme 4.54 Attempted cyclocarbonylation reaction of 328. 
•
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329 (48%) 330 not observed328  
Finally, an attempt was made to extend the scope of the new catalyst to substrates other than 
amino-acid derived allenynes. However, when the diester-tethered allenyne 331 was subjected to 
10 mol % of catalyst, cyclocarbonylation did not occur at 100 °C. 
Scheme 4.55 Attempted cyclocarbonylation reaction of 331. 
•
H
H
10 mol % [Rh(CO)2dppb]BF4
DCE, CO (0.2 atm), 100 oC, 6h
No reaction
recovered starting material
EtO2C
EtO2C
331  
In summary, we have demonstrated a novel Rh(I)-catalyzed cyclocarbonylation reaction 
of amino-ester tethered allenynes selective for the proximal double bond of the allene. Selectivity 
was accomplished under partial pressure of CO using a freshly prepared Rh(I)-catalyst 
containing a dppb ligand. The origin of the observed selectivity is subject to speculation, and 
further studies are required to asses this issue. One potential explanation is based on recent 
computational studies by Brummond and Bayden addressing the selectivity observed in the 
“normal” Rh(I)-catalyzed and Mo-mediated allenic cyclocarbonylation reactions.231 The 
calculations support that the product-determining step in both reactions is the oxidative addition 
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of the metal into the allenyne leading to a metallocycle. The energy difference between the 
transition states in this step is responsible for the double bond selectivity in the respective 
reaction. In the Rh(I)-catalyzed reaction, the transition state leading to a [6,5]-fused metallocycle 
is better accommodated by the square-planar Rh(I)-center, compared to the transition state 
leading to a [5,5]-metallocycle. In contrast, the transition state leading to a [5,5]-metallocycle is 
preferred by the distorted trigonal-bipyramidal molybdenum center in the Mo-mediated reaction. 
These calculations show that the double bond selectivity is result of the geometry constraints 
imposed by the metal center in the oxidative addition step of the reaction. We are speculating 
that the presence of a diphosphine ligand (dppb) on the Rh(I)-center results in a transition-state 
geometry that can better accommodate the formation of the [5,5]-metallocycle. Further studies at 
supporting this hypothesis will be forthcoming. 
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Conclusions 
 
In summary, we have demonstrated a diversity-oriented synthetic strategy based on 
transition metal-catalyzed and mediated reactions of allenes (Scheme 4.56). We have gained 
access to a number of structurally and functionally unique products in a relatively short number 
of synthetic steps. Amino-acid derived allenes accessed via Claisen rearrangement were used as 
pivotal synthetic intermediates. The Rh(I)-catalyzed allenic Alder-ene reaction of allenynes 
proceeds in excellent yield affording cross conjugated trienes. These compounds were studied in 
sequential cycloaddition reactions, gaining access to complex polycyclic skeletons. Furthermore, 
a novel cycloisomerization of propiolamides was developed affording δ-lactams.  Modified 
catalytic conditions were developed to allow the synthesis of 4-alkylidene cyclopentenones. 
While studying the Mo-mediated cyclocarbonylation reaction of amino-ester tethered allenynes, 
a novel stereocontrol element was uncovered based on the amino-acid side chain. The knowledge 
gained from these studies was used to design and synthesize a novel class of tricyclic pyrroles 
via a Stetter/Paal-Knorr reaction sequence.  
 By modifying the substrate to include an alkene instead of an alkyne, a novel catalytic 
pathway was discovered leading to the formation of tetrahydroazepines, for which mechanistic 
rationale was provided. In this project we have successfully combined the goal of developing 
new synthetic methodologies with providing small molecule probes for biological research. The 
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synthetic pathways that were studied resulted in the synthesis of two distinct libraries (triene-
derived polycylic compounds, tricyclic pyrroles), which have been made broadly available to 
biological colaborators. 
Scheme 4.56 Summary of reaction pathways available to allenic amino-esters. 
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Experimental Section 
General Methods. All commercial reagents were used without further purification unless 
otherwise noted. The rhodium catalyst ([Rh(CO)2Cl]2) was purchased from Aldrich Chemical 
Co. or Strem Chemicals and used as received. Carbon monoxide gas (99.9%) was purchased 
from Matheson Tri-Gas and used as received. All reactions were carried out under nitrogen 
atmosphere unless otherwise noted. Toluene, 1,2-dichloroethane and triethylamine (Et3N) were 
all freshly distilled from CaH2 prior to use. 1,4-Dioxane was distilled from CaH2 and stored over 
4Å molecular sieves prior to use. Tetrahydrofuran (THF), diethyl ether (Et2O) and 
dichloromethane (CH2Cl2) were purified over alumina using the SolTek ST-002 solvent 
purification system. ZnCl2 (0.5M solution in THF) was purchased from Aldrich Chemical Co. 
and stored over activated 4Å molecular sieves prior to use. TLC analyses were performed on EM 
Science Silica Gel 60 F254 plates (250 µm thickness). Purification of the compounds by flash 
chromatography was performed by using silica gel (32-63 µm particle size, 60 Å pore size).gg 
HPLC purification was performed on a Varian-Prostar 210 instrument using a Varian Microsorb 
Dynamax 100-5 Si column (5 µm packing, 250 mm x 10 mm). All 1H NMR and 13C NMR 
spectra were obtained on a Bruker Avance 300 or 500 MHz instrument at rt unless otherwise 
specified, and chemical shifts (δ) reported relative to residual solvent peak CHCl3 (7.27 ppm and 
77.0 ppm respectively). High-resolution mass spectra (HRMS) were obtained on a Micromass 
                                                 
gg Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923. 
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Autospec and are reported as m/z (relative intensity). Accurate masses are reported for the 
molecular ion [M]+ for  EI and [M+H] or [M+Na] for ESI or a suitable fragment ion. IR spectra 
were obtained using a Nicolet Avatar E.S.P. 360 FT-IR. The CIF files for 144 (CCDC 618793), 
156a (CCDC 618794) and 186b (CCDC 618795) were deposited at the Cambridge 
Crystallographic Data Centre (CCDC) and are available free of charge 
(http://www.ccdc.cam.ac.uk/). The CIF files for compounds 287b and 296 can be obtained from 
(http://pubs.acs.org/).232 Stick model representations of the X-ray structures used in the text were 
generated using Mercury v.1.4.1. (http://www.ccdc.cam.ac.uk/mercury/). Compounds 56a-58a 
and 56b-58b were prepared using literature protocols and were obtained in comparable yields 
and spectroscopic data.
General notes: 
(a) The majority of Rh(I)-catalyzed and Mo-mediated reactions were perfomed in new 
disposable test tubes of appropriate size in order to eliminate variables from impurities in 
commonly-used glassware. Magnetic stir-bars were used repeatedly and were thoroughly washed 
each time by first soaking into aqua regia (HCl/HNO3) followed by extended rinsing with water 
and acetone (the stir-bars were then dried in an oven at ca. 100 °C prior to use). 
(b) Often, preliminary purification of crude reaction mixtures was performed by first filtering 
over a plug of silica gel using a fritted funnel under vacuum. The amount of silica gel that was 
used is proportional to the reaction size (as a guideline: ca. 10 g of silica gel per 1 g of crude 
residue). In these cases, elution of the desired substance from the silica gel plug was performed 
using an appropriate solvent mixture as determined by TLC analysis (ca. Rf = 0.5).  
(c) Molecular sieves (4Å) used for storage of solvents or to sequester water in reactions were 
activated by three rounds of flame-drying in a round-bottomed flask under vacuum.  
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General procedure A for esterification of benzoyl protected amino acids. 
N
H O
OBz
56c  
2-Benzoylaminopropionic acid prop-2-ynyl ester (56c). To a solution of propargyl alcohol 
(9.7 mL, 0.17 mol) in CH2Cl2 (400 mL) was added DMAP (100 mg, 0.820 mmol) and DCC 
(22.9 g, 0.111 mol) followed by N-Bz-alanine (21.4 g, 0.111 mol). A white precipitate forms 
immediately. After stirring for 36 h at rt, hexanes (~100 mL) were added.  A 150 mL fritted 
funnel equipped with vacuum outlet was filled with silica gel and connected to a 1 L round-
bottomed flask. The reaction mixture was filtered over the plug of silica gel under vacuum 
eluting with hexanes : EtOAc (1 : 1). The resulting colorless solution was concentrated under 
vacuum and dissolved in EtOAc. Recrystallization (hexanes-EtOAc, 4 : 1, v/v) afforded 56c 
(17.4 g, 68%). 
mp range 94.5-97.5 °C; 1H NMR (300 MHz, CDCl3): δ 7.78-7.76 (m, 2H), 7.75-7.35 (m, 3H), 
6.98 (br d, J = 6.9 Hz, 1H), 4.79 (quin, J = 7.2 Hz, 1H), 4.76 (dd, J = 15.5, 2.5 Hz, 1H), 4.69 (dd, 
J = 15.5, 2.5 Hz, 1H), 2.51 (t, J = 2.4 Hz, 1H), 1.50 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 172.3, 166.9, 133.6, 131.6, 128.4, 127.0, 76.9, 75.4, 52.7, 48.3, 18.0; IR (thin film): ν 
3294, 2940, 2128, 1749, 1642, 1536, 1164 cm-1; MS m/z (%) 231 (43), 176 (20), 148 (63), 105 
(100); EI-HRMS calcd for C13H13NO3 m/z [M]+ 231.0895; found 231.0899. 
N
H
Bz
O
O
56d  
2-Benzoylamino-4-methylpentanoic acid prop-2-ynyl ester (56d). Prepared by following 
general procedure A with: N-Bz-leucine (35.0 g, 0.15 mol), propargyl alcohol (26.0 mL, 0.45 
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mol), DCC (30.7 g, 0.15 mol), DMAP (500 mg, 4.1 mmol). Purification of the crude residue 
after filtration by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 56d (36.5 g,  90%).  
1H NMR (300 MHz, CDCl3): δ 7.78-7.75 (m, 2H), 7.46-7.32 (m, 3H), 6.95 (bs, 1H), 4.86-4.80 
(m, 1H), 4.74 (dt, J = 15.6, 2.0 Hz, 1H), 4.65 (dt, J = 15.6, 2.0 Hz, 1H), 2.49 (t, J = 2.3 Hz, 1H), 
1.78-1.63 (m, 3H), 0.94-0.92 (m, 6H); 13C NMR (75 MHz, CDCl3): δ 172.3, 167.2, 133.5, 131.5, 
128.3, 127.0, 75.3, 52.5, 50.9, 41.0, 24.7, 22.7, 21.7; IR (thin film): ν 3298, 2958, 2131, 1750, 
1642, 1355, 1159 cm-1; MS m/z (%) 273 (40), 217 (37), 190 (55), 105 (100); EI-HRMS calcd for 
C16H19NO3 m/z [M]+ 273.1365; found 273.1361. 
N
H
Bz
O
O
MeO
56e  
2-Benzoylamino-3-(4-methoxyphenyl)-propionic acid prop-2-ynyl ester (56e). Prepared by 
following general procedure A with: N-Bz-p-methoxyphenylalanine (25 g, 0.084 mol), propargyl 
alcohol (14.6 mL, 0.25 mol), DCC (17.2 g, 0.084 mol), DMAP (500 mg, 4.1 mmol). Yield of 56e 
(24.1 g, 85 %). 
1H NMR (300 MHz, CDCl3): δ 7.74-7.72 (m, 2H), 7.55-7.41 (m, 3H), 7.12-7.07 (m, 2H), 6.86-
6.81 (m, 2H), 6.53 (d, J = 7.3 Hz, 1H), 5.11 (ddd, J = 7.6, 5.4, 5.4 Hz, 1H), 4.84 (dd, J = 15.6, 
2.5 Hz, 1H), 4.73 (dd, J = 15.5, 2.5 Hz, 1H), 3.79 (s, 3H), 3.31-3.18 (m, 2H), 2.55 (t, J = 2.5 Hz, 
1H). 
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N
H
Bz
O
O
F
56f  
2-Benzoylamino-3-(4-fluorophenyl)propionic acid prop-2-ynyl ester (56f). Prepared by 
following general procedure A with: N-Bz-p-fluorophenylalanine (900 mg, 3.14 mmol), 
propargyl alcohol (916 µL, 15.7 mmol), DCC (646 mg, 3.14 mmol), DMAP (36 mg, 0.30 mmol) 
The reaction was performed in THF (15 mL) instead of CH2Cl2. Purification of the crude residue 
after filtration by flash chromatography (gradient elution, hexanes-EtOAc, 20 : 1 to 3 : 1, v/v) 
afforded 56f (503 mg, 42%).  
1H NMR (300 MHz, CDCl3): δ 7.73 (d, J = 7.7 Hz, 2H), 7.54-7.40 (m, 3H), 7.17-7.12 (m, 2H), 
7.00-6.95 (m, 2H), 6.65 (d, J = 7.2 Hz, 1H), 5.14-5.08 (m, 1H), 4.83 (dd, J = 15.9, 2.2 Hz, 1H), 
4.71 (dd, J = 15.3, 2.3 Hz, 1H), 3.31 (dd, J = 14.0, 5.7 Hz, 1H), 3.23 (dd, J = 14.0, 5.4 Hz, 1H), 
2.56 (s, 1H); 13C NMR (75 MHz, CDCl3): δ 170.7, 166.8, 163.7, 160.4, 133.6, 131.9, 131.2, 
131.0, 130.9, 128.6, 126.9, 115.6, 115.3, 76.8, 75.7, 53.4, 52.9, 36.8; IR (thin film): ν 3298, 
2933, 2129, 1749, 1644, 1510 cm-1; MS m/z (%) 325 (53), 269 (35), 204 (30), 160 (47), 105 
(100); EI-HRMS calcd for C19H16NO3F m/z [M]+ 325.1114; found 325.1110. 
N
H
Bz
O
O
S
56g  
2-Benzoylamino-3-thiophen-2-ylpropionic acid prop-2-ynyl ester (56g). Prepared by 
following general procedure A with: N-Bz-(2-thienyl)-alanine (843 mg, 3.07 mmol), propargyl 
alcohol (895 µL, 15.3 mmol), DCC (631 mg, 3.07 mmol), DMAP (36 mg, 0.30 mmol). The 
reaction was performed in THF (20 mL) instead of CH2Cl2. Purification of the crude residue 
after filtration by flash chromatography (gradient elution, hexanes-EtOAc, 20 : 1 to 1 : 1, v/v) 
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afforded 56g (500 mg, 52%).  
1H NMR (300 MHz, CDCl3): δ 7.80-7.78 (m, 2H), 7.54-7.41 (m, 3H), 7.19-7.17 (m, 1H), 6.96-
6.83 (m, 3H), 5.13 (dt, J = 7.5, 5.0 Hz, 1H), 4.81 (dd, J = 15.9, 2.3 Hz, 1H), 4.74 (dd, J = 15.5, 
2.3 Hz, 1H), 3.54 (d, J = 4.9 Hz, 2H), 2.55547 (t, J = 2.3 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 
170.3, 166.8, 136.8, 133.6, 131.8, 128.5, 127.0, 125.0, 76.7, 75.8, 53.2, 53.0, 31.8; IR (thin film): 
ν 3291, 2932, 2853, 2129, 1748, 1645, 1531 cm-1; MS m/z (%) 313 (7), 230 (5), 192 (53), 105 
(100); EI-HRMS calcd for C17H15NO3S m/z [M]+ 313.0773; found 313.0774. 
N
H
Bz
O
O
NBoc
56h  
3-(2-Benzoylamino-2-prop-2-ynyloxycarbonylethyl)indole-1-carboxylic acid tert-butyl ester 
(56h). Prepared by following general procedure A with: N-Bz-(3-N-Boc-indolyl)-alanine (600 
mg, 1.47 mmol), propargyl alcohol (429 µL, 7.35 mmol), DCC (303 mg, 1.47 mmol), DMAP (10 
mg, 0.08 mmol). Purification of the crude residue after filtration by flash chromatography 
(gradient elution, hexanes-EtOAc, 1 : 0 to 2 : 1, v/v) afforded 56h (430 mg, 66%).  
1H NMR (300 MHz, CDCl3): δ 8.12 (d, J = 7.9 Hz, 1H), 7.71-7.69 (m, 2H), 7.54-7.16 (m, 7H), 
6.73 (d, J = 7.4 Hz, 1H), 5.21 (dt, J = 7.4, 5.2 Hz, 1H), 4.78 (dd, J = 15.5, 2.4 Hz, 1H), 4.69 (dd, 
J = 15.5, 2.4 Hz, 1H), 3.50-3.37 (m, 2H), 2.56 (t, J = 2.3 Hz, 1H), 1.65 (s, 9H); 13C NMR (75 
MHz, CDCl3): δ 170.9, 167.0, 149.5, 135.3, 133.7, 131.8, 130.5, 128.5, 127.1, 124.6, 124.5, 
122.6, 118.9, 115.3, 114.6, 83.7, 76.8, 75.8, 53.0, 28.2, 24.9; IR (thin film): ν 3297, 2979, 2131, 
1732, 1645, 1371 cm-1; ESI-HRMS calcd for C26H26N2O5Na m/z [M+23]+ 469.1739; found 
469.1749. 
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N
H
Bz
MeO2C
•
58c  
2-Benzoylamino-2-methylpenta-3,4-dienoic acid methyl ester (58c). To a solution of ester 56c 
(15.5 g, 67.1 mmol) in MeCN (300 mL), were added successively Et3N (39.0 mL, 282 mmol), 
CCl4 (23.0 mL, 235 mmol) and PPh3 (54.5 g, 208 mmol) all at rt. After 2.5 h the starting material 
was consumed based on TLC analysis, and MeOH (1 mL) was added. The dark brown solution 
was poured in a 1 L Erlenmeyer flask and hexanes (300 mL) were added under vigorous stirring.  
During the addition, a viscous precipitate formed which was filtered over a plug of silica gel 
using a fritted funnel and eluted 2-3 times with hexanes/Et2O (1 : 1). The filtrate was 
concentrated under vacuum and the resulting residue dissolved in MeOH (50 mL) and a sat’d 
solution of HCl in MeOH (10 mL) was added. After stirring for 10 min the reaction mixture was 
poured in Et2O (500 mL) and the resulting solution washed with sat’d aq. NaHCO3 (500 mL). 
The organic layer was dried over MgSO4 and concentrated under vacuum. Purification of the 
crude residue by flash chromatography (hexanes-EtOAc, 3 : 1, v/v) afforded 58c (6.5 g, 40%) as 
a white solid (mp range 135.1-136.6 °C). 
1H NMR (300 MHz, CDCl3): δ 7.79-7.77 (m, 2H), 7.52-7.35 (m, 3H), 6.91 (bs, 1H), 5.64 (t, J = 
6.6 Hz, 1H), 5.04 (d, J = 6.6 Hz, 2H), 3.78 (s, 3H), 1.78 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
206.6, 172.8, 166.4, 134.2, 131.6, 128.5, 126.9, 94.1, 80.2, 58.0, 52.9, 23.1; IR (thin film): ν 
3246, 2998, 1959, 1739, 1630, 1533 cm-1; MS m/z (%) 245 (23), 230 (52), 186 (71), 105 (100); 
EI-HRMS calcd for C14H15NO3 m/z [M]+ 245.1052; found 245.1058. 
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General procedure B for the Claisen rearrangement via an oxazole. 
N
H
Bz
MeO2C
•
58d  
2-Benzoylamino-2-isobutylpenta-3,4-dienoic acid methyl ester (58d). To a solution of 
propargyl ester 56d (36.5 g, 134.0 mmol) in MeCN (500 mL), were added successively Et3N (78 
mL, 560 mmol), CCl4 (45 mL, 470 mmol) and PPh3 (109 g, 414 mmol) all at rt. After 2.5 h the 
starting material was consumed based upon TLC analysis. The solution was concentrated under 
vacuum to a viscous brown paste which was next dissolved in MeOH (50 mL). Then, sat’d 
solution of HCl in MeOH (10 mL, prepared by bubbling HCl gas through MeOH) was added and 
the reaction was stirred for additional 10 min. The solvents were removed using a rotary 
evaporator and the resulting viscous oil was dispersed in Et2O (200 mL) and poured in a 1 L 
Erlenmeyer flask. Hexanes (400 mL) were added under vigorous stirring and a yellow precipitate 
formed. Filtration of the mixture over a plug of silica gel using a fritted funnel was followed by 
rinsing with hexanes/Et2O (1 : 1). The filtrate was concentrated under vacuum and the crude 
residue was purified by silica gel chromatography (hexanes-EtOAc, 6 : 1 to 3 : 1, v/v) to give 
58d (23.8 g, 62%) as a white solid (mp range 68-69 °C). 
1H NMR (300 MHz, CDCl3): δ 7.77-7.74 (m, 2H), 7.44-7.35 (m, 3H), 7.23 (s, 1H), 5.57 (t, J = 
6.6 Hz, 1H), 4.92 (d, J = 6.6 Hz, 2H), 3.75 (s, 3H), 2.47 (dd, J = 14.2, 5.5 Hz, 1H), 2.05 (dd, J = 
14.2, 5.5 Hz, 1H), 1.65 (sept, J = 6.5 Hz, 1H), 0.89 (d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H); 
13C NMR (75 MHz, CDCl3): δ 206.4, 173.1, 165.9, 134.4, 131.3, 128.3, 126.7, 93.9, 79.7, 61.5, 
52.6, 42.7, 24.5, 23.6, 22.6; IR (thin film): ν 3319, 2956, 1958, 1742, 1651, 1526, 1486 cm-1; MS 
m/z (%) 287 (33), 228 (55), 105 (100); EI-HRMS calcd for C17H21NO3 m/z [M]+ 287.1521; found 
287.1535. 
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N
H
Bz
MeO2C
•
58e
MeO
 
2-Benzoylamino-2-(4-methoxybenzyl)-penta-3,4-dienoic acid methyl ester (58e). Prepared by 
following general procedure B with: 56e (24.1 g, 71.4 mmol), Et3N (41.7 mL, 300.0 mmol), 
CCl4 (24.1 mL, 250.0 mmol), PPh3 (58 g, 221 mmol). Yield of 58e (17.5 g, 70%).  
1H NMR (300 MHz, CDCl3): δ 7.71-7.69 (m, 2H), 7.52-739 (m, 3H), 7.03 (d, J = 8.3 Hz, 2H), 
6.84 (s, 1H), 6.76 (d, J = 8.2 Hz, 2H), 5.64 (t, J = 6.7 Hz, 1H), 5.00 (dd, J = 10.6, 6.7 Hz, 1H), 
4.93 (dd, J = 11.1, 6.6 Hz, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.71 (d, J = 13.9 Hz, 1H), 3.47 (d, J = 
13.7 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 206.8, 172.1, 166.5, 158.5, 134.6, 131.5, 131.1, 
128.5, 127.6, 126.8, 113.5, 93.0, 80.1, 62.8, 55.0, 2.9, 39.1; IR (thin film): ν 3413, 2951, 1958, 
1740, 1662, 1513, 1249 cm-1; MS m/z (%) 351 (10), 319 (7), 292 (12), 246 (27), 230 (60), 105 
(100); EI-HRMS calcd for C21H21NO4 m/z [M]+ 351.1471; found 351.1470. 
N
H
Bz
MeO2C
•
58f
F
 
2-Benzoylamino-2-(4-fluorobenzyl)-penta-3,4-dienoic acid methyl ester (58f). Prepared by 
following general procedure B with: 56f (0.40 g, 1.23 mmol), Et3N (0.72 mL, 5.17 mmol), CCl4 
(0.42 mL, 4.31 mmol), PPh3 (0.99 g, 3.81 mmol). Yield of 58f (270 mg, 65%). 
1H NMR (300 MHz, CDCl3): δ 7.70-7.67 (m, 2H), 7.51-7.39 (m, 3H), 7.09-7.04 (m, 2H), 6.92-
6.83 (m, 3H), 5.62 (t, J = 6.7 Hz, 1H), 5.03 (dd, J = 11.2, 6.6 Hz, 1H), 4.62 (dd, J = 11.2, 6.6 Hz, 
1H), 3.83 (s, 3H), 3.75 (d, J = 13.7 Hz, 1H), 3.54 (d, J = 13.7 Hz, 1H); 13C NMR (75 MHz, 
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CDCl3): δ 206.7, 172.0, 166.6, 163.5, 160.3, 134.4, 131.7, 131.5, 128.6, 128.6, 126.8, 115.1, 
114.8, 92.9, 80.4, 62.6, 53.0, 38.8; IR (thin film): ν 3412, 2951, 1958, 1741, 1655, 1510 cm-1; 
MS m/z (%) 338 (28), 230 (57), 198 (19), 105 (100); EI-HRMS calcd for C20H18NO3F m/z [M]+ 
339.1259; found 339.1258. 
N
H
Bz
CO2MeS
58g
•
 
2-Benzoylamino-2-thiophen-2-ylmethylpenta-3,4-dienoic acid methyl ester (58g). Prepared 
by following general procedure B with: 56g (270 mg, 0.863 mmol), Et3N (504 µL, 3.62 mmol), 
CCl4 (291 µL, 3.02 mmol), PPh3 (700 mg, 2.67 mmol). Yield of 58g (235 mg, 83%).  
1H NMR (300 MHz, CDCl3): δ 7.75-7.72 (m, 2H), 7.52-7.38 (m, 3H), 7.13-7.11 (m, 1H), 7.01 (s, 
1H), 6.89-6.86 (m, 1H), 6.79-6.78 (m, 1H), 5.61 (t, J = 6.6 Hz, 1H), 5.04 (dd, J = 11.4, 6.6 Hz, 
1H), 4.99 (dd, J = 11.3, 6.6 Hz, 1H), 4.05 (d, J = 14.7 Hz, 1H), 3.83 (s, 3H), 3.80 (d, J = 14.7 Hz, 
1H); 13C NMR (75 MHz, CDCl3): δ 207.0, 171.7, 166.4, 137.1, 134.5, 131.5, 128.4, 127.4, 
126.8, 126.5, 124.7, 92.6, 80.2, 62.6, 52.9, 34.2; IR (thin film): ν 3410, 2950, 1957, 1740, 1655, 
1521 cm-1; MS m/z (%) 327 (10), 230 (40), 206 (47), 147 (31), 105 (100); EI-HRMS calcd for 
C18H17NO3S m/z [M]+ 327.0929; found 327.0937. 
58h
N
H
Bz
CO2Me
NBoc
•
 
3-(2-Benzoylamino-2-methoxycarbonylpenta-3,4-dienyl)-indole-1-carboxylic acid tert-butyl 
ester (58h). Prepared by following general procedure B with these modifications: (a) the reaction 
mixture was heated to 50 °C for 2 h. (b) methanolysis was performed by addition of Et3N (0.1 
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mL) and MeOH (10 mL) instead of sat’d solution of HCl in MeOH and stirred for 12 h (it was 
reasoned that addition of HCl/MeOH may result in cleavage of the Boc group). After 
concentrating the reaction mixture under vacuum the viscous brown paste was immediately 
purified by flash chromatography (hexanes/EtOAc, 9 : 1 to 4 : 1, v/v) to afford 58h.  
Starting reagents used: 56h (239 mg, 0.535 mmol), Et3N (312 µL, 2.25 mmol), CCl4 (181 µL, 
1.87 mmol), PPh3 (434 mg, 1.66 mmol). Yield of 58h (157 mg, 64%).  
1H NMR (300 MHz, CDCl3): δ 8.24-8.23 (m, 1H), 7.78-7.19 (m, 9H), 7.06 (s, 1H), 5.80 (t, J = 
6.6 Hz, 1H), 5.11 (dd, J = 11.2, 6.7 Hz, 1H), 5.03 (dd, J = 11.2, 6.6 Hz, 1H), 4.01 (d, J = 14.5 
Hz, 1H), 3.87 (s, 3H), 3.74 (d, J = 14.6 Hz, 1H), 1.65 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 
207.1, 172.2, 166.7, 149.4, 135.0, 134.6, 131.5, 130.9, 128.5, 126.9, 125.0, 124.2, 122.4, 119.1, 
115.0, 114.6, 93.1, 83.4, 80.2, 62.6, 53.0, 29.8, 28.0; IR (thin film): ν 3411, 2979, 1959, 1735, 
1666, 1369 cm-1; ESI-HRMS calcd for C27H28N2O5Na m/z [M+23]+ 483.1896; found 483.1893. 
 
2-tert-Butoxycarbonylamino-3-(tert-butyldimethylsilyloxy)propionic acid (59) was prepared 
from N-Boc-serine according to a previously reported procedure.hh
Boc
N
H
TBDMSO
O
O
60  
2-tert-Butoxycarbonylamino-3-(tert-butyldimethylsilyloxy)propionic acid 1-methylprop-2-
ynyl ester (60). To a solution of 3-butyne-2-ol (53 µL, 0.72 mmol) in CH2Cl2 (2 mL) were added 
DCC (149 mg, 0.724 mmol) and DMAP (8 mg, 7 µmol) at rt. Then, a solution of carboxylic acid 
59 (220 mg, 0.69 mmol) in CH2Cl2 (4 mL) was added via a syringe. After 1 h at rt, the reaction 
                                                 
hh Yoo, D.; Oh J. S.; Lee, D. -W.; Kim, Y. G. J. Org. Chem. 2003, 68, 2979. 
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mixture was filtered over a pad of silica gel using a fritted funnel, eluting with hexanes/EtOAc 2 
: 1 (100 mL). The filtrate was concentrated under vacuum and the resulting pale yellow oil was 
purified by flash chromatography (hexanes/EtOAc, 20 : 1, v/v) to give 60 (187 mg, 73%) as a 
colorless oil and a 1 : 1 mixture of diastereomers. 
1H NMR (300 MHz, CDCl3): δ 5.52-5.42 (m, 1H), 5.32 (br d, J = 7.4 Hz, 1H), 4.36-4.30 (m, 
1H), 4.08-4.03 (m, 1H), 3.81 (dd, J = 10.0, 2.9 Hz, 1H), 2.45 (d, J = 2.1 Hz, 0.5H), 2.41 (d, J = 
2.1 Hz, 0.5H), 1.50 (d, J = 6.7 Hz, 1.5H), 1.49 (d, J = 6.6 Hz, 1.5H), 1.44 (s, 9H), 1.85 (s, 4.5H), 
1.85 (s, 4.5H), 0.03-0.01 (m, 6H); 13C NMR (75 MHz, CDCl3): δ 169.6, 155.4, 155.3, 81.6, 79.8, 
73.3, 73.2, 63.6, 63.5, 61.1, 55.7, 55.6, 28.3, 25.7, 25.7, 21.3, 21.2, 18.1, -5.6; IR (thin film): ν 
3451, 3314, 2932, 2122, 1750, 1720 cm-1; MS m/z (%) 372 (11), 316 (22), 258 (51), 206 (43), 57 
(100); EI-HRMS calcd for C18H34NO5Si m/z [M+1]+ 372.2206; found 372.2201. 
Bz
N
H
TBDMSO
O
O
61  
2-Benzoylamino-3-(tert-butyldimethylsilyloxy)propionic acid 1-methylprop-2-ynyl ester 
(61). Boc-protected amine 60 (1.48 g, 3.98 mmol) was dissolved in TFA (5 mL) and stirred for 5 
min at rt, and then the excess TFA was removed under vacuum (rotary evaporator was used with 
a dry ice-cooled trap to collect the TFA). The brown oil was purified by flash chromatography 
(hexanes-EtOAc, 3 : 1, v/v then EtOAc).  After evaporation of the solvents the resulting residue 
(1.54 g) was dissolved in CHCl3 (20 mL) and Et3N (1.65 mL, 12.0 mmol) was added followed by 
benzoyl chloride (444 µL, 3.84 mmol) at 0 °C under nitrogen. The reaction mixture was stirred 
for 1 h after which it was diluted with CHCl3 (120 mL). The organic phase was washed with 5% 
aq. AcOH  (50 mL) and then sat’d aq. NaHCO3 (50 mL), dried over MgSO4 and concentrated 
under vacuum. Purification of the crude residue by flash chromatography (gradient elution, 
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hexanes-EtOAc, 19 : 1 to 4 : 1, v/v) afforded 61 (900 mg, 60%, 2 steps) as a 1 : 1 mixture of 
diastereomers. 
1H NMR (300 MHz, CDCl3): δ 7.84-7.81 (m, 2H), 7.62-7.44 (m, 3H),  6.98 (d, J = 7.5 Hz, 1H), 
5.61-5.44 (m, 1H), 4.97-4.86 (m, 1H), 4.23-4.17 (m, 1H), 4.00-3.96 (m, 1H), 2.49 (d, J = 2.1 Hz, 
0.5H), 2.46 (d, J = 2.1 Hz, 0.5H), 1.57 (d, J = 5.7 Hz, 1.5H), 1.55 (d, J = 5.7 Hz, 1.5H), 0.89 (s, 
4.5H), 0.88 (s, 4.5H), 0.07 (s, 1.5H), 0.06 (s, 1.5H), 0.04 (s, 1.5H), 0.04 (s, 1.5H); 13C NMR (75 
MHz, CDCl3): δ 169.5, 169.4, 167.0, 166.9, 134.0, 131.8, 128.7, 127.0, 81.5, 81.4, 73.6, 73.5, 
63.5, 63.4, 61.5, 61.4, 54.7, 54.5, 25.8, 25.7, 21.3, 21.2, 18.2, 18.1, -5.5, -5.6;  IR (thin film): ν 
3442, 3310, 2930, 2121, 1747, 1665, 1109 cm-1; MS m/z (%) 360 (42), 318 (35), 105 (100); EI 
HRMS calcd for C20H29NO4Si m/z [M]+ 375.1866, found 375.1852. 
MeO2C
•
H
OTBS
NHBz
58i  
2-Benzoylamino-2-(tert-butyldimethylsilyloxymethyl)hexa-3,4-dienoic acid methyl ester 
(58i). To a solution of propargyl ester 61 (730 mg, 1.95 mmol) in MeCN (10 mL), were added in 
consecutive order Et3N (758 µL, 5.45 mmol), CCl4 (430 µL, 4.49 mmol) and PPh3 (1.12 g, 4.29 
mmol) at rt. After 3 h the starting material was consumed based upon TLC analysis. The solution 
was concentrated under vacuum to a viscous brown paste which was next dissolved in MeOH 
(10 mL). Then, Et3N (500 µL) was added and after 3 h the solution was again concentrated under 
vacuum.  The crude residue was diluted with EtOAc (50 mL), and the solution was poured in an 
Erlenmyer flask, and then hexanes (20 mL) were added under vigorous stirring. The resulting 
mixture was filtered through a plug of silica gel using a fritted funnel, and eluted with 
hexanes/Et2O (1 : 1). The filtrate was concentrated under vacuum and the residue was purified by 
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flash chromatography (hexanes-EtOAc, 9 : 1, v/v) to afford 58i (660 mg, 87%) as a mixture of 
diastereomers in ratio of ~ 2 : 1 determined by 1H NMR). 
 1H NMR (300 MHz, CDCl3): δ 7.80-7.77 (m, 2H), 7.57-7.41 (m, 3H), 7.12 (bs, 1H), 5.54 (sex, J 
= 3.2 Hz, 0.66H), 5.44 (sex, J = 3.1 Hz, 0.33H), 5.38-5.30 (m, 1H), 4.40 (d, J = 9.8 Hz, 0.33H), 
4.31 (d, J = 9.8 Hz, 0.66H), 4.09 (d, J = 9.8 Hz, 1H), 3.80 (s, 1H), 3.80 (s, 2H), 1.68-1.64 (m, 
3H), 0.84 (s, 9H), 0.02 (s, 1H), 0.01 (s, 2H), 0.00 (s, 2H), -0.01 (s, 1H); 13C NMR (75 MHz, 
CDCl3): δ 204.0, 204.0, 171.1, 171.6, 166.3, 166.1, 134.8, 134.7, 131.3, 128.4, 126.8, 126.7, 
90.7, 90.4, 89.9, 89.7, 64.6, 64.4, 64.1, 52.8, 52.7, 25.5, 17.9, 13.8, 13.8, -5.6, -5.7; IR (thin 
film): ν 3421, 3298, 2952, 1967, 1741, 1669, 1247 cm-1; MS m/z (%) 374 (10), 332 (92), 244 
(90), 105 (100); EI HRMS calcd for C21H31NO4Si m/z [M]+ 389.2022, found 389.2020. 
 
General procedure C for preparation of esters 64a-f. 
Esters 64a-f were obtained as mixtures of diastereomers in 1 : 1 ratio as a result of using a 
racemic propargylic alcohol. 
N
H O
OCbz
Bu
64b  
2-Benzyloxycarbonylaminopropionic acid 1-isopropylhept-2-ynyl ester (64b). To a solution 
of 2-methylnon-4-yn-3-ol (418 mg, 2.73 mmol) in CH2Cl2 (5 mL) was added DCC (562 mg, 
2.73 mmol) and DMAP (17 mg, 0.14 mmol) at rt. Addition of N-Cbz-alanine (609 mg, 2.73 
mmol) was followed by formation of a white precipitate. After 1 h the reaction mixture was 
filtered on a plug of silica gel using a fritted funnel eluting with hexanes-EtOAc (1 : 1). The 
filtrate was concentrated under vacuum and the crude residue was purified by flash 
chromatography (gradient elution, hexanes-EtOAc, 1 : 0 to 9 : 1, v/v) to give 64b (750 mg, 77%) 
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which was immediately used in the Claisen rearrangement step.
N
H
Bn
O
O
C6H13
Boc
64a  
2-tert-Butoxycarbonylamino-3-phenylpropionic acid 1-hexylbut-2-ynyl ester (64a). Prepared 
by following general procedure C, using: dec-2-yn-4-ol (200 mg, 1.29 mmol), DMAP (15 mg, 
0.12 mmol), DCC (267 mg, 1.29 mmol), N-Boc-phenylalanine (344 mg, 1.29 mmol). Yield of 
64a (458 mg, 88%). 
CbzHN
O
O
64c  
2-Benzyloxycarbonylaminopropionic acid 1-methylprop-2-ynyl ester (64c). Prepared by 
following general procedure C, using: 3-butyn-2-ol (165 µL, 2.24 mmol), DMAP (12 mg, 0.098 
mmol), DCC (462 mg, 2.24 mmol) and N-Cbz-alanine 62c (500 mg, 2.24 mmol). Yield of  64c 
(600 mg, 97%). 
1H NMR (300 MHz, CDCl3): δ 7.34-7.27 m (5H), 5.53-5.45 (m, 2H), 5.11 (s, 2H), 4.45-4.35 (m, 
1H), 2.50-2.45 (m, 1H), 1.53-1.48 (m, 3H), 1.43-1.39 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 
171.7, 155.4, 136.1, 128.3, 127.9, 81.3, 81.2, 73.5, 73.3, 66.7, 61.0, 49.5, 49.4, 20.9, 18.3. 
N
H O
O
TMS
Cbz
64d  
2-Benzyloxycarbonylaminopropionic acid 1-methyl-3-trimethylsilylprop-2-ynyl ester (64d). 
Prepared by following general procedure C using: 4-trimethylsilylbut-3-yn-2-ol (600 mg, 4.22 
mmol), DMAP (51 mg, 0.42 mmol), DCC (956 mg, 4.64 mmol), N-Cbz-alanine (988 mg, 4.43 
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mmol) Yield of 64d (1.35 g, 92%). 
1H NMR (300 MHz, CDCl3): δ 7.36-7.27 (m, 5H), 5.50 (quin, J = 6.8 Hz, 1H), 5.33 (bs, 1H), 
5.12 (s, 2H), 4.41 (sep, J = 7.3 Hz, 1H), 1.52-1.41 (m, 6H), 0.18 (s, 4.5H), 0.17 (s, 4.5H); 13C 
NMR (75 MHz, CDCl3): δ 171.8, 155.6, 136.3, 128.6, 128.2, 103.0, 102.8, 90.5, 90.2, 67.0, 62.0, 
49.7, 21.4, 18.9, 18.6, -0.2; IR (thin film): ν 3341, 2960, 2178, 1727, 1251 cm-1; MS m/z (%) 348 
(5), 270 (10), 178 (13), 134 (26), 91 (100); EI-HRMS calcd for C18H25NO4Si m/z [M]+ 347.1553; 
found 347.1541. 
N
H O
O
TMS
Cbz
64e  
2-Benzyloxycarbonylaminopropionic acid 1-isopropyl-3-trimethylsilylprop-2-ynyl ester 
(64e). Prepared by following general procedure C using: 4-methyl-1-trimethylsilylpent-1-yn-3-ol 
(800 mg, 4.71 mmol), DMAP (63 mg, 0.52 mmol), DCC (1.06 g, 5.15 mmol), N-Cbz-alanine 
(1.15 g, 5.17 mmol). Yield of 64e (1.65 g, 85%). 
1H NMR (300 MHz, CDCl3): δ 7.37-7.27 (m, 5H), 5.44 (m, 1H), 5.29 (d, J = 5.6 Hz, 0.5H), 5.25 
(d, J = 5.7 Hz, 0.5H), 5.12 (s, 2H), 4.49-4.38 (m, 1H), 2.05-1.94 (m, 1H), 1.44 (d, J = 7.1 Hz, 
1H), 1.03-0.98 (m, 3H), 0.18 (s, 4.5H), 0.17 (s, 4.5H); 13C NMR (75 MHz, CDCl3): δ 171.9, 
171.7, 155.5, 136.3, 128.4, 128.1, 128.0, 100.8, 100.6, 91.6, 91.4, 70.4, 70.3, 66.8, 49.8, 49.5, 
32.4, 32.3, 18.8, 18.3, 18.0, 18.0, 17.4; IR (thin film): ν 3340, 2965, 2180, 1728, 1526 cm-1; MS 
m/z (%) 376 (6), 375 (14), 295 (25), 280 (34), 223 (50), 91 (100); EI-HRMS calcd for 
C20H29NO4Si m/z [M]+ 375.1866; found 375.1863. 
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N
H
Bn
O
O
TMS
Boc
64f  
tert-Butyl-1-((4-(trimethylsilyl)but-3-yn-2-yloxy)carbonyl)-2-phenylethylcarbamate (64f). 
Prepared by following general procedure C using: 4-trimethylsilylbut-3-yn-2-ol (6.0 g, 4.2 
mmol), DMAP (200 mg, 1.64 mmol), DCC (8.7 g, 4.2 mmol), N-Boc-phenylalanine (11.2 g, 
4.23 mmol) Yield 64f (16.4 g, >95%). The compound was immediately used in the next Claisen 
rearrangement step. 
 
General procedure D for preparation of 65a-65c via a Claisen rearrangement. 
NHCbzMeO2C
•
H
Bu
65b  
2-Benzyloxycarbonylamino-3-butyl-2,6-dimethylhepta-3,4-dienoic acid methyl ester (65b).  
General procedure for preparation of a THF solution of LDA: i-Pr2NH (5.1 mmol) was added to 
a flame dried 100 mL round-bottomed flask, followed by THF (10 mL) under nitrogen 
atmosphere. The reaction flask was cooled to -20 °C and n-BuLi  (5.1 mmol of 1.6 M solution in 
hexanes) was added dropwise over 5 min. The colorless solution was then cooled to -78 °C and 
held at that temperature for 30 min. 
Step 1. Ester-enolate Claisen rearrangement: To a freshly prepared solution of LDA (5.1 mmol) 
in THF (10 mL) was added 64b (730 mg, 2.04 mmol) in THF (10 mL) at -78 °C. After 2 min of 
stirring, ZnCl2 (4.9 mL of a 0.5 M solution in THF, 2.4 mmol) was added at -78 °C. The reaction 
mixture was allowed to warm to rt over 10 h. The reaction mixture was then poured in Et2O (100 
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mL) and treated with 1M HCl (50 mL).  The aqueous layer was extracted with Et2O (2 x 50 mL), 
and the organic layers were combined, washed with 1M HCl (50 mL), dried over MgSO4,  and 
concentrated under vacuum to afford a yellow oil. 
Step 2. Methyl ester formation: The yellow oil was dissolved in DMF (5 mL). Pulverized 
KHCO3 (515 mg, 5.09 mmol) was added at rt, followed by addition of MeI (256 µL, 4.08 mmol) 
via a syringe. The reaction mixture was stirred for 2 h, and then diluted with water (100 mL). 
The cloudy mixture was extracted with EtOAc (3 x 75 mL), the organic layers were combined, 
washed with brine, dried over MgSO4 and concentrated under vacuum. Purification of the crude 
residue by flash chromatography (gradient elution; hexanes-EtOAc, 10 : 0 to 4 : 1, v/v) afforded 
65b (555 mg, 73%). 
65b : 1H NMR (300 MHz, CDCl3): δ 7.42-7.28 (m, 5H), 5.78 (bs, 1H), 5.49 (dt, J = 7.0, 3.5 Hz, 
1H), 5.13 (d, J = 12.4 Hz, 1H), 5.07 (d, J = 12.3 Hz, 1H), 3.70 (s, 3H), 2.37 (sex, J = 6.3 Hz, 
1H). 1.92-1.86 (m, 2H), 1.70 (s, 3H), 1.36-1.27 (m, 4H), 1.05 (s, 3H), 1.03 (s, 3H), 0.88 (t, J = 
7.2 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 198.7, 173.5, 154.8, 137.0, 128.7, 128.2, 108.0, 
105.8, 77.5, 66.7, 60.9, 52.9, 30.4, 28.9, 27.0, 22.7, 22.6, 14.2; IR (thin film): ν 3416, 2958, 
1728, 1493, 1273 cm-1; MS m/z (%) 373 (11), 314 (9), 183 (21), 91 (100); EI-HRMS calcd for 
C22H31NO4 m/z [M]+ 373.2253; found 373.2268. 
NHBocMeO2C
Bn
•
C6H13
H
65a  
2-Benzyl-2-tert-butoxycarbonylamino-3-methylundeca-3,4-dienoic acid methyl ester (65a). 
Prepared by following general procedure D, using: LDA (1.58 mmol), 64a (265 mg, 0.661 
mmol), ZnCl2 (158 µL of a 0.5 M solution in THF, 0.793 mmol), KHCO3 (62 mg, 0.62 mmol), 
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MeI (38 µL, 0.62 mmol). Yield 65a (60 mg, 22%).  
Note: The intermediate carboxylic acid after the Claisen rearrangement step was purified by 
silica gel flash chromatography (hexanes-EtOAc, 4 : 1 to 1 : 1, v/v) and obtained in 41% yield. 
1H NMR (300 MHz, CDCl3): δ 7.27-7.23 (m, 3H), 7.08-7.06 (m, 2H), 5.27 (bs, 1H), 5.16 (bs, 
1H), 3.78 (s, 3H), 3.55-3.43 (m, 2H), 2.04 (bs, 2H), 1.72 (d, J = 2.7 Hz, 3H), 1.48 (s, 9H), 1.48-
1.28 (m, 8H), 0.88 (t, J = 6.7 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 201.6, 172.8, 153.8, 137.0, 
130.3, 127.9, 126.6, 99.6, 95.7, 64.5, 52.8, 37.9, 31.8, 29.1, 28.8, 28.5, 22.7, 15.5, 14.2. MS m/z 
(%) 416 (27), 359 (25), 324 (30), 268 (100), 57 (100); EI-HRMS calcd for C21H29NO4 m/z [M-
57]+ 359.2097; found 359.2110. 
NHCbzMeO2C
•
H
65c  
2-Benzyloxycarbonylamino-2-methylhexa-3,4-dienoic acid methyl ester (65c).  
Prepared by following general procedure D, using: LDA (7.15 mmol), 64c (820 mg, 2.98 mmol), 
ZnCl2 (7.1 mL of a 0.5 M solution in THF, 3.6 mmol), KHCO3 (752 mg, 7.45 mmol), MeI (460 
µL, 7.45 mmol). Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 65c 
(618 mg, 70%) as a 1 : 1 mixture of diastereomers. 
65c : 1H NMR (300 MHz, C6D6): δ 7.21-7.02 (m, 5H), 5.39 (m, 2H), 5.09-4.98 (m, 3H), 3.32 (s, 
3H), 1.74 (s, 1.5H), 1.70 (s, 1.5H), 1.37-1.32 (m, 3H). 
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General procedure E for the preparation of 65d-f via a three step reaction sequence. 
NHCbzMeO2C
•
H
TMS
CbzHN
O
O
TMS
NHCbzMeO2C
•
H
H
64d 67d 65d
1. LDA, ZnCl2, THF, -78 oC to rt
2. KHCO3, MeI, DMF, rt
TBAF, THF
pH = 7.0 buffer, rt
 
The following is a general procedure based on using 4.0 mmol of propargylic ester: 
General procedure for preparation of a THF solution of LDA: i-Pr2NH (10.0 mmol) was added to 
a flame dried 100 mL round-bottomed flask, followed by THF (10 mL) under nitrogen 
atmosphere. The reaction flask was cooled to -20 °C and n-BuLi (10.0 mmol of 1.6 M solution in 
hexanes) was added dropwise over 5 min. The colorless solution was then cooled to -78 °C and 
held at that temperature for 30 min. 
Step 1. Ester-enolate Claisen rearrangement: The amino acid propargylic ester (4.0 mmol) was 
placed in a pear-shaped flask as a solution in benzene and the solvent was removed under 
vacuum. The atmosphere was subsequently replaced with nitrogen and THF (10 mL) was added. 
The resulting solution was added via a syringe to a freshly prepared solution of LDA  (10 mmol) 
at -78 °C over 5 min. After 3-5 min of stirring, ZnCl2 (4.8 mmol of a 0.5 M solution in THF) was 
added in dropwise manner over 5 min at -78 °C. The reaction mixture was allowed to warm to rt 
over 12 h. The reaction mixture was then poured in Et2O (200 mL), and treated with 1M HCl 
(200 mL). The aqueous layer was extracted with Et2O (2 x 100 mL), and the organic layers were 
combined and washed with brine. Concentration under vacuum afforded an oily residue.  
Step 2. Methyl ester formation: The residue from step 1 was dissolved in DMF (10 mL). 
Pulverized KHCO3 (10 mmol) was added at rt, followed by MeI (8 mmol). The reaction mixture 
was stirred for 2-4 h until complete based upon TLC analysis, and then diluted with water (100 
mL). The cloudy mixture was extracted with EtOAc, the organic layers were combined, washed 
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with brine and concentrated under vacuum to afford a dark-yellow oil.  
Step 3. TMS removal: The dark yellow oil from step 2 was dissolved in THF (20 mL), and 
phosphate buffer (pH = 7.0, 1 mL) was added, followed by dropwise addition of TBAF (8 mmol 
of a 1.0 M solution in THF) at rt. The reaction mixture was stirred for 3 h at rt and then diluted 
with water (100 mL) and the aqueous layer extracted with Et2O (3 x 100 mL). The organic layers 
were combined, dried over MgSO4 and concentrated under vacuum. Purification of the crude 
residue by flash chromatography (hexanes-EtOAc, 4 : 1, v/v) afforded the allenic amino-ester. 
NHCbzMeO2C
•
H
H
65d  
2-Benzyloxycarbonylamino-2-methylhexa-3,4-dienoic acid methyl ester (65d). Prepared by 
the general procedure E, using:  
Step 1: LDA (17 mmol), 64d (2.36 g, 6.80 mmol), ZnCl2 (16.3 mL of a 0.5 M solution in THF, 
8.16 mmol). Step 2: KHCO3 (1.37 g, 13.6 mmol), MeI (0.67 mL, 11 mmol). Step 3: TBAF (6 
mL of a 1.0 M solution in THF, 6 mmol). Yield 65d (970 mg, 49%, 3 steps). 
65d : 1H NMR (300 MHz, CDCl3): δ 7.36-7.32 (m, 5H), 5.50 (bs, 1H), 5.44-5.36 (m, 2H), 5.13 
(d, J = 12.5 Hz, 1H), 5.08 (d, J = 12.3 Hz, 1H), 3.74 (bs, 3H), 1.69-1.66 (m, 6H); 13C NMR (75 
MHz, CDCl3): δ 202.9, 173.2, 154.9, 136.5, 128.6, 128.3, 94.4, 91.9, 66.8, 58.6, 53.0, 23.6, 14.1; 
IR (thin film): ν 3348, 2951, 1966, 1724, 1267 cm-1; MS m/z (%) 289 (21), 274 (10), 230 (42), 
91 (100); EI-HRMS calcd for C16H19NO4 m/z [M]+ 289.1314; found 289.1316. 
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NHCbzMeO2C
•
H
TMS
67d  
Benzyl-2-(methoxycarbonyl)-3-(trimethylsilyl)hexa-3,4-dien-2-ylcarbamate (67d): 1H NMR 
(300 MHz, CDCl3): δ 7.38-7.28 (m, 5H), 5.82 (bs, 1H), 5.18-5.04 (m, 3H), 3.71 (s, 3H), 1.73 (s, 
3H), 1.73-1.68 (m, 3H), 0.10 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 207.8, 174.1, 154.7, 136.9, 
128.7, 128.4, 128.3, 100.4, 85.5, 66.7, 60.8, 52.9, 24.2, 13.5, 0.2; IR (thin film): ν 3417, 2953, 
1940, 1727, 1490 cm-1; MS m/z (%) 362 (35), 361 (361 (43), 302 (45), 91 (100); EI-HRMS calcd 
for C19H27NO4Si m/z [M]+ 361.1709; found 361.1710. 
NHCbzMeO2C
•
H
H
65e  
2-Benzyloxycarbonylamino-2,6-dimethylhepta-3,4-dienoic acid methyl ester (65e). Prepared 
by following the general procedure E, using: Step 1: LDA (5.3 mmol), 64e (800 mg, 2.13 mmol), 
ZnCl2 (5.1 mL of a 0.5 M solution in THF, 2.6 mmol). Step 2: KHCO3 (537 mg, 5.32 mmol), 
MeI (265 µL, 4.26 mmol). Step 3: TBAF (2.1 mL of a 1.0 M solution in THF, 2.1 mmol).Yield 
65e (325 mg, 48%, 3 steps). 
1H NMR (300 MHz, CDCl3): δ 7.38-7.32 (m, 5H), 5.51-5.42 (m, 2H), 5.13 (d, J = 12.3 Hz, 1H), 
5.07 (d, J = 12.2 Hz, 1H), 3.73 (bs, 3H), 2.39-2.24 (m, 1H), 1.67 (s, 3H), 1.01 (d, J = 6.8 Hz, 
3H), 1.01 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 200.5, 173.0, 154.8, 136.4, 128.5, 
128.1, 104.5, 96.0, 66.6, 58.4, 52.7, 27.9, 23.4, 22.2, 22.1; IR (thin film): ν 3353, 2960, 1965, 
1728, 1264 cm-1; MS m/z (%) 318 (22), 317 (61), 302 (44), 274 (40), 258 (51), 91 (100); EI-
HRMS calcd for C18H23NO4 m/z [M]+ 317.1627; found 317.1626. 
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NHBocMeO2C
Bn
•
H
H
65f  
tert-Butyl-2-(methoxycarbonyl)-1-phenylhexa-3,4-dien-2-ylcarbamate (65f). Prepared by 
following the general procedure E, using: Step 1: LDA (74.3 mmol), 64f (11.6 g, 29.7 mmol), 
ZnCl2 (71 mL of a 0.5 M solution in THF, 35.6 mmol). Step 2: KHCO3 (7.4 g, 74 mmol), MeI 
(4.6 mL, 74 mmol). Step 3: TBAF (44.5 mL of a 1.0 M solution in THF, 44.5 mmol).Yield 65f 
(5.9 g, 60%, 3 steps). Notes: Simultaneous dropwise addition of ZnCl2 and 64f to LDA was 
performed at -78 °C. The solution of 64f in THF was cooled to -78 °C and added to LDA via a 
canula. 
1H NMR (300 MHz, CDCl3): δ 7.26-7.24 (m, 3H), 7.13-7.11 (m, 2H), 5.40 (bs, 1H), 5.28 (quin, 
J = 6.8 Hz, 1H), 5.19 (bs, 1H), 3.78 (s, 3H), 3.45 (d, J = 13.2 Hz, 1H), 3.42 (d, J = 13.2 Hz, 1H), 
1.68 (dd, J = 6.9, 3.0 Hz, 3H), 1.48 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 203.1, 172.4, 154.1, 
136.1, 130.3, 128.0, 126.7, 93.5, 91.3, 79.5, 62.5, 52.5, 40.6, 28.3, 13.9; IR (thin film): ν 3430, 
2978, 1969, 1741, 1717, 1494 cm-1; MS m/z (%) 332 (7), 276 (30), 184 (50), 91 (44), 57 (100); 
EI-HRMS calcd for C19H25NO4 m/z [M]+ 331.1784; found 331.1781. 
NHBocMeO2C
Bn
•
H
TMS
67f  
tert-Butyl-2-(methoxycarbonyl)-3-(trimethylsilyl)-1-phenylhexa-3,4-dien-2-ylcarbamate 
(67f). 1H NMR (300 MHz, CDCl3): δ 7.41-7.36 (m, 3H), 7.21-7.18 (m, 2H), 5.65 (bs, 1H), 5.20 
(q, J = 7.0 Hz, 1H), 3.90 (s, 3H), 3.89 (d, J = 13.4 Hz, 1H), 3.54 (d, J = 13.4 Hz, 1H), 1.91 (d, J 
= 6.9 Hz, 3H), 1.65 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 208.3, 173.1, 153.4, 136.8, 130.0, 
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127.8, 126.5, 98.9, 84.6, 78.9, 64.0, 52.4, 40.0, 28.4, 13.3, -0.3; IR (thin film): ν 3426, 2977, 
1938, 1723, 1487  cm-1; MS m/z (%) 403 (5), 347 (7), 256 (100), 178 (49); EI-HRMS calcd for 
C22H33NO4Si m/z [M]+ 403.2179; found 403.2196. 
BocHN
O
O
TMS
69  
tert-Butoxycarbonylaminoacetic acid 1-methyl-3-trimethylsilylprop-2-ynyl ester (69). To a 
solution of 4-trimethylsilyl-3-yn-2-ol (1.17 g, 8.27 mmol), in CH2Cl2 (10 mL), was added 
DMAP (81 mg, 0.66 mmol), DCC (1.38 g, 6.71 mmol) and N-Boc-Glycine 68 (954 mg, 6.71 
mmol) all at rt. The reaction mixture was stirred for 1 h at rt, then filtered through a plug of silica 
gel eluting with hexanes/EtOAc (1 : 1), and the filtrate was concentrated under vacuum. 
Purification of the crude oily residue by flash chromatography (hexanes-EtOAc, 4 : 1, v/v)  
afforded 69 (1.92 g, 92%). 
1H NMR (300 MHz, CDCl3): δ 5.50 (q, J = 6.7 Hz, 1H), 5.06 (br s, 1H), 3.91 (d, J = 5.4 Hz, 2H), 
1.48 (d, J = 6.7 Hz, 1H), 1.44 (s, 9H), 0.15 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 169.4, 155.8, 
102.9, 90.3, 80.1, 61.8, 42.7, 28.4, 21.6, -0.2; IR (thin film): ν 3379, 2978, 1756, 1721, 1169 cm-
1; MS m/z (%) 299 (10), 243 (100); EI-HRMS calcd for C14H25NO4Si m/z [M]+ 299.1553; found 
299.1547. 
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NHBocMeO2C
H
•
H
TMS
70  
2-tert-Butoxycarbonylamino-3-trimethylsilylhexa-3,4-dienoic acid methyl ester (70). Ester-
enolate Claisen rearrangement. To a freshly prepared solution of LDAii (20.4 mmol) in THF (10 
mL) was added 69 (1.6 g, 5.1 mmol) in THF (10 mL) at -78 °C. After 10 min of stirring ZnCl2 
(20 mL of a 0.5 M solution in THF, 9.8 mmol) was added at -78 °C. The reaction mixture was 
allowed to warm to rt over 12 h. Upon completion the reaction mixture was diluted with Et2O 
(100 mL), and treated with 1M HCl (100 mL). The aqueous layer was extracted with Et2O (2 x 
100 mL), and the organic layers were combined and washed with brine. Concentration under 
vacuum afforded a oily residue which was dissolved in DMF (10 mL). Pulverized KHCO3 (1.08 
g, 1.07 mmol) was added at rt, followed by MeI (530 µL, 8.24 mmol). The reaction mixture was 
left stirring for 2h at rt, and then diluted with water (100 mL). The cloudy mixture was extracted 
(benzene-EtOAc, 1 : 9, v/v) (3 x 75 mL), the organic layers were combined, washed with brine 
(2 x 50 mL) and concentrated in vacuo. Purification by flash chromatography (gradient elution: 
hexanes-EtOAc, 32 : 1 to 19 : 1, v/v), afforded 70 (740 mg, 44%). 
1H NMR (300 MHz, CDCl3): δ 5.10-5.03 (m, 2H), 4.75 (d, J = 8.3 Hz, 1H), 3.72 (s, 3H), 1.63 (d, 
J = 7.1 Hz, 1H), 1.45 (s, 9H), 0.15 (s, 9H);  13C NMR (75 MHz, CDCl3): δ 207.2, 172.1, 155.0, 
95.4, 84.5, 80.0, 53.4, 52.1, 28.4, 13.2, -1.1; IR (thin film): ν 3373, 2955, 1943, 1749, 1720 cm-1; 
MS m/z (%) 314 (6), 257 (43), 242 (45), 198 (100); EI-HRMS calcd for C11H19NO4Si m/z [M-
56]+ 257.1083; found 257.1080. 
                                                 
ii LDA was prepared as outlined in general procedure E. 
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NHBocMeO2C
H
•
H
H
71  
2-tert-Butoxycarbonylaminohexa-3,4-dienoic acid methyl ester (71). To a solution of 70 (120 
mg, 0.383 mmol), in THF (5 mL) was added TBAF (0.5 mL of a 1.0 M solution in THF, 0.5 
mmol) premixed with phosphate buffer solution (pH = 7.3) (0.3 mL) at rt. The reaction was 
stirred for 30 min when TBAF (0.3 mL of a 1M solution in THF, 0.3 mmol) was added. The 
reaction was allowed to continue until TLC indicated absence of starting material (~ 3 h). Water 
was added, and the aqueous layer was extracted with Et2O (3 x 20 mL). The organic layers were 
combined, washed with sat’d aq. NH4Cl, dried over MgSO4 and concentrated under vacuum. 
Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 71 (72 mg, 79%). 
1H NMR (300 MHz, CDCl3): δ 5.39-5.36 (m, 1H), 5.29 (bs, 1H), 5.13 (m, 1H), 4.78 (br s, 1H), 
3.76 (s, 3H), 1.69 (dd, J = 7.0, 3.1 Hz, 3H), 1.45 (s, 9H). 
NHBocMeO2C
Me
H
H
H
72  
2-tert-Butoxycarbonylaminohexa-2,4-dienoic acid methyl ester (72). To a solution of 70 (41 
mg, 0.13 mmol) in THF (2 mL) was added TBAF (157 µL of a 2.0 M solution in THF, 0.314 
mmol) at rt. After 10 min. water was added, and the aqueous layer was extracted with Et2O. The 
organic layers were combined, washed with sat’d aq NH4Cl, dried over MgSO4 and concentrated 
under vacuum to afford 72 (35 mg, >95%). Diene 72 was obtained as a mixture of isomers that 
were separated by semipreparative HPLC (hexanes-EtOAc 9 : 1, v/v). 
Spectral data of mixture: IR (thin film): ν 3358, 2980, 1727, 1159 cm-1; MS m/z (%) 241 (26), 
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185 (10), 141 (21), 57 (100); EI-HRMS calcd for C12H19NO4 m/z [M]+ 241.1314; found 
241.1308. 
72a (isomer 1): 1H NMR (300 MHz, CDCl3): δ 7.28 (d, J = 11.7 Hz, 1H), 6.28-6.21 (m, 1H), 
6.11 (bs, 1H), 5.96 (dq, J = 10.7, 7.1 Hz, 1H), 3.82 (s, 3H), 1.90 (d, J = 7.1 Hz, 3H), 1.47 (s, 9H); 
13C NMR (75 MHz, CDCl3): δ 166.0, 153.4, 134.9, 125.9, 124.4, 124.0, 80.9, 52.5, 28.3, 14.2. 
72b (isomer 2): 1H NMR (300 MHz, CDCl3): δ 6.96 (d, J = 10.9 Hz, 1H), 6.35-6.26 (m, 1H), 
6.19-6.07 (m, 1H), 6.02 (bs), 3.79 (s, 3H), 1.89 (d, J = 6.4 Hz, 1H), 1.48 (s, 9H). 
 
General procedure F for N-alkylation allenic amino-esters. 
•
R2
R3
R4
PHN
R1MeO2C NaH, DMF, rt
Br
R5
•
R2
R3
R4
PN
R1MeO2C
R5
73a-l
74a-i
75a-e  
The following is a general procedure based on using 1.0 mmol of allenic amino ester. 
To a solution of N-protected amino-ester (1.0 mmol) in DMF (4 mL), was added NaH (2.0 mmol 
of 95% dry or 60% dispersion in mineral oil) in one portion at rt under nitrogen atmosphere.jj 
The reaction flask was sealed with a rubber septum and after 2 min the propargyl or allyl 
bromide (1.5 – 2.0 mmol) was added dropwise via a syringe. The mixture was stirred at rt for 15 
- 45 min and upon completion as determined by TLC analysis, the reaction was quenched by 
cautiously pouring into water (50 mL). The aqueous mixture was extracted three times with 
EtOAc, the organic layers were combined, washed with brine, dried over MgSO4, and 
concentrated under vacuum. Purification of the crude residue by flash chromatography (hexanes-
                                                 
jj See individual compound for details. In certain cases NaH was added at 0 °C. 
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EtOAc, 9 : 1, v/v) afforded the corresponding alkyl-amide.  
Note: Benzamide protected allenynes 73a-73e and ene-allenes 75a, 75b and 75e were obtained 
as mixtures of diastereomers in ~2 : 1 ratio originating from the starting allenic amino-ester. 
These diastereomers were not separated. 
• H
BzN
BnMeO2C
73a  
2-(Benzoylbut-2-ynylamino)-2-benzylhexa-3,4-dienoic acid methyl ester (73a). Prepared by 
following general procedure F, using: 58a (330 mg, 0.982 mmol), NaH (60 mg of 95%, 2.5 
mmol), 1-bromo-2-butyne (86 µL, 0.98 mmol). Purification by flash chromatography (hexanes-
EtOAc, 9 : 1, v/v) afforded 73a (315 mg, 83%) as a mixture of diastereomers in a ~1.7 : 1 ratio. 
1H NMR (300 MHz, CDCl3): δ 7.67-7.64 (m, 2H), 7.48-7.38 (m, 3H), 7.31-7.21 (m, 5H), 5.89-
85 (m, 1H), 5.52-5.38 (m, 1H), 3.98 (d, J = 13.6 Hz, 0.63H), 3.97 (d, J = 13.5 Hz, 0.37H), 3.75 
(s, 3H), 3.75-3.68 (m, 1H), 3.58-3.51 (m, 1H), 3.40 (d, J = 13.6 Hz, 0.63H), 3.39 (d, J = 13.5 Hz, 
0.37H), 1.80 (dd, J = 7.1, 3.2 Hz, 1.9H), 1.74 (dd, J = 7.1, 3.1 Hz, 1.1H), 1.68 (s, 3H); 13C NMR 
(75 MHz, CDCl3): δ 204.4, 172.5, 171.7, 136.5, 136.1, 131.3, 130.5, 128.4, 128.0, 127.5, 126.9, 
91.0, 90.5, 90.3, 80.5, 76.2, 69.2, 68.0, 52.4, 39.6, 39.2, 25.7, 14.0, 13.8, 3.7; IR (thin film): ν 
2948, 1967, 1744, 1642, 1393 cm-1; MS m/z (%) 386 (10), 328 (41), 296 (15), 105 (100); EI-
HRMS calcd for C25H24NO3 m/z [M-1]+ 386.1756; found 386.1745. 
• H
BzN
BnMeO2C
73b  
2-(Benzoylprop-2-ynylamino)-2-benzylhexa-3,4-dienoic acid methyl ester (73b). Prepared by 
following general procedure F, using: 58a (175 mg, 0.521 mmol), NaH (42 mg of 60% 
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dispersion in mineral oil, 1.0 mmol), propargyl bromide (80% wt. in toluene, 92 µL, 0.83 mmol). 
Purification by flash chromatography (hexanes-EtOAc, 6 : 1, v/v) afforded 73b (143 mg, 73%) 
as a mixture of diastereomers in a ~1.7 : 1 ratio determined by integration of the methyl group 
resonances in the 1H NMR spectrum.  
1H NMR (300 MHz, CDCl3): δ 7.67-7.62 (m, 2H), 7.49-7.39 (m, 3H), 7.28-7.23 (m, 5H), 5.85 
(sex, J = 3.1 Hz, 1H), 5.56-5.41 (m, 1H), 3.97 (d, J = 13.5 Hz, 0.63H), 3.96 (d, J = 13.6 Hz, 
0.37H), 3.76 (s, 1.1H), 3.76 (s, 1.9H), 3.72 (dt, J = 18.9, 3.0 Hz, 1H), 3.51 (dt, J = 18.8, 3.0 Hz, 
1H), 3.42 (d, J =13.6 Hz, 0.63H), 3.41 (d, J = 13.6 Hz, 0.37H), 2.14 (t, J = 2.4  Hz, 0.63H), 2.12 
(t, J = 2.4 Hz, 0.37H), 1.81 (dd, J = 7.2, 3.2 Hz, 1.9H),1.75 (dd, J = 7.1, 3.2 Hz, 1.1H); 13C NMR 
(75 MHz, CDCl3): δ 205.0, 172.7, 171.7, 136.7, 136.6, 136.2, 131.4, 130.7, 128.7, 128.4, 127.5, 
127.1, 91.1, 91.0, 90.7, 81.2, 72.9, 72.9, 69.2, 52.7, 52.7, 39.3, 39.2, 14.1, 13.8; IR (thin film): ν 
2948, 2118, 1968, 1743, 1643 cm-1; MS m/z (%) 372 (50), 282 (40), 105 (100); EI-HRMS calcd 
for C24H22NO3 m/z [M]+ 372.1600; found 372.1613. 
• H
BzN
BnMeO2C
73c
TMS
 
2-[Benzoyl(3-trimethylsilylprop-2-ynyl)amino]-2-benzylhexa-3,4-dienoic acid methyl ester 
(73c). To a solution of 58a (243 mg, 0.723 mmol), in THF (7 mL) was added KH (90 mg of 35% 
wt. dispersion in mineral oil, 0.80 mmol) at rt, followed by addition of (3-bromoprop-1-ynyl)-
trimethylsilane (203 µL, 1.44 mmol). The reaction mixture was stirred at rt for 12 h and then 
carefully poured into a beaker containing EtOAc and water. The aqueous layer was extracted 
with EtOAc and organic layers were combined, washed with brine (20 mL), dried over MgSO4, 
and concentrated under vacuum. Purification by flash chromatography (hexanes-EtOAc, 9 : 1, 
v/v) afforded 73c (240 mg, 75%) as a mixture of diastereomers. 
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1H NMR (300 MHz, CDCl3): δ 7.68-7.64 (m, 2H), 7.46-7.38 (m, 3H), 7.33-7.21 (m, 5H), 5.83-
5.80 (m, 1H), 5.57-5.41 (m, 1H), 3.98-3.91 (m, 1H), 3.76 (s, 1.9H), 3.75 (s, 1.1H), 3.67-3.65 (m, 
1H), 3.52-3.41 (m, 2H), 1.81 (dd, J = 7.2, 3.1 Hz, 1.9H), 1.77 (dd, J = 7.1, 3.1 Hz, 1.1H), 0.16 (s, 
5.7H), 0.15 (s, 3.3H); 13C NMR (75 MHz, CDCl3): δ 204.6, 172.6, 171.5, 136.4, 136.3, 135.8, 
130.9, 130.3, 128.2, 128.0, 127.3, 126.8, 103.2, 90.9, 90.4, 89.4, 68.8, 52.4, 39.8, 38.8, 38.5, 
13.9, 13.7, -0.3; IR (thin film): ν 2952, 2177, 1967, 1745, 1649 cm-1; MS m/z (%) 445 (21), 444 
(36), 354 (50), 244 (74), 105 (100); EI-HRMS calcd for C27H30NO3Si m/z [M-1]+ 444.1995; 
found 444.1984.  
• H
BzN
BnMeO2C
73d
Ph
 
2-[Benzoyl(3-phenylprop-2-ynyl)amino]-2-benzylhexa-3,4-dienoic acid methyl ester (73d). 
Prepared by following general procedure F, using: 58a (72 mg, 0.21 mmol), NaH (17 mg of 60% 
dispersion in mineral oil, 0.43 mmol), (3-bromoprop-1-ynyl)-benzene (66 mg, 0.34 mmol). 
Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 73d (86 mg, 89%) as 
a mixture of diastereomers in a ~1.6 : 1 ratio determined by integration of the methyl group 
resonances in the 1H NMR.  
1H NMR (300 MHz, CDCl3): δ 7.79-7.77 (m, 2H), 7.57-7.51 (m, 4H), 7.41-7.23 (m, 9H), 5.98 
(sept, J = 3.1 Hz, 1H), 5.65-5.50 (m, 1H), 4.11 (d, J = 13.6 Hz, 0.61H), 4.11-4.01 (m, 2H), 3.87 
(s, 1.2H), 3.85 (s, 1.8H), 3.83-3.77 (m, 1H), 3.54 (d, J = 13.5 Hz, 1H), 1.89 (dd, J = 7.2, 3.2 Hz, 
1.8H), 1.83 (dd, J = 7.1, 3.2 Hz, 1.2H); 13C NMR (75 MHz, CDCl3): δ 204.6, 172.7, 172.6, 
171.7, 171.6, 136.4, 136.3, 131.6, 131.5, 131.0, 130.4, 128.4, 128.3, 128.2, 128.0, 127.3, 126.9, 
122.6, 90.9, 90.8, 90.4, 86.4, 86.3, 84.2, 69.0, 68.9, 52.4, 39.8, 39.0, 38.7, 13.9, 13.7; IR (thin 
film): ν 2948, 1967, 1743, 1645, 1392 cm-1; MS m/z (%) 448 (7), 390 (78), 358 (25), 105 (100); 
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EI-HRMS calcd for C30H26NO3 m/z [M-1]+ 448.1913; found 448.1929. 
• H
BzN
MeO2C
73e
TBSO
 
2-(Benzoylbut-2-ynylamino)-2-(tert-butyldimethylsilyloxymethyl)-hexa-3,4-dienoic acid 
methyl ester (73e). Prepared by following general procedure F, using: 58i (245 mg, 0.629 
mmol), NaH (50 mg of a 60% dispersion in mineral oil, 1.3 mmol), 1-bromo-2-butyne (88 µL, 
1.1 mmol). Purification by flash chromatography (gradient elution; hexanes-EtOAc, 19 : 1 to 9 : 
1, v/v) afforded 73e (237 mg, 85%) as a mixture of diastereomers.   
1H NMR (300 MHz, CDCl3): δ 7.71-7.65 (m, 2H), 7.46-7.37 (m, 3H), 5.90-5.86 (m, 1H), 5.41-
5.31 (m, 1H), 4.45 (d, J = 10.1 Hz, 0.66H), 4.44 (d, J = 10.1 Hz, 0.33H), 4.31-4.16 (m, 2H), 3.99 
(dq, J = 18.5, 2.3 Hz, 1H), 3.74 (s, 1H), 3.73 (s, 2H), 1.90-1.87 (m, 3H), 1.71 (dd, J = 7.1, 3.2 
Hz, 1H), 1.71 (dd, J = 7.1, 3.2 Hz, 2H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 205.1, 205.0, 172.3, 172.2, 170.6, 136.1, 130.1, 128.1, 127.3, 127.3, 89.9, 89.8, 
89.7, 79.8, 79.7, 77.2, 68.3, 68.2, 64.0, 63.9, 52.2, 52.1, 39.4, 39.3, 25.8, 25.7, 18.1, 14.0, 13.7, 
3.6, -5.5, -5.6, -5.6, -5.7; IR (thin film): ν 2952, 1968, 1744, 1644 cm-1; MS m/z (%) 384 (35), 
296 (31), 84 (100); EI-HRMS calcd for C21H26NO4Si m/z [M-57]+ 384.1631; found 384.1630. 
• H
CbzN
MeMeO2C
73f  
2-(Benzyloxycarbonylbut-2-ynylamino)-2-methylhexa-3,4-dienoic acid, methyl ester (73f). 
Prepared by following general procedure F, using: 65d (400 mg, 1.38 mmol), NaH (110 mg of 
60% dispersion in mineral oil, 2.76 mmol), 1-bromo-2-butyne (157 µL, 1.79 mmol). Flash 
chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 73f (390 mg, 84%). 
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1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.40-7.31 (m, 5H), 5.49-5.43 (m, 1H), 5.10 s, 2H), 
4.22 (dq, J = 18.3, 2.3 Hz, 1H), 4.11 (dq, J = 18.2, 2.2 Hz, 1H), 3.50 (bs, 3H), 1.78 (d, J = 2.0 
Hz, 3H), 1.66 (dd, J = 6.6, 3.4 Hz, 3H), 1.54 (s, 3H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 
204.0, 171.5, 154.3, 136.1, 127.9, 127.5, 127.2, 92.5, 89.9, 78.5, 75.9, 66.5, 63.4, 51.6, 33.6, 
20.5, 13.0, 2.6; IR (thin film): ν 2917, 1965, 1745, 1702, 1250 cm-1; MS m/z (%) 341 (5), 326 
(7), 282 (15), 91 (100); EI-HRMS calcd for C20H23NO4 m/z [M]+ 341.1627; found 341.1630. 
• H
CbzN
MeMeO2C
H
73g  
2-(Benzyloxycarbonylprop-2-ynylamino)-2-methylhexa-3,4-dienoic acid methyl ester (73g). 
Prepared by following general procedure F, using: 65d (240 mg, 0.83 mmol), NaH (70 mg, 60% 
dispersion in mineral oil, 1.8 mmol), propargyl bromide (80% wt. in toluene, 137 µL, 1.25 
mmol). Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 73g (210 mg, 
77%). 
1H NMR (300 MHz, C6D6, 323K): δ 7.22-7.01 (m, 5H), 5.63 (sex, J = 3.1 Hz, 1H), 5.13-5.04 (m, 
1H), 5.04 (s, 2H), 4.21 (d, J = 18.1 Hz, 1H), 4.04 (dd, J = 18.1, 2.0 Hz, 1H), 3.38 (bs, 3H), 1.88 
(t, J  = 2.4 Hz, 1H), 1.77 (s, 3H), 1.43 (dd, J = 7.1, 3.2 Hz, 1H); 13C NMR (75 MHz, C6D6, 
323K): δ 205.5, 172.2, 155.3, 137.0, 93.8, 90.6, 81.3, 71.5, 67.8, 64.9, 52.1, 34.2, 21.3, 13.6; IR 
(thin film): ν 3288, 2950, 2115, 1966, 1745, 1704, 1254 cm-1; MS m/z (%) 312 (13), 268 (34), 91 
(100); EI-HRMS calcd for C18H18NO4 m/z [M-15]+ 312.1236; found 312.1243. 
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• H
CbzN
MeMeO2C
TMS
73h  
2-[Benzyloxycarbonyl(3-trimethylsilylprop-2-ynyl)amino]-2-methylhexa-3,4-dienoic acid, 
methyl ester (73h). To a solution of 65d (134 mg, 0.464 mmol), in THF (4 mL) was added KH 
(68 mg of 35% wt. dispersion in mineral oil, 0.51 mmol) at rt, followed by addition of (3-
bromoprop-1-ynyl)-trimethylsilane (131 µL, 0.93 mmol). The reaction mixture was stirred at rt 
for 10 h. The reaction mixture was then poured into a beaker containing EtOAc (50 mL) and 
water (50 mL). The aqueous layer was extracted with EtOAc and the organic layers were 
combined, washed with brine, dried over MgSO4, and concentrated under vacuum. Purification 
by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 73h (128 mg, 86%). 
1H NMR (300 MHz, CDCl3, 310 K): δ 7.37-7.27 (m, 5H), 5.48 – 5.34 (m, 2H), 5.20 (d, J = 12.5 
Hz, 1H), 5.15 (d, J = 12.7 Hz, 1H), 4.38 (d, J = 18.3 Hz, 1H), 4.18 (d, J = 18.4 Hz, 1H), 3.59 (bs, 
3H), 1.73 (dd, J = 6.7, 2.9 Hz, 3H), 1.66 (s, 3H), 0.16 (s, 9H); 13C NMR (75 MHz, CDCl3, 310 
K): δ 205.3, 172.5, 155.1, 136.3, 128.3, 127.9, 102.7, 92.9, 90.5, 88.0, 67.5, 64.5, 52.3, 34.8, 
13.8, -0.3; IR (thin film): ν 2954, 2177, 1967, 1748, 1707, 1251 cm-1; MS m/z (%) 399 (5), 384 
(9), 340 (25), 91 (100); EI-HRMS calcd for C22H29NO4Si m/z [M]+ 399.1866; found 339.1875. 
• H
CbzN
MeMeO2C
Ph
73i  
2-[Benzyloxycarbonyl(3-phenylprop-2-ynyl)amino]-2-methylhexa-3,4-dienoic acid methyl 
ester (73i). Prepared by following general procedure F, using: 65d (210 mg, 0.72 mmol), NaH 
(58 mg of 60% dispersion in mineral oil, 1.4 mmol), (3-bromoprop-1-ynyl)-benzene (281 mg, 
1.44 mmol). Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 73i (199 
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mg, 68%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.39-7.31 (m, 10 H), 5.55-5.45 (m, 2H), 5.14 (s, 2H), 
4.52 (d, J = 18.6 Hz, 1H), 4.42 (d, J = 18.6 Hz, 1H), 3.50 (bs, 3H), 1.61 (dd, J = 7.0, 3.3 Hz, 3H), 
1.59 (s, 3H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 204.2, 171.6, 154.4, 136.2, 130.9, 128.4, 
128.3, 128.1, 127.6, 127.3, 122.0, 92.6, 90.2, 86.6, 82.5, 66.7, 63.5, 51.9, 34.1, 13.2; IR (thin 
film): ν 2949, 1966, 1746, 1704, 1251 cm-1; MS m/z (%) 344 (39), 240 (40), 205 (49), 169 (61), 
133 (84), 87 (100); EI-HRMS calcd for C25H25NO4 m/z [M]+ 403.1784, found 403.1788.  
• H
CbzN
MeMeO2C
73j  
2-(Benzyloxycarbonylbut-2-ynylamino)-2,6-dimethylhepta-3,4-dienoic acid, methyl ester 
(73j). Prepared by following general procedure F, using: 65e (125 mg, 0.394 mmol), NaH (31 
mg of a 60% dispersion in mineral oil, 0.79 mmol), 1-bromo-2-butyne (69 µL, 0.79 mmol).  
Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 73j (125 mg, 86%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.40-7.30 (m, 5H), 5.59-5.51 (m, 2H), 5.10 (s, 2H), 
4.21 (dq, J = 18.2, 2.3 Hz, 1H), 4.11 (dq, J = 18.3, 2.4 Hz, 1H), 3.48 (s, 3H), 2.40-2.25 (m, 1H), 
1.75 (t, J = 2.2 Hz, 3H), 1.52 (s, 3H), 1.01 (d, J = 6.8 Hz, 6H); 13C NMR (75 MHz, DMSO-d6, 
323 K): δ 201.6, 171.3, 154.3, 136.0, 127.9, 127.4, 127.1, 102.4, 94.4, 78.5, 75.9, 66.5, 63.5, 
51.6, 33.7, 27.0, 21.7, 21.5, 2.5; IR (thin film): ν 2959, 1964, 1746, 1704, 1253 cm-1; MS m/z 
(%) 369 (24), 326 (18), 167 (20), 91 (50), 83 (100); EI-HRMS calcd for C22H27NO4 m/z [M]+ 
369.1940; found 369.1957. 
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• H
CbzN
MeMeO2C
n-Bu
73k  
2-(Benzyloxycarbonylbut-2-ynylamino)-3-butyl-2,6-dimethylhepta-3,4-dienoic acid methyl 
ester (73k). Prepared by following general procedure F, using: 65b (135 mg, 0.361 mmol), NaH 
(29 mg of 60% dispersion in mineral oil, 0.72 mmol), 1-bromo-2-butyne (51 µL, 0.72 mmol). 
Purification by flash chromatography (hexanes-EtOAc, 19 : 1, v/v) afforded 73k (120 mg, 78%). 
1H NMR (300 MHz, CDCl3): δ 7.41-7.27 (m, 5H), 5.38 (dt, J = 6.1, 3.3 Hz, 1H), 5.23 (d, J = 
12.5 Hz, 1H), 5.13 (d, J = 12.5 Hz, 1H), 4.25 (d, J = 17.7 Hz, 1H), 3.78 (dd, J = 17.7, 2.2 Hz, 
1H), 3.58 (bs, 3H), 2.36 (sex, J = 6.5 Hz, 1H), 1.99 (m, 2H), 1.75 (t, J = 2.1 Hz, 3H), 1.67 (s, 
3H), 1.44-1.26 (m, 4H), 1.06 (d, J = 6.7 Hz, 6H), 0.89 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 202.8, 172.1, 156.5, 136.8, 128.6, 128.2, 107.1, 103.8, 78.9, 76.6, 67.7, 67.5, 52.3, 
35.1, 31.9, 28.8, 27.8, 22.9, 22.8, 22.7, 22.0, 14.3, 3.7; IR (thin film): ν 2957, 1957, 1744, 1707, 
1250 cm-1; MS m/z (%) 425 (30), 383 (36), 366 (32), 223 (68), 183 (100); EI-HRMS calcd for 
C26H35NO4 m/z [M]+ 425.2566; found 425.2565. 
•
C6H13
H
BocN
BnMeO2C
73l  
2-Benzyl-2-(tert-butoxycarbonylbut-2-ynylamino)-3-methylundeca-3,4-dienoic acid methyl 
ester (73l). Prepared by following general procedure F, using: 65a (59 mg, 0.14 mmol), NaH (7 
mg of 95% dry, 0.3 mmol), 1-bromo-2-butyne (25 µL, 0.29 mmol). Purification by flash 
chromatography (hexanes-EtOAc, 4 : 1, v/v) afforded 73l (48 mg, 73%). 
1H NMR (300 MHz, CDCl3): δ 7.34-7.17 (m, 5H), 5.38-5.31 (m, 1H), 3.78-3.76 (m, 1H), 3.70 (s, 
3H), 3.62 (d, J = 13.9 Hz, 1H), 3.5-3.35 (m, 1H), 3.26 (d, J = 13.9 Hz, 1H), 2.11 (q, J = 7.1 Hz, 
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2H), 1.86 (d, J = 2.5 Hz, 3H), 1.80 (s, 3H), 1.44-1.31 (m, 8H), 1.31 (m, 9H), 0.89 (t, J = 6.7 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 205.3, 170.9, 155.3, 137.8, 131.3, 127.9, 126.4, 100.8, 94.4, 
80.8, 78.2, 70.6, 51.8, 40.1, 36.3, 29.2, 29.0, 28.1, 22.7, 17.3, 14.2, 3.7; IR (thin film): ν 2926, 
1957, 1742, 1698, 1165 cm-1; MS m/z (%) 468 (28), 320 (50), 276 (63), 91 (56), 57 (100); EI-
HRMS calcd for C29H42NO4 m/z [M+1]+ 468.3114; found 468.3082. 
•
H
H
BzN
BnMeO2C
74a  
2-(Benzoylbut-2-ynylamino)-2-benzylpenta-3,4-dienoic acid methyl ester (74a). Prepared by 
following general procedure F, using: 58b (450 mg, 1.40 mmol), NaH (123 mg of a 60% 
dispersion in mineral oil, 3.08 mmol), 1-bromo-2-butyne (183 µL, 2.10 mmol). Purification by 
flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 74a (438 mg, 84%).  
1H NMR (300 MHz, CDCl3): δ 7.68-7.65 (m, 2H), 7.46-7.41 (m, 3H), 7.32-7.22 (m, 5H), 5.97 (t, 
J = 6.6 Hz, 1H), 5.10 (dd, J = 9.3, 6.6 Hz, 1H), 5.05 (dd, J = 9.3, 6.6 Hz, 1H), 3.98 (d, J = 13.6 
Hz, 1H), 3.76 (s, 3H), 3.73 (dq, J = 18.6, 2.3 Hz, 1H), 3.55 (dq, J = 18.6, 2.3 Hz, 1H), 3.43 (d, J 
= 13.6 Hz, 1H), 1.69 (t, J = 2.3 Hz, 3H); 13C NMR (75MHz, CDCl3): δ 207.6, 172.4, 171.3, 
136.2, 135.9, 131.1, 130.3, 128.2, 128.2, 127.9, 127.3, 126.8, 90.8, 80.4, 79.2, 75.9, 68.7, 52.2, 
39.4, 39.0, 3.5; IR (thin film): ν 2949, 2228, 1958, 1744, 1641 cm-1; MS m/z (%) 372 (45), 342 
(10), 282 (31), 105 (100); EI-HRMS calcd for C24H22NO3 m/z [M-1]+ 372.1600, found 372.1618. 
•
H
H
BzN
BnMeO2C
74b  
2-(Benzoylprop-2-ynylamino)-2-benzylhexa-3,4-dienoic acid methyl ester (74b). Prepared by 
following general procedure F, using: 58b (495 mg, 1.54 mmol), NaH (154 mg of a 60% 
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dispersion in mineral oil, 3.85 mmol), propargyl bromide (80% wt. in toluene) (257 µL, 2.31 
mmol). Purification by flash chromatography (gradient elution; hexanes-EtOAc, 9 : 1 to 4 : 1, 
v/v) afforded 74b (364 mg, 66%).  
1H NMR (300 MHz, CDCl3): δ 7.66-7.64 (m, 2H), 7.46-7.40 (m, 3H), 7.27-7.24 (m, 5H), 5.94 (t, 
J = 6.6 Hz, 1H), 5.10 (app dd, J = 6.6, 2.9 Hz, 2H), 3.96 (d, J = 13.6 Hz, 1H), 3.76 (s, 3H), 3.73 
(dd, J = 18.8, 1.8 Hz, 1H), 3.51 (dd, J = 18.8, 1.9 Hz, 1H), 3.45 (d, J = 13.7 Hz, 1H), 2.18 (s, 
1H); 13C NMR (75MHz, CDCl3): δ 207.7, 172.4, 171.1, 135.9, 135.5, 130.9, 130.4, 128.3, 128.1, 
127.1, 126.9, 90.5, 80.5, 79.6, 72.8, 68.5, 52.3, 38.8, 38.6; IR (thin film): ν 3302, 2950, 2115, 
1957, 1742, 1640, 1433, 1398, 1266, 1246 cm-1; MS m/z (%) 358 (35), 268 (42), 105 (100); EI 
HRMS calcd for C23H20NO3 m/z [M]+ 358.1443, found 358.1451. 
•
H
H
BzN
MeMeO2C
74c  
2-(Benzoylbut-2-ynylamino)-2-methylpenta-3,4-dienoic acid methyl ester (74c). Prepared by 
following general procedure F, using: 58c (200 mg, 0.816 mmol), NaH (65 mg of a 60% 
dispersion in mineral oil, 1.6 mmol), 1-bromo-2-butyne (142 µL,1.6 mmol). Purification by flash 
chromatography (gradient elution; hexanes-EtOAc, 9 : 1 to 4 : 1, v/v) afforded 74c (226 mg, 
93%).   
1H NMR (300 MHz, CDCl3): δ 7.60-7.57 (m, 2H), 7.40-7.34 (m, 3H), 5.79 (t, J = 6.6 Hz, 1H), 
4.95 (d, J = 6.6 Hz, 1H), 3.96 (q, J = 2.2 Hz, 2H), 3.71 (s, 3H), 1.82 (t, J = 2.2 Hz, 3H), 1.72 (s, 
3H); 13C NMR (75MHz, CDCl3): δ 208.2, 172.2, 171.8, 135.5, 130.2, 128.1, 128.1, 127.0, 92.5, 
80.3, 78.9, 75.8, 63.4, 52.4, 43.0, 37.3, 20.5, 3.4; IR (thin film): ν 2949, 1957, 1742, 1637, 1398, 
1264 cm-1; MS m/z (%) 297 (19), 258 (20), 238 (52), 105 (100); EI HRMS calcd for C18H19NO3 
m/z [M]+ 297.1365, found 297.1359. 
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•H
H
BzN
MeMeO2C
H
74d  
2-(Benzoylprop-2-ynylamino)-2-methylpenta-3,4-dienoic acid methyl ester (74d). Prepared 
by following general procedure F, using: 58c (200 mg, 0.816 mmol), NaH (65 mg of a 60% 
dispersion in mineral oil, 1.6 mmol), propargyl bromide (80% wt. in toluene, 180 µL, 1.6 mmol). 
Purification by flash chromatography (gradient elution; hexanes-EtOAc, 9 : 1 to 4 : 1, v/v) 
afforded 74d (217 mg, 94%).   
1H NMR (300 MHz, CDCl3): δ 7.64-7.61 (m, 2H), 7.46-7.40 (m, 3H), 5.82 (t, J = 6.6 Hz, 1H), 
5.01 (d, J = 6.5 Hz, 2H), 4.05 (d, J = 2.4 Hz, 2H), 3.76 (s, 3H), 2.39 (t, J = 2.4 Hz, 1H), 1.77 (s, 
3H); 13C NMR (75MHz, CDCl3): δ 208.5, 172.2, 172.1, 135.5, 130.4, 128.4, 127.1, 92.6, 80.8, 
79.2, 72.8, 63.8, 52.6, 37.1, 20.7; IR (thin film): ν 3256, 2950, 2115, 1956, 1740, 1640, 1397, 
1264 cm-1; MS m/z (%) 283 (20), 252 (24), 244 (26), 224 (51), 105 (100); EI HRMS calcd for 
C17H17NO3 m/z [M]+ 283.1208, found 283.1198. 
•
H
H
BzN
MeO2C
H
74e  
2-(Benzoylprop-2-ynylamino)-2-isobutylpenta-3,4-dienoic acid methyl ester (74e).  
An oven-dried three-neck flask equipped with an addition funnel was charged with NaH (2.7 g of 
a 60% dispersion in mineral oil, 0.066 mol) and DMF (60 mL) was added. The mixture was 
cooled to 0 °C and a solution of amide 58d (9.5 g, 0.033 mol) in DMF (200 mL) was added via 
the addition funnel in a dropwise manner over 15-20 min. During this time, flow of nitrogen was 
maintained through the reaction setup to flush the H2 generated during deprotonation. Upon 
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completion of the addition, the reaction mixture was stirred for additional 5 min, and then 
propargyl bromide (5.8 mL, 0.066 mol) was added via a syringe. Stirring was continued at 0 °C 
for additional 3 h. The reaction mixture was then slowly poured into cold water and this mixture 
was extracted with EtOAc three times. The organic layers were combined, washed with brine, 
dried over MgSO4 and concentrated under vacuum. The resulting residue was purified by silica 
gel flash chromatography (hexanes/EtOAc, 6 : 1, v/v) to afford the desired allenyne 74e (8.3 g, 
77%) as a pale yellow solid (mp range 108.5-110.0 °C). 
 1H NMR (300 MHz, CDCl3): δ 7.66-7.63 (m, 2H), 7.48-7.38 (m, 3H), 6.06 (t, J = 6.6 Hz, 1H), 
4.96 (d, J = 6.6 Hz, 2H), 4.06 (d, J = 2.3 Hz, 2H), 3.75 (s, 3H), 2.43 (t, J = 2.4 Hz, 1H), 2.31 (dd, 
J = 13.8, 5.8 Hz, 1H), 2.16 (dd, J = 13.8, 5.1 Hz, 1H), 1.91-1.76 (m, 1H), 0.99 (d, J = 6.7 Hz, 
3H), 0.96 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 207.7, 172.6, 171.6, 135.6, 130.5, 
128.4, 127.3, 91.4, 81.1, 79.1, 73.0, 67.2, 52.3, 42.5, 37.8, 24.4, 24.1; IR (thin film): ν 3257, 
2956, 2115, 1957, 1742, 1646 cm-1; MS m/z (%) 324 (76), 310 (55), 294 (45), 266 (35), 105 
(100); EI-HRMS calcd for C20H22NO3 m/z [M]+ 324.1600; found 324.1603. 
•
H
H
BzN
MeO2C
H
MeO 74f  
2-(Benzoylprop-2-ynylamino)-2-(4-methoxybenzyl)-penta-3,4-dienoic acid methyl ester 
(74f). Prepared by following the procedure for preparation of 74e (vide ultra), using: 58e (17.5 g, 
498 mmol), propargyl bromide (13.7 mL, 124 mmol), NaH (5.0 g of a 60% dispersion in mineral 
oil, 124 mmol). Stirred at 0 °C for 2 h. Purification by flash chromatography (gradient elution, 
hexanes/EtOAc, 9 : 1 to 1 : 1, v/v) afforded 74f (16.4 g, 84%).  
1H NMR (300 MHz, CDCl3): δ 7.67-7.64 (m, 2H), 7.46-7.42 (m, 3H), 7.17 (d, J = 8.6 Hz, 2H), 
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6.82 (d, J = 8.6 Hz, 2H), 5.92 (t, J = 6.6 Hz, 1H), 5.14-5.04 (m, 2H), 3.87 (d, J = 13.7 Hz, 1H), 
3.78 (s, 3H), 3.74 (s, 3H), 3.74 (dd, J = 18.8, 2.2 Hz, 1H), 3.51 (dd, J = 19.0, 2.5 Hz, 1H), 3.40 
(d, J = 13.7 Hz, 1H), 2.22 (t, J = 2.3 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 207.8, 172.4, 171.2, 
158.6, 135.5, 131.8, 130.4, 128.3, 127.8, 127.1, 113.5, 90.6, 80.7, 79.6, 72.8, 68.5, 55.1, 52.4, 
38.8, 37.8; IR (thin film): ν 3258, 2949, 2115, 1957, 1742, 1642, 1513 cm-1; MS m/z (%) 388 
(26), 330 (50), 268 (34), 230 (42), 105 (100); EI-HRMS calcd for C24H23NO4 m/z [M]+ 
389.1627; found 389.1614. 
•
H
H
BzN
MeO2C
H
F 74g  
2-(Benzoylprop-2-ynylamino)-2-(4-fluorobenzyl)penta-3,4-dienoic acid methyl ester (74g). 
Prepared by following the general procedure F, using: 58f (165 mg, 0.486 mmol), propargyl 
bromide (160 µL, 1.46 mmol), NaH (60% in mineral oil) (58 mg, 1.5 mmol). Stirred at rt for 1.5 
h. Yield 74g (156 mg, 85%).  
1H NMR (300 MHz, CDCl3): δ 7.66-7.58 (m, 2H), 7.48-7.38 (m, 3H), 7.27-7.19 (m, 2H), 7.01-
6.95 (m, 2H), 5.93 (t, J = 5.8 Hz, 1H), 5.13-5.03 (m, 2H), 3.94 (d, J = 13.8 Hz, 1H), 3.60 (dd, J = 
18.9, 2.2 Hz, 1H), 3.74 (s, 3H), 3.60 (dd, J = 18.8, 2.3 Hz, 1H), 3.39 (d, J = 13.8 Hz, 1H), 2.18 (t, 
J = 2.2 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 207.7, 172.4, 171.0, 163.6, 160.4, 135.4, 132.4, 
132.3, 131.8, 130.5, 128.4, 127.1, 115.0, 114.7, 90.5, 80.5, 79.5, 72.8, 68.6, 52.3, 38.9, 38.1; IR 
(thin film): ν 3298, 2950, 2119, 1957, 1743, 1642, 1510 cm-1; MS m/z (%) 376 (69), 346 (20), 
268 (57), 105 (100); EI-HRMS calcd for C23H19NO3F m/z [ M-1]+ 376.1349; found 376.1358. 
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•H
H
BzN
MeO2C
H
S
74h  
2-(Benzoylprop-2-ynylamino)-2-thiophen-2-ylmethylpenta-3,4-dienoic acid methyl ester 
(74h). Prepared by following the general procedure F, using: 58g (220 mg, 0.673 mmol), 
propargyl bromide (185 µL, 1.68 mmol), NaH (60% in mineral oil) (65 mg, 1.7 mmol). Stirred at 
rt for 30 min. Yield 74h (220 mg, 89%).  
1H NMR (300 MHz, CDCl3): δ 7.69-7.66 (m, 2H), 7.46-7.40 (m, 4H), 7.17 (dd, J = 4.9, 1.3 Hz, 
1H), 6.94-6.90 (m, 2H), 6.02 (t, J = 6.6 Hz, 1H), 5.24-5.13 (m, 2H), 4.22 (d, J = 14.9 Hz, 1H), 
3.78 (s, 3H), 3.72 (dd, J = 18.8, 2.4 Hz, 1H), 3.64 (d, J = 14.9 Hz, 1H), 3.46 (dd, J = 18.8, 2.5 
Hz, 1H), 2.30 (t, J = 2.5 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 208.4, 172.4, 171.0, 137.5, 
135.5, 130.3, 128.3, 128.1, 127.1, 126.6, 125.1, 90.3, 80.8, 80.6, 72.9, 68.0, 52.7, 38.8, 32.2; IR 
(thin film): ν 3264, 2949, 2118, 1956, 1742, 1641 cm-1; MS m/z (%) 334 (6), 306 (21), 268 (15), 
206 (18), 105 (100); EI-HRMS calcd for C20H16NO2S m/z [M-31]+ 334.0902; found 334.0910. 
•
H
H
BzN
MeO2C
H
NBoc
74i  
3-[2-(Benzoylprop-2-ynylamino)-2-methoxycarbonylpenta-3,4-dienyl]-indole-1-carboxylic 
acid tert-butyl ester (74i). Prepared by following the general procedure F, using: 58h (225 mg, 
0.489 mmol), propargyl bromide (134 µL, 1.22 mmol), NaH (60% in mineral oil) (49 mg, 1.2 
mmol). Stirred at rt for 1h. Yield 74i (190 mg, 78%).  
1H NMR (300 MHz, CDCl3): δ 8.21 (d, J = 7.9 Hz, 1H), 7.78-7.20 (m, 9H), 6.04 (t, J = 6.6 Hz, 
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1H), 5.22-5.14 (m, 2H), 4.21 (d, J = 14.6 Hz, 1H), 3.85 (s, 3H), 3.63 (d, J = 14.6 Hz, 1H), 2.14 
(s, 1H), 1.75 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 207.8, 171.4, 171.2, 149.6, 135.5, 135.1, 
131.6, 130.4, 128.3, 127.2, 125.6, 124.3, 122.6, 119.6, 115.0, 114.8, 91.1, 83.6, 80.5, 79.5, 72.7, 
68.8, 52.4, 39.1, 28.9, 28.2; IR (thin film): ν 3291, 2980, 2116, 1957, 1735, 1642, 1369 cm-1; MS 
(EI) m/z (%) 498 (6), 398 (20), 339 (32), 293 (63), 105 (100);  ESI-HRMS calcd for 
C30H30N2O5Na m/z [M+23]+ 521.2052; found 521.2076. 
• H
BzN
BnMeO2C
75a  
2-(Benzoylbut-2-enylamino)-2-benzylhexa-3,4-dienoic acid methyl ester (75a). Prepared by 
following the general procedure F, using: 58a (92 mg, 0.27 mmol), NaH (60% dispersion in 
mineral oil, 22 mg, 0.55 mmol), crotyl bromide (57 µL, 0.55 mmol). Purification by flash 
chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 75a (60 mg, 56%). 
1H NMR (300 MHz, CDCl3): δ 7.39-7.27 (m, 10H), 5.62-5.56 (m, 1H), 5.55-5.21 (m, 2H), 4.96-
4.88 (m, 1H), 4.00 (d, J = 13.5 Hz, 0.63H), 3.97 (d, J = 13.5 Hz, 0.37H), 3.77 (s, 3H), 3.61-3.53 
(m, 1H), 3.44-3.36 (m, 1H), 3.35 (d, J = 13.5 Hz, 1H), 1.80 (dd, J = 7.1, 3.3 Hz, 1.9H), 1.74 (dd, 
J = 7.1, 3.2 Hz, 1.1H), 1.53 (m, 3H); 13C NMR (CDCl3, 75 MHz): δ 204.7, 173.0, 172.1, 137.3, 
137.0, 131.5, 131.5, 129.7, 129.0, 128.6, 128.5, 128.3, 127.7, 127.2, 127.1, 127.0, 126.8, 91.6, 
91.5, 90.7, 90.4, 69.2, 52.6, 52.5, 50.4, 50.3, 39.5, 39.4, 18.0, 14.2, 13.9; IR (thin film): ν 2947, 
1968, 1744, 1637, 1444 cm-1; MS m/z (%) 388 (6), 358 (5), 330 (33), 298 (84), 244 (60), 105 
(100); EI-HRMS calcd for [M-1]+, m/z C25H26NO3 388.1913, found 388.1912. 
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• H
BzN
BnMeO2C
75b  
2-(Allylbenzoylamino)-2-benzylhexa-3,4-dienoic acid methyl ester (75b). Prepared by 
following the general procedure F, using: 58a (100mg, 0.297 mmol), NaH (60% dispersion in 
mineral oil, 24 mg, 0.59 mmol), allyl bromide (40 µL, 0.45 mmol). Purification by flash 
chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 75b (80 mg, 71%). 
1H NMR (300 MHz, CDCl3): δ 7.42-7.26 (m, 10H), 5.58 (dq, J = 9.7, 3.2 Hz, 1H), 5.52-5.41 (m, 
2H), 5.25-5.14 (m, 1H), 5.06-5.03 (m, 1H), 3.99 (d, J = 13.5 Hz, 0.73H), 3.95 (d, J = 13.5 Hz, 
0.37H), 3.78 (s, 1.1H), 3.77 (s, 1.9H), 3.65-3.57 (m, 1H), 3.39 (d, J = 13.5 Hz, 1H), 3.41-3.28 
(m, 1H), 1.80 (dd, J = 7.1, 3.3 Hz, 1.9H), 1.74 (dd, J = 7.0, 3.2 Hz, 1.1H); 13C NMR (CDCl3, 75 
MHz): δ 204.6, 204.5, 172.8, 171.8, 171.7, 136.6, 136.6, 136.5, 136.2, 136.1, 131.1, 131.0, 
129.5, 128.0, 126.9, 126.4, 116.6, 116.5, 91.1, 91.0, 90.6, 90.3, 68.7, 52.3, 50.6, 50.5, 38.9, 38.7, 
13.8, 13.5; IR (thin film): ν 3028, 2947, 1968, 1743, 1639, 1444, 1393, 1266, 1225 cm-1; MS m/z 
(%) 374 (26), 344 (9), 316 (10), 284 (52), 105 (100); EI-HRMS calcd for C24H24NO3 [M-1]+, m/z 
374.1756, found 374.1761. 
• H
CbzN
MeO2C
75c  
2-(Benzyloxycarbonylbut-2-enylamino)-2-methyl-hexa-3,4-dienoic acid methyl ester (75c). 
Prepared by following the general procedure F, using: 65d (66 mg, 0.23 mmol), NaH (60% 
dispersion in mineral oil) (14 mg, 0.34 mmol), crotyl bromide (50 µL, 0.45 mmol). Purification 
by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 75c (52mg, 66%).  
1H NMR (300 MHz, CDCl3): δ 7.36-7.30 (m, 5H), 5.64 (dq, J = 14.5, 6.3 Hz, 1H), 5.51-5.46 (m, 
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2H), 5.39-5.30 (m, 1H), 5.13 (s, 2H), 3.96 (br d, 2H), 3.67 (bs, 3H), 1.68 (dd, J = 7.0, 3.1 Hz, 
3H), 1.69-1.67 (m, 3H), 1.52 (s, 3H); 13C NMR (CDCl3, 75 MHz): δ 205.0, 173.3, 156.0, 136.8, 
128.7, 128.5, 128.2, 127.4, 125.2, 93.9, 90.9, 67.6, 64.5, 52.6, 17.9, 14.0; IR (thin film): ν 2949, 
1965, 1746, 1698, 1450 cm-1; MS (GC/MS) m/z 284 [M-59]+. 
• H
CbzN
MeO2C
75d  
2-(Benzyloxycarbonylbut-2-enylamino)-2,6-dimethylhepta-3,4-dienoic acid methyl ester 
(75d). Prepared by following the general procedure F, using: 65e (60 mg, 0.19 mmol), NaH 
(60% dispersion in mineral oil, 15 mg, 0.38 mmol), crotyl bromide (39 µL, 0.38 mmol). 
Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 75d (43 mg, 61%).  
1H NMR (300 MHz, CDCl3, 323K): δ 7.34-7.27 (m, 5H), 5.69-5.50 (m, 3H), 5.40 (t, J = 6.1 Hz, 
1H), 5.13 (s, 2H), 3.98 (d, J = 4.1 Hz, 2H), 3.59 (s, 3H), 2.41-2.29 (m, 1H), 1.1.68 (d, J = 6.2 Hz, 
3H), 1.54 (s, 3H), 1.04 (d, J = 6.7 Hz, 6H); Two additional signals were observed in the 1H NMR 
spectrum at 4.10 (d, J = 2.8 Hz), 1.61 (d, J = 4.3 Hz) and are attributed to carbamate rotational 
isomerism. 13C NMR (CDCl3, 75 MHz, 323 K): δ 202.4, 172.8, 155.8, 136.6, 128.3, 128.0, 
127.9, 127.0, 103.0, 95.3, 67.3, 64.5, 52.2, 28.1, 22.5, 22.4, 17.5, 12.8;  IR (thin film): ν 2959, 
1962, 1747, 1701, 1252 cm-1; MS m/z (%) 371 (24), 312 (25), 258 (31), 91 (100); EI-HRMS 
calcd for C22H29NO4 [M]+, m/z 371.2097, found 371.2104. 
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• H
BzN
MeO2C
75e
TBSO
 
2-(Benzoylbut-2-enylamino)-2-(tert-butyldimethylsilyloxymethyl)-hexa-3,4-dienoic acid 
methyl ester (75e). Prepared by following the general procedure F, using: 58i (90 mg, 0.23 
mmol), NaH (60% dispersion in mineral oil) (19 mg, 0.46 mmol), crotyl bromide (47 µL, 0.46 
mmol). Purification by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) afforded 75e (43 mg, 
42%).  
1H NMR (300 MHz, CDCl3): δ 7.43-7.27 (m, 5H), 5.65-5.43 (m, 3H), 5.35-5.29 (m, 1H), 4.51-
4.45 (m, 1H), 4.10 (d, J = 10.2 Hz, 1H), 4.09-4.00 (m, 1H), 3.92 (bd, J = 16.4 Hz, 1H), 3.74 (s, 
3H), 1.70-1.67 (m, 6H), 0.89 (s, 9H), 0.07 (s, 6H); 13C NMR (CDCl3, 75 MHz): δ 205.1, 204.9, 
172.5, 170.8, 136.9, 129.8, 129.5, 129.3, 128.1, 127.9, 127.1, 127.0, 126.7, 126.5, 126.5, 89.9, 
89.8, 89.5, 68.3, 64.0, 63.8, 52.1, 50.2, 50.1, 25.8, 25.8, 18.1, 17.7, 13.9, 13.6, 12.7, -5.5, 5.6; IR 
(thin film): ν 2951, 1968, 1743, 1639, 1401, 1250 cm-1; MS m/z (%) 443 (25), 386 (43), 298 
(35), 244 (32), 105 (100); EI-HRMS calcd for C25H37NO4Si [M]+, m/z 443.2492, found 
443.2503. 
 
 
 
 
 
 
 
 
 185 
General procedure G for the Rh(I)-catalyzed allenic Alder-ene reaction.  
N
Bz
Bn
MeO2C
111a  
1-Benzoyl-2-benzyl-5-ethylidene-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid 
methyl ester (111a). Allenyne 73a (20 mg, 52 µmol) was placed in a new 15 mL test tube 
equipped with a stirring bar and toluene (1 mL) was added followed by [Rh(CO)2Cl]2 (1 mg, 3 
µmol) at rt. Upon completion of the reaction based on TLC analysis (10 min) the solution was 
directly applied to a  short column of silica gel. Elution with (hexanes-EtOAc, 9 : 1, v/v) 
afforded 111a (16 mg, 80%) after concentration under vacuum. 
1H NMR (300 MHz, CDCl3): δ 7.47-7.39 (m, 5H), 7.31-7.28 (m, 5H), 6.36 (dd, J = 17.2, 10.7 
Hz, 1H), 5.75 (s, 1H), 5.63 (q, J = 7.0 Hz, 1H), 5.50 (dd, J = 17.2, 1.5 Hz, 1H), 5.27 (dd, J = 
10.7, 1.5 Hz, 1H), 4.13 (d, J = 13.6 Hz, 1H), 4.13 (d, J = 14.6 Hz, 1H),  3.80 (s, 3H), 3.41 (d, J = 
13.6 Hz, 1H), 2.46 (d, J = 14.3 Hz, 1H), 1.42 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
172.3, 171.3, 139.5, 137.0, 136.7, 134.6, 131.0, 130.1, 129.5, 128.8, 128.3, 127.2, 127.0, 123.5, 
123.0, 117.9, 67.0, 53.1, 44.7, 40.3, 13.4; IR (thin film) ν 2949, 1738, 1640, 1415 cm-1; MS m/z 
(%) 387 (8), 356 (7), 296 (25), 105 (100); EI-HRMS calcd for C18H18NO3 m/z [M-91]+ 
296.1287; found 296.1283. 
N
Bz
Bn
MeO2C
111b  
1-Benzoyl-2-benzyl-5-methylene-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid 
methyl ester (111b). Prepared by following general procedure G, using: 73b (29 mg, 78 µmol), 
[Rh(CO)2Cl]2 (1.5 mg, 4 µmol). Yield 111b  (21 mg, 74%). 
1H NMR (300 MHz, CDCl3): δ 7.44-7.38 (m, 5 H), 7.25-7.20 (m, 5H), 6.37 (dd, J = 17.3, 10.8 
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Hz, 1H), 5.85 (s, 1H), 5.52 (dd, J = 17.3, 1.2 Hz, 1H), 5.28 (dd, J = 10.8, 1.1 Hz, 1H), 5.09 (s, 
1H), 4.76 (s, 1H), 4.10 (d, J = 13.7 Hz, 1H), 3.84 (d, J = 13.9 Hz, 1H), 3.77 (s, 3H), 3.39 (d, J = 
13.7 Hz, 1H), 2.67 (d, J = 14.0 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 171.6, 170.6, 137.9, 
136.4, 136.0, 135.8, 133.3, 130.6, 129.9, 128.4, 128.0, 126.9, 126.8, 125.7, 117.8, 112.5, 66.5, 
52.9, 50.6, 39.8; IR (thin film): ν 2949, 1739, 1638, 1410, 1242 cm-1; MS m/z (%) 373 (20), 342 
(8), 314 (8), 282 (25), 105 (100);  EI-HRMS calcd for C24H23NO3 m/z [M]+ 373.1678, found 
373.1664. 
N
Bz
Bn
MeO2C
111c
TMS
 
1-Benzoyl-2-benzyl-5-trimethylsilylmethylene-4-vinyl-1,2,5,6-tetrahydropyridine-2-
carboxylic acid methyl ester (111c). Prepared by following general procedure G, using: 73c (46 
mg, 103 µmol), [Rh(CO)2Cl]2 (2 mg, 5 µmol). Yield 111c (42 mg, 92%).  
1H NMR (300 MHz, CDCl3): δ 7.38-7.18 (m, 10H), 6.32 (dd, J = 17.3, 10.8 Hz, 1H), 5.82 (s, 
1H),  5.52 (s, 1H), 5.43 (dd, J = 17.3, 1.5 Hz, 1H), 5.21 (dd, J = 10.8, 1.5 Hz, 1H), 4.06 (d, J = 
13.7 Hz, 1H), 4.00 (d, J = 14.1 Hz, 1H), 3.75 (s, 3H), 3.34 (d, J = 13.7 Hz, 1H), 2.70 (d, J = 14.1, 
1.2 Hz, 1H), -0.35 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 171.8, 170.3, 142.5, 139.5, 136.5, 
136.3, 134.0, 130.6, 129.7, 128.5, 128.0, 126.9, 126.7, 124.9, 117.7, 65.7, 52.8, 49.3, 39.7, -0.7; 
IR (thin film): ν 3029, 2951, 1740, 1642, 1408, 1252, 1218 cm-1; MS m/z (%) 445 (5), 430 (5), 
354 (40), 105 (100); EI-HRMS calcd for C27H31NO3Si [M]+ m/z 445.2073, found 445.2076. 
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N
Bz
Bn
MeO2C
111d
Ph
 
1-Benzoyl-2-benzyl-5-benzylidene-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid 
methyl ester (111d). Prepared by following general procedure G, using: 73d (26 mg, 58 µmol), 
[Rh(CO)2Cl]2 (1 mg, 3 µmol). Yield 111d (21 mg, 81%).  
1H NMR (300 MHz, CDCl3): δ 7.29-7.00 (m, 13 H), 6.82-6.79 (m, 2H), 6.61 (s, 1H), 6.43 (ddd, 
J = 17.3, 10.7, 0.8 Hz, 1H), 5.89 (s, 1H), 5.56 (dd, J = 17.3, 1.5 Hz, 1H), 5.33 (dd, J = 10.7, 1.5 
Hz, 1H), 4.41 (d, J = 14.2 Hz, 1H), 4.10 (d, J = 13.6 Hz, 1H), 3.77 (s, 3H), 3.41 (d, J = 13.6 Hz, 
1H), 2.68 (d, J = 14.2, 1.4 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 172.1, 171.2, 139.8, 136.9, 
136.1, 135.8, 134.5, 131.0, 130.5, 129.7, 128.8, 128.5, 128.4, 128.0, 127.5, 127.1, 127.0, 125.6, 
118.5, 66.9, 53.2, 45.4, 40.3;  IR (thin film): ν 2918, 1738, 1639, 1413, 1223 cm-1; MS m/z (%) 
449 (10), 390 (15), 358 (50), 105 (100); EI-HRMS calcd for C30H27NO3 m/z [M]+ 449.1991; 
found 449.2011. 
N
Bz
MeO2C
111e
TBSO
 
1-Benzoyl-2-(tert-butyldimethylsilyloxymethyl)-5-ethylidene-4-vinyl-1,2,5,6-
tetrahydropyridine-2-carboxylic acid methyl ester (111e). Prepared by following general 
procedure G, using: 73e (36 mg, 83 µmol), [Rh(CO)2Cl]2 (1.5 mg, 5 µmol). Yield 111e (32 mg, 
89%). 
1H NMR (300 MHz, CDCl3): δ (7.47-7.40 (m, 5H), 6.38 (dd, J = 17.2, 10.7 Hz, 1H), 5.75 (q, J = 
7.0 Hz, 1H), 5.57 (s, 1H), 5.44 (dd, J = 17.2, 1.5 Hz, 1H), 5.21 (dd, J = 10.7, 1.5 Hz, 1H), 4.70 
(d, J = 10.2 Hz, 1H), 4.51 (d, J = 14.1 Hz, 1H), 4.19 (d, J = 10.2 Hz, 1H), 3.99 (d, J = 14.0 Hz, 
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1H), 3.69 (s, 3H), 1.58 (d, J = 7.1 Hz, 1H), 0.85 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 170.9, 170.8, 139.6, 136.2, 134.4, 129.9, 129.7, 128.5, 127.0, 122.6, 122.4, 
117.5, 66.3, 65.4, 52.5, 45.4, 25.8, 18.1, 13.4, -5.4, -5.5; IR (thin film): ν 2954, 2929, 2037, 
1740, 1644 cm-1; MS m/z (%) 441 (23), 411 (63), 384 (66), 296 (100); EI-HRMS calcd for 
C25H35NO4Si m/z [M]+ 441.2335; found 441.2333. 
N
Cbz
MeO2C
111f  
5-Ethylidene-2-methyl-4-vinyl-5,6-dihydro-2H-pyridine-1,2-dicarboxylic acid 1-benzyl 
ester 2-methyl ester (111f). Prepared by following general procedure G, using: 73f (0.515 g, 
1.51 mmol), [Rh(CO)2Cl]2 (24 mg, 62 µmol). Yield 111f (420 mg, 81%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.37-7.33 (m, 5H), 6.40 (dd, J = 17.2, 10.8 Hz  1H), 
5.76 (q, J = 7.0 Hz, 1H),  5.50 (bs, 1H), 5.40 (dd, J = 17.2, 1.3 Hz 1H), 5.19 (dd, J = 10.8, 1.3 
Hz, 1H), 5.15 (d, J = 12.4 Hz, 1H), 5.10 (d, J = 12.4 Hz, 1H), 4.58 (d, J = 14.6 Hz, 1H), 3.79 (d, 
J = 14.6 Hz, 1H), 3.49 (s, 3H), 1.76 (d, J = 7.0 Hz, 3H), 1.55 (s, 3H); 13C NMR (75 MHz, 
DMSO-d6, 323K): δ 171.5, 154.1, 136.1, 135.3, 133.6, 128.9, 128.0, 127.5, 127.2, 123.9, 122.2, 
117.0, 66.4, 61.6, 51.8, 12.7; IR (thin film): ν 2949, 1743, 1704, 1404, 1243, 1110 cm-1; MS m/z 
(%) 341 (26), 282 (26), 238 (15), 91 (100); EI-HRMS calcd for C20H23NO4 [M]+ m/z 341.1621, 
found 341.1627. 
N
Cbz
MeO2C
111g  
2-Methyl-5-methylene-4-vinyl-5,6-dihydro-2H-pyridine-1,2-dicarboxylic acid 1-benzyl ester 
2-methyl ester (111g). Prepared by following general procedure G, using: 73g (37 mg, 110 
µmol), [Rh(CO)2Cl]2 (2 mg, 5 µmol). Yield 111g (31 mg, 84%). 
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1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.35 (m, 5H), 6.43 (dd, J = 17.3, 11.0 Hz, 1H), 5.68 
(s, 1H), 5.48 (d, J = 17.3 Hz, 1H), 5.26-5.24 (m, 2H), 5.11 (s, 2H), 4.39 (d, J = 14.2 Hz, 1H),  
3.88 (d, J = 14.2 Hz, 1H), 3.49 (bs, 3H), 1.55 (s, 3H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 
171.3, 154.0, 136.1, 135.8, 134.2, 132.9, 128.1, 127.6, 127.4, 126.5, 117.3, 112.6, 66.5, 62.0, 
52.0, 45.6, 21.5; IR (thin film): ν 2950, 1743, 1704, 1247 cm-1; MS m/z (%) 327 (12), 268 (85), 
224 (59), 91 (100); EI-HRMS calcd for C19H21NO4 m/z [M]+ 327.1471; found 327.1473. 
N
Cbz
MeO2C
111h
TMS
 
2-Methyl-5-trimethylsilylmethylene-4-vinyl-5,6-dihydro-2H-pyridine-1,2-dicarboxylic acid 
1-benzyl ester 2-methyl ester (111h). Prepared by following general procedure G, using: 73h 
(30 mg, 75 µmol), [Rh(CO)2Cl]2 (1.5 mg, 4 µmol). Yield 111h (26 mg, 87%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.39-7.30 (m, 5H), 6.43 (dd, J = 17.2, 10.8 Hz,  1H), 
5.76 (s, 1H),  5.66 (s, 1H), 5.41 (d, J = 17.2 Hz, 1H), 5.21 (dd, J = 10.8, 0.7 Hz, 1H), 5.13 (1d, J 
= 13.4 Hz, 1H), 5.07 (d, J = 13.4 Hz, 1H), 4.54 (d, J = 14.4 Hz, 1H), 3.94 (d, J = 14.4 Hz, 1H), 
3.52 (s, 3H), 1.57 (s, 3H), 0.13 (s, 9H); 13C NMR (75 MHz, DMSO-d6, 323K): δ 171.2, 153.9, 
143.4, 136.1, 135.9, 123.3, 128.0, 127.6, 127.5, 126.9, 126.8, 126.1 117.3, 66.6, 61.7, 51.9, 44.1, 
21.2, -0.5; IR (thin film): ν 2953, 1745, 1706, 1405, 1248, 1113 cm-1; MS m/z (%) 399 (25), 340 
(34), 296 (15), 91 (100); EI-HRMS calcd for C22H29NO4Si [M]+ m/z 399.1866, found 399.1843. 
N
Cbz
MeO2C
111i
Ph
 
5-Benzylidene-2-methyl-4-vinyl-5,6-dihydro-2H-pyridine-1,2-dicarboxylic acid 1-benzyl 
ester 2-methyl ester (111i). Prepared by following general procedure G, using: 73i (25 mg, 62 
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µmol), [Rh(CO)2Cl]2 (1 mg, 3 µmol). Yield 111i (25 mg, 95%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.46-7.21 (m, 10H), 6.76 (s, 1H), 6.57 (dd, J = 17.1, 
10.7 Hz, 1H), 5.72 (s, 1H), 5.52 (d, J = 17.2 Hz, 1H), 5.29 (d, J = 10.8 Hz, 1H), 5.07 (d, J = 12.6 
Hz, 1H), 5.01 (d, J = 12.7 Hz, 1H), 4.87 (d, J = 14.7 Hz, 1H), 4.09 (d, J = 14.7 Hz, 1H), 3.52 (s, 
3H), 1.60 (s, 3H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 171.4, 153.9, 135.9, 135.9, 135.7, 
133.7, 130.0, 128.8, 128.1, 127.6, 127.2, 127.1, 126.9, 126.0, 117.8, 66.4, 61.8, 52.1, 21.3; IR 
(thin film): ν 2949, 1742, 1704, 1408, 1248 cm-1; MS m/z (%) 403 (37), 344 (45), 300 (17), 91 
(35), 84 (100); EI-HRMS calcd for C25H25NO4 m/z [M]+ 403.1784, found 403.1789. 
 
N
Cbz
MeO2C
111j  
5-Ethylidene-2-methyl-4-(2-methylpropenyl)-5,6-dihydro-2H-pyridine-1,2-dicarboxylic 
acid 1-benzylester 2-methyl ester (111j). Prepared by following general procedure G, using: 
73j (40 mg, 110 µmol), [Rh(CO)2Cl]2 (2 mg, 5 µmol). Yield 111j (40 mg, 95%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.35 (s, 5H), 5.64 (s, 1H), 5.58 (q, J = 6.9 Hz, 1H), 
5.12 (s, 3H), 4.65 (d, J = 14.9 Hz, 1H), 3.71 (d, J = 14.7 Hz, 1H), 3.47 (bs, 3H), 1.77 (s, 3H), 
1.72 (d, J = 6.8 Hz, 3H), 1.58 (s, 3H), 1.52 (s, 3H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 
171.9, 154.2, 137.2, 136.2, 134.2, 130.2, 128.1, 128.1, 127.7, 127.4, 125.5, 122.0, 121.1, 66.5, 
61.5, 51.8, 25.3, 18.5, 12.8; IR (thin film): ν 2930, 1742, 1687, 1424, 1253 cm-1; MS m/z (%) 
369 (10), 310 (50), 266 (36), 91 (100); EI-HRMS calcd for C22H27NO4 m/z [M]+ 369.1940; 
found 369.1952. 
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N
Cbz
MeO2C
111k  
5-Ethylidene-2-methyl-4-(2-methylpropenyl)-3-pentyl-5,6-dihydro-2H-pyridine-1,2-
dicarboxylic acid-1-benzyl ester 2-methyl ester (111k). Prepared by following general 
procedure G, using: 73k (33 mg, 77 µmol), [Rh(CO)2Cl]2 (2 mg, 5 µmol). Yield 111k (29 mg, 
78%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.45-7.38 (m, 5H), 5.61 (s, 1H), 5.52 (q, J = 7.0 Hz, 
1H), 5.20-5.11 (m, 2H), 4.73 (d, J = 14.7 Hz, 1H), 3.66 (d, J = 14.7 Hz, 1H), 2.00-1.93 (m, 1H), 
1.83 (s, 3H), 1.74 (d, J = 7.0 Hz, 1H), 1.57 (s, 3H), 1.48 (s, 3H), 1.34-1.23 (m, 4H), 0.86 (t, J = 
6.5 Hz, 3H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 172.2, 154.6, 137.0, 136.1, 134.0, 133.2, 
131.4, 128.9, 128.4, 128.1, 121.2, 120.7, 67.2, 65.4, 52.2, 31.4, 29.0, 25.0, 23.1, 19.1, 13.9, 13.5; 
IR (thin film): ν 1745, 1703, 1408, 1245 cm-1; MS m/z (%) 425 (20), 366 (6), 135 (95), 133 
(100); EI-HRMS calcd for C26H35NO4 m/z [M]+ 425.2566; found 425.2549. 
N
C5H11
Bn
MeO2C
Boc
111l  
2-Benzyl-5-ethylidene-4-hept-1-enyl-3-methyl-5,6-dihydro-2H-pyridine-1,2-dicarboxylic 
acid 1-tert-butyl ester 2-methyl ester (111l). Prepared by following general procedure G, using: 
73l (45 mg, 96 µmol), [Rh(CO)2Cl]2 (3 mg, 8 µmol). Yield 111l (36 mg, 80%).  
1H NMR (300 MHz, DMSO-d6, 325 K): δ 7.21-7.15 (m, 3H), 7.02-6.93 (m, 2H), 5.82 (d, J = 
16.0 Hz, 1H), 5.44 (dt, J = 16.0, 6.8 Hz, 1H), 5.20 (q, J = 7.1 Hz, 1H), 3.96 (d, J = 14.5 Hz, 1H), 
3.70-3.56 (m, 4H), 3.63 (s, 3H), 3.59 (d, J = 13.7 Hz, 1H), 3.24 (d, J = 13.8 Hz, 1H), 2.90 (d, J = 
14.6 Hz, 1H),  2.11 (q, J = 6.8 Hz, 1H), 1.80 (s, 3H), 1.46 (s, 9H), 1.41 (d, J = 7.0 Hz, 3H), 1.36-
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1.25 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, DMSO-d6, 325 K): δ 171.7, 153.2, 
136.0, 135.9, 134.2, 130.2, 129.8, 127.2, 126.1, 125.3, 123.9, 120.0, 79.9, 67.7, 51.6, 31.9, 30.4, 
27.9, 27.7, 21.5, 15.6, 13.4, 12.4; IR (thin film): ν 2926, 1744, 1696, 1240 cm-1; MS m/z (%) 458 
(6), 394 (42), 376 (30), 276 (78), 91 (50), 57 (100); EI-HRMS calcd for C22H34NO4 m/z [M-91]+ 
376.2488; found 376.2479. 
 
Compounds 120-125 were prepared as part of a preliminary study which was later discontinued; 
These compounds were characterized only by their 1H NMR spectrum: 
The TBS protected diol 118 was prepared according to a previously reported procedure 
(Lafontaine, J. A.; Provencal, D. P.; Gardelli, C.; Leahy, J. W. J. Org. Chem. 2003, 68, 4215). 
Alcohols 116a and 116b were prepared according to a previously reported procedure 
(Aurrecoechea, J. M.; Perez, E.; Solay, M. J. Org. Chem. 2001, 66, 564). 
ON
Ph
OBn
55a  
4-Benzyl-2-phenyloxazol-5(4H)-one (55a). N-Bz-phenylalanine 119 (489 mg, 1.82 mmol) was 
dissolved in CH2Cl2 (10 mL) at rt and DCC (374 mg, 1.82 mmol) was added followed by DMAP 
(11 mg, 0.09 mmol). Dicyclohexylurea byproduct formed immediately as a white precipitate. 
After 10 min, the reaction mixture was filtered over a short pad of silica gel using a fritted funnel 
and eluted with hexanes-EtOAc (3 : 1). The filtrate was concentrated under vacuum to afford 55a 
(365 mg, 80%) as a white solid. This compound was used in the next step without additional 
purification.   
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Bz
N
H
Bn
O
O
OBn
120a  
1-(Benzyloxy)but-3-yn-2-yl 2-(benzamido)-3-phenylpropanoate (120a). Oxazolone 55a (365 
mg, 1.45 mmol) was dissolved in CH2Cl2 and alcohol 116a (329 mg, 1.89 mmol) was added, 
followed by Et3N (100 µL, 0.72 mmol). The solution was concentrated under vacuum, resulting 
in a viscous oil. After 1h the reaction mixture was re-dissolved in benzene (1 mL) and purified 
by flash chromatography (gradient elution, hexanes-EtOAc, 1 : 0 to 4 : 1, v/v) to afford 120a 
(335 mg, 54%) as a mixture of diastereomers in 1 : 1 ratio.  
1H NMR (300 MHz, CDCl3): δ 7.72 (d, J = 7.3 Hz, 2H), 7.54-7.17 (m, 13H), 6.54 (t, J = 6.0 Hz, 
1H),  5.68-5.61 (m, 1H), 5.22-5.14 (m, 1H), 4.67-4.59 (m, 2H), 3.84-3.70 (m, 2H), 3.39-3.23 (m, 
2H), 2.60 (d, J = 2.2 Hz, 0.5H), 2.52 (d, J = 2.1 Hz, 0.5H); IR (thin film): ν 3288, 3030, 2931, 
2124, 1749, 1648 cm-1. 
Bz
N
H
Bn
O
O
OTBS
120b  
1-(tert-Butyldimethylsilyloxy)but-3-yn-2-yl 2-(benzamido)-3-phenylpropanoate (120b). 
Oxazolone 55a (1.50 g, 5.97 mmol) was dissolved in CH2Cl2 (3 mL) and alcohol 116b (1.10 g, 
6.57 mmol) was added, followed by Et3N (83 µL, 0.60 mmol). The solution was concentrated 
under vacuum, resulting in a viscous oil. After 30 min the reaction mixture was re-dissolved in 
benzene (~1 mL) and purified by flash chromatography (gradient elution, hexanes-EtOAc, 20 : 1 
to 10 : 1, v/v) to afford 120b (790 mg, 32%) as a mixture of diastereomers in 1 : 1 ratio. 
1H NMR (300 MHz, CDCl3): δ 7.85 (d, J = 7.0 Hz, 2H), 7.65-7.54 (m, 3H), 7.42-7.32 (m, 5H), 
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6.72 (d, J = 7.6 Hz, 0.5H), 6.68 (d, J = 7.6 Hz, 0.5H), 5.63 (td, J = 5.9, 2.0 Hz, 0.5H), 5.56-5.53 
(m, 0.5H), 5.36-5.25 (m, 1H), 4.04-4.00 (m, 2H), 3.53-3.36 (m, 2H), 2.70 (d, J = 2.0 Hz, 0.5H), 
2.63 (d, J = 2.1 Hz, 0.5H), 1.06 (s, 4.5H), 1.03 (s, 4.5H), 0.27 (s, 1.5H), 0.26 (s, 1.5H), 0.23 (s, 
3H). 
MeO2C
•
H
Bn
NHBz
121a
OBn
 
Methyl 2-(benzamido)-2-benzyl-6-(benzyloxy)hexa-3,4-dienoate (121a). Propargylic ester 
120a (100 mg, 0.234 mmol) was dissolved in MeCN (5 mL) at rt. Then, Et3N (137 µL, 0.983 
mmol), CCl4 (81 µL, 0.84 mmol) and PPh3 (190 mg, 0.725 mmol) were added in consecutive 
order. The reaction mixture was stirred at 40 °C for 1.5 h when MeOH (1 mL) was added and the 
solution was concentrated under vacuum. The crude brown residue was dissolved in MeOH (5 
mL) and Et3N (100 µL) was added and the reaction was stirred for 12 h at rt. The reaction 
mixture was again concentrated under vacuum, and the crude residue was purified by flash 
chromatography (hexanes-EtOAc, 4 : 1, v/v) to afford 121a (102 mg, >95%) as a mixture of 
diastereomers in ~2 : 1 ratio (determined by integration of the allene proton resonances in the 1H 
NMR spectrum). 
1H NMR (300 MHz, CDCl3): δ 7.78 (d, J = 8.07 Hz, 2H), 7.60-7.19 (m, 13H), 6.96 (bs, 0.67H), 
6.92 (bs, 0.33H), 5.88-5.84 (m, 0.67H), 5.79-5.75 (m, 0.33H), 5.73-5.66 (m, 0.33H), 5.62-5.56 
(m, 0.67H), 4.56 (s, 1.34H), 4.46 (1/2 ABq, J = 11.2 Hz, 0.33H), 4.41 (1/2 ABq, J = 11.2 Hz, 
0.33H), 4.20-4.14 (m, 1.34H), 4.06-4.02 (m, 0.66H), 3.91 (s, 1H), 3.90 (s, 2H), 3.84-3.62 (m, 
2H). 
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MeO2C
•
H
Bn
NHBz
121b
OTBS
 
Methyl 2-(benzamido)-2-benzyl-6-(tert-butyldimethylsilyloxy)hexa-3,4-dienoate (121b). 
Propargylic ester 120b (180 mg, 0.429 mmol) was dissolved in MeCN (5 mL) at rt. Then, Et3N 
(251 µL, 1.80 mmol), CCl4 (149 µL, 1.54 mmol) and  PPh3 (348 mg, 1.33 mmol) were added in 
consecutive order. The reaction mixture was stirred at 60 °C for 1.5 h when MeOH (1 mL) was 
added and the solution was concentrated under vacuum. The crude brown residue was dissolved 
in MeOH (5 mL) and Et3N (100 µL) was added and the reaction was stirred for 12 h at rt. The 
reaction mixture was again concentrated under vacuum, and the crude residue was purified by 
flash chromatography (gradient elution, hexanes-EtOAc, 1 : 0 to 4 : 1, v/v) to afford 121b (140 
mg, 76%) as a mixture of diastereomers in ~2 : 1 ratio (determined by integration of the allene 
proton resonances in the 1H NMR spectrum). 
1H NMR (300 MHz, CDCl3): δ 7.85-7.81 (m, 2H), 7.66-7.52 (m, 3H), 7.41-7.34 (m, 3H), 7.26-
7.24 (m, 2H), 6.92 (bs, 0.67H), 6.91 (bs, 0.33H), 5.85 (dt, J = 6.2, 2.6 Hz, 0.67H), 5.77 (dt, J = 
6.2, 2.6 Hz, 0.33H), 5.62 (dt, J1 = J2 = 6.2 Hz, 0.33H), 5.56 (dt, J1 = J2 = 6.2 Hz, 0.67H), 4.31 
(dd, J = 6.0, 2.7 Hz, 1.34H), 4.29-4.17 (m, 0.33H), 4.11-4.07 (m, 0.33H), 3.96 (s, 3H), 3.87 (1/2 
ABq, J = 13.5 Hz, 0.67H), 3.84 (1/2 ABq, J = 13.5 Hz, 0.33H), 3.76 (1/2 ABq, J = 13.5 Hz, 
0.33H), 3.72 (1/2 ABq, J = 13.5 Hz, 0.67H), 1.00 (s, 9H), 0.17 (s, 2H), 0.16 (s, 2H), 0.15 (s, 1H), 
0.13 (s, 1H). 
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• H
BzN
Bn
MeO2C
OBn
122a  
Methyl-2-(N-(but-2-ynyl)benzamido)-2-benzyl-6-(benzyloxy)hexa-3,4-dienoate (122a). 
Prepared by following general procedure F with: 121a (60 mg, 0.14 mmol), 1-bromo-2-butyne 
(30 µL, 0.34 mmol) and NaH (14 mg from a 60% dispersion in mineral oil, 0.34 mmol). Yield of 
122a (54 mg, 81%) obtained as a mixture of diastereomers in ~2 : 1 ratio determined by 
integration of the benzyloxy methylene resonances  (4.73 and 4.70 ppm) in the 1H NMR 
spectrum. 
1H NMR (300 MHz, CDCl3): δ 7.81-7.78 (m, 2H), 7.62-7.39 (m, 13H), 6.21-6.17 (m, 1H), 5.79 
(dt, J1 = J2 = 6.6 Hz, 0.33H), 5.74 (dt, J1 = J2 = 6.6 Hz, 0.67H), 4.73 (s, 1.34H), 4.70 (s, 0.66H), 
4.30 (dd, J = 6.5, 2.2 Hz, 1.34H), 4.25 (dd, J = 6.4, 2.1 Hz, 0.66H), 4.12 (1/2 ABq, J = 13.5 Hz, 
0.67H), 4.11 (1/2 ABq, J = 13.5 Hz, 0.33H), 3.87 (s, 3H), 3.80-3.92 (m, 1.34H), 3.76-71 (m, 
0.66H), 3.56 (1/2 ABq, J = 13.5 Hz, 0.33H), 3.54 (1/2 ABq, J = 13.5 Hz, 0.67H), 1.82-1.80 (m, 
3H); IR (thin film): ν 3029, 2854, 1969, 2228, 1743, 1641 cm-1. 
• H
BzN
Bn
MeO2C
OTBS
122b  
Methyl-2-(N-(but-2-ynyl)benzamido)-2-benzyl-6-(tert-butyldimethylsilyloxy)hexa-3,4-
dienoate (122b). Prepared by following general procedure F with: 121b (380 mg, 0.88 mmol), 1-
bromo-2-butyne (231 µL, 2.65 mmol) and NaH (123 mg from a 60% dispersion in mineral oil, 
3.08 mmol). Yield of 122b (300 mg, 66%) obtained as a mixture of diastereomers in ~2 : 1 ratio 
determined by integration of the allylic methylene resonances  (4.29 and 4.25-4.22 ppm) in the 
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1H NMR spectrum. 
1H NMR (300 MHz, CDCl3): δ 7.67-7.65 (m, 2H), 7.45-7.41 (m, 3H), 7.33-7.25 (m, 5H), 6.04-
6.00 (m, 1H), 5.63-5.52 (m, 1H), 4.29 (dd, J = 6.1, 2.6 Hz, 1.34H), 4.25-4.22 (m, 0.66H), 4.00 
(1/2 ABq, J = 13.6 Hz, 0.67H), 3.94 (1/2 ABq, 13.5 Hz, 0.33H), 3.74 (s, 3H), 3.83-3.73 (m, 1H), 
3.64-3.58 (m, 1H), 3.43 (1/2 ABq, J = 13.3 Hz, 0.33H), 3.39 (1/2 ABq, J = 13.6 Hz, 0.67H), 1.67 
(s, 3H), 0.93 (s, 6H), 0.90 (s, 3H), 0.12 (s, 4H), 0.09 (s, 2H). 
• H
BzN
Bn
MeO2C
OH
122c  
Methyl-2-(N-(but-2-ynyl)benzamido)-2-benzyl-6-hydroxyhexa-3,4-dienoate (122c). To a 
solution of 122b (80 mg, 0.15 mmol, crude residue prior to purification by chromatogprahy) in 
THF (2 mL) was added TBAF (240 µL of a 1.0 M solution in THF, 0.24 mmol). After 1 h, the 
solution was diluted with EtOAc (50 mL) and washed with brine (2 x 20 mL). The organic layer 
was separated, dried over MgSO4 and concentrated under vacuum. The crude residue was 
purified by flash chromatography (gradient elution, hexanes-EtOAc, 4 : 1 to 1 : 1, v/v) to afford 
alcohol 122c (41 mg, 62% for the two steps from 121b) as a ~2 : 1 mixture of diastereomers 
determined by integration of the allenic resonances in the 1H NMR spectrum. 
1H NMR (300 MHz, CDCl3): δ 7.81-7.80 (m, 2H), 7.61-7.56 (m, 3H), 7.47-7.40 (m, 5H), 6.26 
(dt, J = 6.2, 3.1 Hz, 0.33H), 6.12 (dt, J = 6.2, 3.1 Hz, 0.67H), 5.85 (dt, J1 = J2 = 5.7 Hz, 0.33H), 
5.74 (dt, J1 = J2 = 5.7 Hz, 0.67H), 4.34-4.29 (m, 2H), 4.13 (1/2 ABq, J = 13.8 Hz, 0.33H), 4.07-
3.97 (m, 2.67H), 3.90 (s, 1H), 3.83 (s, 2H), 3.63 (1/2 ABq, J = 13.1 Hz, 0.67H), 3.51 (1/2 ABq, J 
= 13.6 Hz, 0.33H), 1.85 (s, 2H), 1.80 (s, 1H). 
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NOBn
MeO2C
Bn
Bz
123a  
1-Benzoyl-2-benzyl-4-(2-benzyloxyvinyl)-5-ethylidene-1,2,5,6-tetrahydro-pyridine-2-
carboxylic acid methyl ester (123a). To a solution of allenyne 122a (22 mg, 0.045 mmol) in 
toluene-d8 (1 mL) was added [Rh(CO)2Cl]2 (1 mg, 2 µmol) at rt. After 1 h, the reaction solution 
was directly applied to a short silica gel column and eluted (hexanes-EtOAc, 4 : 1, v/v) to afford 
123a (14 mg, 64%). Triene 123a was obtained as a mixture of E and Z isomers of the enol-ether 
olefin in 8 : 1 ratio (determined by integration of the olefin resonances in the 1H NMR spectrum). 
123a-(E): 1H NMR (300 MHz, CDCl3): δ 7.43-7.38 (m, 10H), 7.26-7.20 (m, 5H), 6.70 (d, J = 
12.5 Hz, 1H), 5.55 (q, J = 6.9 Hz, 1H), 5.53 (s, 1H), 5.45 (d, J = 12.5 Hz, 1H), 4.86 (s, 2H), 4.09-
4.05 (m, 2H), 3.75 (s, 3H), 3.35 (d, J = 13.6 Hz, 1H), 2.40 (d, J = 14.4 Hz, 1H), 1.36 (d, J = 6.9 
Hz, 3H). 
N
OTBS
MeO2C
Bn
Bz
123b  
1-Benzoyl-2-benzyl-4-[2-(tert-butyldimethylsilanyloxy)vinyl]-5-ethylidene-1,2,5,6-
tetrahydropyridine-2-carboxylic acid methyl ester (123b). To a solution of allenyne 122b (45 
mg, 0.087 mmol) in toluene (1 mL) was added [Rh(CO)2Cl]2 (2 mg, 4 µmol) at rt. After 40 min, 
the reaction solution was directly applied to a short silica gel column and eluted (hexanes-
EtOAc) to afford 123b (27 mg, 60%). Triene 123b was obtained as a mixture of E and Z isomers 
of the enol-ether olefin in >10 : 1 ratio (determined by integration of the olefin resonances in the 
1H NMR spectrum). 
123b-(E): 1H NMR (300 MHz, CDCl3): δ 7.43-7.35 (m, 5H), 7.30-7.20 (m, 5H), 6.60 (d, J = 
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11.9 Hz, 1H), 5.58 (q, J = 6.8 Hz, 1H), 5.54 (d, J = 12.7 Hz, 1H), 5.51 (s, 1H), 4.07 (d, J = 13.8 
Hz, 2H), 3.75 (s, 3H), 3.35 (d, J = 13.5 Hz, 1H), 2.41 (d, J = 14.3 Hz, 1H), 1.36 (d, J = 7.0 Hz, 
3H), 0.96 (s, 9H), 0.21 (s, 3H), 0.20 (s, 3H). 
N
O
MeO2C
Bn
Bz
124 and 125  
Aldehydes 124 and 125 : To a solution of allenyne 122c (20 mg, 0.050 mmol) in DCE (1 mL) 
was added [Rh(CO)2Cl]2 (1 mg, 2 µmol) at rt. After 90 min, the reaction solution was directly 
applied to a short silica gel column and eluted (hexanes-EtOAc, 3 : 1, v/v) to afford a mixture of 
aldehydes 124 and 125 (10 mg, 50% by mass recovery). 
CbzN
N
N
H
Me
H
MeO2C
O
OPh
O
O
Ph
144  
Diels-Alder cycloadduct 144. To a solution of triene 111f (0.018 g, 0.053 mmol), in toluene (1 
mL), was added N-phenylmaleimide (31 mg, 0.23 mmol). The reaction was heated to reflux for 2 
h. The solution was then cooled to rt, and directly applied to a silica gel column and purified by 
flash chromatography (hexanes-EtOAc, 1 : 4, v/v then EtOAc) to afford 144 as a mixture of 
diastereomers (30 mg, 83%). Further purification of the major diastereomer was performed using 
HPLC (hexanes-EtOAc, 3 : 2, v/v, flow rate 3 mL/min, RI detector).  
144 (major diastereomer, Rt = 26.1 min): 1H NMR (500 MHz, CDCl3): δ 7.38-7.13 (m, 5 H), 
7.31-7.22 (m, 5H), 7.20-7.16 (m, 3H), 7.04 (d, J = 7.2 Hz, 2H), 5.11 (d, J = 12.7 Hz, 1H), 5.01 
(d, J = 12.7 Hz, 1H), 4.46 (d, J = 18.9 Hz, 1H), 3.54-2.51 (m, 2H), 3.42-3.39 (m, 1H), 3.36 (s, 
3H), 3.29 (bs, 1H), 3.15 (dd, J = 8.8, 6.7 Hz, 1H), 3.03 (dd, J = 8.8, 5.6 Hz, 1H), 2.65 (dd, J = 
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13.9, 5.3 Hz, 1H), 2.51-2.47 (m, 1H), 2.45 (bs, 1H), 2.25 (bs, 1H), 2.06 (s, 3H), 1.42 (d, J = 7.5 
Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 178.2, 176.2, 175.4, 175.2, 174.3, 156.2, 136.8, 133.4, 
131.8, 131.6, 129.1, 128.7, 128.6, 128.3, 127.6, 127.4, 126.7, 126.2, 67.0, 63.7, 53.0, 45.7, 44.3, 
43.3, 40.8, 40.4, 39.9, 33.5, 32.7, 24.5, 23.2, 12.7; IR (thin film): ν 2945, 1708, 1499, 1383 cm-1; 
EI-HRMS calcd for C40H38N3O8 m/z [M+1]+ 688.2659; found 688.2637. 
152
NH2MeO2C
Bn
•
H
H
 
Methyl-2-amino-2-benzylhexa-3,4-dienoate (152). To a solution of Boc-protected amine 65f 
(0.80 g, 2.4 mmol) in CH2Cl2 (3 mL), was added TFA (3 mL) and the light brown solution was 
stirred at rt for 10 min. The volatiles were removed under vacuum (rotary evaporator was used 
with a dry ice-cooled trap to collect the TFA) to afford a brown oil which was dissolved in 
CH2Cl2 (100 mL) and washed with sat’d aq. NaHCO3 (3 x 50 mL). The organic layer was dried 
over MgSO4 and concentrated under vacuum to afford 152 (0.53 g, 95%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 7.32–7.16 (m, 5H), 5.47 (dq, J = 6.3, 3.1 Hz, 1H), 5.35 (dq, J = 
6.5, 6.5 Hz, 1H), 3.75 (s, 3H), 3.27 (d, J = 13.2 Hz, 1H), 2.91 (d, J = 13.2 Hz, 1H), 1.70 (dd, J = 
7.1, 3.2 Hz); 13C NMR (75 MHz, CDCl3): δ 202.5, 175.1, 135.8, 129.9, 128.0, 126.8, 96.3, 90.6, 
61.0, 52.1, 45.6, 14.0; IR (thin film): ν 3380, 3304, 2950, 1962, 1737, 1197 cm-1; MS m/z (%) 
231 (7), 216 (25), 199 (19), 178 (27), 172 (35), 140 (100), 91 (76), 80 (57); EI-HRMS calcd for 
m/z C14H17NO2 [M]+ 231.1259 found 231.1251. 
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145a  
Methyl 2-benzyl-2-(but-2-ynamido)hexa-3,4-dienoate (145a). To a solution of 2-butynoic acid 
(0.34 g, 4.08 mmol) in THF (25 mL), was added N-methylmorpholine (1.12 mL, 10.2 mmol) at 
rt. The solution was then cooled to -10 °C with a NaCl/ice bath and isobutyl chloroformate (0.53 
mL, 4.08 mmol) was added. After 30 min at -10 °C, amine 152 (0.78 g, 3.40 mmol) in THF (15 
mL) was added and the reaction was allowed to warm to rt and stirred for 3 h. The reaction was 
quenched with sat’d aqueous NaHCO3 and the aqueous layer was extracted twice with EtOAc. 
The combined organic layers were washed with brine, dried over MgSO4 and concentrated under 
vacuum. Purification of the residue by column chromatography (hexanes-EtOAc, 9 : 1, v/v) 
afforded 145a (0.86 g, 85%). 
1H NMR (300 MHz, CDCl3): δ 7.37-7.30 (m, 3H), 7.19-7.16 (m, 2H), 6.42 (s, 1H), 5.51 (sex, J = 
3.1 Hz, 1H), 5.41 (quin, J = 7.0 Hz, 1H), 3.86 (s, 3H), 3.68 (d, J = 13.6 Hz, 1H), 3.48 (d, J = 13.6 
Hz, 1H), 1.99 (s, 3H), 1.77 (dd, J = 7.1, 3.1 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 203.1, 
171.7, 152.2, 135.6, 130.1, 128.1, 126.9, 92.4, 91.6, 82.9, 74.9, 63.6, 52.8, 39.7, 13.8, 3.6; IR 
(thin film): ν 3400, 3292, 2244, 1968, 1740, 1656, 1495 cm-1; EI-HRMS calcd for C16H16NO m/z 
[M-59]+ 238.1232; found 238.1230. 
HN
MeO2C Bn • H
O
145b  
Methyl 2-benzyl-2-(propiolamido)hexa-3,4-dienoate (145b). To a solution of amine 152 
(0.168 g, 0.727 mmol) in CH2Cl2 (4 mL) was added propiolic acid (0.049 mL, 0.800 mmol) 
followed by DCC (0.165 g, 0.800 mmol). Formation of a white precipitate was observed. After 
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15 min the solvent was removed under vacuum and the remaining residue was dissolved in 
EtOAc and filtered through a plug of silica gel on a fritted funnel eluting with EtOAc/hexanes (1 
: 1). Concentration of the solution under vacuum afforded an orange oil that was purified by 
flash chromatography (hexanes-EtOAc, 6 : 1, v/v) to afford 145b (0.170 g, 82%). 
1H NMR (300 MHz, CDCl3): δ 7.38-7.28 (m, 3H), 7.21-7.13 (m, 2H), 6.61 (s, 1H), 5.51 (dq, J = 
6.3, 3.2 Hz, 1H), 5.45 (quin, J = 6.5 Hz, 1H), 3.87 (s, 3H), 3.69 (d, J = 13.7 Hz, 1H), 3.47 (d, J = 
13.7 Hz, 1H), 2.84 (s, 1H), 1.77 (dd, J = 7.0, 3.2 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 203.2, 
171.4, 150.8, 135.3, 129.9, 128.2, 127.0, 92.1, 91.8, 77.2, 72.8, 63.9, 52.9, 39.6, 13.7; IR (thin 
film): ν 3392, 3271, 2950, 2110, 1968, 1740, 1662 cm-1; EI-HRMS calcd for C17H17NO3 m/z 
[M]+ 283.1208; found 283.1198. 
HN
MeO2C Bn • H
O
TMS
145c  
Methyl 2-(3-(trimethylsilyl)propiolamido)-2-benzylhexa-3,4-dienoate (145c). To a solution of 
3-(trimethylsilyl)propiolic acid (74 mg, 520 µmol) in THF (6 mL), was added N-
methylmorpholine (0.21 mL, 1.9 mmol) at rt. The solution was then cooled to -10 °C and 
isobutyl chloroformate (68 µL, 520 µmol) was added. After 30 min at -10 °C amine 152 (110 
mg, 480 µmol) in THF (4 mL) was added and the reaction was allowed to warm to rt, then stirred 
for additional 3 h. The reaction was quenched with sat’d aq. NaHCO3 (50 mL) and the aqueous 
layer was extracted with EtOAc. The combined organic layers were washed with brine, dried 
over MgSO4 and concentrated under vacuum. Purification of the residue by column 
chromatography (hexanes-EtOAc, 19 : 1, v/v) afforded 145c (121 mg, 72%). 
1H NMR (300 MHz, CDCl3): δ 7.45-7.35 (m, 3H), 7.26-7.19 (m, 2H), 6.61 (s, 1H), 5.59 (dq, J = 
6.3, 3.2 Hz, 1H), 5.55–5.45 (m, 1H), 3.93 (s, 3H), 3.79 (d, J = 13.7 Hz, 1H), 3.52 (d, J = 13.6 Hz, 
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1H), 1.84 (dd, J = 7.1, 3.2 Hz, 3H), 0.36 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 203.3, 171.6, 
151.6, 135.5, 130.0, 128.1, 126.9, 97.6, 92.3, 91.6, 90.9, 64.1, 52.9, 39.7, 13.7, -0.8; IR (thin 
film): ν 3397, 2955, 2165, 1968, 1741, 1662 cm-1; EI-HRMS calcd for C20H25NO3Si m/z [M]+ 
355.1604; found 355.1589. 
HN
MeO2C Bn • H
O
Ph
145d  
Methyl 2-(3-phenylpropiolamido)-2-benzylhexa-3,4-dienoate (145d). To a solution of amine 
152 (131 mg, 567 µmol) in CH2Cl2 (4 mL) was added 3-phenylpropiolic acid (83 mg, 568 µmol) 
and DCC (117 mg, 570 µmol). The reaction mixture was stirred for 30 min, and then filtered to 
remove the white solid. The solution was concentrated under vacuum and the resulting oil 
purified by flash chromatography to afford 145d (112 mg, 55%). 
1H NMR (300 MHz, CDCl3): δ 7.63-7.61 (m, 2H), 7.53-7.30 (m, 6H), 7.25-7.23 (m, 2H), 6.66 (s, 
1H), 5.60–5.55 (m, 1H), 5.52-5.44 (m, 1H), 3.90 (s, 3H), 3.78 (d, J = 13.7 Hz, 1H), 3.53 (d, J = 
13.7 Hz, 1H), 1.81 (dd, J = 7.1, 3.1 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 203.3, 171.7, 152.3, 
135.6, 132.6, 130.1, 130.0, 128.4, 128.2, 127.0, 120.1, 92.4, 91.7, 84.2, 83.1, 64.1, 53.0, 39.8, 
13.8; IR (thin film): ν 3393, 3292, 2950, 2214, 1968, 1741, 1654 cm-1; EI-HRMS calcd for 
C23H21NO3 m/z [M]+ 359.1521; found 359.1526. 
N
MeO2C Bn • H
O
Bz
145e  
2-[Benzoyl-(1-oxobut-2-ynyl)-amino]-2-benzylhexa-3,4-dienoic acid methyl ester (145e). To 
a solution of 145a (0.15 g, 0.49 mmol), in 1,2-dichloroethane (5 mL) were added Et3N (0.399 
mL, 2.44 mmol), DMAP (catalytic amount ~ 10 mg), and 4Å molecular sieves (0.5 g) at rt. 
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Benzoyl chloride (0.169 mL, 1.46 mmol) was added and the reaction mixture was heated to 70 
°C for 1 h. Upon completion of the reaction, as observed by TLC, the reaction solution was 
transferred to a separate flask via a pipette, and concentrated under vacuum. The crude residue 
was purified by flash chromatography (EtOAc /hexanes, 1 : 9, v/v) to afford 145e (0.19 g, 69%). 
1H NMR (300 MHz, CDCl3): δ 8.09-8.06 (m, 2H), 7.61-7.56 (m, 1H), 7.50-7.45 (m, 2H), 7.27-
7.23 (m, 5H), 5.54 (dq, J = 6.3, 3.1 Hz, 1H), 5.43–5.33 (m, 1H), 3.72 (d, J = 13.0 Hz, 1H), 3.70 
(s, 3H), 3.21 (d, J = 13.0 Hz, 1H), 1.68 (dd, J = 7.1, 3.2 Hz, 3H), 1.50 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 204.1, 172.8, 170.9, 152.5, 137.1, 135.1, 133.5, 130.8, 130.4, 128.6, 128.0, 
127.0, 93.7, 90.9, 90.9, 74.8, 69.0, 52.5, 41.4, 13.6, 3.6; IR (thin film): ν 2945, 2238, 1972, 1744, 
1706, 1653, 1234 cm-1; MS m/z (%) 401 (43), 310 (28), 244 (15), 105 (100), 67 (43); EI-HRMS 
calcd for C25H23NO4 m/z [M]+ 401.1627; found 401.1621. 
 
General procedure H for the Rh(I)-catalyzed Alder-ene reaction of 145a-d. 
HN
O
Bn
MeO2C
146a  
2-Benzyl-5-ethylidene-6-oxo-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid methyl 
ester (146a). Allenyne 145a (0.996 g, 3.35 mmol) was placed in a reaction vessel equipped with 
a magnetic stirring bar, a septum and an Ar balloon inlet, and toluene (130 mL, ~0.03 M) was 
added. The solution was degassed by bubbling argon via a needle for 5 min and then 
[Rh(CO)2Cl]2 (0.13 g, 0.33 mmol) was added. The reaction vessel was then immersed in an oil 
bath pre-heated to 90 °C. The progress of the reaction was followed by TLC and upon 
completion (30 min) it was cooled to rt. The solution was then directly applied to a silica gel 
column and eluted (hexanes-EtOAc, 3 : 1, v/v) to give cross-conjugated triene 146a (0.916 g, 
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92%).  
1H NMR (300 MHz, CDCl3): δ 7.30-7.22 (m, 3H), 7.11-7.08 (m, 2H), 6.30 (dd, J = 17.2, 10.7 
Hz, 1H), 6.15 (bs, 1H), 6.13 (q, J = 7.5 Hz, 1H), 6.00 (s, 1H), 5.49 (dd, J = 17.2, 1.5 Hz, 1H), 
5.25 (dd, J = 10.8, 1.4 Hz, 1H), 3.77 (s, 3H), 3.21 (d, J = 13.1 Hz, 1H), 2.97 (d, J = 13.1 Hz, 1H), 
2.16 (d, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 171.7, 164.9, 139.2, 138.7, 134.1, 133.9, 
130.8, 128.7, 127.8, 126.1, 119.7, 118.5, 64.8, 53.3, 47.9, 16.3; IR (thin film): ν 3206, 2952, 
2029, 1739, 1674, 1241 cm-1; MS m/z (%) 297 (25), 238 (40), 206 (100), 174 (77), 146 (71), 91 
(83); EI-HRMS calcd for C18H19NO3 m/z [M]+ 297.1365; found 297.1375. 
HN
O
Bn
MeO2C
146b  
Methyl 2-benzyl-1,2,5,6-tetrahydro-5-methylene-6-oxo-4-vinylpyridine-2-carboxylate 
(146b).  Prepared by following general procedure H, using: 145b (20 mg, 78 µmol), 
[Rh(CO)2Cl]2 (3.0 mg, 7.8 µmol).  Reaction time 2 h.  Yield 145b (10 mg, 45%). 
 1H NMR (300 MHz, CDCl3): δ 7.40-7.36 (m, 3H), 7.21-7.15 (m, 2H), 6.49 (ddd, J = 17.2, 10.9, 
1.0 Hz, 1H), 6.39 (s, 1H), 6.24 (s, 1H), 5.65 (d, J = 0.8 Hz, 1H), 5.64 (dd, J = 17.2, 1.5 Hz, 1H), 
5.39 (dd, J = 10.8, 1.4 Hz, 1H), 3.84 (s, 3H), 3.38 (d, J = 13.2 Hz, 1H), 3.07 (d, J = 13.2 Hz, 1H); 
13C NMR (75 MHz, CDCl3): δ 170.9, 163.0, 135.6, 133.3, 132.6, 132.1, 130.3, 128.6, 127.6, 
121.8, 121.3, 118.4, 64.6, 53.1, 47.6; IR (thin film): ν 3215, 2952, 1738, 1679, 1234 cm-1. 
HN
O
Bn
MeO2C
TMS
146c  
(5Z)-Methyl-2-benzyl-1,2,5,6-tetrahydro-5-((trimethylsilyl)methylene)-6-oxo-4-vinyl-
pyridine-2-carboxylate (146c).  Prepared by following general procedure H, using: 145c (40 
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mg, 0.11 mmol), [Rh(CO)2Cl]2 (4 mg, 11 µmol).  Reaction time 15 min.  Isolated yield 146c (30 
mg, 75%). 
1H NMR (300 MHz, CDCl3): δ 7.42-7.39 (m, 3H), 7.25-7.22 (m, 2H), 6.57 (dd, J = 17.1, 10.8 
Hz, 1H), 6.56 (bs, 1H), 6.32 (s, 1H), 6.26 (s, 1H), 5.65 (dd, J = 17.1, 1.1 Hz, 1H), 5.41 (dd, J = 
10.8, 1.2 Hz, 1H), 3.90 (s, 3H), 3.42 (d, J = 13.1 Hz, 1H), 3.16 (d, J = 13.1 Hz, 1H), 0.29 (s, 9H); 
13C NMR (75 MHz, CDCl3): δ 171.1, 163.5, 143.0, 138.1, 137.4, 133.6, 133.4, 130.4, 128.5, 
127.5, 121.3, 118.1, 64.6, 53.0, 47.3, 0.2; IR (thin film): ν 3205, 2951, 1736, 1673, 1243 cm-1; 
MS m/z (%) 355 (3), 340 (30), 296 (36), 264 (95), 249 (57), 73 (100); EI-HRMS calcd for 
C20H25NO3Si m/z [M]+ 355.1604; found 355.1593. 
HN
O
Bn
MeO2C
Ph
146d  
(5Z)-Methyl-2-benzyl-5-benzylidene-1,2,5,6-tetrahydro-6-oxo-4-vinylpyridine-2-
carboxylate (146d). Prepared by following general procedure H, using: 145d (30 mg, 84 µmol), 
[Rh(CO)2Cl]2 (3.0 mg, 8.4 µmol).  Reaction time 30 min.  Isolated yield 146d (20 mg, 66%). 
Note: the reaction also resulted in minor amount (<10%) of the exocyclic olefin isomer which 
was separable by silica gel chromatography. 
1H NMR (300 MHz, CDCl3): δ 7.47-7.44 (m, 2H), 7.34-7.13 (m, 8H), 6.80 (s, 1H), 6.45 (ddd, J 
= 17.1, 10.9, 0.7 Hz, 1H), 6.34 (bs, 1H), 6.19 (s, 1H), 5.62 (dd, J = 17.1, 1.5 Hz, 1H), 5.36 (dd, J 
= 10.9, 1.5 Hz, 1H), 3.81 (s, 3H), 3.27 (d, J = 13.2 Hz, 1H), 3.06 (d, J = 13.2 Hz, 1H); 13C NMR 
(75 MHz, CDCl3): δ 171.1, 163.6, 139.2, 138.0, 135.3, 133.7, 133.6, 130.5, 130.3, 128.4, 127.6, 
127.5, 125.4, 121.8, 118.8, 64.7, 53.1, 47.3; IR (thin film): ν 3197, 3061, 2952, 1738, 1673, 1242 
cm-1. MS m/z (%) 359 (10), 300 (23), 268 (100), 208 (67), 91 (74); EI-HRMS calcd for 
C23H21NO3 m/z [M]+ 359.1521; found 359.1517. 
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146e  
1-Benzoyl-2-benzyl-5-ethylidene-6-oxo-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid 
methyl ester (146e). To a solution of 145e (28 mg, 70 µmol), in toluene (2 mL), was added 
[Rh(CO)2Cl]2 (2.7 mg, 6.9 µmol) at rt under Ar atmosphere. The reaction was stirred for 1 h at rt 
and the yellow solution was then applied to a small silica gel column and eluted 
(EtOAc/hexanes, 1 : 9, v/v) to give 146e (21 mg, 75%) after removal of the solvents. 
1H NMR (300 MHz, CDCl3): δ 7.58-7.55 (m, 2H), 7.49-7.44 (m, 1H), 7.39–7.34 (m, 2H), 6.27 
(dd, J = 17.3, 10.8  Hz, 1H), 6.01 (q, J = 7.5 Hz, 1H), 5.80 (s, 1H), 5.56 (dd, J = 17.3, 1.4 Hz, 
1H), 5.31 (dd, J = 10.8, 1.4 Hz, 1H), 4.03 (d, J = 13.8 Hz, 1H), 3.75 (s, 3H), 3.41 (d, J = 13.8 Hz, 
1H), 1.78 (d, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 176.1, 171.3, 165.6, 141.1, 138.6, 
136.4, 134.5, 133.1, 131.5, 131.5, 128.3, 128.1, 127.8, 127.1, 125.9, 120.0, 118.6, 69.9, 53.3, 
42.0, 16.3; IR (thin film): ν 3027, 2945, 1746, 1686, 1271, 1219 cm-1; EI-HRMS calcd for 
C25H23NO4 m/z [M]+ 401.1627; found 401.1639. 
 
General procedure I for preparation of diamides 154a and 154b. 
HN
O
O
H
N
Bn
MeO2C
154a  
[(2-Benzyl-5-ethylidene-6-oxo-4-vinyl-1,2,5,6-tetrahydropyridine-2-carbonyl)amino]acetic 
acid methyl ester (154a). To a solution of ester 146a (0.916 g, 3.08 mmol) in THF (60 mL) was 
added water (60 mL) at rt, followed by LiOH·H2O (0.264 g, 6.15 mmol). The homogeneous 
solution was stirred for 5 min, and then acidified with sat’d aq. NH4Cl (200 mL) and 1M HCl (20 
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mL).kk The aqueous layer was extracted with EtOAc (3 x 100 mL) and the extracts were 
combined, dried over MgSO4 and concentrated under vacuum to afford the desired carboxylic 
acid, which was then dissolved in CH2Cl2 (70 mL). To this solution were then added, HOBt 
(0.407 g 3.10 mmol), EDCI (0.579 g, 3.10 mmol), DMAP (0.738 g, 6.20 mmol) and gycine 
methylester·HCl (0.379 g, 3.10 mmol) at rt. The reaction was stirred at rt for 90 min, and then 
diluted with CH2Cl2 (150 mL). The solution was washed with water (50 mL), sat’d aq. NH4Cl (2 
x 50 mL), then dried over MgSO4, filtered and concentrated under vacuum. Purification of the 
crude residue by flash chromatography (hexanes-EtOAc, 4 : 1 to 1 : 1, v/v) afforded 154a (0.710 
g, 65%) which was used in the next step without additional purification. 
1H NMR (300 MHz, CDCl3): δ 7.40-7.35 (m, 1H), 7.28-7.15 (m, 5H), 6.96 (bs, 1H), 6.27 (dd, J 
= 17.1, 10.7 Hz, 1H), 6.14 (q, J = 7.5 Hz, 1H), 5.88 (s, 1H), 5.45 (dd, J = 17.1, 1.6 Hz, 1H), 5.21 
(dd, J = 10.8, 1.63 Hz, 1H), 4.16 (dd, J = 18.0, 5.9 Hz, 1H), 3.93 (dd, J = 18.0, 5.2 Hz, 1H), 3.72 
(s, 3H), 3.41 (d, J = 13.4 Hz, 1H), 3.16 (d, J = 13.4 Hz, 1H), 2.12 (d, J = 7.4 Hz, 3H); 13C NMR 
(75 MHz, CDCl3): δ 171.8, 170.2, 165.8, 138.9, 137.4, 134.5, 133.6, 130.8, 128.1, 127.1, 125.1, 
120.9, 118.2, 65.8, 52.3, 44.9, 41.4, 16.0; IR (thin film): ν 3304, 2951, 1745, 1669, 1635, 1209 
cm-1; MS m/z (%) 354 (9), 263 (40), 238 (100), 174 (31), 91 (90); EI-HRMS calc’d for 
C20H22N2O4 m/z [M]+ 354.1580; found 354.1582. 
 
 
                                                 
kk In certain cases the homogeneous solution separated into two layers upon addition of LiOH and saponification did 
not proceed to completion. In these cases it is advantageous to add additional amount of water under vigorous 
stirring until the reaction mixture becomes homogeneous again. 
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2-Benzyl-5-ethylidene-6-oxo-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid isobutyl-
amide (154b). Prepared by following general procedure I, using 146a (0.240 g, 0.808 mmol), 
HOBt (0.109 g, 0.808 mmol), EDCI (0.155 g, 0.808 mmol), DMAP (0.098 g, 0.81 mmol) and i-
butylamine (0.081 mL, 0.81 mmol). Isolated yield 154b (0.178 g, 60%).  
1H NMR (300 MHz, CDCl3): δ 7.28-7.15 (m, 5H), 6.55 (bs, 1H), 6.43-6.35 (m, 1H), 6.31 (ddd, J 
= 17.2, 10.8, 0.9 Hz, 1H), 6.24 (q, J = 7.5 Hz, 1H), 5.98 (s, 1H), 5.47 (dd, J = 17.2, 1.6 Hz, 1H), 
5.23 (dd, J = 10.8, 1.6 Hz, 1H), 3.53 (d, J = 13.2 Hz, 1H), 3.04-2.96 (m, 3H), 2.18 (d, J = 7.5 Hz, 
3H), 1.70 (sep, J = 6.7 Hz, 1H), 0.79 (d, J = 6.7 Hz, 3H), 0.78 (d, J = 6.7 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 170.8, 165.7, 139.0, 136.6, 134.3, 133.6, 130.5, 128.4, 127.2, 125.2, 122.1, 
118.2, 65.8, 47.2, 45.3, 28.2, 19.9, 16.1; IR (thin film): ν 3337, 2959, 1671, 1636 cm-1; MS m/z 
(%) 338 (9), 247 (11), 238 (100), 91 (65).   
 
General procedure J for preparation of imino-oxazolidinones 155a and 15b.  
N
O
N
O
Bn
O
MeO2C
155a  
8a-Benzyl-6-ethylidene-1-ethylimino-7-vinyl-6,8a-dihydro-1H-oxazolo[3,4-a]pyridine-3,5-
dione (155a). A solution of diamide 154a (0.710 g, 2.01 mmol) in CH2Cl2 (150 mL) was cooled 
to -10 ºC, and Et3N (0.839 mL, 6.03 mmol) was added. Then, phosgene (1.42 mL, 3.02 mmol of 
a 20 % solution in toluene) was added dropwise, and the reaction was stirred for 10 min at -10 
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ºC. After quenching the reaction by adding water (10 mL), the organic layer was washed with 
diluted NH4Cl solution (2 x 100 mL) to remove the excess Et3N, dried over MgSO4, and 
concentrated under vacuum. The crude residue was purifed by flash chromatography (hexanes-
EtOAc, 4 : 1 to 1 : 1, v/v) to afford the imino-oxazolidinone 155a (0.645 g, 85%). Note: 
extended exposure of 155a to silica gel causes hydrolysis to 154a. All operations during the 
aqueous workup procedure and chromatography were performed fast in order to minimize the 
decomposition of 155a. 
1H NMR (300 MHz, CDCl3): δ 7.25-7.21 (m, 3H), 7.09-7.06 (m, 2H), 6.23 (s, 1H), 6.23 (q, J = 
7.5 Hz, 1H), 6.19 (dd, J = 17.2, 10.8 Hz, 1H), 5.56 (dd, J = 17.2, 1.2 Hz, 1H), 5.32 (dd, J = 10.8, 
1.2 Hz, 1H), 4.25 (s, 2H), 3.81 (s, 3H), 3.22 (d, J = 13.6 Hz, 1H), 3.11 (d, J = 13.6 Hz, 1H), 2.04 
(d, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 169.5, 160.4, 153.3, 146.0, 144.7, 138.8, 
132.7, 132.1, 131.0, 128.5, 128.0, 126.8, 119.6, 118.9, 66.6, 52.3, 49.2, 47.5, 16.3; IR (thin film): 
ν 2953, 1840, 1744, 1272 cm-1; MS m/z (%) 380 (32), 336 (14), 245 (61), 217 (35), 91 (100); EI-
HRMS calcd for C21H20N2O5 m/z [M]+ 380.1372; found 380.1370. 
N
O
N
O
Bn
O
155b  
8a-Benzyl-6-ethylidene-1-isobutylimino-7-vinyl-6,8a-dihydro-1H-oxazolo[3,4-a]pyridine-
3,5-dione (155b). Prepared by following general procedure J, using 154b (0.170 g, 0.503 mmol), 
Et3N (0.182 mL, 0.159 mmol) and phosgene (0.310 mL, 0.657 mmol of a 20 % solution in 
toluene). Isolated yield 155b (0.125 g, 68%).  
1H NMR (300 MHz, CDCl3): δ 7.22-7.20 (m, 3H), 7.05-7.03 (m, 2H), 6.22-6.12 (m, 3H), 5.54 
(dd, J = 17.4, 1.2 Hz, 1H), 5.29 (dd, J = 10.8, 1.2 Hz, 1H), 3.23 (d, J = 6.8 Hz, 2H), 3.12 (d, J = 
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13.5 Hz, 1H), 3.03 (d, J = 13.5 Hz, 1H), 1.99 (d, J = 7.5 Hz, 3H), 1.90 (sep, J = 6.7 Hz, 1H), 0.96 
(d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 160.5, 149.1, 146.9, 
144.0, 138.5, 132.7, 132.2, 130.8, 128.2, 127.8, 126.8, 119.3, 119.2, 66.0, 55.3, 47.4, 29.2, 20.4, 
16.2; IR (thin film): ν 2956, 1836, 1743, 1269 cm-1; MS m/z (%) 364 (6), 320 (19), 229 (33), 173 
(100), 91 (63); EI-HRMS calcd for C22H24N2O3 m/z [M]+ 364.1787; found 364.1786.         
 
General procedure K for preparation of cycloadducts 156a and 156b.  
N
O
N
O
Bn
O
MeO2C
H
N
O
OPh
156a  
(10c-Benzyl-5-ethylidene-3,4,8,10-tetraoxo-9-phenyl-4,5,7,7a,8,9,10,10a,10b,10c-decahydro-
2-oxa-3a,9-diazadicyclopenta[a,h]naphthalen-1-ylideneamino)-acetic acid methyl ester 
(156a). A solution of triene 155a (0.063 g, 0.17 mmol) and N-phenylmaleimide (0.037 g, 0.22 
mmol) in toluene (4 mL) was heated to 90 ºC until the starting material was completely 
consumed as evidenced by TLC analysis. During this time, 156a began precipitating as a white 
solid. The mixture was cooled to 0 ºC in a test tube and centrifuged for 15 min. The toluene was 
decanted away and the solid was rinsed with hexanes and dried under vacuum to afford 156a 
(0.067 g, 73%).  
1H NMR (300 MHz, CDCl3): δ 7.41-7.29 (m, 6H), 7.09-7.00 (m, 4H), 6.65 (q, J = 7.3 Hz, 1H), 
6.25-6.19 (m, 1H), 4.36 (d, J = 18.0 Hz, 1H), 4.34 (dd, J = 9.0, 5.2 Hz, 1H), 4.22 (d, J = 18.1 Hz, 
1H), 3.78 (s, 3H), 3.46 (t, J = 7.9 Hz, 1H), 3.37 (d, J = 13.5 Hz, 1H), 3.27 (d, J = 13.5 Hz, 1H), 
3.10 (bs, 1H), 3.09-3.02 (m, 1H), 2.31 (d, J = 7.4 Hz, 3H), 2.35-2.25 (m, 1H); 13C NMR (75 
MHz, CDCl3): δ 177.8, 176.1, 170.1, 159.5, 153.6, 146.2, 141.3, 135.6, 132.2, 131.1, 130.0, 
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129.8, 129.0, 128.7, 128.4, 126.2, 126.0, 123.7, 66.2, 52.2, 48.9, 48.4, 41.6, 40.6, 39.6, 25.7, 
16.0; IR (thin film): ν 1842, 1741, 1711, 1290 cm-1; MS m/z (%) 553 (5), 509 (18), 462 (76), 418 
(85), 319 (83), 91 (100); EI-HRMS calcd for C31H27N3O7 m/z [M]+ 553.1849; found 553.1830. 
N
O
N
O
Bn
O
H
N
O
O
156b  
10c-Benzyl-5-ethylidene-1-isobutylimino-9-methyl-5,7,7a,10a,10b,10c-hexahydro-1H-2-oxa-
3a,9-diaza-dicyclopenta[a,h]naphthalene-3,4,8,10-tetraone (156b). Prepared by following 
general procedure K, using 155b (0.115 g, 0.276 mmol), N-methylmaleimide (0.040 g, 0.359 
mmol). Precipitation of the product from the toluene solution was accomplished by addition of 
hexanes (2 mL) and refrigeration at -10 °C for 2 days under nitrogen atmosphere. Isolated yield 
156b (0.133 g, >95%).  
1H NMR (300 MHz, CDCl3): δ 7.31-7.27 (m, 3H), 6.98-6.95 (m, 2H), 6.58 (q, J = 7.4, 1H), 6.12-
6.08 (m, 1H), 3.88 (dd, J = 8.9, 5.2 Hz, 1H), 3.36-3.20 (m, 5H), 3.16 (d, J = 13.4 Hz, 1H), 3.02-
2.92 (m, 2H), 2.86 (d, J = 3.8 Hz, 1H), 2.83 (s, 3H), 2.28 (d, J = 7.4 Hz, 3H), 1.91 (sep, J = 6.7 
Hz, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 178.6, 
176.5, 159.8, 149.7, 147.1, 140.7, 135.6, 132.5, 130.2, 129.8, 128.9, 128.2, 123.4, 65.8, 55.5, 
48.6, 41.4, 40.7, 39.5, 29.3, 25.3, 25.1, 20.8, 20.7, 15.8; IR (thin film): ν 2955, 1835, 1740, 1699 
cm-1; MS m/z (%) 475 (15), 384 (77), 340 (100), 284 (80), 257 (63), 91 (58); EI-HRMS calcd for 
C27H29N3O5 m/z [M]+ 475.2107; found 475.2107.    
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157a  
(5-Ethoxy-7,12c-dimethyl-3,10,12-trioxo-11-phenyl-6,7,9,9a,10,11,12,12a,12b,12c-
decahydro-5H-2,4-dioxa-3a,11-diazadicyclopenta[a,l]phenanthren-1-ylideneamino)-acetic 
acid methyl ester (157a). To a solution of unsaturated amide 156a (10 mg, 18 µmol) in 1,2-
dichloroethane (100 µL), were added ethyl vinyl ether (50 µL) and Eu(fod)3 (2 mg, 2 µmol). The 
reaction vessel was then sealed and placed in a sonicator (Branson 2510), and sonication was 
continued at rt for 6h. The reaction mixture was purified by flash chromatography (hexanes-
EtOAc, 1 : 1, v/v) to afford 157a (11 mg, >95%).  
1H NMR (300 MHz, CDCl3): δ 7.39-7.28 (m, 6H), 7.14-7.07 (m, 4H), 5.72-5.65 (m, 1H), 5.30 (t, 
J = 2.6 Hz, 1H), 4.35 (d, J = 18.1 Hz, 1H), 4.20 (d, J = 18.1 Hz, 1H), 4.21 (dd, J = 8.8, 4.4 Hz, 
1H), 3.87-3.76 (m, 1H), 3.79 (s, 3H), 3.58 (dq, J = 9.9, 7.1 Hz, 1H), 3.45-3.43 (m, 1H), 3.42 (d, J 
= 13.4 Hz, 1H), 3.09 (d, J = 13.4 Hz, 1H),3.07 (bs, 1H), 2.99 (dd, J = 15.2, 7.7 Hz, 1H), 2.81 (dt, 
J = 10.3, 6.9 Hz, 1H), 2.41-2.31 (m, 1H), 2.28 (ddd, J = 13.9, 6.7, 2.5 Hz, 1H), 1.86-1.77 (m, 
1H), 1.23 (d, J = 6.7 Hz, 3H), 0.93 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, toluene-d8): δ 177.7, 
176.1, 170.1, 156.0, 146.4, 137.9, 134.5, 132.9, 132.7, 130.7, 128.7, 128.1, 126.8, 116.0, 99.6, 
97.4, 66.1, 64.5, 51.4, 40.0, 45.0, 44.7, 42.1, 41.8, 37.0, 26.0, 21.4, 21.2, 20.4, 19.7, 14.7; IR 
(thin film): ν 2594, 1822, 1735, 1712 cm-1; MS m/z (%) 649 (50), 648 (100), 576 (15); HRMS 
calcd. for C35H35N3O8Na [M+23]+ m/z 648.2322, found 648.2310.   
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MeO2C
N
O
OPh
H
158a
O
H
 
[10c-Methyl-5-(1-methyl-3-oxo-propyl)-3,4,8,10-tetraoxo-9-phenyl-
4,6,7,7a,8,9,10,10a,10b,10c-decahydro-2-oxa-3a,9-diaza-dicyclopenta[a,h]naphthalen-1-
ylideneamino]-acetic acid methyl ester (158a). A solution of pyran 157a (11 mg, 18 µmol) in 
CDCl3 was allowed to stand at rt for 24 h (slow hydrolysis to 158a was catalyzed by traces of 
acid in CDCl3). The solvent was removed under vacuum to afford 158a (11mg, >95%). 
Alternatively, addition of 1M HCl (50 µL) accelerates the hydrolysis to 3 h.  
1H NMR (300 MHz, CDCl3): δ 9.58 (s, 1H), 7.48-7.31 (m, 6H), 7.18-7.16 (m, 2H), 7.08-7.06 (m, 
2H), 4.36 (d, J = 18.0 Hz, 1H), 4.37-4.34 (m, 1H), 4.21 (d, J = 18.1 Hz, 1H), 3.79 (s, 3H), 3.44-
3.31 (m, 7H), 2.87 (dd, J = 19.1, 6.2 Hz, 1H), 2.72 (dd, J = 19.2, 5.7 Hz, 1H), 2.60-2.46 (m, 1H), 
2.28-2.13 (m, 1H), 1.25 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 200.8, 176.8, 175.8, 
170.1, 158.3, 153.6, 147.7, 146.0, 134.2, 132.0, 131.1, 130.0, 128.9, 128.5, 128.4, 125.8, 64.5, 
52.2, 49.0, 48.9, 47.4, 41.2, 40.6, 39.8, 27.0, 26.6, 20.2, 18.5; IR (thin film): ν 2954, 2256, 1838, 
1743, 1710 cm-1. 
N
O
N
O
Bn
O
MeO2C
H
N
O
OPh
161a  
(10c-Benzyl-5-ethyl-3,4,8,10-tetraoxo-9-phenyl-4,6,7,7a,8,9,10,10a,10b,10c-decahydro-2-
oxa-3a,9-diazadicyclopenta[a,h]naphthalen-1-ylideneamino)acetic acid methyl ester (161a). 
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To a solution of diene 156a (20 mg, 36 µmol) in THF (2.5 mL) was added Pd/C (5 mg, 10% by 
wt.), and the reaction vessel was sealed with a rubber septum and H2 atmosphere was introduced 
from a balloon via a needle. The heterogeneous reaction mixture was stirred for 4 h at rt. The 
mixture was then filtered over a plug of celite eluting with CH2Cl2 and the collected solution was 
concentrated under vacuum. The crude residue was purified by flash chromatography (EtOAc : 
hexanes, 1 : 1 to 1 : 0, v/v) to afford 161a (16 mg, 80%). 
1H NMR (300 MHz, CDCl3): δ 7.43-7.30 (m, 6H), 7.08-7.03 (m, 4H), 4.37 (d, J = 18.2 Hz, 1H), 
4.38-4.34 (m, 1H), 4.21 (d, J = 18.2 Hz, 1H), 3.78 (s, 3H), 3.43-3.33 (m, 3H), 3.22 (d, J = 13.2 
Hz, 1H),  2.68-2.65 (m, 2H), 2.50 (dq, J = 12.9, 2.6 Hz, 1H), 2.34 (sept, J = 7.2 Hz, 2H), 2.27-
2.15 (m, 1H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 177.1, 175.9, 170.2, 158.4, 
153.8, 146.0, 133.6, 132.3, 131.0, 130.0, 129.2, 128.9, 128.8, 128.4, 125.9, 64.7, 52.2, 48.9, 47.9, 
40.8, 40.6, 40.1, 26.1, 20.0, 19.3, 12.7; IR (thin film): ν 2953, 1837, 1743, 1709 cm-1; MS m/z 
(%) 555 (10), 464 (80), 420 (65), 321 (100); HRMS calcd. for C31H29N3O7 [M]+ m/z 555.2005, 
found 555.1992. 
N
O
N
O
Bn
O
H
N
O
O
161b  
10c-Benzyl-5-ethyl-1-isobutylimino-9-methyl-6,7,7a,10a,10b,10c-hexahydro-1H-2-oxa-3a,9-
diazadicyclopenta[a,h]naphthalene-3,4,8,10-tetraone (161b). To a solution of diene 156b (56 
mg, 0.12 mmol) in THF (7 mL) was added Pd/C (10 mg, 10% by wt.), and the reaction vessel 
was sealed with a rubber septum and H2 atmosphere was introduced from a balloon via a needle. 
The heterogeneous reaction mixture was stirred for 4 h at rt. The mixture was then filtered over a 
plug of celite eluting with CH2Cl2 and the collected solution was concentrated under vacuum. 
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The crude residue was purified by flash chromatography (EtOAc : hexanes, 1 : 1 to 1 : 0, v/v) to 
give 161b (56 mg, 95%). 
1H NMR (300 MHz, CDCl3): δ 7.42-7.40 (m, 3H), 7.16-7.12 (m, 2H), 4.05 (dd, J = 9.4, 5.6 Hz, 
1H), 3.42 (dd, J = 13.3, 7.0 Hz, 1H), 3.39 (d, J = 13.2 Hz, 1H), 3.37-3.29 (m, 3H), 3.22 (d, J = 
13.3 Hz, 1H), 2.95 (s, 3H), 2.75-2.64 (m, 2H), 2.58-2.40 (m, 2H), 2.35-2.22 (m, 2H), 2.04 (sept, 
J = 6.7 Hz, 1H), 1.13 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H), 1.04 (t, J = 7.4 Hz, 3H); 13C 
NMR (75 MHz, CDCl3): δ 178.0, 176.5, 158.4, 149.8, 147.1, 145.9, 133.2, 132.5, 129.9, 128.7, 
128.2, 64.3, 55.5, 48.0, 41.0, 40.1, 40.0, 29.3, 25.8, 24.7, 20.8, 20.7, 19.5, 19.1, 12.5; IR (thin 
film): ν 2959, 1832, 1741, 1700 cm-1; MS [M+H2O]+  m/z (%) 495 (50), 386 (77), 342 (100), 286 
(90).  
N
O
NH
O
BnMeO2C
H
N
O
OPh
O
NH
i-Bu
163a  
[(9-Benzyl-6-ethyl-8-isobutylcarbamoyl-1,3,7-trioxo-2-phenyl-2,3,3a,4,5,7,8,9,9a,9b-
decahydro-1H-pyrrolo[3,4-h]isoquinoline-9-carbonyl)amino]acetic acid methyl ester 
(163a). i-Butylamine (~10 µmol) was added to a solution of imino-oxazolidinone 161a (8 mg, 14 
µmol) in CDCl3 (1 mL) and the reaction was stirred at rt for 15 min. The reaction mixture was 
diluted with CHCl3 and washed with sat’d aq. NH4Cl. The organic layer was separated, dried 
over MgSO4 and concentrated under vacuum. The crude residue was purified by flash 
chromatography (EtOAc : hexanes, 1 : 1 to 1 : 0, v/v) to give 163a (7 mg, 75%). 
1H NMR (300 MHz, CDCl3): δ 9.20 (t, J = 5.8 Hz, 1H), 8.46 (dd, J = 7.1, 4.6 Hz, 1H), 7.45-7.37 
(m, 3H), 7.22-7.17 (m, 3H), 7.12-7.04 (m, 4H), 4.64 (dd, J = 9.6, 3.9 Hz, 1H), 4.48 (dd, J = 17.7, 
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7.4 Hz, 1H), 4.00 (d, J = 14.4 Hz, 1H), 3.72 (s, 3H), 3.60 (dd, J = 17.7, 4.6 Hz, 1H), 3.57 (d, J = 
14.4 Hz, 1H), 3.40-3.35 (m, 1H), 3.28-3.10 (m, 3H), 2.34-2.22 (m, 2H), 2.17-2.09 (m, 1H), 1.94-
1.81 (m, 2H), 1.75-1.60 (m, 2H), 0.98 (d, J = 6.7 Hz, 6H), 0.53 (t, J = 7.5 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 179.0, 177.7, 171.5, 171.4, 166.5, 154.9, 143.5, 138.1, 132.7, 131.3, 130.0, 
129.2, 128.9, 128.4, 126.9, 126.2, 66.9, 52.1, 48.0, 45.3, 44.2, 42.5, 41.6, 41.1, 28.5, 25.2, 20.9, 
20.2, 20.2, 19.4, 12.6; IR (thin film): ν 3305, 2958, 1748, 1704, 1637 cm-1; HRMS calcd. for 
C23H24N3O6 [M-190]+ m/z 438.1665, found 438.1675.  
Note: Fragment with m/z = 438 likely results from loss of a benzyl group and the CONH-i-Bu 
fragment. 
N
O
NH
O
Bn
H
N
O
O
O
NH
All
163b  
9-Benzyl-6-ethyl-2-methyl-1,3,7-trioxo-2,3,3a,4,5,9,9a,9b-octahydro-1H,7H-pyrrolo[3,4-
h]isoquinoline-8,9-dicarboxylic acid 8-allylamide 9-(isobutylamide) (163b). Allylamine (18 
µL, 250 µmol) was added to a solution of 161b (12 mg, 25 µmol) in CHCl3 (1 mL) and the 
reaction was stirred at rt for 1.5 h. The reaction mixture was diluted with CHCl3 and washed with 
sat’d aq. NH4Cl. The organic layer was separated, dried over MgSO4 and concentrated under 
vacuum. The crude residue was purified by flash chromatography (EtOAc : hexanes, 1 : 1 to 1 : 
0, v/v) to give 163b (12 mg, 92%). 
1H NMR (300 MHz, CDCl3): δ 9.19 (t, J = 5.6 Hz, 1H), 7.90 (dd, J = 6.6, 3.9 Hz, 1H), 7.21-7.11 
(m, 3H), 7.04-7.01 (m, 2H), 6.04-5.90 (m, 1H), 5.33 (dq, J = 17.2, 1.5 Hz, 1H), 5.20 (dq, J = 
10.2, 1.4 Hz, 1H), 4.17-4.08 (m, 1H), 4.02 (d, J = 14.4 Hz, 1H), 3.99-3.90 (m, 1H), 3.54 (d, J = 
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14.4 Hz, 1H), 3.49-3.39 (m, 2H), 3.13-3.08 (bm, 2H), 2.85 (s, 3H), 2.79-2.71 (m, 1H), 2.23-2.21 
(m, 1H), 2.15-1.94 (m, 3H), 1.80 (sept, J = 6.6 Hz, 1H),  1.69-1.63 (m, 2H), 1.45 (sex, J = 6.2 
Hz, 1H), 0.95 (d, J = 6.7 Hz, 6H), 0.57 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 178.6, 
178.3, 170.5, 166.5, 154.5, 143.0, 138.4, 134.1, 132.7, 129.8, 128.3, 126.8, 116.3, 67.2, 47.3, 
45.0, 44.7, 43.0, 42.3, 41.0, 28.2, 25.0, 24.7, 20.5, 20.4, 20.3, 19.4, 12.5; IR (thin film): ν 3325, 
2959, 1770, 1697, 1642 cm-1; MS  m/z (%) 534 (7), 469 (70), 360 (90), 287 (55); HRMS calcd. 
for C30H38N4O5 [M]+ m/z 534.2842, found 534.2851. 
 
Compounds 172-174 were synthesized as part of a preliminary study and only partial spectral 
data was collected: 
• H
BzHN
BnHO
172  
N-(1-Benzyl-1-hydroxymethylpenta-2,3-dienyl)benzamide (172). To a solution of methyl 
ester 58a (100 mg, 0.297 mmol) in CH2Cl2 (1.2 mL) was added DIBAL-H (750 µL of 1.0 M 
solution in hexanes, 0.75 mmol) at -78 °C via a syringe in a dropwise manner. The reaction 
mixture was allowed to warm up to -10 °C and maintained at that temperature until TLC 
indicated absence of starting material (~10 min). The reaction was quenched by adding MeOH 
(200 µL) followed by sat’d aq. NH4Cl (600 µL). Vigorous stirring for 10 min led to formation of 
white solid that was filtered on a fritted funnel and washed with excess CH2Cl2. The filtrate was 
concentrated under vacuum, and the crude residue was purified by flash chromatography 
(gradient elution, hexanes-EtOAc, 4 : 1 to 3 : 2, v/v) to afford 172 (61 mg, 67%). 
1H NMR (300 MHz, CDCl3): δ 7.67-7.20 (m, 10H), 6.33 (s, 1H), 5.43-5.19 (m, 2H), 3.94-3.83 
(m, 2H), 3.59 (d, J = 13.6 Hz, 0.5H), 3.45 (d, J = 13.5 Hz, 0.5H), 3.08 (d, J = 13.5 Hz, 0.5H), 
 219 
3.00 (d, J = 13.6 Hz, 0.5H), 1.64-1.60 (m, 3H), 1.45 (dd, J = 7.1, 3.2 Hz, 3H). 
• H
BzN
BnO
173  
N-(1-Benzyl-1-but-2-ynyloxymethylpenta-2,3-dienyl)-N-but-2-ynylbenzamide (173). To a 
solution of amide-alcohol 172 (170 mg, 0.554 mmol) in DMF (1.5 mL) was added NaH (110 mg 
of a 60% dispersion in mineral oil, 2.75 mmol), followed by 1-bromo-2-butyne (145 µL, 1.65 
mmol) at rt. The reaction mixture was stirred at rt for 30 min when it was quenched by pouring 
into water. The aqueous mixture was extracted with EtOAc, the organic layers were combined, 
dried over MgSO4, and concentrated under vacuum. The crude oily residue was purified by flash 
chromatography to afford 173 (150 mg, 66%). 
1H NMR (300 MHz, CDCl3): δ 7.54-7.23 (m, 10H), 5.83-5.79 (m, 1H), 5.35-5.21 (m, 1H), 4.28-
4.14 (m, 3H), 3.93-3.73 (m, 4H), 3.25 (d, J = 13.0 Hz, 0.5H), 3.16 (d, J = 13.1 Hz, 0.5H), 1.86 (t, 
J = 2.2 Hz, 3H), 1.71 (dd, J = 7.0, 3.2 Hz, 0.5H), 1.67-1.64 (m, 6H). 
N
O
Bz
Bn
174  
(6-But-2-ynyloxymethyl-3-ethylidene-6-methyl-4-vinyl-3,6-dihydro-2H-pyridin-1-yl)-
phenylmethanone (174). To a solution of allene-diyne 173 (140 mg, 0.340 mmol) in toluene 
(1.5 mL) was added [Rh(CO)2Cl]2 (7 mg, 18 µmol) at rt. The reaction mixture was stirred at rt 
for 1 h and then directly applied to a silica gel column. Elution (hexanes-EtOAc, 9 : 1, v/v) 
afforded 174 (112 mg, 80%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3): δ 7.38-7.19 (m, 10H), 6.32 (dd, J = 17.2, 10.7 Hz, 1H), 5.80 (s, 
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1H), 5.49 (dd, J = 17.3, 1.8 Hz, 1H), 5.43 (q, J = 7.1 Hz, 1H), 5.18 (dd, J = 10.7, 1.8 Hz, 1H), 
4.46 (d, J = 9.0 Hz, 1H), 4.23-4.11 (m, 2H), 4.06 (d, J = 9.0 Hz, 1H), 4.02 (d, J = 13.3 Hz, 1H), 
3.78 (d, J = 14.2 Hz, 1H), 3.35 (d, J = 14.1 Hz, 1H), 2.95 (d, J = 13.2 Hz, 1H), 1.86 (t, J = 2.3 
Hz, 3H), 1.30 (d, J = 7.1 Hz, 1H). 
 
176: Synthesized according to the following scheme:   
BzHN
•
N O
Ph
O
•
O
O BzN
•
O
O
N
O
Bz
O
a b c
176180 333 334
a) 2-butyne-1-ol (2 equiv.), Et3N (cat.); b) NaH (2 equiv.), 1-bromo-2-butyne (2 equiv.), DMF; c) 5 mol% [Rh(CO)2Cl]2, toluene, rt.
>95% >95% 89%
 
2-Benzoylamino-2-methylhexa-3,4-dienoic acid but-2-ynyl ester (333). 2-Butyn-1-ol (0.170 
mL, 2.23 mmol) was added to neat oxazolone 180ll (0.253 g, 1.11 mmol) followed by addition of 
Et3N (10 µL) and the reaction was stirred for 30 min. All volatiles were removed under vacuum, 
and the remaining yellow residue was purified by flash chromatography (hexanes/EtOAc, 4 : 1, 
v/v) to afford 333 (0.320 g, 96% as a mixture of inseparable diastereomers in 1.5 : 1 ratio).  
1H NMR (300 MHz, CDCl3): δ 7.78-7.75 (m, 2H), 7.50-7.38 (m, 3H), 6.93 (bs, 0.4H), 6.90 (bs, 
0.6H), 5.56-5.38 (m, 2H), 4.80-4.64 (m, 2H), 1.83-1.81 (m, 3H), 1.79 (s, 1.2H), 1.77 (s, 1.8H), 
1.73-1.69 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 203.0, 202.9, 171.9, 171.8, 166.3, 166.3, 
134.3, 131.4, 128.4, 128.2, 126.9, 94.0, 91.6, 83.3, 83.2, 72.8, 72.8, 58.4, 54.0, 54.0, 23.0, 22.9, 
13.9, 13.9, 3.5; IR (thin film): ν 3308, 2322, 2923, 2243, 2117, 1968, 1744, 1640 cm-1; MS m/z 
(%) 297 (38), 282 (21), 244 (73), 200 (55), 105 (100); EI-HRMS calcd for C18H19NO3 m/z [M]+ 
297.1365; found 297.1364. 
                                                 
ll See page 224 for preparation of intermediate 180. 
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334  
2-(Benzoylbut-2-ynyl-amino)-2-methylhexa-3,4-dienoic acid but-2-ynyl ester (334). A 
solution of amide 333 (0.320 g, 1.08 mmol) in DMF (8 mL) was cooled to 0 °C, and NaH (95% 
wt) (0.056 g, 2.23 mmol) was added in one portion. After 2 min, 1-bromo-2-butyne (0.19 mL, 
2.23 mmol) was added via a syringe and the reaction mixture was stirred for 30 min at rt. The 
reaction mixture was then carefully poured over cold water (100 mL), and the aqueous layer was 
extracted with EtOAc (2 x 50 mL). The organic layers were combined and washed with brine, 
dried over MgSO4, and concentrated under vacuum to afford 334 (0.415 g, >95% as a mixture of 
inseparable diastereomers in 1.5 : 1 ratio).  
1H NMR (300 MHz, CDCl3): δ 7.61-7.59 (m, 2H), 7.42-7.38 (m, 3H), 5.73-5.66 (m, 1H), 5.42-
5.34 (m, 1H), 4.77-4.65 (m, 2H), 4.05-4.01 (m, 2H), 1.85-1.83 (m, 6H), 1.76-1.71 (m, 6H); 13C 
NMR (75 MHz, CDCl3): δ 205.2, 205.2, 171.8, 171.7, 171.3, 136.0, 129.9, 128.3, 128.2, 127.1, 
127.0, 92.5, 92.4, 90.2, 90.1, 82.8, 82.7, 80.3, 76.0, 73.4, 64.2, 64.0, 53.6, 53.6, 37.5, 37.4, 20.6, 
20.6, 13.8, 13.7, 3.6, 3.5; IR (thin film): ν 2921, 2242, 1967, 1746, 1643 cm-1; MS m/z (%) 349 
(21), 296 (50), 268 (48), 252 (35), 105 (100); EI-HRMS calcd for C22H23NO3 m/z [M]+ 
349.1678; found 349.1685. 
N
O
Bz
O
176  
1-Benzoyl-5-ethylidene-2-methyl-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid but-
2-ynyl ester (176). To a solution of allene-diyne 334 (0.173 g, 0.495 mmol) in toluene (5 mL) 
was added [Rh(CO)2Cl]2 (7 mg, 18 µmol) under nitrogen atmosphere. The light yellow solution 
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was stirred at rt for 1 h when it was directly applied to a silica gel column and eluted (gradient 
elution, hexanes-EtOAc, 1 : 0 to 4 : 1, v/v) to afford 176 (0.154 g, 89%) after removal of the 
solvents.  
1H NMR (300 MHz, CDCl3): δ 7.51-7.39 (m, 5H), 6.36 (dd, J = 17.2, 10.6 Hz, 1H), 5.78 (q, J = 
7.1 Hz, 1H), 5.61 (s, 1H), 5.46 (dd, J = 17.2, 1.7 Hz, 1H), 5.22 (dd, J = 10.7, 1.7 Hz, 1H), 4.75 
(dq, J = 15.2, 2.3 Hz, 1H), 4.61 (dq, J = 15.2, 2.3 Hz, 1H), 4.45 (d, J = 14.6 Hz, 1H), 3.70 (d, J = 
14.6 Hz, 1H), 1.81 (t, J = 2.3 Hz, 3H), 1.78 (s, 3H), 1.62 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 171.1, 171.0, 137.5, 136.0, 134.3, 130.2, 130.0, 128.5, 127.5, 124.7, 122.8, 117.8, 
82.8, 73.4, 62.8, 53.8, 43.5, 20.7, 13.3, 3.6; IR (thin film): ν 2921, 2242, 1743, 1642, 1412, 1106 
cm-1. MS m/z (%) 349 (17), 284 (5), 252 (40), 105 (100); EI-HRMS calcd for C22H23NO3 m/z 
[M]+ 349.1678; found 349.1674. 
O
O
N
H
Bz
178  
N-[2-(4-Methyl-5-oxo-2-vinyl-2,5-dihydrofuran-2-yl)-but-2-enyl]benzamide (178). To a 
solution of trienyne 176 (15 mg, 43 µmol) in 1,2-dichloroethane (0.5 mL), was added 
[Rh(dppe)Cl]2  (4 mg, 4 µmol), and  AgSbF6 (172 µL of a 0.05 M solution in 1,2-dichloroethane, 
8 µmol). The reaction was heated to 95 °C for 12 h. After cooling to rt the reaction mixture was 
directly applied to a silica gel column and eluted (hexanes-EtOAc, 1 : 1, v/v), to afford 178 (10 
mg, 78%).  
1H NMR (300 MHz, CDCl3): δ 7.80-7.74 (m, 2H), 7.52-7.40 (m, 3H), 7.14 (q, J = 1.6 Hz, 1H), 
6.39 (bs, 1H), 5.90 (dd, J = 17.3, 10.7 Hz, 1H), 5.84 (q, J = 6.9 Hz, 1H), 5.38 (d, J = 17.3 Hz, 
1H), 5.26 (d, J = 10.7 Hz, 1H), 4.20 (dd, J = 14.5, 5.8 Hz, 1H), 4.11 (dd, J = 14.5, 5.8 Hz, 1H), 
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1.93 (d, J = 1.6 Hz, 3H), 1.85 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 172.7, 166.8, 
149.6, 135.4, 134.2, 131.4, 130.3, 129.0, 128.6, 128.3, 126.8, 116.9, 90.5, 35.9, 13.9, 10.7; IR 
(thin film): ν 3344, 2924, 1758, 1639 cm-1; MS m/z (%) 297 (81), 252 (38), 192 (49), 174 (84), 
105 (100); EI-HRMS calcd for C18H19NO3 m/z [M]+ 297.1365; found 297.1379. 
• H
BzHN
HOOCN O
Ph
O
•
H
179
1M HCl
70 oC
>95%
180 181
BzHN
O
O
PPh3
CCl4
Et3N
MeCN
 
2-(Benzamido)-2-methylhexa-3,4-dienoic acid (181). Propargylic ester 179 (1.05g, 4.29 mmol) 
was dissolved in acetonitrile (10 mL) at rt. Then Et3N (1.67 mL, 12.0 mmol), CCl4 (0.99 mL, 
10.3 mmol) and  PPh3 (2.36 g, 9.0 mmol) were added in consecutive order. The reaction mixture 
was stirred for 2 h at rt while gradually turning brown color. The volatiles were removed under 
vacuum (using a rotary evaporator heated to ~40 °C) and the crude brown residue was dissolved 
in acetone (5 mL) and poured in an Erlenmeyer flask. Under vigorous stirring, Et2O (50 mL) was 
added followed by hexanes (20 mL) which led to formation of a viscous precipitate (Ph3PO). The 
mixture was filtered on a fritted funnel over a plug of silica gel (~ 2 cm height) eluting with 
hexanes-EtOAc (1 : 1). The collected filtrate was concentrated under vacuum to afford allenyl 
oxazolone 180 (718 mg, 74%). 
Oxazolone 180 (105 mg, 0.415 mmol) was dissolved in 1,4-dioxane (3 mL) in a 25 mL round-
bottom flask and 1M HCl (3 mL) was added. The flask was sealed with a rubber septum and 
heated to 70 °C for 10 min. The reaction solution was then diluted with water and extracted with 
Et2O. The organics were combined, washed with brine, dried over MgSO4 and concentrated 
under vacuum to afford acid 181 (100 mg, >95%) which was used in the next step without 
additional purification. 
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• H
BzN
HOOC
182  
2-(N-(but-2-ynyl)benzamido)-2-methylhexa-3,4-dienoic acid (182). To a solution of amido-
acid 181 (100 mg, 0.408 mmol) in DMF (3 mL) was added NaH (23 mg, 0.90 mmol) at rt. The 
reaction mixture turned bright yellow and after 2 min, 1-bromo-2-butyne (39 µL, 0.45 mmol) 
was added. The reaction mixture was stirred at rt for 1 h and then poured into a diluted aq. 
NaHCO3 solution. The aqueous layer was extracted once with EtOAc and the organic layer was 
discarded. The aqueous layer was acidified to approximately pH = 2.0 by dropwise addition of 
6M HCl (pH was followed using pHydrion strips) and then extracted with EtOAc (3 x 25 mL). 
The organics were combined, washed with water, dried over MgSO4 and concentrated under 
vacuum to afford 182 (103 mg, 85%) as a mixture of diastereomers in ~ 2 : 1 ratio. 
1H NMR (300 MHz, CDCl3): δ 9.61 (bs, 1H), 7.79-7.76 (m, 0.67H), 7.65-7.63 (m, 1.33H), 7.53-
36 (m, 3H), 5.74-5.68 (m, 1H), 5.54-5.34 (m, 1H), 4.03-4.00 (m, 2H), 1.85 (s, 3H), 1.75 (s, 3H), 
1.75-1.68 (m, 3H); IR (thin film): ν 3062, 2990, 2629, 1967, 1714, 1641 cm-1; MS m/z (%) 297 
(42), 282 (15), 252 (70), 200 (55), 105 (100); EI-HRMS calcd for C18H19NO3 m/z [M]+ 
297.1365, found 297.1363. 
N
OH
Bz
O
177  
1-Benzoyl-5-ethylidene-2-methyl-4-vinyl-1,2,5,6-tetrahydropyridine-2-carboxylic acid 
(177). Allenyne 182 (103 mg, 0.347 mmol) was placed in a 15 mL test tube and toluene (3 mL) 
was added. The resulting solution was deoxygenated by bubbling Ar via a needle for 3 min. 
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Then, [Rh(CO)2Cl]2 (7 mg, 18 µmol) was added at rt, and the test-tube was sealed with a rubber 
septum and heated to 35 °C in an oil bath. After 1 h, another portion of [Rh(CO)2Cl]2 (7 mg, 18 
µmol) was added by briefly opening the reaction vessel, and heating was continued for 1 h. 
During this time, the product of the reaction (177) partially percipitated from the solution as a 
light orange solid. The precipitate was collected by filtering the reaction mixture through a small 
pipette over a cotton plug. The filtrate was concentrated under vacuum and the crude residue was 
purified by flash chromatography (hexanes-EtOAc, 9 : 1 to 0 : 1, v/v) to give 177 (60 mg, 58% 
after combining with the portion obtained by filtration). 
1H NMR (300 MHz, CDCl3): δ 7.91-7.71 (bs, 1H), 7.55-7.39 (m, 5H), 6.33 (dd, J = 17.2, 10.7 
Hz, 1H), 5.78 (q, J = 7.1 Hz, 1H), 5.62 (s, 1H), 5.47 (dd, J = 17.2, 1.3 Hz, 1H), 5.21 (dd, J = 
10.7, 1.3 Hz, 1H), 4.41 (d, J = 14.5 Hz, 1H), 3.71 (d, J = 14.5 Hz, 1H), 1.75 (s, 3H), 1.60 (d, J = 
7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.6, 171.6, 137.4, 135.5, 134.0, 130.4, 129.6, 
128.5, 127.5, 124.6, 123.1, 118.0, 62.8, 43.7, 20.6, 13.3; IR (thin film): ν 2983, 2025, 1742, 1593 
cm-1; MS m/z (%) 297 (7), 253 (67), 252 (80), 105 (100); EI-HRMS calcd for C18H19NO3 m/z 
[M]+ 297.1365; found 297.1372.   
 
184: Synthesized according to the following scheme: 
N
OMe
Cbz
O
a N
OH
Cbz b
N
O
Cbz
O
a) DIBALH (3 equiv.), CH2Cl2, -78 oC-rt; b) acryloyl chloride (1.2 equiv.), Et3N (1.2 equiv.), CH2Cl2.
111f 183 184
 
3-Ethylidene-6-hydroxymethyl-6-methyl-4-vinyl-3,6-dihydro-2H-pyridine-1-carboxylic acid 
benzyl ester (183). A solution of 111f (50 mg, 0.15 mmol), in toluene (1 mL), was cooled to -50 
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°C and DIBAL-H (0.440 mL of a 1.0M solution in hexanes, 0.440 mmol), was added dropwise. 
The reaction was allowed to warm up to rt over a period of 1 h, when it was quenched by 
addition of MeOH (0.1 mL) and sat’d aq. NH4Cl (0.5 mL). Vigorous stirring for 10 min led to 
formation of white solid that was filtered on a fritted funnel and washed with excess CH2Cl2. The 
filtrate was concentrated under vacuum, and the crude residue was purified by flash 
chromatography (hexanes-EtOAc, 4 : 1, v/v) to afford 183 (30 mg, 65%).  
1H NMR (300 MHz, CDCl3): δ 7.39-7.33 (m, 5H), 6.34 (dd, J = 17.2, 10.7 Hz, 1H), 5.69 (q, J = 
7.0 Hz, 1H), 5.46-5.40 (m, 2H), 5.22-5.13 (m, 2H), 4.71 (d, J = 14.3 Hz, 1H), 3.97-3.90 (m, 1H), 
3.78 (d, J = 14.3 Hz, 1H), 3.66 (d, J = 9.0 Hz, 1H), 1.76 (d, J = 7.0 Hz, 3H), 1.43 (s, 3H). 13C 
NMR (75 MHz, CDCl3): δ 155.8, 136.7, 136.4, 134.5, 130.2, 129.4, 128.5, 128.0, 127.7, 122.1, 
116.8, 69.0, 67.3, 61.5, 41.3, 20.2, 13.4;  IR (thin film): ν 3427, 2927, 1685, 1406 cm-1; MS m/z 
(%) 313 (32), 282 (45), 238 (29), 192 (30), 91 (100); EI-HRMS calcd for C18H20NO2 m/z [M-
31]+ 282.1494; found 282.1485. 
N
O
Cbz
O
184  
6-Acryloyloxymethyl-3-ethylidene-6-methyl-4-vinyl-3,6-dihydro-2H-pyridine-1-carboxylic 
acid benzyl ester (184). To a solution of alcohol 183 (30 mg, 0.096 mmol), in CH2Cl2 (0.5 mL) 
was added Et3N (0.016 mL, 0.11 mmol), followed by acryloyl chloride (0.010 mL, 0.11 mmol) at 
rt. After 10 min at rt, the reaction was diluted with benzene (0.5 mL) and purified by flash 
chromatography (hexanes-EtOAc, 9 : 1, v/v) to afford ester 184 (18 mg, 51%).  
1H NMR (300 MHz, CDCl3): δ 7.38-7.34 (m, 5H), 6.37-6.28 (m, 1H), 6.31 (dd, J = 17.3, 1.6 Hz, 
1H), 6.04 (dd, J = 17.3, 10.4 Hz, 1H), 5.77 (dd, J = 10.4, 1.6 Hz, 1H), 5.66 (q, J = 7.1 Hz, 1H), 
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5.44 (s, 1H), 5.39 (dd, J = 17.2, 1.8 Hz, 1H), 5.22 (d, J = 12.4 Hz, 1H), 5.16 (d, J = 12.4 Hz, 1H), 
5.14 (dd, J = 10.7, 1.8 Hz, 1H), 4.79 (d, J = 10.9 Hz, 1H), 4.40-4.34 (m, 2H), 4.18 (d, J = 14.3 
Hz, 1H), 1.78 (d, J = 6.9 Hz, 3H), 1.54 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 165.7, 155.2, 
136.6, 136.3, 134.5, 130.7, 130.1, 128.6, 128.5, 128.2, 127.9, 127.7, 121.9, 116.8, 67.5, 67.0, 
58.6, 42.0, 22.8, 13.4; IR (thin film): ν 2924, 1727, 1699, 1403 cm-1; MS m/z (%) 367 (40), 282 
(66), 238 (45), 91 (100); EI-HRMS calcd for C22H25NO4 m/z [M]+ 367.1784; found 367.1775. 
N
Cbz
O
O
H
H
185  
3-Ethylidene-9a-methyl-7-oxo-2,3,5,6a,7,9,9a,9b-octahydro-6H-8-oxa-1-azaphenalene-1-
carboxylic acid benzyl ester (185). A solution of tetraene 184 (0.120 g, 0.327 mmol) in DMSO 
(60 mL), was heated to 80 °C for 8 h. The solution was then allowed to cool to rt and diluted 
with 120 mL of water. The cloudy mixture was extracted with Et2O (3 x 70 mL), the extracts 
were combined and washed with water (100 mL), dried over MgSO4 and concentrated under 
vacuum. Purification of the crude residue by flash chromatography (hexanes-EtOAc, 1 : 1, v/v) 
afforded 185 (0.052 g, 43%).  
1H NMR (CDCl3, 300 MHz): δ 7.41-7.32 (m, 5H), 6.34 (bs, 1H), 5.93 (q, J = 7.1 Hz, 1H), 5.18  
(d, J = 12.2 Hz, 1H),  5.11 (d, J = 12.2 Hz, 1H), 5.00 (d, J = 14.9 Hz, 1H), 4.89 (d, J = 10.8 Hz, 
1H), 3.96 (d, J = 10.8 Hz, 1H), 3.56 (d, J = 14.9 Hz, 1H), 3.10 (dt, J = 6.6, 3.8 Hz, 1H), 3.00-
2.97 (m, 1H), 2.49 (dq, J = 12.9, 3.4 Hz, 1H), 2.14-2.11 (m, 2H), 1.72 (s, 3H), 1.71 (d, J = 7.1 
Hz, 3H), 1.55 (m, 1H); 13C NMR (CDCl3, 75 MHz): δ 172.0, 154.6, 136.2, 131.8, 128.6, 128.2, 
128.0, 121.8, 116.9, 70.5, 67.4, 55.5, 42.0, 40.1, 37.0, 24.4, 21.0, 19.6, 13.4; IR (thin film): ν 
2920, 1732, 1693, 1403, 1354, 1221, 1167, 1053 cm-1; MS m/z (%) 367 (10), 316 (15), 276 (23), 
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129 (62), 91 (100); EI-HRMS  calculated for C22H25NO4  m/z [M]+ 367.1784; found 367.1785. 
 
General procedure L for preparation of cycloadducts 186a-c. 
N
N
N
Cbz
O
O
H
H
N
O
O
PhH
186a  
3a,6-Dimethyl-1,7,9-trioxo-8-phenyl-3,3a,6,8,9,9b,10,11,11a,11b-decahydro-1H,5H,7H-2-
oxa-4,6a,8,9a-tetraazacyclopenta[a]pyrene-4-carboxylic acid benzyl ester (186a). To a 
solution of diene 185 (10 mg, 27 µmol) in toluene (0.5 mL) was added 4-phenyl-1,2,4-
triazoline-3,5-dione (5 mg, 27 µmol) and the reaction was stirred at rt for 10 min until the red 
color of the dienophile disappeared. The reaction mixture was then directly purified by flash 
chromatography (hexanes/EtOAc, 4 : 1 to 1 : 1, v/v) to afford 186a (15 mg, >95%).  
1H NMR (300 MHz, CDCl3): δ 7.48-7.28 (m, 10H), 5.19 (d, J = 12.1 Hz, 1H), 5.14 (d, J = 12.2 
Hz, 1H), 4.62-4.57 (m, 1H), 4.51-4.41 (m, 2H), 4.20-4.14 (m, 1H), 3.64 (d, J = 15.4 Hz, 1H), 
3.26-3.17 (m, 1H), 3.00-2.96 (m, 1H), 2.86-2.81 (m, 1H), 2.07-1.95 (m, 1H), 1.75 (s, 3H), 1.71-
1.59 (m, 1H), 1.31 (d, J = 6.5 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 172.8, 154.7, 154.6, 
150.5, 135.8, 131.0, 130.8, 129.1, 128.8, 128.5, 128.4, 128.3, 128.3, 125.6, 72.8, 67.9, 56.1, 54.1, 
51.1, 42.8, 42.3, 33.6, 23.4, 21.7, 19.4, 16.4;  IR (thin film): ν 2928, 1772, 1713, 1415 cm-1; MS 
m/z (%) 542 (18), 451 (32), 91 (100); EI-HRMS calcd for C30H30N4O6 m/z [M]+ 542.2165; found 
542.2181. 
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186b  
3a,6-Dimethyl-1,7,9-trioxo-8-phenyl-3,3a,5,6,6a,7,8,9,9a,9b,10,11,11a,11b-tetradecahydro-
1H-2-oxa-4,8-diazacyclopenta[a]pyrene-4-carboxylic acid benzyl ester (186b).  Prepared by 
following general procedure L, using 185 (10 mg, 27 µmol), N-phenylmaleimide (7 mg, 40 
µmol). Reaction time (6 h at rt). Isolated yield 186b (15 mg, >95%). 1H NMR (300 MHz, 
CDCl3): δ 7.44-7.33 (m, 8H), 7.14-7.09 (m, 2H), 5.31 (d, J = 11.8 Hz, 1H), 5.13 (s, 2H), 4.44 (d, 
J = 18.1 Hz, 1H), 4.13 (d, J = 11.8 Hz, 1H), 3.67 (dq, J = 18.1, 2.2 Hz, 1H), 3.30 (dd, J = 8.5, 6.3 
Hz, 1H), 3.19 (dd, J = 8.5, 5.2 Hz, 1H), 3.13-3.04 (m, 1H), 2.69-2.61 (m, 2H), 2.45 (bs, 1H), 
2.30-2.17 (m, 1H), 2.13-1.90 (m, 2H), 1.54 (d, J = 7.3 Hz, 3H), 1.40 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 176.4, 176.2, 173.8, 155.9, 136.2, 132.1, 131.5, 129.1, 128.6, 128.6, 128.1, 127.7, 
127.4, 126.1, 71.1, 67.3, 56.1, 46.4, 44.4, 42.1, 41.6, 36.9, 33.0, 23.3, 21.8, 20.7, 12.9, 1.0; IR 
(thin film): ν 2940, 1747, 1706, 1381 cm-1; MS m/z (%) 540 (8), 495 (37), 449 (29), 405 (65), 91 
(100); EI-HRMS calcd for C32H32N2O6 m/z [M]+ 540.2260; found 540.2281. 
N
Cbz
O
O
H
H
O
O
O
H
186c  
3a,6-Dimethyl-1,7,9-trioxo-3,3a,6,6a,7,9,9a,9b,10,11,11a,11b-dodecahydro-1H,5H-2,8-
dioxa-4-azacyclopenta[a]pyrene-4-carboxylic acid benzyl ester (186c). Prepared by following 
general procedure L, using 185 (18 mg, 49 µmol), maleic anhydride (7 mg, 71 µmol). Reaction 
time (3 h at rt). Isolated yield 186c (18 mg, 78%).  
1H NMR (300 MHz, CDCl3): δ 7.40-7.33 (m, 5H), 5.22 (d, J = 11.9 Hz, 1H), 5.13 (s, 2H), 4.37 
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(d, J = 18.0 Hz, 1H), 4.14 (d, J = 11.9 Hz, 1H), 3.69 (d, J = 16.5 Hz, 1H), 3.40 (dd, J = 9.2, 6.2 
Hz, 1H), 3.30 (dd, J = 9.1, 4.8 Hz, 1H), 3.08 (q, J = 8.1 Hz, 1H), 2.64-2.62 (m, 1H), 2.41 (bs, 
1H), 2.10-1.89 (m, 2H), 1.47 (d, J = 7.0 Hz, 3H), 1.45 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
173.6, 171.2, 171.1, 155.8, 136.9, 132.8, 128.6, 128.1, 128.1, 127.8, 71.5, 67.5, 56.1, 47.2, 45.1, 
42.1, 41.7, 36.5, 35.6, 32.3, 22.7, 22.1, 20.4, 12.5; IR (thin film): ν 2947, 1775, 1746, 1705 cm-1. 
MS m/z (%) 465 (10), 437 (28), 330 (38), 91 (100); EI-HRMS calcd for C26H27NO7 m/z [M]+ 
465.1788; found 465.1782. 
 
General procedure M for the Rh(I)-catalyzed cycloisomerization of ene-allenes. 
N
MeO2C
Bn
Bz
189  
1-Benzoyl-2-benzyl-4-ethylidene-5-methyl-2,3,4,5-tetrahydro-1H-azepine-2-carboxylic acid 
methyl ester (189). To a solution of ene-allene 75a  (30 mg,  77 µmol) in 1,2-dichloroethane (1 
mL) in a test tube, was added [Rh(CO)2Cl]2 (1.5 mg, 3.8 µmol) at rt under Ar atmosphere. The 
test tube was then immersed in an oil-bath preheated to 90 °C and heating was continued for 2 h. 
After this time, another portion of the catalyst was added [Rh(CO)2Cl]2 (1.5 mg, 3.8 µmol) and 
the reaction was heated to 90 °C for additional 15 min when it was complete according to TLC. 
The reaction mixture was then cooled to rt, and filtered through a plug of silica gel eluting with 
(hexanes-EtOAc, 1 : 1, v/v) to give azepine 189 (30 mg, > 95%). 
1H NMR (300 MHz, CDCl3): δ 7.57-7.54 (m, 2H), 7.42-7.35 (m, 3H), 7.23-7.19 (m, 5H), 5.52 
(q, J = 6.8 Hz, 1H), 5.03 (dd, J = 8.1, 2.5 Hz, 1H), 4.53 (dd, J = 8.1, 4.1 Hz, 1H), 4.20 (d, J = 
13.6 Hz, 1H), 3.75 (s, 3H), 3.40 (bs, 1H), 3.14 (d, J = 13.6 Hz, 1H), 2.83 (d, J = 14.6 Hz, 1H), 
2.66 (d, 14.6 Hz, 1H), 1.63 (d, J = 6.8 Hz, 3H), 1.08 (d, J = 7.1 Hz, 1H); 13C NMR (CDCl3, 75 
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MHz): δ 172.7, 171.4, 137.0, 136.4, 135.1, 130.9, 130.4, 128.4, 128.1, 128.0, 127.8, 126.8, 
125.7, 121.9, 69.0, 52.5, 40.4, 36.9, 34.7, 21.4, 13.6; IR (thin film): ν 2950, 1736, 1637, 1446, 
1350, 1223 cm-1; MS m/z (%) 389 (38), 358 (15), 330 (42), 298 (42), 105 (100); EI-HRMS calcd 
for C25H27NO3 [M]+, m/z 389.1991 found 389.1984. 
N
MeO2C Bn
Bz
211  
1-Benzoyl-2-benzyl-4-ethylidene-2,3,4,5-tetrahydro-1H-azepine-2-carboxylic acid methyl 
ester (211). Prepared by following general procedure M using: 75b (0.12 g, 0.32 mmol). First 
portion of [Rh(CO)2Cl]2 (6 mg, 15 µmol) was added at 70 °C. After 2 h at 90 °C another portion 
of [Rh(CO)2Cl] (6 mg, 15 µmol) was added and the reaction was heated to 90 °C for additional 2 
h. Upon completion, the reaction mixture was filtered through a plug of silica gel to afford 211 
(80 mg, 66%) as a mixture of E and Z olefin isomers in ratio of ~2.5 : 1. The isomers were 
separated by semi-preparative HPLC (hexanes-EtOAc, 24 : 1, v/v, flow rate 3 mL/min, UV 
detector at 254 nm) and assigned by nOe spectroscopy. 
N CH3
MeO2C Bn
Bz
H
H
H
0%
2.9%
1%
N
MeO2C Bn
Bz
H
H
H
CH3
1.8% 0%
major 211a minor 211b  
N
MeO2C Bn
Bz
211a  
(Z)-211a:  (major isomer – Rt  = 35 min): 1H NMR (CDCl3, 300MHz): δ 7.55-7.51 (m, 2H), 
7.42-7.34 (m, 3H), 7.26-7.16 (m, 5H), 5.44 (q, J = 7.0 Hz, 1H), 5.13 (dd, J = 7.7, 2.5 Hz, 1H), 
 232 
4.98 (dt, J = 7.7, 5.1 Hz, 1H), 4.19 (d, J = 13.7 Hz, 1H), 3.75 (s, 3H), 3.36 (d, J = 16.6 Hz, 1H), 
3.14 (d, J = 13.7 Hz, 1H), 2.84 (d, J = 14.9 Hz, 1H), 2.71-2.58 (m, 2H), 1.62 (d, J = 7.0 Hz, 3H); 
13C NMR (CDCl3, 75 MHz): δ 172.7, 171.2, 136.9, 136.4, 130.9, 130.4, 129.9, 129.6, 128.2, 
128.1, 128.0, 126.8, 122.2, 120.0, 68.3, 52.4, 40.3, 35.6, 33.1, 13.4; IR (thin film): ν 2949, 1736, 
1663, 1635, 1446, 1352 cm-1; MS m/z (%) 375 (38), 344 (8), 316 (15), 284 (22), 105 (100);  EI-
HRMS calcd for C24H25NO3 [M] +, m/z 375.1834; found 375.1831. 
N
MeO2C Bn
Bz
211b  
(E)-211b: (minor isomer – Rt  = 37 min): 1H NMR (CDCl3, 300MHz): δ 7.54-7.51 (m, 2H), 
7.45-7.34 (m, 3H), 7.25-7.17 (m, 5H), 5.38 (bq, 1H), 5.16 (dd, J = 7.6, 2.6 Hz, 1H), 5.04 (dt, J = 
7.8, 4.8 Hz, 1H), 4.18 (d, J = 13.7 Hz. 1H), 3.71 (s, 3H), 3.16-3.11 (m, 1H), 3.08 (d, J = 13.7 Hz, 
1H), 2.90 (d, J = 14.3 Hz, 1H), 2.75 (dd, J = 17.6, 8.2 Hz, 1H), 2.36 (d, J = 14.3 Hz, 1H), 1.58 
(d, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 75MHz): δ 172.8, 171.1, 137.0, 136.5, 130.9, 130.6, 
130.4, 128.1, 126.7, 121.8, 120.0, 69.2, 52.0, 44.2, 40.0, 26.3, 13.1; IR (thin film): ν 2948, 1736, 
1664, 1635, 1446, 1353 cm-1; MS m/z (%) 375 (45), 344 (26), 316 (47), 284 (22), 105 (100);  EI-
HRMS calcd for C24H25NO3 [M]+, m/z 375.1834; found 375.1850. 
N
MeO2C
Cbz
212  
4-Ethylidene-2,5-dimethyl-2,3,4,5-tetrahydroazepine-1,2-dicarboxylic acid 1-benzyl ester 2-
methyl ester (212). Prepared by following general procedure M using: 75c (0.105 g, 0.306 
mmol). First portion of [Rh(CO)2Cl]2 (6 mg, 15 µmol) was added at 70 °C. After 2 h at 90 °C 
another portion of [Rh(CO)2Cl] (6 mg, 15 µmol) was added and the reaction was heated to 90 °C 
 233 
for additional 2 h.. Upon completion, the reaction mixture was purified by flash chromatography 
(hexanes-EtOAc, 30 : 1 to 20 : 1, v/v) to afford 212 (70 mg, 63%).  
1H NMR (300 MHz, CDCl3): δ 7.36-7.29 (m, 5H), 6.24 (d, J = 8.8 Hz, 1H), 5.48 (q, J = 6.9 Hz, 
1H), 5.19 (d, J = 12.3 Hz, 1H), 5.10 (d, J = 12.3 Hz, 1H), 4.91 (dd, J = 8.8, 4.1 Hz, 1H), 3.66 (bs, 
3H), 3.23 (m, 1H), 2.73 (d, J = 14.6 Hz, 1H), 2.51 (d, J = 14.6 Hz, 1H), 1.61 (s, 3H), 1.56 (d, J = 
6.9 Hz, 3H), 1.14 (d, J = 7.2 Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 173.6, 154.8, 135.5, 128.6, 
128.2, 123.9, 123.0, 122.1, 67.8, 65.9, 52.5, 38.2, 37.3, 23.7, 21.6, 14.0; IR (thin film): ν 3400, 
2951, 1742, 1710, 1456, 1387, 1304 cm-1; MS (by GC/MS) m/z 284 [M-59]+. 
N
MeO2C
Cbz
213  
4-Isobutylidene-2,5-dimethyl-2,3,4,5-tetrahydroazepine-1,2-dicarboxylic acid 1-benzyl ester 
2-methyl ester (213). Prepared by following general procedure M using: 75d (35 mg, 94 µmol), 
[Rh(CO)2Cl]2 (3.6 mg, 9.4 µmol) added in one portion at rt. Heated at 90 °C for 5 h. Yield of 213 
(18 mg, 51 %).  
1H NMR (CDCl3, 300MHz): δ 7.35 (s, 5H), 6.23 (d, J = 7.2 Hz, 1H), 5.22-5.09 (m, 3H), 4.99 (s, 
1H), 3.67 (bs, 3H), 3.29 (s, 1H), 2.72 (d, J = 14.9 Hz, 1H), 2.53 (d, J = 15.0 Hz, 1H), 2.48-2.30 
(m, 1H), 1.61 (s, 3H), 1.15 (d, J = 7.0 Hz, 3H), 0.91 (d, J = 6.4 Hz, 6H); 13C NMR (CDCl3, 
75MHz): δ 173.5, 154.7, 135.0, 131.9, 128.6, 128.2, 124.2, 67.7, 65.2, 52.3, 38.2, 36.3, 29.8, 
27.4, 23.4, 20.4; IR (thin film): ν 2956, 1743, 1710, 1306 cm-1. 
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NMeO2C
Bz
OTBS
214  
1-Benzoyl-2-(tert-butyl-dimethylsilyloxymethyl)-4-ethylidene-5-methyl-2,3,4,5-tetrahydro-
1H-azepine-2-carboxylic acid methyl ester (214). Prepared by following general procedure M 
using: 75e (32 mg, 72 µmol). First portion of [Rh(CO)2Cl]2 (1.5 mg, 3.8 µmol) was added at rt 
°C. After 15 min at 90 °C another portion of [Rh(CO)2Cl] (3 mg, 7.6 µmol) was added and the 
reaction was heated to 90 °C for additional 2 h. Upon completion, the reaction mixture was 
purified by flash chromatography (pentanes-Et2O, 3 : 1, v/v) to afford 214 (23 mg, 72 %)  as a 4 : 
1 mixture of diastereomers determined by 1H NMR. 
214: (major diastereomer): 1H NMR (CDCl3, 300MHz): δ 7.57-7.52 (m, 2H), 7.42-7.33 (m, 3H), 
5.89 (dd, J = 8.3, 2.6 Hz, 1H), 5.55 (q, J = 6.8 Hz, 1H), 4.83 (dd, J = 8.3, 3.9 Hz, 1H), 4.66 (d, J 
= 9.9 Hz, 1H), 3.89 (d, J = 9.9 Hz, 1H), 3.69 (s, 3H), 3.46 (bs, 1H), 3.04 (d, J = 14.9 Hz, 1H), 
2.64 (d, J = 14.8 Hz, 1H), 1.58 (d, J = 6.8 Hz, 3H), 1.19 (d, J = 7.2 Hz, 3H), 0.86 (s, 9H), 0.07 (s, 
3H), 0.03 (s, 3H): 13C NMR (CDCl3, 75MHz): δ 171.5, 171.4, 136.2, 135.3, 130.4, 129.2, 128.6, 
128.0, 124.1, 121.9, 69.2, 64.6, 52.2, 37.8, 32.4, 25.8, 21.9, 18.0, 13.6, -5.3, -5.6; IR (thin film): 
ν 2953, 1734, 1641, 1342 cm-1; MS m/z (%) 443 (67), 428 (49), 413 (37), 386 (40), 105 (100);  
EI-HRMS calcd for C25H37NO4Si [M]+, m/z 443.2492; found 443.2500. 
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General procedure N for the Rh(I)-catalyzed cyclocarbonylation reaction affording 4-
alkylidene cyclopentenones. 
N
Bz
MeO2C
Bn
O
270a  
2-Benzoyl-3-benzyl-5,7-dimethyl-6-oxo-2,3,5,6-tetrahydro-1H-[2]pyrindine-3-carboxylic 
acid methyl ester (270a). To a test tube equipped with a magnetic stirring bar was added 
[Rh(CO)2Cl]2 (18 mg, 46 µmol) and DCE (1 mL). To this solution, PPh3 (36 mg, 137 µmol) in 
DCE (1 mL) was added dropwise via a syringe at rt. The test tube was evacuated under vacuum 
by inserting a needle and charged three times with CO from a balloon. After 5 min, AgBF4 (2 
mL of a 0.05 M solution in DCE, 0.102 mmol) was added dropwise via a syringe. The mixture 
was stirred for additional 5 min at rt and then the allenyne 73a (0.180 g, 0.465 mmol) in DCE (1 
mL) was added via a syringe. After 1 h the reaction mixture was directly applied to a silica gel 
column eluted (gradient elution, hexanes-EtOAc, 4 : 1 to 1 : 1, v/v) to afford the 4-alkylidene 
cyclopentenone 270a (0.142 g, 73%) in 1.7 : 1 diastereomeric ratio determined by integration of 
the olefin resonances in the 1H NMR spectrum. 
Notes: [Rh(CO)2Cl]2 and PPh3 were both weighed out in an open atmosphere. AgBF4 was 
weighed out in a vial, in the glove box under nitrogen atmosphere and caution was taken to limit 
exposure to light by wrapping the vial in aluminum foil. DCE solution of AgBF4 was prepared 
by sonication for 5 min. 
IR (thin film): ν 3027, 2918, 1740, 1704, 1644, 1384, 1250 cm-1; MS m/z (%) 415 (15), 384 (15), 
324 (31), 105 (100); EI-HRMS calcd for C26H25NO4 [M]+ m/z 415.1784, found 415.1802. 
The diastereomers were separated by HPLC (hexanes:EtOAc 4 : 1, flow rate 3 mL/min, UV 
detector at 254 nm). 
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270a (major diastereomer-eluting first, Rf = 0.21, TLC, hexanes : EtOAc, 2 : 1): 1H NMR (300 
MHz, CDCl3): δ 7.46-6.98 (m, 10H), 5.71 (s, 1H), 4.34 (d, J = 17.7 Hz, 1H),  4.15 (d, J = 13.7 
Hz ,1H), 3.79 (s, 3H), 3.38 (d, J = 13.7 Hz, 1H), 2.86 (d, J = 17.7 Hz, 1H), 2.84 (q, J = 7.4 Hz, 
1H), 1.46 (s, 3H), 1.25 (d, J = 7.4Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 206.5, 171.8, 171.6, 
153.6, 140.8, 136.4, 135.9, 134.4, 130.6, 130.2, 128.9, 128.4, 127.4, 126.7, 119.9, 66.3, 53.2, 
44.4, 42.0, 40.0, 13.6, 8.1.  
270a (minor diastereomer-eluting second, Rf = 0.16, TLC, hexanes : EtOAc, 2 : 1): 1H NMR 
(300 MHz, CDCl3): δ 7.47-6.89 (m, 10H), 5.72 (s, 1 H), 4.34 (d, J = 18.2 Hz, 1H),  4.16 (d, J = 
13.8 Hz 1H), 3.81 (s, 3H), 3.39 (d, J = 13.8 Hz, 1H), 2.99 (d, J = 18.2 Hz, 1H), 2.86 (q, J = 7.6 
Hz, 1H), 1.44 (s, 3H), 1.31 (d, J = 7.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 206.6, 172.1, 
171.9, 154.0, 140.5, 136.5, 134.5, 130.9, 130.3, 129.1, 128.4, 127.5, 126.8, 120.2, 66.3, 53.3, 
44.9, 41.9, 40.2, 14.5, 8.1.  
N
Bz
MeO2C
Bn
TMS
O
270c  
2-Benzoyl-3-benzyl-5-methyl-6-oxo-7-trimethylsilyl-2,3,5,6-tetrahydro-1H-[2]pyrindine-3-
carboxylic acid methyl ester (270c). Prepared by following general procedure N, using: 
73c (50 mg, 112 µmol), [Rh(CO)2Cl]2 (4 mg, 11 µmol), PPh3 (9 mg, 34 µmol), AgBF4 (250 µL 
of 0.1 M solution in DCE, 25 µmol). The reaction was heated at 35 °C for 1 h.   
Yield 270c (52 mg, 98%) as a mixture of diastereomers in 1.6 : 1 ratio. The diastereomers were 
separated by semi-preparative HPLC (hexanes-EtOAc, 4 : 1 v/v, flow rate 3 mL/min, UV 
detector at 254 nm). 
270c (major diastereomer – eluting first): 1H NMR (300 MHz, CDCl3): δ 7.45-7.19 (m, 10H), 
5.78 (s, 1H), 4.41 (d, J = 18.1 Hz, 1H), 4.15 (d, J = 13.7 Hz, 1H), 3.82 (s, 3H), 3.38 (d, J = 13.7 
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Hz, 1H), 2.86-2.79 (m, 1H), 2.82 (d, J = 16.8 Hz, 1H), 1.23 (d, J = 7.4 Hz, 1H), -0.14 (s, 9H). 
13C NMR (75 MHz, CDCl3): δ 210.2, 171.7, 171.6, 165.5, 142.8, 138.2, 136.3, 136.0, 130.6, 
130.0, 128.9, 128.4, 127.3, 126.3, 121.5, 65.7, 53.2, 46.4, 42.9, 40.0, 13.8, -1.3; IR (thin film): ν 
2952, 1742, 1694, 1647, 1250 cm-1; MS m/z (%) 473 (5), 458 (22), 382 (45), 105 (100); EI-
HRMS calcd for C28H31NO4Si m/z [M]+ 473.2022; found 473.2033. 
270c (minor diastereomer – eluting second): 1H NMR (300 MHz, CDCl3): δ 7.45-7.42 (m, 3H), 
7.34-7.31 (m, 2H), 7.27-7.24 (m, 3H), 7.19-7.16 (m, 2H), 5.77 (d, J = 1.0 Hz, 1H), 4.39 (d, J = 
18.5, 1.2 Hz, 1H), 4.15 (d, J = 13.7 Hz, 1H), 3.83 (s, 3H), 3.38 (d, J = 13.7 Hz, 1H), 2.94 (d, J = 
18.5 Hz, 1H), 2.80 (q, J = 7.6 Hz, 1H), 1.29 (d, J = 7.5 Hz, 3H), -0.15 (s, 9H); 13C NMR (75 
MHz, CDCl3): δ 210.0, 171.7, 171.5, 165.8, 142.2, 138.0, 136.0, 130.7, 129.9, 128.8, 128.1, 
127.2, 126.2, 121.5, 65.5, 53.0, 46.7, 42.5, 39.9, 14.2, -1.5; IR (thin film): ν 2953, 1742, 1695, 
1649, 1250 cm-1; MS m/z (%) 473 (5), 458 (22), 382 (45), 105 (100);  EI-HRMS calcd for 
C28H31NO4Si m/z [M]+ 473.2022; found 473.2042. 
N
Bz
MeO2C
Bn
Ph
O
270d  
2-Benzoyl-3-benzyl-5-methyl-6-oxo-7-phenyl-2,3,5,6-tetrahydro-1H-[2]pyrindine-3-
carboxylic acid methyl ester (270d). Prepared by following general procedure N, using: 
73d (37 mg, 82 µmol), [Rh(CO)2Cl]2 (3 mg, 8 µmol), PPh3 (6 mg, 25 µmol), AgBF4 (180 µL of 
0.1 M solution in DCE, 18 µmol). The reaction was heated at 35 °C for 1 h.   
Yield 270d (29 mg, 74%) as a mixture of diastereomers in ratio 1.6 : 1. The diastereomers were 
separated by semi-preparative HPLC (hexanes/EtOAc, 5 : 1, v/v, flow rate 3 mL/min, UV 
detector at 254 nm). 
270d (major diastereomer, Rt = 15 min, HPLC, hexanes/EtOAc, 5 : 1, v/v): 1H NMR (300 MHz, 
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CDCl3): δ 7.42-7.17 (m, 13H), 7.04-7.00 (m, 2H), 5.88 (d, J = 1.1 Hz, 1H), 4.60 (d, J = 17.7 Hz, 
1H), 4.18 (d, J = 13.7 Hz, 1H), 3.81 (s, 3H), 3.44 (d, J = 13.8 Hz, 1H), 3.10-2.98 (m, 2H), 1.36 
(d, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 204.7, 171.8, 171.7, 153.6, 141.2, 136.6, 
135.9, 135.5, 130.8, 130.3, 130.1, 128.9, 128.8, 128.7, 128.7, 128.6, 127.6, 126.8, 122.2, 66.6, 
59.9, 53.3, 45.2, 42.9, 40.3, 13.9; IR (thin film): ν 2949, 1741, 1706, 1643 1259 cm-1; MS m/z 
(%) 477 (6), 418 (63), 386 (55), 105 (100); EI-HRMS calcd for C31H27NO4 m/z [M]+ 477.1940; 
found 477.1954. 
270d (minor diastereomer, Rt  = 18 min HPLC, hexanes/EtOAc 5 : 1, v/v): 1H NMR (300 MHz, 
CDCl3): δ 7.40-7.20 (m, 13H), 7.03-6.99 (m, 2H), 5.90 (d, J = 0.9 Hz, 1H), 4.59 (d, J = 18.2, 1.2 
Hz, 1H), 4.19 (d, J = 13.8 Hz, 1H), 3.83 (s, 3H), 3.45 (d, J = 13.8 Hz, 1H), 3.17 (d, J = 18.3 Hz, 
1H), 3.03 (q, J = 7.5 Hz, 1H), 1.41 (d, J = 7.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 204.9, 
172.1, 171.7, 153.8, 140.7, 136.4, 136.0, 135.5, 130.9, 130.3, 130.1, 129.1, 128.8, 128.7, 128.6, 
128.5, 127.6, 126.8, 122.5, 66.4, 53.3, 45.6, 42.6, 40.3, 14.9; IR (thin film): ν 2950, 1741, 1706, 
1645, 1235 cm-1; MS m/z (%) 477 (10), 418 (15), 386 (25), 105 (100); EI-HRMS calcd for 
C31H27NO4 m/z [M]+ 477.1940; found 477.1941. 
N
Bz
MeO2C
O
270e
TBSO
 
2-Benzoyl-3-(tert-butyldimethylsilyloxymethyl)-5,7-dimethyl-6-oxo-2,3,5,6-tetrahydro-1H-
[2]pyrindine-3-carboxylic acid methyl ester (270e). Prepared by following general procedure 
N, using: 73e (50 mg, 113 µmol), [Rh(CO)2Cl]2 (4 mg, 11 µmol), PPh3 (9 mg, 34 µmol), AgBF4 
(250 µL of 0.1 M solution in DCE, 25 µmol). The reaction was heated at 35 °C for 1 h.   
Yield 270e (43 mg, 81%) as a mixture of diastereomers in 1.7 : 1 ratio. The diastereomers were 
separated by semi-preparative HPLC (hexanes-EtOAc, 6 : 1 v/v, flow rate 3 mL/min, UV 
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detector at 254 nm). 
IR (thin film): ν 2953, 1741, 1708, 1648, 1258 cm-1. 
270e (major diastereomer, Rt  = 17 min, HPLC, hexanes-EtOAc, 6 : 1 v/v): 1H NMR (300 MHz, 
CDCl3): δ 7.49-7.43 (m, 5H), 5.56 (s, 1H), 4.75 (d, J = 17.1 Hz, 1H), 4.74 (d, J = 10.4 Hz, 1H), 
4.45 (d, J = 17.4 Hz, 1H), 4.15 (d, J = 10.3 Hz, 1H), 3.74 (s, 3H), 2.89 (q, J = 7.5 Hz, 1H), 1.65 
(s, 3H), 1.28 (d, J  = 7.5 Hz, 3H), 0.81 (s, 9H), 0.07 (s, 3H), 0.02 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 206.5, 171.7, 170.5, 154.3, 144.3, 141.3, 135.9, 134.3, 130.0, 128.8, 126.5, 118.8, 
66.1, 65.3, 52.6, 45.6, 41.9, 25.7, 18.0, 13.6, 7.9, -5.4, -5.6; MS m/z (%) 469 (37), 439 (30), 412 
(30), 324 (20), 105 (100); EI-HRMS calcd for C26H35NO5Si m/z [M]+ 469.2285; found 469.2280. 
270e (minor diastereomer, Rt  = 26 min, HPLC, hexanes-EtOAc, 6 : 1 v/v): 1H NMR (300 MHz, 
CDCl3): δ 7.50-7.42 (m, 5H), 5.59 (s, 1H), 4.74 (d, J = 18.0 Hz, 1H), 4.72 (d, J = 10.2 Hz, 1H), 
4.47 (1d, J = 17.8 Hz, 1H), 4.15 (d, J = 10.3 Hz, 1H), 3.75 (s, 3H), 2.91 (q, J = 7.6 Hz, 1H), 1.64 
(s, 3H), 1.27 (d, J = 7.6 Hz, 9H), 0.80 (s, 3H), 0.07 (s, 3H), 0.02 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 206.6, 171.9, 170.4, 154.6, 141.2, 135.9, 134.2, 130.0, 128.9, 126.5, 118.8, 65.9, 65.1, 
52.6, 45.9, 41.6, 25.6, 17.9, 14.2, 7.9, -5.5, -5.7; MS m/z (%) 469 (7), 439 (30), 412 (35), 324 
(22), 105 (100); EI-HRMS calcd for C26H35NO5Si m/z [M]+ 469.2285; found 469.2299. 
N
O
MeO2C
Cbz
270f  
3,5,7-Trimethyl-6-oxo-1,3,5,6-tetrahydro-[2]pyrindine-2,3-dicarboxylic acid 2-benzyl ester 
3-methyl ester (270f).  Prepared by following general procedure N, using: 73f (25 mg, 73 µmol), 
[Rh(CO)2Cl]2 (3 mg, 8 µmol), PPh3 (5 mg, 20 µmol), AgBF4 (150 µL of 0.1 M solution in DCE, 
15 µmol). The reaction was stirred at rt for 1 h.  Yield 270f (19 mg, 75%). 
1H NMR (300 MHz, DMSO-d6): δ 7.41-7.30 (m, 5H), 5.72 (s, 1H), 5.15 (s, 2H), 4.86 (d, J = 
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18.6 Hz, 1H), 4.34 (d, J = 18.0 Hz, 1H), 3.48 (bs, 3H), 2.87 (q, J = 7.4 Hz, 1H), 1.73 (s, 3H), 
1.57 (s, 3H), 1.07 (d, J = 7.5 Hz, 3H); 13C NMR (75 MHz, DMSO-d6): δ 206.4, 192.6, 172.7, 
155.5, 154.9, 138.6, 137.0, 134.6, 129.2, 128.8, 128.5, 121.7, 67.7, 62.5, 53.1, 41.6, 40.7, 22.9, 
14.1, 8.5; IR (thin film): ν 2916, 1744, 1700, 1234 cm-1; MS m/z (%) 369 (15), 310 (40), 266 
(27), 91 (100); EI-HRMS calcd for C21H23NO5 m/z [M]+ 369.1576; found 369.1581. 
N
O
TMS
MeO2C
Cbz
270h  
3,5-Dimethyl-6-oxo-7-trimethylsilyl-1,3,5,6-tetrahydro-[2]pyrindine-2,3-dicarboxylic acid 
2-benzyl ester 3-methyl ester (270h). Prepared by following general procedure N, using: 73h 
(30 mg, 75 µmol), [Rh(CO)2Cl]2 (3 mg, 8 µmol), PPh3 (6 mg, 23 µmol), AgBF4 (335 µL of 0.05 
M solution in DCE, 17 µmol). The reaction was stirred at rt for 2 h.  Yield 270h (25 mg, 78%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.37 (s, 5H), 5.80 (s, 1H), 5.18-5.09 (m, 2H), 5.01 (d, 
J = 18.6 Hz, 1H), 4.46 (d, J = 18.6 Hz, 1H), 3.53 (s, 3H), 2.84 (q, J = 7.4 Hz, 1H), 1.61 (s, 3H), 
1.07 (d, J = 7.4 Hz, 3H), 0.12 (s, 9H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 209.5, 171.4, 
166.2, 154.4, 139.7, 136.7, 135.9, 128.1, 127.8, 127.4, 122.9, 66.8, 61.3, 52.1, 41.7, 41.6, 21.3, 
13.3, -1.3; IR (thin film): ν 2953, 1746, 1694, 1248 cm-1; MS m/z (%) 427 (11), 384 (30), 368 
(32), 324 (27), 91 (100); EI-HRMS calcd for C23H29NO5Si m/z [M]+ 427.1815; found 427.1821. 
N
O
Ph
MeO2C
Cbz
270i  
3,5-Dimethyl-6-oxo-7-phenyl-1,3,5,6-tetrahydro-[2]pyrindine-2,3-dicarboxylic acid 2-
benzyl ester 3-methyl ester (270i). Prepared by following general procedure N, using: 73i (31 
mg, 77 µmol), [Rh(CO)2Cl]2 (3 mg, 8 µmol), PPh3 (6 mg, 23 µmol), AgBF4 (340 µL of 0.05 M 
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solution in DCE, 17 µmol). The reaction was stirred at rt for 2 h.  Yield 270i (25 mg, 75%). 
1H NMR (300 MHz, DMSO-d6, 323 K): δ 7.47-7.32 (m, 10H), 5.90 (s, 1H), 5.16-5.08 (m, 2H), 
4.99 (d, J = 18.6 Hz, 1H), 4.66 (d, J = 18.6 Hz, 1H), 3.51 (s, 3H), 3.09 (q, J = 7.4 Hz, 1H), 1.65 
(s, 3H), 1.20 (d, J = 7.4 Hz, 3H); 13C NMR (75 MHz, DMSO-d6, 323 K): δ 203.7, 171.4, 154.4, 
154.1, 137.7, 135.9, 134.3, 130.0, 128.4, 128.2, 128.1, 127.7, 127.3, 123.2, 66.7, 61.7, 52.1, 40.2, 
21.4, 13.1; IR (thin film): ν 2931, 1745, 1703, 1241 cm-1; MS m/z (%) 431 (10), 372 (86), 328 
(45), 91 (100); EI-HRMS calcd for C26H25NO5 m/z [M]+ 431.1733; found 431.1735. 
N
O
MeO2C
Cbz
270j  
5-Isopropyl-3,7-dimethyl-6-oxo-1,3,5,6-tetrahydro-[2]pyrindine-2,3-dicarboxylic acid 2-
benzyl ester 3-methyl ester (270j). Prepared by following general procedure N, using: 111j (98 
mg, 265 µmol), [Rh(CO)2Cl]2 (5 mg, 13 µmol), PPh3 (10 mg, 39 µmol), AgBF4 (583 µL of 0.05 
M solution in DCE, 29 µmol). The reaction was heated to 35 °C for 2 h.  Yield 270j (78 mg, 
74%). 
1H NMR (300 MHz, CDCl3, 320 K): δ 7.39-7.33 (m, 5H), 5.54 (s, 1H), 5.25 (d, J = 12.2 Hz, 
1H), 5.17 (d, J = 12.2 Hz, 1H), 4.95 (d, J = 18.6 Hz, 1H), 4.21 (d, J = 18.6 Hz, 1H), 3.56 (bs, 
3H), 2.77-2.76 (m, 1H), 2.30-2.17 (m, 1H), 1.81 (s, 3H), 1.69 (s, 3H), 0.93 (d, J = 7.0 Hz, 3H), 
0.86 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3, 320 K): δ 205.9, 172.5, 155.4, 155.3, 
136.0, 135.9, 135.8, 128.5, 128.3, 121.6, 67.8, 62.3, 52.5, 52.1, 40.5, 29.8, 22.5, 19.7, 17.9, 7.9; 
IR (thin film): ν 2958, 1745, 1701, 1238 cm-1; MS m/z (%) 397 (33), 338 (30), 294 (21), 91 
(100); EI-HRMS calcd for C23H27NO5 m/z [M]+ 397.1889; found 397.1888. 
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O
MeO2C
Bz
277  
2-Benzoyl-3,7-dimethyl-6-oxo-2,3,5,6-tetrahydro-1H-[2]pyrindine-3-carboxylic acid methyl 
ester (277). [Rh(CO)2Cl]2 (1.5 mg, 3.8 µmol) was placed in a test tube and  DCE (0.3 mL) was 
added. The test tube was sealed with a rubber septum, the atmosphere evacuated by inserting a 
needle and replaced with CO (balloon) three times. Allenyne 74c (23 mg, 77 µmol) in DCE (0.7 
mL) was added via syringe and the reaction was stirred for 2.5 h at rt. The light yellow solution 
was directly applied to a silica gel column and eluted (hexanes-EtOAc, 4 : 1 to 2 : 1, v/v) to 
afford 277 (18 mg, 72%). 
1H NMR (300 MHz, CDCl3): δ 7.51-7.43 (m, 5H), 5.69 (s, 1H), 4.78 (d, J = 17.6 Hz, 1H), 4.19 
(dd, J = 17.6, 0.9 Hz, 1H), 3.74 (s, 3H), 3.02 (s, 1H), 1.79 (s, 3H), 1.69 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 203.5, 172.1, 171.8, 155.3, 136.2, 135.2, 133.0, 130.6, 128.8, 127.1, 123.0, 
62.4, 52.9, 43.2, 37.4, 20.6, 8.0; IR (thin film): ν 2950, 1740, 1704, 1645, 1394 cm-1. MS m/z 
(%) 325 (25), 294 (9), 266 (47), 105 (100); EI-HRMS calcd for C19H19NO4 m/z [M]+ 325.1314; 
found 325.1324. 
N
MeO2C
Bn
Bz
280a  
2-Benzoyl-3-benzyl-5,6,7-trimethyl-2,3-dihydro-1H-[2]pyrindine-3-carboxylic acid methyl 
ester (280a).  CeCl3·7H2O (2.7 g) was dried under vacuum for 24 h at 140 °C and then THF (10 
mL) was added to prepare a 0.72 M suspension. The suspension was stirred overnight at rt.  
To a 10 mL round-bottom flask was added CeCl3 (180 µL of a 0.72 M suspension in THF, 130 
µmol). THF (2 mL) was added and the suspension was cooled to -78 °C. CH3Li (1.2 M in Et2O, 
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81 µL, 98 µmol) was added and the suspension was stirred at -78 °C for 1.5 h. The resulting 
suspension was cannulated to a solution of 270a (27 mg, 65 µmol) in THF (1 mL) at -78 °C. 
After 1h the reaction was quenched with 0.2 M HCl (10 mL) at -78 °C and warmed to rt. After 
30 min sat’d aq. NaHCO3 was added and the aqueous layer was extracted with Et2O (3 x 20 mL). 
The combined organic layers were dried with MgSO4, filtered and concentrated under vacuum. 
The dark yellow residue was purified by flash chromatography (hexanes-EtOAc, 9 : 1, v/v) to 
afford  280a (20 mg, 74%). The product was stored as a solution in benzene under nitrogen 
atmosphere. 
1H NMR (300 MHz, DMSO-d6): δ 7.48-7.47 (m, 2H), 7.27-7.13 (m, 8H), 6.29 (s, 1H),  4.04 (d, J 
= 15.8 Hz, 1H), 3.92 (d, J = 13.4 Hz, 1H), 3.63 (s, 3H), 3.40 (d, J = 13.4 Hz, 1H), 2.79 (d, J = 
15.8 Hz, 1H), 1.87 (s, 3H), 1.71 (s, 3H), 1.39 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 171.0, 
170.7, 143.3, 140.4, 136.2, 136.0, 134.4, 130.2, 129.7, 128.7, 128.1, 126.9, 126.0, 124.8, 121.9, 
117.5, 66.4, 52.5, 44.1, 10.7, 10.5, 8.9; IR (thin film): ν 3348, 2949, 1740, 1636 cm-1; MS m/z 
(%) 413 (10), 322 (18), 105 (100); EI-HRMS calcd for C27H27NO3 [M]+ m/z 413.1991, found 
413.2007. 
N O
MeO2C
Cbz
274f  
6-Ethylidene-1,4-dimethyl-5-oxo-3,5,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-1,2-
dicarboxylic acid 2-benzyl ester 1-methyl ester (274f). To a solution of allenyne 73f (56 mg, 
0.16 mmol) in toluene (1 mL) was added DMSO (116 µL, 1.64 mmol) followed by Mo(CO)6 (54 
mg, 0.20 mmol) at rt. The reaction vessel was immersed in a preheated oil bath at 70 °C and then 
slowly heated to 90 °C where it was stirred for 45 min. The reaction mixture was then cooled to 
rt, and applied directly to a silica gel column.  Gradient elution (hexanes-EtOAc, 9 : 1 to 4 : 1 
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v/v) afforded a mixture of compounds (60 mg, >95%). The major component of the mixture (Z)-
274f (Rt = 20.5 min) was purified for characterization by semipreparative HPLC (hexanes-
EtOAc, 4 : 1 v/v, flow rate 3 mL/min, UV detector 254 nm). 
(Z)-274f : 1H NMR (300 MHz, DMSO-d6 353K): δ 7.38-7.33 (m, 5H), 5.98 (q, J = 7.3 Hz, 1H), 
5.11 (s, 2H), 4.43 (d, J = 16.2 Hz, 1H), 4.36 (d, J = 16.3 Hz, 1H), 3.89 (s, 1H), 3.67 (s, 3H), 2.20 
(d, J = 7.3 Hz, 3H), 1.75 (s, 3H), 1.06 (s, 3H); 13C NMR (75 MHz, DMSO-d6 353K): δ 195.9, 
172.0, 160.4, 152.7, 135.9, 135.8, 135.5, 132.0, 127.7, 127.3, 127.0, 66.0, 65.4, 53.7, 51.7, 44.8, 
12.9, 12.7, 7.7; IR (thin film): ν 2951, 1743, 1698, 1646, 1408 cm-1; MS m/z (%) 369 (13), 310 
(7), 266 (10), 91 (100); EI-HRMS calcd for C21H23NO5 m/z [M]+ 369.1576 found 369.1580. 
 
General procedure O, for the Mo(CO)6-mediated cyclocarbonylation reaction.  
BzN
MeO2C
Bn
O
287a
H
 
2-Benzoyl-1-benzyl-4-methyl-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydrocyclopenta[c]-
pyrrole-1-carboxylic acid methyl ester (287a). To a solution of allenyne 74a (338 mg, 0.906 
mmol) in toluene (5 mL), were added DMSO (323 µL, 4.55 mmol) and Mo(CO)6 (300 mg, 1.13 
mmol) at rt under nitrogen atmosphere. The reaction mixture was heated to 90 °C for 45 min. 
After cooling to rt, the reaction mixture was directly purified by flash chromatography (gradient 
elution, hexanes-EtOAc, 19 : 1 to 3 : 2, v/v) to afford 287a (210 mg, 57%) and a mixture of 288a 
and 289a  (82 mg, 22%). The correct product ratios listed in Scheme 4.30 were determined by 
integration of the olefinic resonances in the 1H NMR spectrum taken after complete removal of 
all volatiles from a small reaction sample. 
287a (Rf = 0.3, TLC, hexanes-EtOAc, 3 : 1 v/v): 1H NMR (300 MHz, CDCl3): δ 7.60-7.28 (m, 
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10 H), 6.21 (s, 1H), 5.62 (s, 1H), 4.24 (d, J = 14.6 Hz, 1H), 4.19 (d, J = 14.3 Hz, 1H), 3.99 (d, J 
= 14.6, 1.2 Hz, 1H), 3.90 (s, 1H), 3.61 (s, 3H), 3.38 (d, J = 14.3 Hz, 1H), 1.69 (s, 3H); 13C NMR 
(75 MHz, CDCl3): δ 195.5, 171.0, 170.2, 162.6, 140.6, 136.1, 135.9, 134.7, 131.3, 131.1, 128.7, 
128.5, 127.5, 127.3, 117.6, 71.0, 52.2, 50.5, 49.5, 37.9, 8.9; IR (thin film): ν 2950, 1741, 1707, 
1644, 1378, 1340 cm-1; MS m/z (%) 401 (40), 342 (22), 296 (35), 105 (100); EI-HRMS calcd for 
C25H23NO4 m/z [M]+ 401.1627 found 401.1641.  
 
Mixture of 288a and 289a (Rf = 0.2, TLC, hexanes-EtOAc, 3 : 1 v/v). 
BzN
MeO2C
Bn
O
H
288a  
288a: 1H NMR (300 MHz, CDCl3): δ 7.59-7.44 (m, 5H), 7.17-7.10 (m, 3H), 7.01-6.98 (m, 2H), 
6.43 (d, J = 1.9 Hz, 1H), 5.66 (d, J = 1.3 Hz, 1H), 4.32 (d, J = 15.7, 1H), 4.01 (bs, 1H), 3.94 (s, 
3H), 3.84 (d, J = 14.3 Hz, 1H), 3.59 (d, J = 15.6 Hz, 1H), 3.29 (d, J = 14.3 Hz, 1H), 1.22 (s, 3H). 
N
O
Bn
MeO2C
Bz
289a  
289a: 1H NMR (300 MHz, CDCl3): δ 7.46-7.22 (m, 10H), 5.77 (s, 1H), 4.34 (d, J = 17.8 Hz, 
1H), 4.15 (d, J = 13.8 Hz, 1H), 3.80 (s, 3H), 3.37 (d, J = 13.7 Hz, 1H), 3.03 (s, 2H), 2.91 (d, J = 
17.9 Hz, 1H), 1.45 (s, 3H). 
BzN
MeO2C
Bn
O
287b
H
 
2-Benzoyl-1-benzyl-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (287b). Prepared by following general procedure O, using: 74b 
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(435 mg, 1.21 mmol), DMSO (429 µL, 6.06 mmol), Mo(CO)6 (400 mg, 1.51 mmol). Heated to 
90 °C for 20 min. The crude mixture was purified by flash chromatography (gradient elution, 
hexanes-EtOAc, 19 : 1 to 2 : 1, v/v) to afford 287b (260 mg, 55%). The correct product ratios 
listed in Scheme 4.30 were determined in a separate experiment by integration of the olefinic 
resonances in the 1H NMR spectrum taken after complete removal of all volatiles from a small 
reaction sample. 
287b:  1H NMR (300 MHz, CDCl3): δ 7.52-7.27 (m, 10H), 6.19 (s, 1H), 6.07 (s, 1H), 5.63 (s, 
1H), 4.24 (d, J = 14.9 Hz, 1H), 4.23 (d, J = 14.2 Hz, 1H), 4.03 (d, J = 15.0 Hz, 1H), 3.98 (s, 1H), 
3.62 (s, 3H), 3.39 (d, J = 14.3 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 195.2, 170.9, 170.2, 
170.1, 140.6, 135.7, 135.5, 131.1, 128.6, 128.5, 127.3, 126.2, 118.0, 70.8, 52.3, 51.5, 50.9, 37.7; 
IR (thin film): ν 3027, 1741, 1710, 1641, 1383 cm-1; MS m/z (%) 387 (15), 328 (10), 282 (22), 
105 (100); EI-HRMS calcd for C24H21NO4 m/z [M]+ 387.1471 found 387.1470.  
 
N
O
Bz
MeO2C
Bn
289b  
2-Benzoyl-3-benzyl-6-oxo-2,3,5,6-tetrahydro-1H-[2]pyrindine-3-carboxylic acid methyl 
ester (289b). 1H NMR (300 MHz, CDCl3): δ 7.49-7.41 (m, 3H), 7.34-7.27 (m, 5H), 7.21-7.17 
(m, 2H), 5.90 (s, 1H), 5.70 (s, 1H), 4.39 (d, J = 18.1 Hz, 1H), 4.15 (d, J = 13.8 Hz, 1H), 3.81 (s, 
3H), 3.38 (d, J = 13.8 Hz, 1H), 3.05 (s, 2H), 3.01 (d, J = 18.1 Hz, 1H); 13C NMR (75 MHz, 
CDCl3): δ 202.9, 171.3, 171.1, 161.1, 135.8, 135.4, 135.2, 130.3, 129.9, 128.7, 128.3, 127.4, 
127.2, 126.3, 123.5, 65.9, 53.0, 45.1, 39.6, 37.7; IR (thin film): ν 2950, 1740, 1710, 1643, 1391 
cm-1; MS m/z (%) 387 (47), 356 (15), 328 (12), 296 (30), 105 (100); EI-HRMS calcd for 
C24H21NO4 m/z [M]+ 387.1471 found 387.1489.  
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O
290b  
2-Benzoyl-1-benzyl-6-methylene-5-oxo-1,2,3,4,5,6-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (290b). 1H NMR (300 MHz, CDCl3): δ 7.46-7.35 (m, 5H), 7.27-
7.25 (m, 3H), 7.11-7.08 (m, 2H), 5.94 (s, 1H), 5.58 (s, 1H), 4.08 (d, J = 15.7 Hz, 1H), 4.04 (d, J 
= 13.8 Hz, 1H), 3.84 (s, 3H), 3.56-3.52 (m, 2H), 2.85 (d, J = 22.5 Hz, 1H), 2.70 (d, J = 22.5 Hz, 
1H); 13C NMR (75 MHz, CDCl3): δ 201.5, 170.1, 169.2, 145.2, 142.5, 138.5, 136.2, 136.1, 
130.1, 128.5, 127.9, 127.0, 126.4, 112.6, 74.3, 55.1, 52.9, 38.4, 36.2; IR (thin film): ν 2950, 
1743, 1631, 1405, 1253 cm-1; ESI-HRMS calcd for C24H21NO4Na m/z [M+23]+ 410.1368; found 
410.1375. 
 
N OBz
MeO2C
H
287c  
2-Benzoyl-1,4-dimethyl-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (287c). Prepared by following general procedure O, using: 
74c (50 mg, 0.17 mmol), DMSO (120 µL, 1.68 mmol), Mo(CO)6 (55 mg, 0.21 mmol). Heated to 
80 °C for 2 hours. The crude mixture (53 mg, >95%) was purified by flash chromatography 
(gradient elution, hexanes-EtOAc, 9 : 1 to 2 : 1, v/v) to afford 287c (41 mg, 74 %). The correct 
product ratios listed in Scheme 4.32 were determined in a separate experiment by integration of 
the olefinic resonances in the 1H NMR spectrum taken after complete removal of all volatiles 
from a small reaction sample. 
287c: (Rf = 0.23, TLC, hexanes-EtOAc, 2 : 1, v/v) 1H NMR (300 MHz, CDCl3): δ 7.54-7.44 (m, 
5H), 6.26 (d, J = 1.9 Hz, 1H), 5.44 (s, 1H), 4.58 (d, J = 15.7 Hz, 1H), 4.22 (d, J = 15.7 Hz, 1H), 
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4.02 (s, 1H), 3.88 (s, 3H), 1.82 (s, 3H), 1.31 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 195.7, 172.6, 
169.3, 162.4, 139.6, 136.0, 136.0, 130.2, 128.6, 126.5, 119.2, 66.5, 53.3, 52.9, 47.8, 14.6, 9.0; IR 
(thin film): ν 2950, 1740, 1707, 1689, 1642, 1404 cm-1; MS m/z (%) 325 (30), 266 (28), 220 
(15), 105 (100); EI-HRMS calcd for C19H19NO4 m/z [M]+ 325.1314; found 325.1305. 
BzN O
MeO2C
H
288c  
288c: 1H NMR (300 MHz, CDCl3): δ 7.61-7.59 (m, 2H), 7.54-7.44 (m, 3H), 6.17 (d, J = 1.9 Hz, 
1H), 5.54 (s, 1H), 4.58 (d, J = 14.9 Hz, 1H), 4.30 (d, J = 14.9 Hz, 1H), 3.76 (s, 1H), 3.55 (s, 3H), 
2.04 (s, 3H), 1.77 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 195.4, 171.2, 170.5, 162.7, 140.2, 
135.9, 135.1, 131.0, 128.6, 127.5, 118.0, 68.3, 55.0, 52.1, 50.3, 23.6, 9.1; IR (thin film): ν 2950, 
1734, 1707, 1689, 1643, 1378 cm-1; MS m/z (%) 325 (10), 266 (18), 105 (100); EI-HRMS calcd 
for C19H19N1O4 m/z [M]+ 325.1314; found 325.1308. 
 
N
O
MeO2C
Bz
289c  
289c: 1H NMR (300 MHz, CDCl3): δ 7.51-7.43 (m, 5H), 5.69 (s, 1H), 4.78 (d, J = 17.6 Hz, 1H), 
4.19 (d, J = 17.6, 0.9 Hz, 1H), 3.74 (s, 3H), 3.02 (s, 1H), 1.79 (s, 3H), 1.69 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 203.5, 172.1, 171.8, 155.3, 136.2, 135.2, 133.0, 130.6, 128.8, 127.1, 123.0, 
62.4, 52.9, 43.2, 37.4, 20.6, 8.0; IR (thin film): ν 2950, 1740, 1704, 1645, 1394 cm-1; MS m/z 
(%) 325 (25), 294 (9), 266 (47), 105 (100); EI-HRMS calcd for C19H19NO4 m/z [M]+ 325.1314; 
found 325.1324. 
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N OBz
MeO2C
H
287d  
2-Benzoyl-1-methyl-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (287d). Prepared by following general procedure O, using: 
74d (72 mg, 0.25 mmol), DMSO (180 µL, 2.54 mmol), Mo(CO)6 (84 mg, 0.32 mmol). Heated to 
80 °C for 2 hours. The crude mixture (80 mg, >95%) was purified by flash chromatography 
(gradient elution, hexanes-EtOAc, 9 : 1 to 2 : 1, v/v) to afford 287d (49 mg, 62 %). The correct 
product ratios listed in Scheme 4.32 were determined in a separate experiment by integration of 
the olefinic resonances in the 1H NMR taken after complete removal of all volatiles from a small 
reaction sample. 
287d: Rf = 0.15 (TLC, hexanes-EtOAc, 2 : 1, v/v) 1H NMR (300 MHz, CDCl3): δ 7.51-7.41 (m, 
5H), 6.26-6.25 (m, 2H), 5.46 (s, 1H), 4.66 (d, J = 16.0 Hz, 1H), 4.29 (d, J = 16.0 Hz, 1H), 4.13 
(s, 1H), 3.88 (s, 3H), 1.35 (s, 3H); 13C NMR (75 MHz, CDCl3): δ  195.6, 172.8, 170.4, 169.6, 
140.2, 136.2, 130.6, 129.0, 127.9, 126.8, 120.0, 66.8, 55.4, 53.3, 49.2, 17.3, 15.0; IR (thin film): 
ν 2950, 1739, 1709, 1638, 1402 cm-1; MS m/z (%) 311 (18), 252 (22), 206 (9), 105 (100); EI-
HRMS calcd for C18H17NO4 m/z [M]+ 311.1158; found 311.1151. 
N OBz
MeO2C
H
287e  
2-Benzoyl-1-isobutyl-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (287e). Prepared by following general procedure O, using: 
74e (199 mg, 0.612 mmol), DMSO (218 µL, 3.06 mmol), Mo(CO)6 (202 mg, 0.765 mmol). 
Heated to 80 °C for 1.5 hours. Flash chromatography (gradient elution, hexanes-EtOAc 20 : 1 to 
1 : 1 v/v (1% AcOH)) did not afford complete separation of all compounds. Yield of mixture 
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(207 mg, 96%) consisting of 287e (74%), 288e (14%) and 289e (7%) determined by integration 
of the olefinic resonances in the 1H NMR spectrum.  
Isomerization of 287e to 290e: addition of Et3N to a solution of  287e in CDCl3 or adsorbing 
287e onto silica gel gave rapid isomerization to 290e (~1h). 
287e: 1H NMR (300 MHz, CDCl3): δ 7.46 (s, 5H), 6.27 (d, J = 1.9 Hz, 1H), 6.23 (s, 1H), 5.50 (s, 
1H), 4.62 (d, J = 16.4 Hz, 1H), 4.39 (d, J = 16.4 Hz, 1H), 4.13 (s, 1H), 3.89 (s, 3H), 2.31 (dd, J = 
15.0, 7.5 Hz, 1H), 1.63 (dd, J = 15.3, 3.6 Hz, 1H), 1.60-1.51 (m, 1H), 0.90 (d, J = 6.5 Hz, 3H), 
0.81 (d, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 195.5, 172.7, 171.6, 169.6, 140.3, 136.3, 
130.0, 128.8, 126.5, 126.0, 119.4, 69.1, 55.7, 53.0, 50.0, 37.8, 25.2, 23.7, 23.4; IR (thin film): ν 
2956, 1739, 1709, 1640, 1400 cm-1; MS m/z (%) 354 (26), 353 (40), 297 (67), 265 (70), 105 
(100); EI-HRMS calcd for C21H23NO4 m/z [M]+ 353.1627; found 353.1625. 
N OBz
MeO2C
H
288e  
2-Benzoyl-1-isobutyl-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (288e). 1H NMR (300 MHz, CDCl3): δ 7.54-7.39 (m, 5H), 6.14 (s, 
1H), 6.11 (d, J = 1.8 Hz, 1H), 5.49 (s, 1H), 4.62 (d, J = 15.2 Hz, 1H), 4.38 (d, J = 15.2 Hz, 1H), 
4.10 (s, 1H), 3.51 (s, 3H), 2.77 (dd, J = 15.2, 7.0 Hz, 1H), 2.13 (dd, J = 15.2, 4.6 Hz, 1H), 2.01-
1.86 (m, 1H), 1.11 (d, J = 6.7 Hz, 3H), 1.06 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
195.2, 170.9, 170.5, 170.5, 140.7, 135.5, 131.0, 128.5, 127.2, 126.4, 118.0, 70.9, 52.0, 51.9, 51.8, 
39.9, 25.3, 24.3, 23.7; IR (thin film): ν 2955, 1740, 1709, 1640, 1383 cm-1; MS m/z (%) 353 (51), 
310 (15), 294 (32) 105 (100); EI-HRMS calcd for C21H23NO4 m/z [M]+ 353.1627; found 
353.1632. 
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N OBz
MeO2C
290e  
2-Benzoyl-1-isobutyl-6-methylene-5-oxo-1,2,3,4,5,6-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (290e). 1H NMR (300 MHz, CDCl3): δ 7.51-7.40 (m, 5H), 5.81 (s, 
1H), 5.40 (s, 1H), 4.54 (d, J = 16.6 Hz, 1H), 4.40 (d, J = 16.6 Hz, 1H), 3.76 (s, 3H), 2.98 (s, 2H), 
2.69 (dd, J = 15.0, 7.1 Hz, 1H), 2.35 (dd, J = 15.0, 5.2 Hz, 1H), 1.64-1.49 (m, 1H),  1.01 (d, J = 
6.6 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 201.6, 170.7, 169.7, 143.6, 
143.5, 138.3, 136.4, 130.1, 128.5, 126.3, 112.4, 74.3, 55.6, 52.6, 38.6, 38.2, 24.7, 24.2, 23.7; IR 
(thin film): ν 2954, 1742, 1632, 1399 cm-1; MS m/z (%) 329 (5), 294 (43), 84 (100). 
N
Bz
O
MeO2C
289e  
2-Benzoyl-3-isobutyl-6-oxo-2,3,5,6-tetrahydro-1H-[2]pyrindine-3-carboxylic acid methyl 
ester (289e). 1H NMR (300 MHz, CDCl3): δ 7.50-7.41 (m, 5H), 5.97 (q, J = 1.6 Hz, 1H), 5.80 
(d, J = 1.2 Hz, 1H), 4.72 (d, J = 18.2 Hz, 1H), 4.57 (d, J = 18.6 Hz, 1H), 3.76 (s, 3H), 3.05 (s, 
2H), 2.75 (dd, J = 14.7, 5.8 Hz, 1H), 2.09 (dd, J = 14.7, 6.4 Hz, 1H), 1.80-1.67 (m, 1H), 0.98 (d, 
J = 6.7 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 203.0, 172.2, 171.5, 
161.5, 135.8, 134.1, 130.3, 128.9, 127.6, 126.6, 125.3, 65.6, 52.8, 45.8, 42.7, 37.9, 24.5, 24.3; IR 
(thin film): ν 2954, 1740, 1709, 1644 cm-1; MS m/z (%) 353 (5), 294 (25), 105 (100). 
N OBz
CO2Me
MeO H
287f  
2-Benzoyl-1-(4-methoxybenzyl)-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydro-
cyclopenta[c]pyrrole-1-carboxylic acid methyl ester (287f). Prepared by following general 
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procedure O, using: 74f (110 mg, 0.286 mmol), Mo(CO)6 (95 mg, 0.36 mmol), DMSO (102 µL, 
1.43 mmol). The reaction was heated to 80 °C for 4 h. Flash chromatography (gradient elution, 
hexanes-EtOAc v/v (1% AcOH)) afforded the major diastereomer 287f (50 mg, 42%) and an 
unseparable mixture of minor diastereomer and [6,5] product (62 mg, 53%). 
When the reaction was performed with 5.25 g of 73f, the yield of 287f was 2.0 g  (36%). 
287f: 1H NMR (300 MHz, CDCl3): δ 7.52-7.41 (m, 5H), 7.23-7.18 (m, 2H), 6.94-6.89 (m, 2H), 
6.18 (d, J = 2.1 Hz, 1H), 6.07 (s, 1H), 5.61 (s, 1H), 4.24 (d, J = 15.0 Hz, 1H), 4.15 (d, J = 14.5 
Hz, 1H), 4.06 (dt, J = 14.9, 1.5 Hz, 1H), 3.97 (s, 1H), 3.82 (s, 3H), 3.60 (s, 3H), 3.32 (d, J = 14.5 
Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 195.3, 170.8, 170.4, 170.1, 158.9, 140.7, 135.5, 132.1, 
131.1, 128.7, 127.5, 127.3, 126.1, 118.0, 113.9, 71.0, 55.2, 52.3, 51.5, 50.9, 36.8; IR (thin film): 
ν 2951, 1740, 1709, 1640, 1513, 1383 cm-1; ESI-HRMS calcd for C25H23NO5Na m/z [M+23]+ 
440.1474; found 440.1479. 
N OBz
CO2Me
F H
287g  
2-Benzoyl-1-(4-fluorobenzyl)-6-methylene-5-oxo-1,2,3,5,6,6a-
hexahydrocyclopenta[c]pyrrole-1-carboxylic acid methyl ester (287g). Prepared by following 
general procedure O, using: 74g (70 mg, 0.19 mmol), Mo(CO)6 (61 mg, 0.23 mmol), DMSO 
(132 µL, 1.87 mmol). The reaction was heated to 85 °C for 2 h. After filtration of the reaction 
mixture on a small silica gel pad eluting with (hexanes-EtOAc 3 : 1 to 1 : 1 v/v (1% AcOH)), the 
major component was isolated by flash chromatography (hexanes-EtOAc 20 : 1 to 1 : 1 v/v (1% 
AcOH)) to give 287g (25 mg, 33%). Yield of mixture (57mg, 76%). 
287g: 1H NMR (300 MHz, CDCl3): δ 7.55-7.43 (m, 5H), 7.29-7.24 (m, 2H), 7.11-7.06 (m, 2H), 
6.20 (d, J = 1.7 Hz, 1H), 6.10 (s, 1H), 5.62 (s, 1H), 4.27 (d, J = 15.1 Hz, 1H), 4.21 (d, J = 14.5 
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Hz, 1H), 4.07 (d, J = 15.0 Hz, 1H), 3.93 (s, 1H), 3.62 (s, 3H), 3.37 (d, J = 14.5 Hz, 1H); 13C 
NMR (75 MHz, CDCl3): δ 195.1, 171.1, 170.0, 169.9, 163.9, 160.7, 140.7, 135.5, 132.7, 132.6, 
131.5, 131.5, 131.3, 128.7, 127.3, 126.4, 118.0, 115.6, 115.4, 71.0, 52.3, 51.6, 51.0, 37.1; IR 
(thin film): ν 2951, 1742, 1709, 1640, 1509 cm-1; MS m/z (%) 405 (15), 346 (5), 300 (20), 296 
(13), 105 (100); EI-HRMS calcd for C24H20NO4F m/z [M]+ 405.1376; found 405.1371. 
N OBz
CO2Me
H
S
287h  
2-Benzoyl-6-methylene-5-oxo-1-thiophen-2-ylmethyl-1,2,3,5,6,6a-
hexahydrocyclopenta[c]pyrrole-1-carboxylic acid methyl ester (287h). Prepared by following 
general procedure O, using: 74h (115 mg, 0.315 mmol), Mo(CO)6 (104 mg, 0.393 mmol), 
DMSO (224 µL, 3.15 mmol). Heated to 85 °C for 2 h. Flash chromatography (gradient elution, 
hexanes-EtOAc v/v (1% AcOH)) afforded the major diastereomer 287h (48 mg, 39%) and an 
unseparable mixture of minor diastereomer and [6,5] product (67 mg, 54%). 
287h: 1H NMR (300 MHz, CDCl3): δ 7.65-7.62 (m, 2H), 7.55-7.44 (m, 3H), 7.33-7.32 (m, 1H), 
7.05-7.01 (m, 2H), 6.16 (d, J = 2.0 Hz, 1H), 6.11 (s, 1H), 5.53 (s, 1H), 4.41-4.30 (m, 3H), 3.99 
(s, 1H), 3.78 (d, J = 15.6 Hz, 1H), 3.61 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 195.4, 171.1, 
170.5, 170.0, 141.0, 137.8, 135.8, 131.5, 129.1, 128.9, 127.8, 127.2, 126.8, 126.3, 118.4, 71.4, 
52.6, 52.0, 51.7, 33.5; IR (thin film): ν 2951, 1741, 1708, 1640, 1378 cm-1; ESI-HRMS calcd for 
C22H19NO4NaS m/z [M+23]+ 416.0932; found 416.0950. 
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N OBz
CO2Me
H
BocN 287i
 
3-(2-Benzoyl-1-methoxycarbonyl-6-methylene-5-oxo-1,2,3,5,6,6a-
hexahydrocyclopenta[c]pyrrol-1-ylmethyl)-indole-1-carboxylic acid tert-butyl ester (287i). 
Prepared by following general procedure O, using: 74i (65 mg, 0.13 mmol), Mo(CO)6 (43 mg, 
0.16 mmol), DMSO (93 µL, 1.3 mmol). The reaction was heated to 85 °C for 1 h. Flash 
chromatography (gradient elution, hexanes-EtOAc v/v (1% AcOH)) did not afford complete 
separation of all compounds. 287i (12 mg)  and the [6,5] product (3 mg) were collected pure for 
characterization purposes. Yield of mixture (53 mg, 77%). 
287i: 1H NMR (300 MHz, CDCl3): δ 8.22 (d, J = 8.3 Hz, 1H), 7.58-7.1 (m, 10H), 6.23 (d, J = 2.0 
Hz, 1H), 6.07 (s, 1H), 5.74 (s, 1H), 4.28 (d, J = 15.5 Hz, 1H), 4.28 (d, J = 15.0 Hz, 1H), 4.15 (d, 
J = 14.9 Hz, 1H), 4.05 (s, 1H), 3.65 (s, 3H), 3.64 (d, J = 15.2 Hz, 1H), 1.66 (s, 9H); 13C NMR 
(75 MHz, CDCl3): δ 195.2, 171.1, 170.3, 170.1, 149.5, 140.9, 135.6, 135.3, 131.5, 131.1, 128.6, 
127.4, 126.2, 125.7, 124.8, 123.1, 118.9, 117.9, 115.4, 114.7, 84.0, 71.2, 52.3, 51.8, 28.2, 27.6; 
IR (thin film): ν 2979, 2244, 1736, 1712, 1640, 1371 cm-1; ESI-HRMS calcd for C31H30N2O6Na 
m/z [M+23]+ 549.2002; found 549.2015. 
N
O
Bz
CO2MeBocN
 
3-(2-Benzoyl-3-methoxycarbonyl-6-oxo-2,3,4,4a,5,6-hexahydro-1H-[2]pyrindin-3-
ylmethyl)indole-1-carboxylic acid tert-butyl ester. 1H NMR (300 MHz, CDCl3): δ 8.12 (d, J = 
8.1 Hz, 1H), 7.63-7.11 (m, 9H), 5.95 (d, J = 1.3 Hz, 1H), 5.68 (d, J = 1.4 Hz, 1H), 4.40 (d, J = 
18.3 Hz, 1H), 4.36 (d, J = 14.7 Hz, 1H), 3.84 (s, 3H), 3.45 (d, J = 14.8 Hz, 1H), 3.34 (d, J = 18.5 
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Hz, 1H), 3.05 (d, J = 20.2 Hz, 1H), 2.93 (d, J = 20.8 Hz, 1H), 1.63 (s, 9H); 13C NMR (75 MHz, 
CDCl3): δ 202.5, 177.8, 171.9, 171.2, 161.0, 149.3, 135.6, 135.4, 135.2, 130.8, 130.0, 128.7, 
127.5, 126.5, 124.9, 124.7, 123.9, 122.7, 119.6, 115.3, 114.9, 83.9, 65.9, 53.1, 45.5, 37.8, 29.4, 
28.2; IR (thin film): ν 2979, 1736, 1717, 1644, 1371 cm-1; ESI-HRMS calcd for C31H30N2O6Na 
m/z [M+23]+ 549.2002; found 549.2018. 
 
General procedure P for the Stetter reaction with butyraldehyde. 
O
O
C3H7
BzN
Bn
MeO2C H
293a  
2-Benzoyl-1-benzyl-4-methyl-5-oxo-6-(2-oxopentyl)-1,2,3,5,6,6a-
hexahydrocyclopenta[c]pyrrole-1-carboxylic acid methyl ester (293a). To a solution of 
cyclopentenone 287a (163 mg, 0.403 mmol) in 1,4-dioxane (2 mL), were added Et3N (42 µL, 
0.30 mmol), butyraldehyde (184 µL, 2.03 mmol) and 3-benzyl-5-(2-hydroxyethyl)-4-
methylthiazolium chloride 292 (22 mg, 0.080 mmol). The reaction vessel was sealed with a 
rubber septum and heated to 70 °C for 6 h. The reaction mixture was then poured into water, and 
the aqueous layer extracted with Et2O. The combined organic layers were washed with brine, 
dried over MgSO4 and concentrated under vacuum. Hexanes (5 mL) was added and a white 
precipitate formed. The precipitate was collected by decantation, and purified by flash 
chromatography (gradient elution; hexanes-EtOAc, 4 : 1 to 2 : 1, v/v) to afford 293a (121 mg, 
63%). The decanted liquid was concentrated under vacuum and the crude residue was purified by 
flash chromatorgraphy (gradient elution; hexanes-EtOAc, 4 : 1 to 2 : 1, v/v) to afford 293b (19 
mg, 10%). 
293a: 1H NMR (300 MHz, CDCl3): δ 7.55-7.44 (m, 5H), 7.33-7.27 (m, 3H), 7.17-7.14 (m, 2H), 
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4.17 (d, J = 15.0 Hz, 1H), 4.10 (d, J = 14.2 Hz, 1H), 3.99 (d, J = 15.1 Hz, 1H), 3.75 (s, 3H), 
3.44-3.39 (m, 1H), 3.28 (d, J = 14.2 Hz, 1H), 3.03 (dd, J = 18.4, 5.1 Hz, 1H), 2.86 (dd, J = 18.4, 
3.9 Hz, 1H), 2.50 (t, J = 7.2 Hz, 2H), 2.13 (dd, J = 8.5, 4.1 Hz, 1H), 1.66 (sex, J = 7.4 Hz, 2H), 
1.62 (s, 3H), 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 208.4, 207.8, 171.6, 171.3, 
166.0, 136.1, 136.0, 131.8, 131.2, 131.0, 128.6, 128.4, 128.3, 127.4, 127.2, 71.7, 52.4, 51.7, 50.8, 
45.4, 44.5, 40.9, 37.7, 17.1, 13.7, 8.8;  IR (thin film): ν 2953, 1740, 1719, 1687, 1638, 1390 cm-1; 
MS m/z (%) 473 (7), 441 (8), 414 (17), 382 (20), 350 (18), 105 (100); EI HRMS calcd for 
C29H31NO5 m/z [M]+ 473.2202, found 473.2181.  
293b: 1H NMR (300 MHz, CDCl3): δ 7.55-7.29 (m, 10H), 4.21 (d, J = 14.8 Hz, 1H), 4.03-3.94 
(m, 2H), 3.71 (s, 3H), 3.68 (bs, 1H), 3.34-3.27 (m, 1H), 3.11 (d, J = 14.1 Hz, 1H), 2.91 (dd, J = 
19.2, 3.5 Hz, 1H), 2.52 (t, J = 7.4 Hz, 2H), 2.43 (dd, J = 19.2, 11.3 Hz, 1H), 1.73 (sex, J = 7.4 
Hz, 2H), 1.62 (s, 3H), 1.00 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 209.0, 208.9, 
172.6, 171.6, 168.2, 136.5, 135.8, 131.6, 131.4, 131.2, 128.7, 128.2, 127.6, 127.0, 69.7, 52.4, 
50.7, 49.0, 44.1, 42.0, 39.4, 36.3, 17.2, 13.8, 8.5. 
O
O
C3H7
BzN
Bn
MeO2C
294a
H
 
2-Benzoyl-1-benzyl-5-oxo-6-(2-oxo-pentyl)-1,2,3,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (294a). Prepared by using general procedure P, using: 287b (100 
mg, 0.258 mmol), Et3N (107 µL, 0.774 mmol), butyraldehyde (117 µL, 1.29 mmol) and 3-
benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride 292 (14 mg, 0.052 mmol). Flash 
chromatography (gradient elution; hexanes-EtOAc, 9 : 1 to 2 : 1, v/v) afforded 294a (major 
diastereomer) (78 mg, 66%). The minor diastereomer remains in the decanted liquid. 
294a (major diastereomer, eluting second, TLC, hexanes-EtOAc) 1H NMR (300 MHz, CDCl3): δ 
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7.50-7.45 (m, 5H), 7.31-7.27 (m, 3H), 7.16-7.14 (m, 2H), 5.91 (s, 1H), 4.24 (d, J = 15.5 Hz, 1H), 
4.08 (d, J = 14.1 Hz, 1H), 4.06 (d, J = 15.5 Hz, 1H), 3.76 (s, 3H), 3.55 (s, 1H), 3.28 (d, J = 14.2 
Hz, 1H), 3.04 (dd, J = 18.5, 5.0 Hz, 1H), 2.84 (dd, J = 18.5, 3.6 Hz, 1H), 2.49 (t, J = 7.2 Hz, 2H), 
2.15 (q, J = 4.2 Hz, 1H), 1.66 (sex, J = 7.3 Hz, 2H), 0.98 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 208.4, 207.6, 173.7, 171.5, 171.3, 135.9, 135.7, 131.0, 130.5, 128.6, 128.4, 127.2, 
124.1, 123.7, 123.3, 71.6, 53.2, 52.5, 51.7, 45.9, 44.4, 40.6, 37.6, 17.0, 13.7; IR (thin film): ν 
2960, 1713, 1645, 1383 cm-1; MS m/z (%) 459 (7), 388 (58), 358 (54), 298 (78), 105 (100); EI-
HRMS calcd for C28H29NO5 m/z [M]+ 459.2046, found 459.2061. 
 
General procedure Q for reduction of enones. 
O
O
C3H7
BzN
Bn
MeO2C
H
296
H
 
2-Benzoyl-1-benzyl-4-methyl-5-oxo-6-(2-oxopentyl)octahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (296). To a solution of the enone 293a (121 mg, 0.256 mmol) in 
MeOH (15 mL) was added Pd/C (100 mg of 10 % by wt.) at rt. The reaction vessel was 
connected to a hydrogenation apparatus and purged with H2 three times. The reaction mixture 
was stirred at rt under H2 pressure (2.5 atm) for 4 h. The mixture was then filtered using a fritted 
funnel through a plug of celite and washed with CH2Cl2. The filtrate was concentrated under 
vacuum to afford 296 (115 mg, 95%).  
1H NMR (300 MHz, CDCl3): δ 7.47-7.42 (m, 5H), 7.34-7.24 (m, 5H), 4.22 (d, J = 13.8 Hz, 1H), 
3.84 (s, 3H), 3.27 (d, J = 13.8 Hz, 1H), 3.20-3.00 (m, 3H), 2.85 (dd, J = 10.2, 6.9 Hz, 1H), 2.63-
2.46 (m, 3H), 2.39 (t, J = 7.3 Hz, 2H), 1.79-1.68 (m, 1H), 1.61 (sex, J = 7.4 Hz, 2H), 0.94 (t, J = 
7.3 Hz, 3H), 0.75 (d, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 218.2, 208.6, 171.9, 169.9, 
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137.1, 136.9, 130.4, 129.8, 128.5, 127.1, 126.1, 72.8, 52.6, 51.5, 50.3, 44.4, 44.2, 44.0, 41.6, 
41.4, 39.8, 17.2, 13.6, 10.2; IR (thin film): ν 2962, 1737, 1712, 1639, 1404, 1250 cm-1; MS m/z 
(%) 416 (16), 384 (43), 352 (21), 324 (23), 105 (100); EI-HRMS calcd for C27H30NO3 m/z [M-
59]+ 416.2226, found 416.2239. 
O
O
C3H7
BzN
Bn
MeO2C
H
297
H
 
2-Benzoyl-1-benzyl-5-oxo-6-(2-oxopentyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid 
methyl ester (297). Prepared by following the general procedure Q, using: 294a (140 mg, 0.305 
mmol), MeOH (10 mL), Pd/C (50 mg of 10% by wt.), H2 (1 atm). The reaction mixture was 
stirred for 4 h at rt. Yield of 297 (140 mg, >95%). Note: The reaction was performed under 1 atm 
of H2 using a balloon. 
1H NMR (300 MHz, CDCl3): δ 7.49-7.24 (m, 10H), 4.18 (d, J = 13.7 Hz, 1H), 3.83 (s, 3H), 3.37-
3.12 (m, 3H), 2.96-2.88 (m, 2H), 2.66-2.57 (m, 2H), 2.43 (t, J = 7.3 Hz, 2H), 2.33 (dd, J = 19.0, 
8.3 Hz, 1H), 1.99 (d, J = 19.0 Hz, 1H), 1.89-1.77 (m, 1H), 1.64 (sex, J = 7.3 Hz, 2H), 0.96 (t, J = 
7.3 Hz, 3H); 13C NMR : δ 216.6, 208.4, 171.8, 169.6, 137.0, 136.7, 130.5, 129.9, 128.5, 127.1, 
126.2, 72.9, 56.5, 52.6, 52.2, 45.1, 44.5, 41.6, 39.6, 36.1, 17.2, 13.6; IR (thin film): ν 2959, 1740, 
1712, 1636, 1405, 1250 cm-1; EI-HRMS calcd for C26H28NO3 m/z [M-59]+ 402.2069, found 
402.2069. 
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General procedure R for preparation of alkyl pyrroles. 
BzN N
C3H7
MeO2C
Bn
298a
H
H
 
5-Benzoyl-1,4-dibenzyl-2-propyl-3b,4,5,6,6a,7-hexahydro-1H-1,5-diazacyclopenta[a]-
pentalene-4-carboxylic acid methyl ester (298a). To a solution of 297 (10 mg, 0.021 mmol) in 
MeOH (0.5 mL), was added benzylamine (23 µL, 0.21 mmol), AcOH (12 µL, 0.21 mmol) and 
molecular sieves (4 Å) (30 mg). The reaction mixture was stirred at 70 °C for 4 h. Upon 
completion, the reaction mixture was diluted with EtOAc and washed with 1M HCl. The organic 
layer was then dried over MgSO4, and the solvents removed under vacuum. The crude residue 
was purified by flash chromatography (gradient elution; hexanes-EtOAc, 19 : 1 to 3 : 1, v/v), to 
afford 298a (10 mg, 90%). 
1H NMR (300 MHz, CDCl3): δ 7.43-7.22 (m, 13H), 6.87 (d, J = 7.0 Hz, 2H), 5.70 (s, 1H), 4.85 
(s, 2H), 4.24 (d, J = 13.6 Hz, 1H), 3.91 (d, J = 7.2 Hz, 1H), 3.71 (s, 3H), 3.37 (d, J = 13.6 Hz, 
1H), 3.36-3.30 (m, 1H), 3.20-3.14 (m, 1H), 2.39 (t, J = 7.6 Hz, 2H), 2.39-2.31 (m, 1H), 2.22 
(quin, J = 7.6 Hz, 1H), 2.01 (d, J = 14.5 Hz, 1H), 1.55 (sex, J = 7.6 Hz, 2H), 0.93 (t, J = 7.3 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 172.4, 169.9, 138.5, 138.0, 137.6, 137.5, 134.9, 131.2, 
129.6, 128.7, 128.4, 128.2, 127.3, 126.7, 126.4, 126.1, 122.4, 73.1, 56.8, 52.9, 52.1, 48.3, 45.5, 
39.4, 29.1, 28.8, 22.4, 14.1; IR (thin film): ν 2950, 1734, 1642, 1402 cm-1; MS m/z (%) 532 (24), 
441 (16), 250 (20), 105 (100); EI-HRMS calcd for C35H36N2O3 m/z [M]+ 532.2726; found 
532.2724. 
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BzN N
C3H7
MeO2C
Bn
298b
H
H
CO2Me
 
5-Benzoyl-4-benzyl-1-methoxycarbonylmethyl-2-propyl-3b,4,5,6,6a,7-hexahydro-1H-1,5-
diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (298b). Prepared by following 
the general procedure R, using: 297 (17 mg, 0.037 mmol), MeOH (1 mL), glycine methyl ester 
hydrochloride (23 mg, 0.18 mmol), AcOH (10 µL, 0.18 mmol), molecular sieves (4 Å) (50 mg). 
The reaction mixture was stirred at 70 °C for 4 h. Upon completion, the reaction mixture was 
concentrated under vacuum. The crude residue was purified by flash chromatography (hexanes-
EtOAc, 4 : 1, v/v) to afford 298b (14 mg, 70%). 
1H NMR (300 MHz, CDCl3): δ 7.46-7.27 (m, 10H), 5.66 (s, 1H), 4.40 (d, J = 17.7 Hz, 1H), 3.82 
(d, J = 17.8 Hz, 1H), 4.23 (d, J = 13.5 Hz, 1H), 3.90 (d, J = 7.3 Hz, 1H), 3.72 (s, 3H), 3.69 (s, 
3H), 3.41 (d, J = 13.6 Hz, 1H), 3.37 (dd, J = 10.3, 8.5 Hz, 1H), 3.24-3.18 (m, 1H), 2.46 (dd, J = 
14.3, 7.0 Hz, 1H), 2.39 (t, J = 7.7 Hz, 2H), 2.27-2.17 (m, 1H), 2.09 (d, J = 14.6 Hz, 1H), 1.59 
(sex, J = 7.6 Hz, 2H), 0.98 (t, J = 7.4 Hz, 1H); IR (thin film): ν 2952, 1736, 1638, 1403, 1205 
cm-1; MS m/z (%) 514 (21), 455 (7), 423 (33), 105 (100); EI-HRMS calcd for C31H34N2O5, m/z 
[M]+ 514.2468; found 514.2471.  
BzN N
C3H7
MeO2C
Bn
298c
H
H OMe
 
5-Benzoyl-4-benzyl-1-(4-methoxyphenyl)-2-propyl-3b,4,5,6,6a,7-hexahydro-1H-1,5-
diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (298c). Prepared by following 
the general procedure R, using: 297 (20 mg, 0.043 mmol) in methanol (0.5 mL), p-anisidine (27 
mg, 0.22 mmol), AcOH (12 µL, 0.22 mmol), molecular sieves (4 Å) (50 mg). The reaction 
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mixture was stirred at 60 °C for 2 h. The crude residue was purified by flash chromatography 
(gradient elution; hexanes-EtOAc, 9 : 1 to 3 : 1, v/v) to afford 298c (20 mg, 85%). 
1H NMR (300 MHz, CDCl3): δ 7.47-7.27 (m, 10H), 7.08 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 
2H), 4.26 (d, J = 13.5 Hz, 1H), 3.92 (d, J = 7.2 Hz, 1H), 3.82 (s, 3H), 3.75 (s, 3H), 3.44 (d, J = 
13.5 Hz, 1H), 3.37-3.21 (m, 2H), 2.43-2.39 (m, 1H), 2.39 (t, J = 7.5 Hz, 2H), 2.22 (quin, J = 7.5 
Hz, 1H), 2.06 (d, J = 14.9 Hz, 1H), 1.48 (sex, J = 7.5 Hz, 2H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR 
(75 MHz, CDCl3): δ 172.2, 169.7, 158.5, 138.3, 138.0, 137.4, 135.2, 131.9, 131.1, 129.4, 128.3, 
128.1, 127.4, 126.7, 126.3, 122.7, 114.2, 73.0, 56.7, 55.4, 52.9, 52.0, 45.2, 39.4, 29.4, 29.1, 22.5, 
13.9; IR (thin film): ν 2954, 1734, 1641, 1515, 1403, 1249 cm-1; MS m/z (%) 548 (52), 457 (36), 
425 (24), 266 (52), 105 (100); EI-HRMS calcd for C35H36N2O4 m/z [M]+ 548.2675, found 
548.2677. 
BzN N
C3H7
MeO2C
Bn H
H
OH
298d  
5-Benzoyl-4-benzyl-1-(2-hydroxyethyl)-2-propyl-3b,4,5,6,6a,7-hexahydro-1H-1,5-
diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (298d). Prepared by following 
the general procedure R, using: 297 (20 mg, 0.043 mmol), ethanolamine (26 µL, 0.43 mmol), 
AcOH (20 µL, 0.36 mmol), molecular sieves (4 Å) (50 mg). The reaction mixture was stirred at 
70 °C for 1 h. The crude residue was purified by flash chromatography (gradient elution; 
hexanes-EtOAc, 3 : 1 to 2 : 1, v/v) to afford 298d (16 mg, 76%). 
1H NMR (300 MHz, CDCl3): δ 7.45-7.27 (m, 10 H), 5.65 (s, 1H), 4.20 (d, J = 13.6 Hz, 1H), 3.89 
(d, J = 7.2 Hz, 1H), 3.79-3.73 (m, 4H), 3.67 (s, 3H), 3.37 (d, J = 13.5 Hz, 1H), 3.26-3.23 (m, 
2H), 2.55 (dd, J = 14.4, 7.1 Hz, 1H), 2.47 (t, J = 7.8 Hz, 2H), 2.37 (quind, J = 7.2, 2.0 Hz, 1H), 
2.29 (d, J = 14.3 Hz, 1H), 2.06-1.94 (bs, 1H), 1.70-1.58 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H); 13C 
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NMR (75 MHz, CDCl3): δ 172.3, 169.7, 137.7, 137.3, 137.2, 135.4, 131.1, 129.5, 128.3, 128.1, 
126.7, 126.4, 122.0, 101.2, 73.1, 62.3, 56.4, 52.6, 52.0, 47.1, 45.7, 39.1, 29.4, 29.0, 22.3, 14.1; 
IR (thin film): ν 3418, 2928, 1732, 1622, 1405, 1259 cm-1; MS m/z (%) 486 (26), 395 (30), 105 
(76), 57 (100). EI-HRMS calcd for C30H34N2O4 m/z [M]+ 486.2519; found 486.2510. 
 
General procedure S for the Stetter reaction with glyoxylamides. 
BzN O
Bn
MeO2C
H O
O
N
305  
2-Benzoyl-1-benzyl-6-(2,3-dioxo-3-pyrrolidin-1-ylpropyl)-5-oxo-1,2,3,5,6,6a-
hexahydrocyclopenta[c]pyrrole-1-carboxylic acid methyl ester (305). To a solution of 287b 
(840 mg, 2.17 mmol) in 1,4-dioxane (20 mL) was added oxo-pyrrolidin-1-yl-acetaldehyde 303mm 
(1.38 g, 11.8 mmol), 292 (175 mg, 0.651 mmol) and Et3N (905 µL, 6.51 mmol). The reaction 
mixture was heated to 70 °C for 10 min and then poured in water (200 mL). The aqueous layer 
was extracted with Et2O (3 x 100 mL) and the extracts were combined, washed with brine, dried 
over MgSO4 and concentrated under vacuum. The crude residue was purified by flash 
chromatography (gradient elution; hexanes-EtOAc, 3 : 1 to 0 : 1, v/v) to give 305 (1.17 g, 
>95%). 
1H NMR (300 MHz, CDCl3): δ 7.54-7.42 (m, 5H), 7.36-7.29 (m, 3H), 7.23-7.20 (m, 2H), 5.91 (s, 
1H), 4.27 (d, J = 15.7 Hz, 1H), 4.17 (d, J = 14.3 Hz, 1H), 4.07 (d, J = 15.7 Hz, 1H), 3.82 (s, 3H), 
3.66 (t, J = 6.4 Hz, 2H), 3.58 (t, J = 6.4 Hz, 2H), 3.52-3.44 (m, 2H), 3.33 (dd, J = 18.7, 5.3 Hz, 
1H), 3.23 (d, J = 14.3 Hz, 1H), 2.47 (q, J = 4.7 Hz, 1H), 1.99-1.90 (m, 4H); 13C NMR (75 MHz, 
                                                 
mm Aldehydes 302 and 303 was prepared according to previously reported procedures.208, 209 
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CDCl3): δ 207.4, 198.2, 174.1, 171.2, 161.9, 135.6, 131.2, 131.0, 128.6, 128.4, 127.2, 123.4, 
71.5, 53.2, 52.6, 51.7, 47.3, 46.4, 46.0, 37.6, 37.1, 26.3, 23.6; IR (thin film): ν 2952, 1716, 1638, 
11447, 1384 cm-1; MS m/z (%) 514 (13), 455 (6), 416 (17), 105 (100); EI-HRMS calcd for 
C30H30N2O6 m/z [M]+ 514.2104; found 514.2115. 
BzN O
Bn
MeO2C
H O
O
N
304  
2-Benzoyl-1-benzyl-6-(2-dimethylcarbamoyl-2-oxoethyl)-5-oxo-1,2,3,5,6,6a-hexahydro-
cyclopenta[c]pyrrole-1-carboxylic acid methyl ester (304). Prepared by following the general 
procedure S, with: 287b (94 mg, 0.24 mmol), N,N-dimethyl-2-oxo-acetamide (125 mg, 1.21 
mol), Et3N (100 µL, 0.729 mmol), 292 (19 mg, 0.073 mmol). Yield of 304 (76 mg, 70%). 
1H NMR (300 MHz, CDCl3): δ 7.52-7.40 (m, 5H), 7.35-7.22 (m, 5H), 5.90 (s, 1H), 4.25 (d, J = 
15.7 Hz, 1H), 4.16 (d, J = 14.2 Hz, 1H), 4.04 (d, J = 15.7 Hz, 1H), 3.80 (s, 3H), 3.51-3.49 (m, 
1H), 3.40 (dd, J = 18.9, 5.1 Hz, 1H), 3.27 (dd, J = 18.9, 5.1 Hz, 1H), 3.23 (d, J = 14.4 Hz, 1H), 
3.05 (s, 3H), 3.02 (s, 3H), 2.43 (q, J = 4.6 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 207.3, 198.3, 
174.2, 171.3, 165.8, 135.8, 135.6, 131.3, 131.0, 128.6, 128.4, 127.2, 123.3, 71.6, 53.1, 52.5, 51.7, 
45.9, 38.0, 37.2, 37.0, 34.7; IR (thin film): ν 2951, 1716, 1647, 1386 cm-1; MS m/z (%) 488 (45), 
416 (73), 365 (43), 281 (51), 105 (100); EI-HRMS calcd for C28H28N2O6 m/z [M]+ 488.1947; 
found 488.1943. 
BzN O
Bn
MeO2C
H O
O
N
307
H
 
2-Benzoyl-1-benzyl-6-(2,3-dioxo-3-pyrrolidin-1-ylpropyl)-5-
oxooctahydrocyclopenta[c]pyrrole-1-carboxylic acid methyl ester (307). Prepared by 
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following the general procedure  Q, using: 305 (1.17g, 2.27 mmol), Pd/C (200 mg of 10 % by 
wt.), H2 (1 atm). Note: the reaction was performed under 1 atm of H2 using a balloon. 
1H NMR (300 MHz, CDCl3): δ 7.50-7.24 (m, 10H), 4.18 (d, J = 13.8 Hz, 1H), 3.86 (s, 3H), 3.65 
(t, J = 6.7, 2H), 3.53 (t, J = 6.7 Hz, 2H), 3.30-3.17 (m, 3H), 3.11-3.08 (m, 2H), 2.89-2.87 (m, 
2H), 2.22 (dd, J = 19.3, 8.5 Hz, 1H), 2.08-1.80 (m, 7H); 13C NMR (75 MHz, CDCl3): δ 216.6, 
198.1, 171.5, 169.6, 161.9, 136.9, 136.7, 130.6, 129.9, 128.5, 127.1, 126.3, 72.8, 55.4, 52.7, 52.1, 
47.3, 46.5, 45.6, 39.3, 38.7, 36.1, 26.3, 23.6; IR (thin film): ν 2950, 1737, 1636, 1404 cm-1; MS 
m/z (%) 516 (8), 485 (7), 457 (36), 425 (51), 105 (100); EI-HRMS calcd for C30H32N2O6 m/z 
[M]+ 516.2260; found 516.2255. 
BzN O
Bn
MeO2C
H O
O
N
306
H
 
2-Benzoyl-1-benzyl-6-(2-dimethylcarbamoyl-2-oxoethyl)-5-
oxooctahydrocyclopenta[c]pyrrole-1-carboxylic acid methyl ester (306). Prepared by 
following general procedure Q using: 304 (85 mg, 0.17 mmol), Pd/C (15 mg of 10% by weight), 
H2 (1 atm). Yield of 306 (69 mg, 81%). Note: the reaction was performed under 1 atm of H2 
using a balloon. 
1H NMR (300 MHz, CDCl3): δ 7.50-7.42 (m, 5H), 7.36-7.25 (m, 5H), 4.18 (d, J = 13.8 Hz, 1H), 
3.86 (s, 3H), 3.34-2.77 (m, 7H), 3.05 (s, 3H), 3.01 (s, 3H), 2.23 (dd, J = 19.3, 8.4 Hz, 1H), 2.05 
(dd, J = 19.3, 2.9 Hz, 1H), 1.92-1.79 (m, 1H); 13C NMR (75 MHz, CDCl3): δ 216.5, 198.4, 
171.5, 169.5, 165.6, 136.9, 136.7, 130.6, 129.9, 128.5, 127.0, 126.2, 72.7, 55.4, 52.6, 51.9, 45.3, 
39.2, 39.0, 37.0, 36.1, 34.8; IR (thin film): ν 2950, 1740, 1644, 1405, 1250 cm-1; MS m/z (%) 
490 (10), 459 (18), 431 (68), 399 (43), 105 (100); EI-HRMS calcd for C28H30N2O6 m/z [M]+ 
490.2104; found 490.2099. 
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General procedure T for preparation of pyrroles 308a-p. 
BzN
Bn
MeO2C
H
H
N
O
N
308m  
5-Benzoyl-4-benzyl-1-(3-methylbutyl)-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308m). To a 
solution of 307 (35 mg, 0.068 mmol) in EtOH (0.9 mL) was added 3-methyl butylamine (21 µL, 
0.020 mmol) followed by glacial acetic acid (90 µL) at rt. The test tube was then heated to 50 °C 
in an oil bath for 2 h when the reaction was complete based upon TLC. The light yellow solution 
was then diluted with EtOAc and poured into 1M HCl. The aqueous layer was extracted with 
EtOAc and the extracts combined and washed again with 1M HCl. The organic layer was then 
separated, dried over MgSO4 and concentrated under vacuum. The crude residue was purified by 
flash chromatography (gradient elution, hexanes-EtOAc, v/v) to afford 308m (36 mg, 95%). 
1H NMR (300 MHz, CDCl3): δ 7.48-7.27 (m, 10H), 4.23 (d, J = 13.5 Hz, 1H), 4.17-4.10 (m, 
1H), 3.98-3.85 (m, 2H), 3.74-3.55 (m, 7H), 3.40 (d, J = 13.7 Hz, 1H), 3.37-3.30 (m, 1H), 3.21-
3.15 (m, 1H), 2.53 (dd, J = 15.1, 6.9 Hz, 1H), 2.36-2.25 (m, 1H), 2.21 (d, J = 16.1 Hz, 1H), 2.01-
1.85 (m, 4H), 1.50-1.45 (m, 3H), 0.85 (d, J = 5.7 Hz, 6H); 13C NMR (75 MHz, CDCl3): δ 172.2, 
169.7, 162.0, 140.3, 137.6, 137.1, 130.9, 130.6, 129.5, 129.2, 128.5, 128.3, 128.1, 126.7, 126.2, 
122.1, 72.9, 56.3, 52.0, 45.4, 45.2, 40.3, 39.2, 28.5, 25.7, 22.5, 22.4; IR (thin film): ν 2951, 1735, 
1639, 1611, 1446, 1399 cm-1; MS m/z (%) 567 (32), 476 (41), 405 (24), 301 (61), 91 (100); EI-
HRMS calcd for C35H41N3O4 m/z [M]+ 567.3097; found 567.3114. 
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BzN
Bn
MeO2C
H
H
N
O
N
Ph
308a  
5-Benzoyl-1,4-dibenzyl-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-hexahydro-1H-1,5-diaza-
cyclopenta[a]pentalene-4-carboxylic acid methyl ester (308a). Prepared by following general 
procedure T with: 307 (20 mg, 0.039 mmol), benzylamine (13 µL, 0.12 mmol), AcOH (50 µL). 
Yield  308a (18 mg, 80%).  
1H NMR (300 MHz, CDCl3): δ 7.42-7.19 (m, 13H), 6.98 (d, J = 6.8 Hz, 1H), 6.23 (s, 1H), 5.44 
(d, J = 15.4 Hz, 1H), 5.14 (d, J = 15.4 Hz, 1H), 4.23 (d, J = 13.6 Hz, 1H), 3.88 (d, J = 7.2 Hz, 
1H), 3.62 (s, 3H), 3.59-3.49 (m, 4H), 3.42-3.29 (m, 2H), 3.19-3.13 (m, 1H), 2.40 (dd, J = 15.0, 
6.9 Hz, 1H), 2.34-2.25 (m, 1H), 2.12 (d, J = 15.2 Hz, 1H), 1.92-1.78 (m, 4H); 13C NMR (75 
MHz, CDCl3): δ 172.2, 169.8, 162.1, 140.8, 138.7, 137.7, 137.2, 131.0, 130.1, 129.6, 128.5, 
128.4, 128.2, 127.2, 126.9, 126.8, 126.3, 122.8, 108.6, 73.9, 56.4, 52.2, 52.0, 50.0, 45.6, 39.4, 
28.8; IR (thin film): ν 2949, 1735, 1639, 1447, 1400 cm-1; MS m/z (%) 587 (66), 496 (83), 425 
(75), 321 (86), 105 (100); EI-HRMS calcd for C37H37N3O4 m/z [M]+ 587.2784; found 587.2777. 
BzN
Bn
MeO2C
H
H
N
O
N
308b
MeO
OMe
 
5-Benzoyl-4-benzyl-1-(3,4-dimethoxybenzyl)-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diaza-cyclopenta[a]pentalene-4-carboxylic acid methyl ester (308b). 
Prepared by following general procedure T with: 307 (26 mg, 0.05 mmol), 3,4-
dimethoxybenzylamine (22 µL, 0.15 mmol), AcOH (65 µL). Yield  308b (29 mg, 88%).  
1H NMR (300 MHz, CDCl3): δ 7.41-7.27 (m, 10H), 6.72 (d, J = 8.2 Hz, 1H), 6.62 (d, J = 1.9 Hz, 
 267 
1H), 6.52 (dd, J = 8.2, 1.8 Hz, 1H), 6.22 (s, 1H), 5.34 (d, J = 15.1 Hz, 1H), 5.11 (d, J = 15.1 Hz, 
1H), 4.23 (d, J = 13.6 Hz, 1H), 3.87 (d, J = 7.3 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.62 (s, 3H), 
3.59-3.55 (m, 4H), 3.39 (d, J = 13.7 Hz, 1H), 3.36-3.30 (m, 1H), 3.18-3.12 (m, 1H), 2.42 (dd, J = 
15.1, 6.9 Hz, 1H), 2.33-2.23 (m, 1H), 2.13 (d, J = 15.6 Hz, 1H), 1.82-1.92 (m, 4H); 13C NMR 
(75 MHz, CDCl3): δ 172.3, 169.9, 162.2, 149.0, 148.2, 141.0, 137.7, 137.2, 131.3, 131.1, 129.8, 
129.7, 128.5, 128.3, 126.9, 126.4, 122.9, 119.3, 110.9, 110.5, 108.8, 73.1, 56.5, 56.0, 55.9, 52.2, 
49.8, 48.0, 45.7, 39.4, 28.8, 25.5; IR (thin film): ν 2949, 1734, 1638, 1605, 1445, 1400 cm-1; MS 
m/z (%) 647 (51), 556 (42), 381 (27), 151 (100), 105 (65); EI-HRMS calcd for C39H41N3O6 m/z 
[M]+ 647.2995; found 647.2991. 
BzN
Bn
MeO2C
H
H
N
O
N
MeO
OH
308c  
5-Benzoyl-4-benzyl-1-(4-hydroxy-3-methoxybenzyl)-2-(pyrrolidine-1-carbonyl)-
3b,4,5,6,6a,7-hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester 
(308c). Prepared by following general procedure T with: 307 (35 mg, 0.068 mmol), 4-
aminomethyl-2-methoxyphenol hydrochloride (39 mg, 0.20 mmol), AcOH (80 µL). Yield  308c 
(31 mg, 72%).  
1H NMR (300 MHz, CDCl3): δ 7.41-7.27 (m, 10H), 6.75 (d, J = 8.1 Hz, 1H), 6.64 (s, 1H), 6.44 
(d, J = 8.1 Hz, 1H), 6.21 (s, 1H), 5.72 (bs, 1H), 5.31 (d, J = 15.0 Hz, 1H), 5.07 (d, J = 15.0 Hz, 
1H), 4.22 (d, J = 13.6 Hz, 1H), 3.86 (d, J = 7.2 Hz, 1H), 3.79 (s, 3H), 3.61 (s, 3H), 3.61-3.50 (m, 
4H), 3.44-3.29 (m, 2H), 3.18-3.11 (m, 1H), 2.42 (dd, J = 15.2, 7.0 Hz, 1H), 2.33-2.22 (m, 1H), 
2.13 (d, J = 15.4 Hz, 1H), 1.93-1.80 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 172.2, 169.8, 162.1, 
146.5, 144.8, 140.8, 137.5, 137.0, 130.9, 130.5, 129.7, 129.6, 128.4, 128.2, 126.8, 126.2, 122.7, 
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119.9, 114.1, 109.9, 108.6, 73.0, 56.4, 55.8, 52.0, 49.7, 45.5, 39.2, 28.7; IR (thin film): ν 3253, 
2949, 1734, 1602, 1447, 1401 cm-1; ESI-HRMS calcd for C38H40N3O6 m/z [M+1]+ 634.2917; 
found 634.2938. 
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308d  
5-Benzoyl-4-benzyl-1-(5-methylfuran-2-ylmethyl)-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308d). 
Prepared by following general procedure T with: 307 (35 mg, 0.068 mmol), C-(5-Methylfuran-2-
yl)-methylamine (23 µL, 0.20 mmol), AcOH (90 µL). Yield  308d (34 mg, 85%).  
1H NMR (300 MHz, CDCl3): δ 7.45-7.27 (m, 10H), 6.18 (s, 1H), 6.01 (d, J = 3.0 Hz, 1H), 5.81 
(d, J = 2.2 Hz, 1H), 5.35 (d, J = 15.5 Hz, 1H), 5.06 (d, J = 15.5 Hz, 1H), 4.22 (d, J = 13.6 Hz, 
1H), 3.85 (d, J = 7.3 Hz, 1H), 3.65-3.55 (m, 4H), 3.57 (s, 3H), 3.39 (d, J = 13.6 Hz, 1H), 3.35-
3.29 (m, 1H), 3.21-3.16 (m 1H), 2.53 (dd, J = 15.1, 7.3 Hz, 1H), 2.33-2.20 (m, 2H), 2.17 (s, 3H), 
1.97-1.86 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 172.2, 169.7, 162.1, 151.6, 149.5, 140.7, 
137.6, 137.0, 130.9, 129.5, 129.4, 128.3, 128.1, 126.7, 126.2, 122.5, 108.6, 106.2, 72.9, 56.3, 
52.1, 52.0, 48.7, 45.4, 42.9, 39.2, 28.6, 13.5; IR (thin film): ν 2949, 1734, 1638, 1605, 1445, 
1400 cm-1; MS m/z (%) 591 (30), 500 (16), 406 (10), 105 (88), 95 (100); EI-HRMS calcd for 
C36H37N3O5 m/z [M]+ 591.2733; found 591.2735. 
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308e  
5-Benzoyl-4-benzyl-1-[2-(4-hydroxyphenyl)ethyl]-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diaza-cyclopenta[a]pentalene-4-carboxylic acid methyl ester (308e). 
Prepared by following general procedure T with: 307 (29 mg, 0.056 mmol), 4-(2-aminoethyl)-
phenol (23 µL, 0.17 mmol), AcOH (70 µL). Yield  308e (22 mg, 63%).  
1H NMR (300 MHz, CDCl3): δ 7.44-7.41 (m, 5H), 7.34-7.27 (m, 5H), 6.75 (d, J = 8.3 Hz, 1H), 
6.62 (d, J = 8.3 Hz, 1H), 6.19 (s, 1H), 4.35-4.15 (m 2H), 4.22 (d, J = 13.6 Hz, 1H), 3.82 (d, J = 
7.2 Hz, 1H), 3.66 (s, 3H), 3.63-3.53 (m, 4H), 3.39 (d, J = 13.6 Hz, 1H), 3.28 (dd, J = 10.2, 8.2 
Hz, 1H), 3.03-2.97 (m, 1H), 2.89-2.76 (m, 2H), 2.29-2.16 (m, 2H), 1.98-1.86 (m, 4H), 1.82 (d, J 
= 14.5 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 172.2, 169.8, 162.0, 154.8, 141.1, 137.6, 137.0, 
130.9, 130.1, 130.0, 129.7, 128.8, 128.5, 128.2, 126.8, 126.3, 122.1, 115.2, 109.1, 73.1, 56.3, 
52.1, 48.7, 45.2, 39.3, 37.1, 28.2, 25.4; IR (thin film): ν 3237, 2950, 1733, 1601, 1447 cm-1; MS 
m/z (%) 617 (18), 526 (22), 351 (11), 335 (9), 105 (100); EI-HRMS calcd for C38H39N3O5 m/z 
[M]+ 617.2890; found 617.2875. 
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5-Benzoyl-4-benzyl-1-(3-morpholin-4-ylpropyl)-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diaza-cyclopenta[a]pentalene-4-carboxylic acid methyl ester (308f). 
Prepared by following general procedure T with: 307 (34 mg, 0.066 mmol), 3-Morpholin-4-yl 
propylamine (29 µL, 0.20 mmol), AcOH (80 µL). Yield  308f (16 mg, 39%).  
1H NMR (300 MHz, CDCl3): δ 7.45-7.28 (m, 10H), 6.21 (s, 1H), 4.23 (d, J = 13.7 Hz, 1H), 4.18-
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4.11 (m, 1H), 4.07-3.98 (m, 1H), 3.87 (d, J = 7.3 Hz, 1H), 3.70-3.56 (m, 8H), 3.62 (s, 3H), 3.39 
(d, J = 13.6 Hz, 1H), 3.33 (dd, J = 10.4, 8.3 Hz, 1H), 3.17 (dd, J = 10.2, 8.3 Hz, 1H), 3.09 (q, J = 
7.3 Hz, 2H), 2.55 (dd, J = 15.0, 6.9 Hz, 1H), 2.41-.2.20 (m, 9H); IR (thin film): ν 2950, 1734, 
1637, 1603, 1445, 1400 cm-1; MS m/z (%) 624 (25), 211 (32), 105 (100); EI-HRMS calcd for 
C37H44N4O5 m/z [M]+ 624.3312; found 624.3291. 
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5-Benzoyl-4-benzyl-1-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-2-(pyrrolidine-1-carbonyl)-
3b,4,5,6,6a,7-hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester 
(308g). Prepared by following general procedure T with: 307 (39 mg, 0.076 mmol), 1-(3-
aminopropyl)-pyrrolidin-2-one (32 µL, 0.23 mmol), AcOH (90 µL). Yield  308g (38 mg, 81%). 
1H NMR (300 MHz, CDCl3): δ 7.43-7.38 (m, 5H), 7.34-7.27 (m, 5H), 6.20 (s, 1H), 4.21 (d, J = 
13.6 Hz, 1H), 4.14-4.04 (m, 1H), 3.94-3.84 (m, 2H), 3.67-3.57 (m, 4H), 3.61 (s, 3H), 3.39-3.30 
(m, 4H), 3.25-3.14 (m, 3H), 2.53 (dd, J = 15.1, 7.0 Hz, 1H), 2.35-2.30 (m, 3H), 2.21 (d, J = 15.3 
Hz, 1H), 2.00-1.87 (m, 9H); 13C NMR (75 MHz, CDCl3): δ 174.9, 172.2, 169.7, 140.6, 137.5, 
136.9, 130.9, 129.6, 129.1, 128.3, 128.1, 126.8, 126.2, 122.4, 108.8, 72.9, 56.2, 52.0, 46.9, 45.4, 
44.8, 39.9, 39.2, 31.0, 28.9, 28.5, 17.8, 14.1; IR (thin film): ν 2948, 1733, 1683, 1639, 1606, 
1445, 1399 cm-1; MS m/z (%) 622 (21), 531 (24), 460 (6), 105 (100); EI-HRMS calcd for 
C37H42N4O5 m/z [M]+ 622.3155; found 622.3147. 
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5-Benzoyl-4-benzyl-1-(2-hydroxyethyl)-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-hexahydro-
1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308h). Prepared by 
following general procedure T with: 307 (50 mg, 0.097 mmol), ethanolamine (18 µL, 0.29 
mmol), AcOH (100 µL). Yield  308h (42 mg, 80%).  
1H NMR (300 MHz, CDCl3): δ 7.48-7.40 (m, 5H), 7.36-7.30 (m, 5H), 6.26 (s, 1H), 4.23 (d, J = 
13.6 Hz, 1H), 4.18-4.09 (m, 2H), 3.88 (d, J = 7.4 Hz, 1H), 3.80 (t, J = 5.1 Hz, 1H), 3.75-3.57 (m, 
4H), 3.64 (s, 3H), 3.39 (d, J = 13.7 Hz, 1H), 3.37-3.20 (m, 2H), 2.57 (dd, J = 15.3, 8.1 Hz, 1H), 
2.41-2.31 (m, 1H), 2.25 (d, J = 15.4 Hz, 1H), 2.03-1.90 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 
172.2, 169.7, 162.0, 141.3, 137.5, 137.0, 131.0, 129.7, 129.6, 128.4, 128.2, 126.8, 126.3, 123.2, 
109.3, 72.9, 62.6, 56.2, 52.1, 52.0, 49.9, 48.8, 46.7, 45.6, 39.2, 28.6, 26.5, 24.1; IR (thin film): ν 
3394, 2949, 1734, 1600, 1448, 1402 cm-1; MS m/z (%) 541 (45), 482 (13), 450 (54), 379 (28), 
328 (20), 105 (100); EI-HRMS calcd for C32H35N3O5 m/z [M]+ 541.2577; found 541.2574. 
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5-Benzoyl-4-benzyl-1-(2-methoxyethyl)-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308i). 
Prepared by following general procedure T with: 307 (35 mg, 0.068 mmol), 2-
methoxyethylamine (18 µL, 0.20 mmol), AcOH (80 µL). Yield  308i (35 mg, 93%).  
1H NMR (300 MHz, CDCl3): δ 7.44-7.27 (m, 10H), 6.23 (s, 1H), 4.32 (dt, J = 14.1, 4.9 Hz, 1H), 
4.23 (d, J = 13.6 Hz, 1H), 4.07 (dt, J = 14.1, 5.0 Hz, 1H), 3.88 (d, J = 7.4 Hz, 1H), 3.70-3.51 (m, 
9H), 3.40 (d, J = 13.7 Hz, 1H), 3.37-3.31 (m, 1H), 3.21 (s, 3H), 3.21-3.15 (m, 1H), 2.58 (dd, J = 
15.6, 7.0 Hz, 1H), 2.33-2.26 (m, 1H), 2.25 (d, J = 16.0 Hz, 1H), 2.00-1.90 (m, 4H); 13C NMR (75 
MHz, CDCl3): δ 172.3, 169.7, 161.9, 141.8, 137.6, 137.0, 131.0, 129.5, 129.0, 128.3, 128.1, 
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126.8, 126.2, 109.0, 72.9, 58.7, 56.4, 52.2, 52.0, 47.0, 45.2, 39.3, 28.8, 25.7; IR (thin film): ν 
2948, 1733, 1640, 1605, 1445, 1399 cm-1; MS m/z (%) 555 (46), 496 (10), 465 (43), 289 (42), 
105 (100); EI-HRMS calcd for C33H37N3O5 m/z [M]+ 555.2733; found 555.2742. 
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5-Benzoyl-4-benzyl-1-prop-2-ynyl-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-hexahydro-1H-
1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308j). Prepared by 
following general procedure T with: 307 (37 mg, 0.072 mmol), propargylamine (15 µL, 0.22 
mmol), AcOH (90 µL). Yield  308j (34 mg, 89%).  
1H NMR (300 MHz, CDCl3): δ 7.45-7.39 (m, 5H), 7.35-7.27 (m, 5H), 6.25 (s, 1H), 5.09 (dd, J = 
17.6, 1.7 Hz, 1H), 4.87 (dd, J = 17.6, 1.4 Hz, 1H), 4.23 (d, J = 13.6 Hz, 1H), 3.87 (d, J = 7.2 Hz, 
1H), 3.74-3.58 (m, 4H), 3.62 (s, 3H), 3.39 (d, J = 13.3 Hz, 1H), 3.37-3.31 (m, 1H), 3.23-3.17 (m, 
1H), 3.65 (dd, J = 15.8, 7.4 Hz, 1H), 2.35-2.23 (m, 3H), 1.98-1.90 (m, 4H); 13C NMR (75 MHz, 
CDCl3): δ 172.2, 169.7, 161.5, 141.0, 137.5, 137.0, 130.9, 129.6, 129.0, 128.4, 128.2, 126.8, 
126.2, 123.1, 109.3, 79.0, 72.8, 72.1, 56.2, 52.1, 52.0, 45.5, 39.2, 35.9, 28.7; IR (thin film): ν 
3254, 2949, 2115, 1733, 1637, 1603, 1446, 1401 cm-1; MS m/z (%) 535 (5), 444 (11), 269 (10), 
105 (100); EI-HRMS calcd for C33H33N3O4 m/z [M]+ 535.2471; found 535.2485. 
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5-Benzoyl-4-benzyl-1-cyclopropylmethyl-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308k). 
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Prepared by following general procedure T with: 307 (30 mg, 0.058 mmol), C-
cyclopropylmethylamine (15 µL, 0.17 mmol), AcOH (70 µL). Yield  308k (22 mg, 69%).  
1H NMR (300 MHz, CDCl3): δ 7.45-7.27 (m, 10H), 6.20 (s, 1H), 4.24 (d, J = 13.6 Hz, 1H), 4.06 
(dd, J = 14.1, 7.0 Hz, 1H), 3.89 (d, J = 7.4 Hz, 1H), 3.81 (dd, J = 14.1, 6.8 Hz, 1H), 3.70-3.60 
(m, 4H), 3.63 (s, 3H), 3.41 (d, J = 13.7 Hz, 1H), 3.34 (dd, J = 10.1, 8.3 Hz, 1H), 3.23-3.17 (m, 
1H), 2.58 (dd, J = 14.9, 6.8 Hz, 1H), 2.37-2.27 (m, 1H), 2.25 (d, J = 14.6 Hz, 1H), 2.00-1.88 (m, 
4H), 1.16-1.02 (m, 1H), 0.49-0.38 (m, 2H), 0.23-0.18 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 
172.3, 169.7, 162.3, 140.3, 137.6, 137.1, 131.0, 129.6, 129.4, 128.4, 128.2, 126.8, 126.3, 122.3, 
108.5, 73.0, 56.3, 52.1, 51.0, 45.5, 39.3, 29.0, 12.6, 3.8, 3.5; IR (thin film): ν 2948, 1734, 1638, 
1609, 1445, 1400 cm-1; MS m/z (%) 551 (36), 460 (37), 389 (19), 105 (100); EI-HRMS calcd for 
C34H37N3O4 m/z [M]+ 551.2784; found 551.2768. 
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5-Benzoyl-4-benzyl-1-methoxycarbonylmethyl-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308l). 
Prepared by following general procedure T with: 307 (24 mg, 0.047 mmol), glycine methyl ester 
hydrochloride (18 mg, 0.14 mmol), AcOH (70 µL) and Et3N (19 µL, 0.14 mmol). Yield  308l (21 
mg, 79%). Note: Et3N was added to help dissolve the insoluble hydrochloride salt of the primary 
amine. 
1H NMR (300 MHz, CDCl3): δ 7.45-7.27 (m, 10H), 6.32 (m, 1H), 4.98 (d, J = 17.3 Hz, 1H), 4.67 
(d, J = 17.3 Hz, 1H), 4.23 (d, J = 13.6 Hz, 1H), 3.92 (d, J = 7.4 Hz, 1H), 3.72 (s, 3H), 3.65 (s, 
3H), 3.71-3.58 (m, 4H), 3.40 (d, J = 13.5 Hz, 1H), 3.38-3.32 (m, 1H), 3.24-3.18 (m, 1H), 2.52 
(dd, J = 15.1, 7.1 Hz, 1H), 2.39-2.29 (m, 1H), 2.18 (d, J = 15.5 Hz, 1H), 2.03-1.86 (m, 4H); 13C 
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NMR (75 MHz, CDCl3): δ 172.2, 169.8, 169.5, 161.5, 141.5, 137.5, 137.0, 131.0, 129.6, 129.4, 
128.4, 128.2, 126.8, 126.3, 124.8, 122.8, 109.5, 72.8, 56.2, 52.3, 52.1, 48.4, 45.3, 39.2, 28.2; IR 
(thin film): ν 2950, 1736, 1638, 1601, 1447, 1401 cm-1; MS m/z (%) 569 (18), 478 (50), 303 
(49), 105 (100); EI-HRMS calcd for C33H35N3O6 m/z [M]+ 569.2526; found 569.2538. 
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5-Benzoyl-4-benzyl-2-(pyrrolidine-1-carbonyl)-3b,4,5,6,6a,7-hexahydro-1H-1,5-
diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308n). Prepared by following 
general procedure T with: 307 (42 mg, 0.081 mmol), ammonium acetate (19 mg, 0.24 mmol), 
AcOH (100 µL). Yield  308n (27 mg, 64%).  
1H NMR (300 MHz, CDCl3): δ 9.81 (s, 1H), 7.44-7.27 (m, 10H), 6.27 (s, 1H), 4.24 (d, J = 13.6 
Hz, 1H), 3.89 (d, J = 7.4 Hz, 1H), 3.76-3.55 (m, 4H), 3.62 (s, 3H), 3.43-3.32 (m, 2H), 3.23-3.17 
(m, 1H), 2.59 (dd, J = 15.3, 6.9 Hz, 1H), 2.39-2.29 (m, 1H), 2.27 (d, J = 15.2 Hz, 1H), 2.12-1.81 
(m, 4H); 13C NMR (75 MHz, CDCl3): δ 172.3, 169.8, 160.4, 137.9, 137.5, 137.0, 130.9, 129.8, 
129.5, 128.4, 128.2, 126.8, 126.2, 126.0, 72.9, 56.3, 52.0, 47.9, 47.0, 46.0, 39.2, 28.8, 26.6, 23.8; 
IR (thin film): ν 3219, 2949, 1733, 1635, 1579, 1456, 1401 cm-1; MS m/z (%) 497 (20), 438 (16), 
406 (33), 105 (100); EI-HRMS calcd for C30H31N3O4 m/z [M]+ 497.2315; found 497.2292. 
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5-Benzoyl-4-benzyl-2-dimethylcarbamoyl-1-(4-hydroxy-3-methoxy-benzyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308o). 
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Prepared by following general procedure T with: 306 (29 mg, 0.059 mmol), 4-aminomethyl-2-
methoxyphenol hydrochloride (34 mg, 0.18 mmol), AcOH (80 µL) and Et3N (25 µL, 0.18 
mmol). Yield  308o (13 mg, 36%). Note: Et3N was added to help dissolve the insoluble 
hydrochloride salt of the primary amine.  
1H NMR (300 MHz, CDCl3): δ 7.42-7.38 (m, 5H), 7.34-7.29 (m, 5H), 6.77 (d, J = 8.1 Hz, 1H), 
6.61 (s, 1H), 6.44 (d, J = 8.0 Hz, 1H), 6.10 (s, 1H), 5.54 (bs, 1H), 5.19 (d, J = 15.2 Hz, 1H), 5.00 
(d, J = 15.2 Hz, 1H), 4.23 (d, J = 13.6 Hz, 1H), 3.87 (d, J = 7.2 Hz, 1H), 3.81 (s, 3H), 3.62 (s, 
3H), 3.39 (d, J = 13.6 Hz, 1H), 3.36-3.29 (m, 1H), 3.18-3.12 (m, 1H), 3.07 (s, 6H), 2.41 (dd, J = 
15.0, 6.8 Hz, 1H), 2.34-2.24 (m, 1H), 2.12 (d, J = 15.3 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 
172.2, 169.8, 164.2, 146.6, 144.9, 140.5, 137.7, 137.1, 131.0, 130.4, 129.6, 128.8, 128.4, 128.2, 
126.8, 126.3, 122.8, 120.0, 114.2, 110.0, 108.5, 73.1, 56.4, 55.9, 53.4, 52.1, 51.9, 49.5, 45.7, 
39.4, 28.9; IR (thin film): ν 3273, 2950, 1733, 1616, 1514, 1403 cm-1; MS m/z (%) 607 (25), 516 
(20), 471 (5), 105 (100); EI-HRMS calcd for C36H37N3O6 m/z [M]+ 607.2682; found 607.2687. 
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5-Benzoyl-4-benzyl-2-dimethylcarbamoyl-1-(5-methylfuran-2-ylmethyl)-3b,4,5,6,6a,7-
hexahydro-1H-1,5-diazacyclopenta[a]pentalene-4-carboxylic acid methyl ester (308p). 
Prepared by following general procedure T with: 306 (38 mg, 0.078 mmol), C-(5-methylfuran-2-
yl)methylamine (26 µL, 0.23 mmol), AcOH (90 µL). Yield  308p (31 mg, 70%).  
1H NMR (300 MHz, CDCl3): δ 7.43-7.39 (m, 5H), 7.34-7.28 (m, 5H), 6.07 (s, 1H), 5.98 (d, J = 
 276 
3.0 Hz, 1H), 5.82-5.80 (m, 1H), 5.22 (d, J = 15.6 Hz, 1H), 4.98 (d, J = 15.6 Hz, 1H), 4.22 (d, J = 
13.6 Hz, 1H), 3.85 (d, J = 7.4 Hz, 1H), 3.57 (s, 3H), 3.39 (d, J = 13.6 Hz, 1H), 3.32 (dd, J = 10.5, 
8.3 Hz, 1H), 3.19 (dd, J = 10.3, 8.3 Hz, 1H), 3.11 (s, 6H), 2.51 (dd, J = 15.0, 6.6 Hz, 1H), 2.34-
2.24 (m, 2H), 2.17 (d, J = 0.5 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 172.2, 169.8, 164.3, 
151.8, 149.3, 140.4, 137.7, 137.1, 131.0, 129.5, 128.4, 128.2, 126.8, 126.2, 122.5, 108.6, 106.2, 
73.0, 56.4, 52.1, 51.9, 45.6, 42.7, 39.3, 37.6, 28.6, 13.4; IR (thin film): ν 2948, 1734, 1622, 1402 
cm-1; ESI-HRMS calcd for C38H40N3O6 m/z [M+1]+ 566.2655; found 566.2653. 
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2-Benzoyl-1-isobutyl-4-methyl-6-methylene-5-oxo-1,2,3,5,6,6a-
hexahydrocyclopenta[c]pyrrole-1-carboxylic acid methyl ester (322). [Rh(CO)2Cl]2 (3 mg, 7 
µmol) was placed in an oven-dried test tube, the atmosphere was replaced with Ar and DCE (0.5 
mL) was added. Then dppb (6.3 mg, 15 µmol) in DCE (0.5 mL) was added at rt via a syringe 
followed by AgBF4 (163 µL of a 0.1 M solution in toluene, 16 µmol). After 1 min, allenyne 321 
(25 mg, 74 µmol) in DCE (0.5 mL) was added. After 30 min, half of the reaction mixture (0.6 
mL) was taken out via a syringe and filtered on a small plug of silica gel to give 322 (5 mg, 
37%). 
1H NMR (300 MHz, CDCl3): δ 7.60-7.57 (m, 2H), 7.52-7.43 (m, 3H), 6.15 (d, J = 2.0 Hz, 1H), 
5.50 (d, J = 1.4 Hz, 1H), 4.56 (dt, J = 14.9, 1.6 Hz, 1H), 4.33 (d, J = 14.9 Hz, 1H), 3.52 (s, 3H), 
2.80 (dd, J = 15.1, 7.0 Hz, 1H), 2.14 (dd, J = 15.1, 4.7 Hz, 1H), 2.05-1.90 (m, 1H), 1.77 (t, J = 
1.8 Hz, 3H), 1.13 (d, J = 6.7 Hz, 3H), 1.08 (d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
195.6, 171.0, 170.7, 162.9, 140.5, 135.7, 135.0, 131.1, 128.6, 127.4, 117.8, 71.0, 52.1, 50.8, 50.4, 
40.0, 25.4, 24.4, 23.8, 9.1; IR (thin film): ν 2951, 1735, 1703, 1689, 1643, 1378 cm-1; MS m/z 
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(%) 367 (60), 308 (72), 262 (8), 105 (100); EI-HRMS calcd for C22H25N1O4 m/z [M]+ 367.1784; 
found 367.1771. 
[Rh(dppb)(CO)2]BF4 (325). [Rh(cod)2]BF4 (30 mg, 0.074 mmol) was placed in an oven-dried 
25 mL Schlenk flask under Ar, and DCE (3 mL) was added to form a dark red solution. Then a 
solution of dppb (34 mg, 0.081 mmol) in DCE (2 mL) was added via a syringe over 1 min and 
the reaction mixture turned bright yellow. The atmosphere was replaced with CO via a balloon 
and the reaction vessel was immersed in an oil-bath preheated to 70 °C and stirred for 5 min. 
After cooling to rt, the solution was transferred to an oven-dried test tube under Ar via a canula 
and Et2O (10 mL) and hexanes (2 mL) were added to form a yellow precipitate. The test tube 
was centrifuged for 15 min, and the pale yellow liquid was removed via a syringe. After removal 
of the residual solvent under vacuum, 325 (45 mg, 91%) was obtained as a yellow powder.  
Note: this complex was stored under Ar at -10 °C and used for up to two weeks without 
noticeable effect on the performance in the cyclocarbonylation reaction. 
31P NMR (121.4 MHz, CDCl3, external standard H3PO4): δ 21.40 (d, J = 119.7 Hz); IR (thin 
film): ν 2024 (CO), 1481, 1435, 1049 cm-1
BzN O
MeO2C
H
288c  
2-Benzoyl-1,4-dimethyl-6-methylene-5-oxo-1,2,3,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-
carboxylic acid methyl ester (288c). To a solution of allenyne 74c (21 mg, 0.071 mmol) in 
DCE (1.4 mmol) in a new 15 mL test tube was added [Rh(CO)2(dppb)]BF4 (2 mg, 3 µmol) under 
Ar atmosphere. The test tube was sealed with a rubber septum and CO (3 mL) was injected via a 
syringe. The reaction vessel was heated to 80 °C for 1.5 h, and then cooled to rt and filtered on a 
plug of silica gel eluting with EtOAc : hexanes 1 : 1 to afford a mixture of products (26 mg, 
 278 
87%). The diastereomeric ratio (288c : 287c = 2.1 : 1) was determined by integration of the two 
olefinic resonances in the 1H NMR spectrum.  
287c has been characterized previously from the Mo-mediated cyclocarbonylation reaction of 
74c. Separation of 288c from 287c was achieved by HPLC (35 % EtOAc/hexanes, flow rate 3 
mL/min, UV detection at 254 nm) with the following retention times: 288c (15.15 min); 287c 
(15.62 min). 
288c: 1H NMR (300 MHz, CDCl3): δ 7.61-7.59 (m, 2H), 7.54-7.44 (m, 3H), 6.17 (d, J = 1.9 Hz, 
1H), 5.54 (s, 1H), 4.58 (d, J = 14.9 Hz, 1H), 4.30 (d, J = 14.9 Hz, 1H), 3.76 (s, 1H), 3.55 (s, 3H), 
2.04 (s, 3H), 1.77 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 195.4, 171.2, 170.5, 162.7, 140.2, 
135.9, 135.1, 131.0, 128.6, 127.5, 118.0, 68.3, 55.0, 52.1, 50.3, 23.6, 9.1; IR (thin film): ν 2950, 
1734, 1707, 1689, 1643, 1378 cm-1; MS m/z (%) 325 (10), 266 (18), 105 (100); EI-HRMS calcd 
for C19H19N1O4 m/z [M]+ 325.1314; found 325.1308. 
 
N
O
Bz
MeO2C
329  
2-Benzoyl-3,4,7-trimethyl-6-oxo-2,3,5,6-tetrahydro-1H-[2]pyrindine-3-carboxylic acid 
methyl ester (329). To a solution of allenyne 328 (31 mg, 0.10 mmol) in DCE/toluene (3 mL, 9 : 
1) in a 15 mL test tube was added [Rh(CO)2(dppb)]BF4 (3 mg, 5 µmol) under Ar atmosphere. 
The test tube was sealed with a rubber septum and CO (3 mL) was injected via syringe. The 
reaction vessel was heated to 80 °C for 6 h, and then cooled to rt. Purification by flash 
chromatography (hexanes-EtOAc, v/v) afforded 329 (16.5 mg, 48%). 
1H NMR (300 MHz, CDCl3): δ 7.50-7.40 (m, 5H), 4.84 (d, J = 17.6 Hz, 1H), 4.01 (d, J = 17.7 
Hz, 1H), 3.73 (s, 3H), 3.01 (d, J = 20.1 Hz, 1H), 2.94 (d, J = 20.1 Hz, 1H), 1.79 (s, 3H), 1.76 (s, 
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3H), 1.67 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 203.3, 171.7, 171.1, 155.8, 135.2, 134.2, 130.6, 
130.3, 129.8, 128.8, 127.2, 65.2, 52.7, 42.6, 37.1, 18.1, 15.4, 7.8; MS m/z (%) 339 (25), 280 (94), 
77 (100); EI-HRMS calcd for C20H21N1O4 m/z [M]+ 339.1471; found 339.1481. 
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APPENDIX A: X-ray crystal structure of 144 
 
 
 281 
Table 1.  Crystal data and structure refinement for 144. 
 
Identification code  BM144 
Empirical formula  C55 H52 N3 O8 
Formula weight  883.00 
Temperature  294(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2/n 
Unit cell dimensions a = 21.898(2) Å α= 90°. 
 b = 10.0835(10) Å β= 111.998(2)°. 
 c = 23.066(2) Å γ = 90°. 
Volume 4722.3(8) Å3 
Z 4 
Density (calculated) 1.242 Mg/m3 
Absorption coefficient 0.083 mm-1 
F(000) 1868 
Crystal size 0.27 x 0.23 x 0.23 mm3 
Theta range for data collection 1.62 to 27.50°. 
Index ranges -28<=h<=28, -13<=k<=13, -29<=l<=29 
Reflections collected 45046 
Independent reflections 10857 [R(int) = 0.0391] 
Completeness to theta = 27.50° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9811 and 0.9779 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10857 / 0 / 596 
Goodness-of-fit on F2 1.007 
Final R indices [I>2sigma(I)] R1 = 0.0530, wR2 = 0.1396 
R indices (all data) R1 = 0.0928, wR2 = 0.1547 
Largest diff. peak and hole 0.240 and -0.191 e.Å-3 
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APPENDIX B: X-ray crystal structure of 156a 
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Table 1.  Crystal data and structure refinement for 156a. 
 
Identification code  BM156a 
Empirical formula  C31 H27 N3 O7 
Formula weight  553.56 
Temperature  200(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.6228(6) Å α= 90.994(2)°. 
 b = 10.7043(8) Å β= 94.584(2)°. 
 c = 16.4329(13) Å γ = 96.331(2)°. 
Volume 1327.97(18) Å3 
Z 2 
Density (calculated) 1.384 Mg/m3 
Absorption coefficient 0.099 mm-1 
F(000) 580 
Theta range for data collection 1.91 to 25.00°. 
Index ranges -9<=h<=9, -12<=k<=12, -19<=l<=19 
Reflections collected 10796 
Independent reflections 4671 [R(int) = 0.0462] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4671 / 0 / 372 
Goodness-of-fit on F2 1.120 
Final R indices [I>2sigma(I)] R1 = 0.0771, wR2 = 0.1696 
R indices (all data) R1 = 0.1168, wR2 = 0.1847 
Largest diff. peak and hole 0.366 and -0.220 e.Å-3 
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APPENDIX C: X-ray crystal structure of 186b 
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Table 1.  Crystal data and structure refinement for 186b. 
 
Identification code  BM186b 
Empirical formula  C32 H32 N2 O6 
Formula weight  540.60 
Temperature  273(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 9.7369(19) Å α= 90°. 
 b = 9.4212(19) Å β= 90.290(4)°. 
 c = 14.780(3) Å γ = 90°. 
Volume 1355.8(5) Å3 
Z 2 
Density (calculated) 1.324 Mg/m3 
Absorption coefficient 0.092 mm-1 
F(000) 572 
Theta range for data collection 2.09 to 32.66°. 
Index ranges -14<=h<=14, -14<=k<=13, -21<=l<=22 
Reflections collected 17593 
Independent reflections 9201 [R(int) = 0.1028] 
Completeness to theta = 32.66° 95.6 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9201 / 1 / 363 
Goodness-of-fit on F2 0.940 
Final R indices [I>2sigma(I)] R1 = 0.0954, wR2 = 0.1984 
R indices (all data) R1 = 0.1901, wR2 = 0.2444 
Absolute structure parameter 6.3(18) 
Largest diff. peak and hole 0.383 and -0.307 e.Å-3 
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APPENDIX D: X-ray crystal structure of 287b 
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Table 1.  Crystal data and structure refinement for 287b. 
Identification code  BM287b 
Empirical formula  C24 H21 N O4 
Formula weight  387.42 
Temperature  295(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pna2(1) 
Unit cell dimensions a = 15.4047(9) Å α= 90°. 
 b = 8.2720(5) Å β= 90°. 
 c = 15.9411(9) Å γ = 90°. 
Volume 2031.3(2) Å3 
Z 4 
Density (calculated) 1.267 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 816 
Crystal size 0.16 x 0.11 x 0.04 mm3 
Theta range for data collection 2.56 to 24.98°. 
Index ranges -18<=h<=18, -9<=k<=9, -18<=l<=18 
Reflections collected 15471 
Independent reflections 3576 [R(int) = 0.1112] 
Completeness to theta = 24.98° 100.0 %  
Absorption correction Sadabs 
Max. and min. transmission 0.9966 and 0.9863 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3576 / 1 / 262 
Goodness-of-fit on F2 1.089 
Final R indices [I>2sigma(I)] R1 = 0.0704, wR2 = 0.1252 
R indices (all data) R1 = 0.1158, wR2 = 0.1393 
Largest diff. peak and hole 0.151 and -0.175 e.Å-3 
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APPENDIX E: X-ray crystal structure of 296 
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 Table 1.  Crystal data and structure refinement for 296. 
Identification code  BM296 
Empirical formula  C29 H33 N O5 
Formula weight  475.56 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 26.4650(13) Å α= 90°. 
 b = 9.6298(5) Å β= 105.3700(10)°. 
 c = 21.3983(11) Å γ = 90°. 
Volume 5258.4(5) Å3 
Z 8 
Density (calculated) 1.201 Mg/m3 
Absorption coefficient 0.082 mm-1 
F(000) 2032 
Crystal size 0.14 x 0.14 x 0.18 mm3 
Theta range for data collection 1.92 to 25.00°. 
Index ranges -31<=h<=31, -11<=k<=11, -25<=l<=25 
Reflections collected 40981 
Independent reflections 9272 [R(int) = 0.0604] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9272 / 0 / 641 
Goodness-of-fit on F2 1.088 
Final R indices [I>2sigma(I)] R1 = 0.0718, wR2 = 0.1676 
R indices (all data) R1 = 0.1235, wR2 = 0.1877 
Largest diff. peak and hole 0.387 and -0.159 e.Å-3 
 
 
 
 
 
 290 
APPENDIX F: QikProp property predictions for 308h  
QikProp v2.1 (rel  8) - Property predictions for tricyclic pyrrole 308h.                                   
 
Principal Descriptors:                             (Range 95% of Drugs) 
     Solute        Molecular Weight      =   541.6  ( 130.0 / 725.0)  
     Solute        Molecular Volume (A3) =  1602  ( 500.0 /2000.0)  
     Solute        No. of Rotatable Bonds=     8.000  (   0.0 /  15.0)  
     Solute as Donor -    Hydrogen Bonds =     1.000  (   0.0 /   6.0)  
     Solute as Acceptor - Hydrogen Bonds =     9.7  (   2.0 /  20.0)  
 Predictions for Properties: 
   QP log P  for     octanol/water       =     5.11  (  -2.0 /   6.0)  
   QP log S  for   aqueous solubility    =    -6.12  (  -6.0 /   0.5)  
   QP log K hsa Serum Protein Binding    =    0.86  (  -1.5 /   1.2)  
   No. of Primary Metabolites            =         4  (   1.0 /   8.0)  
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APPENDIX G: 1H NMR and 13C NMR spectra of selected compounds: 
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1H and 13C NMRs of 74b 
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1H and 13C NMRs of 73f 
 294 
 
1H and 13C NMRs of 111a 
 295 
 
1H and 13C NMRs of 146a 
 296 
 
1H and 13C NMRs of 155a 
 297 
 
1H and 13C NMRs of 144 
 298 
 
1H and 13C NMRs of 156a 
 299 
 
1H and 13C NMRs of 185 
 300 
 
1H and 13C NMRs of 186b 
 301 
 
1H and 13C NMRs of 189 
 302 
 
1H and 13C NMRs of 270h 
 303 
 
1H and 13C NMRs of 287a 
 304 
 
1H and 13C NMRs of 287b 
 305 
 
1H and 13C NMRs of 305 
 306 
 
1H and 13C NMRs of 307 
 307 
 
1H and 13C NMRs of 308h 
 308 
 
1H and 13C NMRs of 308n 
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